{
    "paper_id": "xml_output_cochrane\\Bromley_et_al-2023-Cochrane_Database_of_Systematic_Reviews",
    "header": {
        "generated_with": "S2ORC 1.0.0",
        "date_generated": "2024-04-05T17:20:11.637129Z"
    },
    "title": "Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child",
    "authors": [
        {
            "first": "Rebecca",
            "middle": [],
            "last": "Bromley",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Naghme",
            "middle": [],
            "last": "Adab",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Matt",
            "middle": [],
            "last": "Bluett-Duncan",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Jill",
            "middle": [],
            "last": "Clayton-Smith",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Jakob",
            "middle": [],
            "last": "Christensen",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Katherine",
            "middle": [],
            "last": "Edwards",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Janette",
            "middle": [],
            "last": "Greenhalgh",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Ruaraidh",
            "middle": [
                "A"
            ],
            "last": "Hill",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Cerian",
            "middle": [
                "F"
            ],
            "last": "Jackson",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Sonia",
            "middle": [],
            "last": "Khanom",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Ronan",
            "middle": [
                "N"
            ],
            "last": "Mcginty",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Catrin",
            "middle": [],
            "last": "Tudur Smith",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Jennifer",
            "middle": [],
            "last": "Pulman",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Anthony",
            "middle": [
                "G"
            ],
            "last": "Marson",
            "suffix": "",
            "affiliation": {},
            "email": ""
        }
    ],
    "year": "",
    "venue": null,
    "identifiers": {},
    "abstract": "",
    "pdf_parse": {
        "paper_id": "xml_output_cochrane\\Bromley_et_al-2023-Cochrane_Database_of_Systematic_Reviews",
        "_pdf_hash": "",
        "doi": "10.1002/14651858.cd010224.pub3",
        "keywords": [],
        "abstract": [],
        "body_text": [
            {
                "text": "Prenatal exposure to certain anti-seizure medications (ASMs) is associated with an increased risk of major congenital malformations (MCM).The majority of women with epilepsy continue taking ASMs throughout pregnancy and, therefore, information on the potential risks associated with ASM treatment is required.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "A B S T R A C T Background",
                "sec_num": null
            },
            {
                "text": "To assess the e ects of prenatal exposure to ASMs on the prevalence of MCM in the child.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Objectives",
                "sec_num": null
            },
            {
                "text": "For the latest update of this review, we searched the following databases on 17 February 2022: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to February 16, 2022) , SCOPUS (1823 onwards), and ClinicalTrials.gov,WHO International Clinical Trials Registry Platform (ICTRP).No language restrictions were imposed.",
                "cite_spans": [
                    {
                        "start": 143,
                        "end": 154,
                        "text": "(Ovid, 1946",
                        "ref_id": null
                    },
                    {
                        "start": 158,
                        "end": 176,
                        "text": "February 16, 2022)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Search methods",
                "sec_num": null
            },
            {
                "text": "We included prospective cohort controlled studies, cohort studies set within pregnancy registries, randomised controlled trials and epidemiological studies using routine health record data.Participants were women with epilepsy taking ASMs; the two control groups were women without epilepsy and untreated women with epilepsy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selection criteria",
                "sec_num": null
            },
            {
                "text": "ASMs readily cross the placenta from the mother into the foetusus (Brent 2004 ; Tetro 2017).Prospective observational studies (e.g.Milan Study 1999), registry-based studies (e.g.Tomson 2011), case-control studies (Jentink 2010a) , and epidemiological studies using datasets of routine health records (e.g.Denmark Health Record Registers) provide evidence of an association between ASM treatment and an increased prevalence of major congential malformations.The level of risk varies for di erent types of ASM, with first trimester valproate (VPA) exposure associated with the largest increase in prevalence (EURAP 2018; Meador 2006; Milan Study 1999; North American Epilepsy and Pregnancy Register; UK and Ireland Epilepsy and Pregnancy Register).The mechanisms through which prenatal exposure to ASMs are associated with an increased prevalence of major malformations likely di ers by treatment type and may be multifactorial.This review investigates the outcomes for monotherapy treatment with di erent ASMs to identify currently available evidence on which to base treatment decisions.",
                "cite_spans": [
                    {
                        "start": 66,
                        "end": 77,
                        "text": "(Brent 2004",
                        "ref_id": null
                    },
                    {
                        "start": 213,
                        "end": 228,
                        "text": "(Jentink 2010a)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "The decision to continue ASM treatment during pregnancy requires taking a risk-benefit decision.On the one hand, there is the potential risk posed to the foetus when the medication is a teratogen yet on the other hand, there is the health and well-being of the mother, who requires treatment throughout her pregnancy to minimise the risk of seizures (Tomson 2015); the choice of ASM depends on the type of epilepsy and the seizures (Marson 2007).A lack of knowledge regarding foetal safety limits treatment options for women with epilepsy in their childbearing years, as women and their doctors may avoid ASMs with limited data.Conversely, a lack of evidence may lead to an ASM with a higher foetal risk profile being used extensively, prior to a full understanding of its risks.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "While a number of studies indicate a teratogenic risk from certain ASMs, there are conflicting results regarding the degree of risk and the types of malformations associated with specific ASMs.Data are slow to accumulate and an earlier version of this review (Weston 2016) found extremely limited data on ASMs with a decade or more of clinical use.Such a lack of evidence makes it di icult to counsel women about treatment choices before or during pregnancy.There is, therefore, a clear need for a systematic review and meta-analysis of existing data to inform these decisions.Randomised controlled trials (RCTs) would provide the most reliable evidence about the e ects of ASMs in pregnancy, but are essentially precluded by ethical considerations and logistical challenges pertaining to study design, recruitment and interpretation.",
                "cite_spans": [
                    {
                        "start": 259,
                        "end": 272,
                        "text": "(Weston 2016)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "In view of this, we performed a systematic review of all available evidence including registry-based, prospective cohort studies, RCTs and epidemiological studies using routine health record databases.At the protocol stage, we decided not to include malformation case-control studies (e.g.Jentink 2010a; Jentink 2010b) due to the substantial di erences in the approach in these studies and how these methods compare to prospective observational cohort studies.This decision is discussed further in Overall completeness and applicability of evidence.This review is an update of two previous reviews (Adab 2004 ; Weston 2016).Evidence from this review, along with the related review by the same Cochrane team (Bromley 2014) , will aid the decisions that clinicians and women with epilepsy have to make about the treatment of epilepsy during the potential childbearing years.",
                "cite_spans": [
                    {
                        "start": 598,
                        "end": 608,
                        "text": "(Adab 2004",
                        "ref_id": "BIBREF47"
                    },
                    {
                        "start": 707,
                        "end": 721,
                        "text": "(Bromley 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "To assess the e ects of prenatal exposure to commonly prescribed ASMs on the prevalence of major congenital malformations in the child.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "O B J E C T I V E S",
                "sec_num": null
            },
            {
                "text": "This review examines the association between specific ASM exposures and the prevalence of major congenital malformations compared to the general population or unexposed pregnancies in women with epilepsy.It also compares the prevalence of specific major congenital malformations types across the ASM treatment groups.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "O B J E C T I V E S",
                "sec_num": null
            },
            {
                "text": "We considered the following types of studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of studies",
                "sec_num": null
            },
            {
                "text": "1. Randomised controlled trials (RCTs).These studies included women with epilepsy who were randomised to a particular ASM prior to conception.The intervention group(s) comprised women with epilepsy taking ASM monotherapy.2. Prospective observational cohort studies.These included consecutive participants whose clinical information was collected prior to the birth of the child.The intervention group(s) comprised women with epilepsy treated with ASM monotherapy.3. Registry studies.These involve the collection of data from a wide region, country or number of countries, and recruitment is o en based on self-referral or clinician-referral, leading to nonsequential case ascertainment.We considered both diseasebased registries (e.g.pregnancy and epilepsy registries) and industry-sponsored product registry datasets.Pregnant women",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of studies",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews with epilepsy prescribed ASM monotherapy were recruited prospectively prior to childbirth. 4. Population-based routine health record datasets.These studies utilise data collected for routine health monitoring, administrative or reimbursement reasons for entire national populations or specific populations (e.g.medical insurance databases).Individual recruitment of participants is not required.The intervention group(s) comprised women with epilepsy taking ASM monotherapy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pregnant women with epilepsy taking a single ASM of interest were eligible for the intervention group.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "Participants eligible for the comparator groups were:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "\u2022 pregnant women with epilepsy taking an ASM;",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "\u2022 pregnant women with epilepsy taking no ASM; or \u2022 pregnant women who do not have epilepsy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "We excluded studies reporting ASM use solely in pregnant women with other conditions (e.g.mood disorders, pain).We included studies involving women taking ASMs for epilepsy and other conditions if the non-epilepsy conditions accounted for 30% or less of the total treatment group.This percentage criterion was increased from the previous review to accommodate data from population healthcare datasets, which o en include a wider group of participant indications.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "Women with epilepsy who received any of the following ASMs as monotherapy: acetazolmide, brivaracetam, bromide, carbamazepine, cenobamate, clomethiazole, clonazepam, clorazepate, diazepam, dimethyloxazolidinedione, eslicarbazepine, ethosuximide, estazolam, felbamate, flunarizine, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, magnesium sulphate, medazepam, methylphenobarbital, mephenytoin, meprobamate, methazolamide, methsuximide, methyloxazepam, midazolam, nimetazepam, nitrazepam, oxcarbazepine, perampanel, phenobarbitone, phenytoin, primidone, pregabalin, remacemide, retigabine, rufinamide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, trimethadione, trifluoromethoxy benzothiazole, valnoctamide, vigabatrin, or zonisamide.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Intervention group",
                "sec_num": null
            },
            {
                "text": "We used two separate types of comparator groups in this review, as currently there is no clear evidence regarding the reliability of combining data from these two di erent groups.The two comparator groups are:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Comparator groups",
                "sec_num": null
            },
            {
                "text": "\u2022 controls: women with a diagnosis of epilepsy who were not taking ASMs and women without epilepsy.\u2022 comparator treatment: women with epilepsy treated with ASM monotherapy, evaluated in subgroup analyses to enable treatment comparisons.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Comparator groups",
                "sec_num": null
            },
            {
                "text": "The proportion of children who present with any type of major congenital malformation (as defined by study authors).Major malformations are structural abnormalities of the body or organs present from birth and which require intervention (e.g., corrective surgery) or have a significant level of impact on the child's daily functioning (EUROCAT).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Major congenital malformations",
                "sec_num": null
            },
            {
                "text": "The proportion of children who present with the following specific major congenital malformations by area of the body.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "\u2022 Neural tube malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "\u2022 Cardiac malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "\u2022 Oro-facial cle /craniofacial malformation.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "\u2022 Skeletal or limb malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "We chose the above disorders because they are important major malformations associated with exposure to ASMs in utero, because these are the most prevalent congenital malformations in the general population (ref: https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en), and because of the availability of data within the included studies.When extracting data from included studies, we compiled a list of all the specified malformations.Author JCS, a clinical geneticist, then reviewed the list and classified the items into one of the four specific malformation categories.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Specific major congenital malformations",
                "sec_num": null
            },
            {
                "text": "We did not impose any language restrictions in the search and, when necessary, we obtained translations of articles written in languages other than English.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "We reviewed conference abstracts from neurology meetings published from 2010 to 2022, including abstracts from the International League Against Epilepsy meetings (American Epilepsy Society, International Epilepsy Congress, European Congress on Epileptology, Asian and Oceanian Epilepsy Congress and Latin American Congress on Epilepsy) and Teratology meetings (Teratology Society and European Teratology Society).Where possible, we linked abstracts to published datasets or categorised them as awaiting classification.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "We cross-matched reference lists of original research and review articles to the studies generated from the electronic searches.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "We handsearched reference lists of recent review articles and contacted lead and corresponding authors in the area for any relevant unpublished material.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "Five authors (RB, JW, JG, KE, RMcG) reviewed the titles and abstracts of articles highlighted by the searches and removed studies that obviously did not meet the inclusion criteria.Four authors (RB, JW, KE, RMcG) used full-text reports to determine study eligibility.We discussed disagreements and sought the opinion of a third author (JG, CJ, RB), when necessary.Multiple reports from single studies are common in this field.To ensure that each cohort was represented only once in our analysis, therefore to avoid double-counting the population across papers of included studies, we linked studies by recruitment date and sought confirmation from authors whether reports referred to single study populations.Where this was unclear, we contacted study authors for clarification.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selection of studies",
                "sec_num": null
            },
            {
                "text": "Eight authors (RB, JW, NA, JG, AM, KE, RMcG, SK, CJ) undertook data extraction of the included studies.We used pre-standardised electronic data extraction forms that members of the review team piloted and then amended, where necessary.We then crosschecked data extraction.All entries into RevMan were also doublechecked.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data extraction and management",
                "sec_num": null
            },
            {
                "text": "Due to the observational design of the majority of the studies, we utilised the Risk Of Bias In Non-Randomized Studiesof Interventions (ROBINS-I) tool which the Cochrane Non-Randomised Studies Methods Group has developed (Sterne 2016).The ROBINS-I tool for assessing risk of bias examines bias in the domains of confounding, selection, treatment classification, missing data, measurement and reported results.ROBINS-I uses signalling questions on a four-point scale to determine level of bias in specific elements of biases for each of these domains.Overall domain bias ratings are then classed as low, moderate, serious, critical or no information.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "ROBINS-I was developed for treatment studies and not pharmacovigilance studies, where the person taking the medication (the mother) is not the same person in which the outcome can occur (the child).Therefore, ROBINS-I needed to be adapted for use in this review.The adaption was led by author RB with input from other authors.Important confounder and mediator variables were selected based on published evidence of an association both in the general population and specifically in investigations regarding in utero ASM exposure and congential malformation outcomes.See Appendix 6 for further information.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "Eight authors completed risk of bias ratings (RB, JW, NA, JG, AM, KE, SK, MBD).Each included study was reviewed by two independent raters and the opinion of a third author (RB) was sought where there were disagreements in the domain level ratings.For RCTs, we intended to use the original Cochrane tool for assessing risk of bias (RoB1) (Higgins 2011 ).",
                "cite_spans": [
                    {
                        "start": 337,
                        "end": 350,
                        "text": "(Higgins 2011",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "We intended, where applicable, to create Summary of findings tables for outcomes and to grade each outcome accordingly using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (Guyatt 2008 ).However, we found GRADE to not be optimised for these types of data and using it would have led to di erential ratings across comparisons, depending on whether there was a di erence in MCM rate or not; thus, producing ratings of lower evidence confidence for comparisons with no di erence between the ASMs.Further work is required on GRADE and ROBINS-I to optimise them for pregnancy pharmacovigilance investigations.",
                "cite_spans": [
                    {
                        "start": 212,
                        "end": 224,
                        "text": "(Guyatt 2008",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "We considered that di erent study design types or comparator groups may lead to di erent outcome results and, therefore, we did not combine all data into a single meta-analysis containing mixed study types, groups of di erent ASMs and comparator groups.Meta-analyses were instead stratified by study type, by comparator group (e.g.women with epilepsy untreated and women without epilepsy and with no treatment), and by ASM versus ASM comparison.We computed pooled prevalences of malformations within AED (antiepileptic drug) groups (using fixede ect models, unless otherwise stated) and reported them at the beginning of each drug section.The primary and secondary outcomes are presented as risk ratios (RRs).We also computed risk di erences (RDs) using Review Manager (RevMan) to take into account studies with no reported events.We calculated these e ect estimates in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported them in the results section (Higgins 2011) .Where treatment e ects were reported from individual studies, we used the summary e ect measure that had been utilised by the study authors to report results from the study.In some cases, OR instead of RR was reported by individual study authors.",
                "cite_spans": [
                    {
                        "start": 989,
                        "end": 1003,
                        "text": "(Higgins 2011)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "The RR is a measure of relative e ect expressed as the ratio of the risk of an event in the two groups.If the 95% confidence interval includes the value of 1.00, this implies there is no di erence between the groups (i.e. a non-significant result).If the value of 1.00 lies outside the 95% confidence interval, this implies there is a di erence between the groups (i.e. a significant result).The RD is a measure of absolute e ect expressed as the di erence of the risk of an event in the two groups.If the 95% confidence interval contains the value of 0.00, this implies there is no di erence between the groups (i.e. both groups have the same risk).If the value of 0.00 lies outside the 95% confidence interval, this implies there is a di erence between the groups (i.e. a significant result).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The significance of the RR and RD may be di erent, as the RD takes into account comparisons where there were no events in either arm, whilst the other does not.Although the RR estimates are large in many comparisons, the corresponding risk di erence estimates are fairly small; but even a small increase in risk for a specific major malformation is clinically meaningful.In these cases, it would be up to the patient/clinician to interpret these risk estimates in the context of the adverse outcome and in relation to the potential benefits of treatment (e.g.seizure control).We did not account for multiple testing and the totality of the evidence for a particular exposure should be considered rather than the outcomes of a single comparison.Finally, we did not carry out any formal analysis of a dose-response relationship.We have taken any dose-response results reported directly from the study papers.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Data published in studies are o en duplicated as they are updated, particularly in the case of the prospective pregnancy registries, which update their publications as the numbers of enrolled pregnancies increase.In such cases, we considered the latest time point as the 'primary' study for inclusion.In some cohorts, this meant that we used di erent publications for di erent ASMs.Further, there are studies that report combined data from a number of di erent registers (e.g.EURAP 2018; Samren 1997) which also report independently and routine health record studies with cohort overlap (e.g.UK Clinical Research Practice Database; UK Health Record THIN Register).Where the combined data reported provided greater numbers for a particular ASM comparison, it was included in the meta-analysis but, where individual initiatives had greater numbers for a specific comparison (e.g.ASM vs control group), we included the individual study data and provided a narrative report of the collaborative initiatives.We carefully examined data to ensure that we did not include them more than once in the analysis and that we did not omit any non-duplicated data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unit of analysis issues",
                "sec_num": null
            },
            {
                "text": "We contacted study authors to obtain missing statistics from included studies to input into the meta-analysis.We also investigated study reasons for missing data to determine if they were missing at random or not.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Dealing with missing data",
                "sec_num": null
            },
            {
                "text": "We assessed clinical heterogeneity by examining the di erences in study characteristics in order to inform decisions regarding the combination of study data in meta-analysis.A priori hypotheses of sources of clinical heterogeneity included: type of population (regional, national or international, single or multicentre), loss to follow-up, maternal factors including age, duration of ASM treatment, family history of congenital malformation, lifestyle factors, monotherapy, socioeconomic status, type of epilepsy, use of other medications and years of education.Child factors included: age of assessment, sex, seizure exposure, length of follow-up and outcome measurement.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of heterogeneity",
                "sec_num": null
            },
            {
                "text": "Where applicable, we also assessed statistical heterogeneity by examining the I 2 statistic and a Chi 2 test, using the guidelines outlined in Higgins 2011 for interpreting the results.According to these guidelines, an I 2 statistic of 0% to 40% may not be important, 30% to 60% may indicate moderate heterogeneity, 50% to 90% may indicate substantial heterogeneity and 75% to 100% may indicate considerable heterogeneity.Therefore, for this review, we considered an I 2 statistic of more than 50% to indicate significant heterogeneity.The I 2 statistic was not applicable in comparisons where there was only a single study or when only one study contributed data to the analysis.When interpreting the Chi 2 test, a P value of less than 0.01 was considered to indicate significant heterogeneity.When we found statistical heterogeneity, we presented both fixed-e ect and random-e ects analyses to enable exploration of di erences.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of heterogeneity",
                "sec_num": null
            },
            {
                "text": "We included studies using the Outcome Reporting Bias in Trials (ORBIT) classification system if we suspected selective outcome reporting bias.We requested all protocols from included study authors to enable comparison of outcomes of interest; however, we received very few responses, complicating our performance of this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of reporting biases",
                "sec_num": null
            },
            {
                "text": "Our comprehensive search of multiple sources and data types, together with our requests for unpublished data or clarification from authors, minimised the risk of publication bias.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of reporting biases",
                "sec_num": null
            },
            {
                "text": "We employed both fixed-e ect and random-e ects meta-analyses to synthesise the data.We presented the primary outcome (major congenital malformations) and the secondary outcome of specific malformations as a risk ratio (RR).Within certain comparisons, we have also presented the risk di erences (RD) for both primary outcome (overall malformation rate).In the event that we deemed meta-analysing inappropriate (e.g.presence of clinical heterogeneity), we applied a narrative form to the review, discussing all comparisons according to the findings presented within the studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "Comparisons carried out included:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "1. specific ASM monotherapy group versus controls on major congenital malformations; 2. specific ASM monotherapy group versus controls on specific major congential malformation types; 3. specific ASM monotherapy group versus specific ASM monotherapy group on major congential malformations; 4. specific ASM monotherapy group versus specific ASM monotherapy group on specific major congential malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "We stratified each comparison by control group, comparator group and study design to ensure appropriate combination of study data.For example, cases reported in a national pregnancy and epilepsy register may also be represented in epidemiological datasets of routine health data which covers the same region or a case in an administrative insurance database may also have been reported to a national epilepsy and pregnancy register and therefore data were not combined across these di erent data sources.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "Subgroup analysis was stratified by ASM and type of control or comparator group.When heterogeneity was present across outcomes, we carried out a random-e ects analysis.We examined di erences between analyses and reported the appropriate analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Subgroup analysis and investigation of heterogeneity",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We adopted a cautious approach to combining data extracted from di erent types of study, and also where di erent comparator groups were included as outlined in Measures of treatment e ect.Additionally, we only included studies where over 70% of the cohort were women taking ASMs for the treatment of epilepsy.This was due to the heterogeneity around doses prescribed, across women taking ASMs for di erent conditions.This decision is supported by the findings of Hernandez Diaz and colleagues (US Medicaid Registers) who found that di erences in the dose of topiramate prescribed for women with epilepsy compared to women prescribed it for other conditions altered the risk of orofacial anomalies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "In this review, we considered ASM use in during pregnancy in women with epilepsy and the major malformation rate in their exposed children (Figure 1 ).Comparisons were made across the di erent ASM treatments and to unexposed children.The outcomes are summarised in Table 1 along with Summary of findings 1, Summary of findings 2 for lamotrigine and levetiracetam and in Table 2 , Table 3 , Table 4 , and Table 5 for carbamazepine, oxcarbazepine, topiramate and valproate, respectively.The data for other ASMs were too limited at this time for useful tables to be compiled.Relative risks and risk di erences are displayed in Table 6 ",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 147,
                        "end": 148,
                        "text": "1",
                        "ref_id": "FIGREF1"
                    },
                    {
                        "start": 271,
                        "end": 272,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 376,
                        "end": 377,
                        "text": "2",
                        "ref_id": null
                    },
                    {
                        "start": 386,
                        "end": 387,
                        "text": "3",
                        "ref_id": "TABREF571"
                    },
                    {
                        "start": 396,
                        "end": 397,
                        "text": "4",
                        "ref_id": null
                    },
                    {
                        "start": 410,
                        "end": 411,
                        "text": "5",
                        "ref_id": "TABREF573"
                    },
                    {
                        "start": 630,
                        "end": 631,
                        "text": "6",
                        "ref_id": "TABREF574"
                    }
                ],
                "eq_spans": [],
                "section": "Summary of findings and assessment of the certainty of the evidence",
                "sec_num": null
            },
            {
                "text": "The Robins-I was adapted for use here to understand the risk of biases but is not yet optimised for pregnancy pharmacovigilance work and, therefore, caution is required in the interpretation of its ratings.It did, however, show that di erent methodological approaches have di erent patterns of biases and are therefore in part complimentary (Figure 2 ).Cohort studies with primary data collection, for example, tend to have lower risks of misclassification of treatment and standardised review of the congenital malformation outcome in the children (leading to low risk of bias ratings), yet they are at higher risk of bias for cohort selection.The use of routine health record data at a national population level does not have these selection risks, however.Stratification of the results by study type provides an internal validation for the results (Figure 3 ) and the evidence presented in this review should be considered more certain when the results of di erent comparisons are consistent across study types.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 349,
                        "end": 350,
                        "text": "2",
                        "ref_id": null
                    },
                    {
                        "start": 859,
                        "end": 860,
                        "text": "3",
                        "ref_id": "FIGREF0"
                    }
                ],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews Malformations are rare outcomes and therefore larger groups are needed to reliably detect a higher risk of malformation in one group over another.Therefore, the certainty of the evidence is greater for medications such as VPA, carbamazepine (CBZ) and lamotrigine (LTG) where the numbers of children are higher within and across the comparisons.The available data were more moderate for levetiracetam (LEV), phenytoin (PHT) and phenobarbital (PB) in certain comparisons.Care should be taken in the interpretation of comparisons where there were fewer than 1000 pregnancies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In this updated review, electronic searches identified 1067 additional publications; this was in addition to the 11,695 records previously detected in searches for an earlier version of this review (Weston 2016 ).We found two additional records through handsearching.Following the removal of duplicates, 12,296 abstracts were screened for inclusion in the review across the original and this update.We excluded 12,013 abstracts due to irrelevance, leaving 283 full texts (156 new for this update) to be assessed for eligibility.As the inclusion criteria had been extended to include studies using routine health records in this update, we re-evaluated search results from the last version for such studies and identified eight additional studies (14 papers).In total, we excluded 155 full-text papers where they did not meet the inclusion criteria.See Characteristics of excluded studies and Figure 1 for the study flow diagram.We ultimately included 49 studies (128 publications) in this review.Of these, 113 records and 45 studies contributed data to the meta-analyses, two studies had certain data included in the meta-analysis whilst other data were narratively reviewed.",
                "cite_spans": [
                    {
                        "start": 198,
                        "end": 210,
                        "text": "(Weston 2016",
                        "ref_id": null
                    }
                ],
                "ref_spans": [
                    {
                        "start": 899,
                        "end": 900,
                        "text": "1",
                        "ref_id": "FIGREF1"
                    }
                ],
                "eq_spans": [],
                "section": "Results of the search",
                "sec_num": null
            },
            {
                "text": "A total of 128 included full-text publications reported on the 49 independent studies included in this review, of which all but one were non-randomised studies.The high number of publications per study were from longitudinal research initiatives such as epilepsy and pregnancy registers which update their results periodically.These full texts were related to an included study, as they presented information on the same cohort of children but either at a di erent time point or on a related, but not included, outcome (i.e.obstetric or neurodevelopmental outcome).Reported outcomes for each ASM were taken from the most relevant publication within a series; therefore, malformation information for specific ASMs may come from di erent publications within a series.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Included studies",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We excluded 42 studies (55 papers) from the review (Excluded studies).Several of these papers were not written in the English language and, therefore, were sent for translation and data extraction in order to determine the study design and methodology used.The most frequent reasons for exclusion, however, were absence of reported ASM monotherapy-specific malformation outcomes, retrospective study design, and case-control study design.Studies were also excluded where the maternal indication was not epilepsy in 70% or more of participants, or if a subgroup analysis was not provided for women with epilepsy indication.These decisions were made to limit the likely heterogeneity regarding doses of ASMs used across indications, as dose is a significant driver of higher malformation risk (Brent 2004 ).",
                "cite_spans": [
                    {
                        "start": 791,
                        "end": 802,
                        "text": "(Brent 2004",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Excluded studies",
                "sec_num": null
            },
            {
                "text": "Robins-I ratings are displayed in Figure 2 .",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 41,
                        "end": 42,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "For bias in confounding, no studies were rated as low as no studies were comparable to a randomised controlled trial.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias in confounding",
                "sec_num": null
            },
            {
                "text": "For bias in selection, three studies were rated as low (Denmark Health Record Registers, Finland Health Record Registers, Norwegian Health Record Registers) as they represented national datasets and one study was rated as moderate (Sweden Health Record Registers).All cohort or pregnancy register studies were at risk of selection biases and therefore 37 studies were rated as serious ( ",
                "cite_spans": [
                    {
                        "start": 385,
                        "end": 386,
                        "text": "(",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias in selection",
                "sec_num": null
            },
            {
                "text": "For bias in classification, 14 studies were rated as low ( ",
                "cite_spans": [
                    {
                        "start": 57,
                        "end": 58,
                        "text": "(",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias in classification",
                "sec_num": null
            },
            {
                "text": "This domain was di icult to assess as, for most of the studies, no protocol was available (particularly for older studies) or contact with the authors could not be established ( ",
                "cite_spans": [
                    {
                        "start": 176,
                        "end": 177,
                        "text": "(",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias in reporting",
                "sec_num": null
            },
            {
                "text": "See: Summary of findings 1 Summary of findings -Lamotrigine; Summary of findings 2 Summary of findings -Levetiracetam Each included comparison is reviewed below with both the meta-analysis results being reported alongside any studies which required narrative review only.In comparisons where there were less than 50 children in both groups, the meta-analysis is not reported, but the data is summarised narratively.Summary tables displaying the pooled prevalences, RR and RDs for each comparison are available in Table 1 along with Summary of findings 1 for lamotrigine; Summary of findings 2 for levetiracetam, Table 2 for carbamazepine, Table 3 for oxcarbazepine, Table 4 for topiramate, and Table 5 for valproate.A complete summary of all included ASM pooled prevalences, RR and RDs can be found in Table 1 , Table 6 , and Table 7 , respectively with a visual presentation of the major malformation rates displayed in Figure 3 .",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 519,
                        "end": 520,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 618,
                        "end": 619,
                        "text": "2",
                        "ref_id": null
                    },
                    {
                        "start": 645,
                        "end": 646,
                        "text": "3",
                        "ref_id": "TABREF571"
                    },
                    {
                        "start": 672,
                        "end": 673,
                        "text": "4",
                        "ref_id": null
                    },
                    {
                        "start": 700,
                        "end": 701,
                        "text": "5",
                        "ref_id": "TABREF573"
                    },
                    {
                        "start": 808,
                        "end": 809,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 818,
                        "end": 819,
                        "text": "6",
                        "ref_id": "TABREF574"
                    },
                    {
                        "start": 832,
                        "end": 833,
                        "text": "7",
                        "ref_id": "TABREF577"
                    },
                    {
                        "start": 928,
                        "end": 929,
                        "text": "3",
                        "ref_id": "FIGREF0"
                    }
                ],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in the cohort studies for children of women without epilepsy (N = 3537), based on data from 12 studies, was 2.1% (95% CI 1.5 to 3.0).The prevalence of major malformations in routine health record studies for children of women without epilepsy (N = 373,028), based on data from three studies, was 3.3% (95% CI 1.5 to 7.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Women without epilepsy",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in the cohort studies for children of women with epilepsy (no medication) (N = 1708), based on data from 21 studies, was 3.0% (95% CI 2.1 to 4.2).The prevalence of major malformations in routine health record studies for children of women with epilepsy (no medication) (N = 11,286), based on data from three studies, was 3.2% (95% CI 1.7 to 6.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Women with epilepsy (no medication)",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in the cohort studies for children exposed to carbamazepine (CBZ) (N = 5415), based on data from 37 studies, was 4.7% (95% CI 3.7 to 5.9).The prevalence of major malformations in routine health record studies for children exposed to CBZ (N = 2806), based on data from five studies, was 4.0% (95% CI 2.9 to 5.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine",
                "sec_num": null
            },
            {
                "text": "1.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus controls",
                "sec_num": "1"
            },
            {
                "text": "Pooled results from 13 cohort studies suggested an increased risk with CBZ (RR 2.30, 95% CI 1.47 to 3.59; I 2 = 0%), with children exposed to CBZ (N = 1448) experiencing more major malformations than control children (N = 3599) (Analysis 1.1).The RD also suggested a higher absolute risk (RD 0.02, 95% CI 0.01 to 0.03; I 2 = 0%) (Analysis 1.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "1.1.1"
            },
            {
                "text": "The multicentre study, Samren 1997, reported 22 (8%) cases of major malformations from 280 infants exposed to CBZ.However, the numbers from centres with a control group were smaller, with four cases of malformation out of just 14 exposed infants.This suggested an increased risk relative to the control children born to women without epilepsy (RR 4.9, 95% CI 1.3 to 18.0).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "1.1.1"
            },
            {
                "text": "Pooled findings from 20 cohort studies suggested an increased risk with CBZ (RR 1.44, 95% CI 1.05 to 1.96; I 2 = 0%), with children exposed to CBZ (N = 3598) experiencing more major malformations than control children (N = 1691) (Analysis 1.1).The RD also suggested an increased risk with CBZ (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 1%) (Analysis 1.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.1.2"
            },
            {
                "text": "Results from two routine health record studies suggested no evidence of a di erence in risk (RR 1.14 95% CI 0.80 to 1.64; I 2 = 0%), with children exposed to CBZ (N = 983) experiencing a similar major malformation rate to control children (N = 372,111) (Analysis 1.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "1.1.3"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%) (Analysis 1.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "1.1.3"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from four routine health record studies suggested an increased risk with CBZ (RR 1.42 95% CI 1.10 to 1.83; I 2 = 0%), with children exposed to CBZ (N = 2116) experiencing more major malformations than control children (N = 12,218) (Analysis 1.1).The RD suggested an increased level of risk for CBZ (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 0%) (Analysis 1.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "1.1.4"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 3.09, 95% CI 0.38 to 25.40;I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 269) and compared to control children (N = 1801) (Analysis 1.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%) (Analysis 1.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Neural tube malformations 1.2.1 CBZ versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "1.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested a comparable level of risk (RR 2.54, 95% CI 0.63 to 10.20; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 1194) and in control children (N = 679) (Analysis 1.2).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.02; I 2 = 0%) (Analysis 1.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.2.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "1.2.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "1.2.4"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 1.46, 95% CI 0.43 to 4.99; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to CBZ (N = 269) and in control children (N = 1801) (Analysis 1.3).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%) (Analysis 1.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "1.3.1"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested no evidence of a di erence in risk (RR 0.87, 95% CI 0.41 to 1.84; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to CBZ (N = 1212) and control children (N = 691) (Analysis 1.3).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%) (Analysis 1.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.3.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "1.3.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "1.3.4"
            },
            {
                "text": "Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 9.04, 95% CI 2.16 to 37.87; I 2 = 10%), with children exposed to CBZ (N = 269) experiencing more oro-facial cle /craniofacial malformations than control children (N = 1801) (Analysis 1.4).The RD suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%) (Analysis 1.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oro-facial cle /craniofacial malformations 1.4.1 CBZ versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "1.4"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 0.99, 95% CI 0.27 to 3.62; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to CBZ (N = 709) and control children (N = 347) (Analysis 1.4).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%) (Analysis 1.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.4.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "1.4.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "1.4.4"
            },
            {
                "text": "1.5 Skeletal/limb malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "1.4.4"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 5.13, 95% CI 0.52 to 50.67,I 2 = 0%), with no di erence in skeletal/limb malformations in children exposed to CBZ (N = 269) and control children (N = 1801) (Analysis 1.5).The RD also suggested a comparable level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%) (Analysis 1.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.5.1"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 0.96, 95% CI 0.35 to 2.82; I 2 = 0%), with no di erence in the number of skeletal and limb malformations in children exposed to CBZ (N = 1194) and control children (N = 679) (Analysis 1.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%) (Analysis 1.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "1.5.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The EURAP 2018 collaboration has reported on the largest uniformly assessed group of children exposed to CBZ (N = 1957).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine dose",
                "sec_num": null
            },
            {
                "text": "They reported a higher malformation rate with higher doses of CBZ.Doses =/< 700 mg/d were found to have a malformation risk of 4.5% (95% CI 3.5% to 5.8%), whilst dose > 700 mg/d were associated with a prevalence of 7.2%, (95% CI 5.4 to 9.4); a di erence which suggested a dose association (OR 1.56, 95% CI 1.03 to 2.37, P = 0.0352).When compared to children exposed to =/< 325 mg/d of LTG, the prevalence was higher for doses =/< 700 mg/d (OR 1.71 95% CI 1.12 to 2.61, P = 0.0143), and doses over 700 mg/d were also higher (OR 2.68, 95% CI 1.71 to 4.19, P = 0.0002).In contrast, however, the North American Epilepsy and Pregnancy Register (N = 1033) failed to document an association between the risk of major malformation and the dose of CBZ; however, this group was smaller.The Australian Epilepsy and Pregnancy Register, the UK and Ireland Epilepsy and Pregnancy Register, and a number of smaller studies also did not identify a dose e ect (Kaaja 2003; Kaneko 1999; Milan Study 1999; Motherisk Registry; Samren 1997).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine dose",
                "sec_num": null
            },
            {
                "text": "Data regarding the impact of dose are limited from routine healthcare record-based studies.Data analyses from Finland Health Record Registers did not establish a dose relationship, however, the number of carbamazepine monotherapy cases was small (N = 32).Results from the Norwegian Health Record Registers and Sweden Health Record Registers did not capture ASM doses, and researchers using the UK Health Record THIN Register or the UK Clinical Research Practice Database were not able to access dose information.Dose data have not currently been provided by the Denmark Health Record Registers for CBZ dose.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to clonazepam (CZP) (N = 95), based on data from four studies, was 2.1% (95% CI 0.2 to 17.3).The prevalence of major malformations in routine health record studies for children exposed to CZP (N = 161), based on data from one study, was 2.5% (95% CI 0.0 to 131.8).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "All major malformations",
                "sec_num": "2.1"
            },
            {
                "text": "Pooled results from two cohort studies suggested no evidence of a di erence in risk (RR 2.76, 95% CI 0.55 to 13.94;I 2 = 0%), with children exposed to CZP (N = 65) experiencing comparable rates of major malformations to control children (N = 504) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "2.1.1"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.03 to 0.07; I 2 = 0%) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "2.1.1"
            },
            {
                "text": "Pooled findings from three cohort studies suggested no evidence of a di erence in risk (RR 1.08, 95% CI 0.21 to 5.42; I 2 = 0%), with children exposed to CZP (N = 31) experiencing comparable rates of major malformations to control children (N = 524) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "2.1.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.11 to 0.04; I 2 = 0%) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "2.1.2"
            },
            {
                "text": "One study suggested no evidence of a di erence in risk (RR 0.70, 95% CI 0.18 to 2.77; I 2 = NA (not available)) with children exposed to CZP (N = 113) experiencing comparable rates of major malformations to control children (N = 369,267).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = NA) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "2.1.3"
            },
            {
                "text": "One study suggested no evidence of a di erence in risk (RR 0.69, 95% CI 0.17 to 2.79; I 2 = NA) with children exposed to CZP (N = 113) experiencing comparable rates of major malformations to control children (N = 1900).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = NA) (Analysis 2.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "2.1.4"
            },
            {
                "text": "Specific malformation types were not reviewed due to the small amount of data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "2.1.4"
            },
            {
                "text": "There is too little experience with CZP in pregnancy to be able to report on the potential of an association between the dose of CZP and MCM risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP Dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to gabapentin (GBP) (N = 192) based on data from four studies was 2.0% (95% CI 0.1 to 32.2).The prevalence of major malformations in routine health record studies for children exposed to GBP (N = 18), was based on data from one study and therefore could not be calculated.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin",
                "sec_num": null
            },
            {
                "text": "Pooled results from two cohort studies suggested no evidence of a di erence in risk of major malformations for the children exposed to gabapentin (N = 147) in comparison to children born to women without epilepsy (N = 570) (RR 1.78, 95% CI 0.50 to -6.29, P = 0.37, I 2 = 89%), but there was heterogeneity in the results (Analysis 3.1).A random-e ects RR was calculated which also suggested a comparable level of risk (RR 8.04, 95% CI 0.03 to 1898.73,P = 0.45, I 2 = 89%).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.03; I 2 = 75%).Due to heterogeneity, a random-e ects RD was calculated which also found a comparable level of risk (RD 0.19, 95% CI -0.37 to 0.74, P = 0.51, I 2 = 75%) (Analysis 3.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "3.1.1"
            },
            {
                "text": "Pooled results from two cohort studies suggested no evidence of a di erence in risk of major malformation for the children exposed to gabapentin (n=47) in comparison to control children (n= 721) (RR 1.77, 95% CI 0.46 to 6.90, P = 0.41, I 2 = 0% (Analysis 3.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "3.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "There were no studies that provided data for this comparison in a format that could be combined in a meta-analysis.However, Patorno and colleagues (US Medicaid Registers) conducted a sensitivity analysis that was restricted to epilepsy indications and included 347 pregnancies exposed to gabapentin in comparison to an unexposed reference group of 11,861 pregnancies.There was no reported di erence in the malformation outcome either in the epilepsy subgroup (RR 1.40, 95% CI 0.73 to 2.71, P = 0.31) or in the main analysis which included 3745 gabapentin-exposed children (RR 1.07, 95% CI 0.94 to 1.21, P = 0.33).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "3.1.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "3.1.4"
            },
            {
                "text": "We were unable to estimate a RR for the included study due to there being no reported neural tube malformations in children exposed to GBP (N = 2) or control children (N = 128) (Analysis 3.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "3.2.1"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "3.2.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "3.2.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "3.2.4"
            },
            {
                "text": "Data from one study suggested a di erence in risk (RR 129.00, 95% CI 6.49 to 2562.48,I 2 = NA) with children exposed to GBP (N = 2) being at higher risk than control children (N = 128) (Analysis 3.3).However, the RD suggested no di erence in the level of risk (RD 0.50, 95% CI -0.07 to 1.07; I 2 = NA)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "3.3.1"
            },
            {
                "text": "Included studies did not reach the threshold for reporting in the meta-analysis (Analysis 3.3).However, available data showed that there was one case of cardiac malformation in children exposed to GBP (N = 2) in comparison to zero cases in the control children (N = 4), based on data from one study (Miskov 2016).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "3.3.2"
            },
            {
                "text": "Patorno and colleagues, using data including the US Medicaid Registers, found a comparable level of risk for cardiac anomalies in children exposed to gabapentin (N = 347) versus children born to women without epilepsy (N = 11,861) (RR 1.40, 95% CI 0.73 to 2.71, P = 0.31).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "3.3.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "3.3.4"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no oro-facial cle / craniofacial malformations in children exposed to GBP (n=2) in comparison to no cases in 128 control children (Analysis 3.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "3.4.1"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "3.4.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "3.4.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "3.4.4"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (n=2) or 128 control children, based on data from one study (Analysis 3.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "3.5.1"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "3.5.2"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "3.5.3"
            },
            {
                "text": "There were no studies that provided data for this comparison.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GBP versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "3.5.4"
            },
            {
                "text": "The investigation of GBP dose and its potential association with an increased rate of malformations is limited due to the relatively small number of pregnancies where data are currently available.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin dose",
                "sec_num": null
            },
            {
                "text": "The US Medicaid Registers is the most reliable data source currently available.The study authors did not find that malformation risk increased with dose according to tertiles of the first and the highest prescribed daily dose filled.Doses of 600 mg/d through to 900 mg/d (RR 1.00, 95% CI 0.80 to 1.24, P = 0.98) or doses above 900 mg/d (RR 1.17, 95% CI 0.95 to 1.44, P = 0.15) were not associated with a risk above the baseline risk.The largest cohort study of GBP-exposed pregnancies was from the North American Epilepsy and Pregnancy Register (N = 145) and no association between increasing dose and increased malformation risk was identified in this study.The participant numbers in other included studies of GBP were too small to investigate any e ect of dose size and MCM risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin dose",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to levetiracetam (LEV) (N = 1242), based on data from 11 studies, was 2.6% (95% CI 1.6 to 4.4).The prevalence of major malformations in routine health record studies for children exposed to LEV (N = 248), based on data from two studies, was 2.8% (95% CI 0.0 to 321.9).Pooled results from four cohort studies suggested no evidence of a di erence in risk (RR 2.20, 95% CI 0.98 to 4.93; I 2 = 0%), with children exposed to LEV (N = 574) experiencing comparable rates of major malformations to control children (N = 1022) (Analysis 4.1).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Levetiracetam",
                "sec_num": null
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.71, 95% CI 0.39 to 1.28; I 2 = 0%), with children exposed to LEV (N = 724) experiencing comparable rates of major malformations to control children (N = 1101) (Analysis 4.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "4.1.2"
            },
            {
                "text": "One study suggested no evidence of a di erence in risk (RR 0.67, 95% CI 0.17 to 2.66; I 2 = NA) for children exposed to LEV (N = 118) experiencing comparable rates of major malformations to control children (N = 369,267).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "4.1.3"
            },
            {
                "text": "Pooled results from two routine health record studies suggested no evidence of a di erence in risk (RR 0.82, 95% CI 0.39 to 1.71; I 2 = 0%), with children exposed to LEV (N = 248) experiencing comparable rates of major malformations to control children (N = 10,377) (Analysis 4.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "4.1.4"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported cases of neural tube malformation in children exposed to LEV (N = 105) or control children (N = 383) (Analysis 4.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "4.2.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no skeletal / limb malformations in children exposed to LEV (N = 105) or control children (N = 383) (Analysis 4.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "4.5.1"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 3.21, 95% CI 0.46 to 22.50; I 2 = NA), with children exposed to LEV (N = 272) experiencing comparable rates of skeletal/limb malformations to control children (N = 376) (Analysis 4.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "4.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "4.5.3"
            },
            {
                "text": "No included studies reported data for this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "4.5.4"
            },
            {
                "text": "EURAP 2018 had the largest cohort of LEV-exposed children to conduct dose investigations in 599 exposed children.Whilst they did not make comparisons between di erent levels of LEV dose directly, they did report that there was evidence of lower risk of any LEV dose (250-4000 mg/d) in comparison to doses of VPA </= 650 mg/d and dose of CBZ > 700 mg/d, whilst there was no evidence of di erence in comparison to doses of LTG either at </= 325 mg/d or > 325 mg/d, or in comparison to OXC at doses ranging from 75-4500 mg/d.Additionally, the North American Epilepsy and Pregnancy Register reporting on LEV-exposed children (N = 450), the UK and Ireland Epilepsy and Pregnancy Register (N = 304), the Australian Epilepsy and Pregnancy Register (N = 139), the Kerala Epilepsy and Pregnancy Registry (N = 106) and the MONEAD 2020 study (N = 99) also failed to find an association between increasing doses of LEV and congenital anomaly risk; however, group sizes may still be too limited at higher dose levels to detect increased levels of MCM risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Levetiracetam dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to lamotrigine (LTG) (N = 4704), based on data from 15 studies, was 2.7% (95% CI 1.9 to 3.8).The prevalence of major malformations in routine health record studies for children exposed to LTG (N = 2502), based on data from four studies, was 3.5% (95% CI 2.5 to 4.9).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine",
                "sec_num": null
            },
            {
                "text": "Pooled results from seven studies suggested an increased risk with LTG (RR 1.97, 95% CI 1.16 to 3.39; I 2 = 0%), with children exposed to LTG (N = 1899) experiencing more major malformations to control children (N = 2693) (Analysis 5.1).The RD also suggested a higher risk (RD 0.01, 95% CI 0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "5.1.1"
            },
            {
                "text": "Pooled results from eight studies suggested no evidence of a di erence in risk (RR 1.04, 95% CI 0.66 to 1.63; I 2 = 0%), with children exposed to LTG (N = 2767) experiencing comparable rates of major malformations to control children (N = 1151) (Analysis 5.1).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "5.1.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 1.19, 95% CI 0.86 to 1.64; I 2 = 18%), with children exposed to LTG (N = 1177) experiencing comparable rates of major malformations to control children (N = 372,111) (Analysis 5.1).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.02; I 2 = 22%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "5.1.3"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 1.00, 95% CI 0.79 to 1.28; I 2 = 0%), with children exposed to LTG (N = 2166) experiencing comparable rates of major malformations to control children (N = 11,279) (Analysis 5.1).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "5.1.4"
            },
            {
                "text": "Pooled results from five studies suggested an increased risk with LTG (RR 7.55, 95% CI 1.05 to 54.09;I 2 = 0%), with children exposed to LTG (N = 313) experiencing more major malformations to control children (N = 1654) (Analysis 5.2).However, the RD suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women without epilepsy)",
                "sec_num": "5.2.1"
            },
            {
                "text": "We were unable to estimate a RR from five studies, as there were no reported neural tube malformations in children exposed to LTG (N = 521) or control children (N = 563) (Analysis 5.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women with epilepsy)",
                "sec_num": "5.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "5.2.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "5.2.4"
            },
            {
                "text": "Pooled results from six studies suggested an increased risk with LTG (RR 2.71, 95% CI 1.05 to 6.98; I 2 = 0%), with children exposed to LTG (N = 348) experiencing more major malformations to control children (N = 1658) (Analysis 5.3).However, the RD suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "5.3.1"
            },
            {
                "text": "The EURAP 2018 collaboration has reported on a large, uniformly assessed, group of children exposed to LTG (N = 2514).It reported a higher MCM rate with higher doses of LTG.Doses =/< 325 mg/d were found to have an MCM risk of 2.5% (95% CI 1.8% to 3.3%), whilst doses > 325 mg/d were associated with MCM in 4.3% of children (95% CI 2.9% to 6.2%); a di erence which suggested a dose association (OR 1.68, 95% CI 1.01 to 2.80, P = 0.0463).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine dose",
                "sec_num": null
            },
            {
                "text": "When EURAP 2018 compared lower dose LTG (=/< 325 mg/d) to other monotherapy ASMs, they found evidence suggesting a lower MCM risk in comparison to CBZ at =/< 700 mg/d (OR 1.71 95% CI 1.12 to 2.61, P = 0.0143) and lower risk than CBZ doses > 700 mg/d (OR 2.68, 95% CI 1.71 to 4.19, P = 0.0002).In comparison to LEV, there was no evidence of a di erence between lower doses of LTG (</= 325 mg/d) and LEV doses between =/> 250-4000 mg/d (OR 1.11, 95% CI 0.62 to 2.00, P = 0.7282).Comparisons to VPA demonstrated lower MCM risks for lower LTG dose (=/< 325 mg/d) in comparison to VPA doses at =/< 650 mg/d (OR 2.70, 95% CI 1.67 to 4.38, P = 0.0002), > 650 mg/d to =/< 1450 mg/d (OR 4.72, 95% CI 3.11 to 7.18, P < 0.0002), or at doses of VPA > 1450 mg/d (OR 13.52, 95% CI 7.73 to 23.64, P = 0.0002).Exposure to LTG at a dose =/< 325 mg daily was associated with a lower MCM risk than PB exposure at doses of between > 80 and =/< 130 mg/d (OR 2.46, 95% CI 1.16 to 5.23, P = 0.0196) and at PB doses > 130 mg/d (OR 5.81, 95% CI 2.40 to 14.08, P = 0.0002).There was, however, no evidence of a di erence in comparison of LTG doses =/< 325 mg/d to the lowest investigated PB dose of =/ < 80 mg/d (OR 1.07, 95% CI 0.25 to 4.60, P = 0.923).Rates of PHT, TPM, and OXC-exposed pregnancies were lower in the EURAP study which should be considered with regard to findings suggesting that there is no dose association here.In comparison to lower dose LTG (=/< 325 mg/d), there was no evidence of di erence for PHT doses between =/30 mg/d and 730 mg/d (OR 1.93, 95% CI 0.78 to 4.75, P = 0.1554) or TPM doses =/> 25 mg/d to 500 mg/d (OR 1.67, 95% CI 0.69 to 4.04, P = 0.2524) or OXC doses between =/> 75 to 4500 mg/d (OR 1.13, 95% CI 0.55 to 2.31, P = 0.7358).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine dose",
                "sec_num": null
            },
            {
                "text": "The EURAP 2018 collaboration also compared higher doses of LTG (> 325 mg/d) and found a comparable level of risk to higher doses of CBZ (> 700 mg/d, OR 0.63, 95% CI 0.38 to 1.05, P = 0.0766), to LEV doses between =/> 250-4000 mg/d (OR 1.51, 95% CI 0.79 to 2.88, P = 0.2077) and to OXC doses between 75-4500 mg/d (OR 1.49, 95% CI 0.70 to 3.17, P = 0.3051).Higher doses of LTG (> 325 mg/ d) were not associated with lower rates of MCM compared to the",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine dose",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews lowest investigated dose range for VPA (=/< 650 mg/d, OR 0.62, 95% CI 0.36 to 1.09, P = 0.0959) but there was evidence suggesting higher doses of LTG were associated with a lower MCM risk than VPA doses between > 650 to =/< 1450 mg/d (OR 2.81, 95% 1.70 to 4.65, P = 0.0002).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In contrast to the data from EURAP, the UK and Ireland Epilepsy and Pregnancy Register (N = 2198) found no evidence of risk with increasing doses of LTG (0 to 200 mg/d vs 200 to 400 mg/d; 0 to 200 mg/d vs > 400 mg/d).The North American Epilepsy and Pregnancy Register (N = 1562), the Australian Epilepsy and Pregnancy Register (N = 406), and the Israeli Teratogen Service (N = 114) studies did not identify dose-related risks associated with LTG.The frequency of MCM was too low in other included studies to allow reliable investigation of dose.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to oxcarbazepine (OXC) (N = 378), based on data from 11 studies, was 2.8% (95% CI 1.1 to 6.6).The prevalence of major malformations in routine health record studies for children exposed to OXC (N = 507), based on data from four studies, was 4.8% (95% CI 0.7 to 31.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine",
                "sec_num": null
            },
            {
                "text": "6.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus controls",
                "sec_num": "6"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 2.20, 95% CI 0.67 to 7.27; I 2 = 18%), with children exposed to OXC (N = 184) experiencing comparable rates of major malformations to control children (N = 767) (Analysis 6.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "6.1.1"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "6.1.1"
            },
            {
                "text": "Pooled results from six studies suggested no evidence of a di erence in risk (RR 1.40, 95% CI 0.68 to 2.91; I 2 = 23%), with children exposed to OXC (N = 134) experiencing comparable rates of major malformations to control children (N = 788) (Analysis 6.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "6.1.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.03 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "6.1.2"
            },
            {
                "text": "Results from one study found no evidence of a di erence in risk (RR 0.70, 95% CI 0.10 to 4.86; I 2 = N/A), with children exposed to OXC (N = 57) experiencing comparable rates of major malformations to control children (N = 369,267) (Analysis 6.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.04 to 0.03; I 2 = N/A).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "6.1.3"
            },
            {
                "text": "Pooled results from three studies suggested an increased risk with OXC (RR 1.75, 95% CI 1.22 to 2.52; I 2 = 94%), with children exposed to OXC (N = 503) experiencing higher rates of major malformations than control children (N = 11,316) (Analysis 6.1).Due to high heterogeneity, a random-e ects RR was calculated and found no evidence of a di erence in risk (RR 1.61, 95% CI 0.26 to 9.86; I 2 = 94%).The RD suggested a higher risk for OXC (RD 0.03, 95% CI 0.01 to 0.05; I 2 = 94%); however, a random-e ects RD due to heterogeneity found no di erence in the level of risk (RD 0.04, 95% CI -0.05 to 0.12; I 2 = 94%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "6.1.4"
            },
            {
                "text": "No included studies reported data for this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "6.2.1"
            },
            {
                "text": "We were unable to estimate a RR from the two included studies due to there being no reported neural tube malformations in children exposed to OXC (N = 102) or control children (N = 361) (Analysis 6.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "6.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "OXC versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "6.2.2"
            },
            {
                "text": "The limited published experience of OXC in pregnancy limits dose comparisons, even in the EURAP 2018 study for di erent doses of OXC (N = 333).In EURAP 2018, there was no evidence that doses of OXC between =/> 75 to 4500 mg/d were di erent from those for lower dose LTG (=/< 325 mg/d) (OR 1.13, 95% CI 0.55 to 2.31, P = 0.7282) or dose of LTG > 325 mg/d (OR 1.49, 95% CI 0.70 to 3.17, P = 0.3051).Similarly, a lack of di erence was also found in comparison to any dose of LEV exposure (OR 1.02, 95% CI 0.45 to 2.30, P = 0.9644).A lower prevalence of MCM was found for any dose of OXC (3.0%, 95% CI 1.4 to 5.4) in comparison to low dose VPA (=/< 650 mg/ d, 6.3%, 95% CI 4.5 to 8.6) (OR 2.39, 95% CI 1.13 to 5.08, P = 0.0235), but was not reported for any higher-dose VPA.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine dose",
                "sec_num": null
            },
            {
                "text": "Other studies were limited to the number of OXC-exposed pregnancies or had not published dose data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to phenobarbital (PB) (N = 840), based on data from 26 studies, was 6.3% (95% CI 4.8 to 8.3).The prevalence of major malformations in routine health record studies for children exposed to PB (N = 34), based on data from two studies, was 8.8% (95% CI 0.0 to 9722.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital",
                "sec_num": null
            },
            {
                "text": "7.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus controls",
                "sec_num": "7"
            },
            {
                "text": "Pooled results from eight studies suggested an increased risk with PB (RR 3.22, 95% CI 1.84 to 5.65; I 2 = 0%), with children exposed to PB (N = 353) experiencing more major malformations than control children (N = 2042) (Analysis 7.1).The RD also suggested a higher risk for PB (RD 0.04, 95% CI 0.01 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "7.1.1"
            },
            {
                "text": "Samren 1997 reported five cases of major malformation out of 48 exposed infants (10%).Numbers were more limited in the comparison to control children (as not all centres in the study included control children), with just one malformation case out of six PB-exposed children; analysis suggested no evidence of a di erence between the groups (RR 2.4, 95% CI 0.3 to 23.0).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "7.1.1"
            },
            {
                "text": "Pooled results from 13 studies suggested no evidence of a di erence in risk (RR 1.64, 95% CI 0.94 to 2.83; I 2 = 0%), with no di erence in the number of major malformations in children exposed to PB (N = 438) and control children (N = 999) (Analysis 7.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.1.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.01 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.1.2"
            },
            {
                "text": "The results from one study suggested no evidence of a di erence in risk (RR 2.94, 95% CI 0.77 to 11.15;I 2 = NA), with children exposed to PB (N = 27) experiencing comparable rates of major malformations to control children (N = 369,267) (Analysis 7.1).The RD also suggested no di erence in the level of risk (RD 0.05, 95% CI -0.05 to 0.15; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "7.1.3"
            },
            {
                "text": "The results from one study suggested no evidence of a di erence in risk (RR 2.87, 95% CI 0.74 to 11.21;I 2 = NA), with children exposed to PB (N = 27) experiencing comparable rates of major malformations to control children (N = 1900) (Analysis 7.1).The RD also suggested no di erence in the level of risk (RD 0.05, 95% CI -0.05 to 0.15; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "7.1.4"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no neural tube malformations in children exposed to PB (N = 7) or control children (N = 244) (Analysis 7.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "7.2.1"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 3.85, 95% CI 0.47 to 31.26,I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to PB (N = 146) and control children (N = 512) (Analysis 7.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.2.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.2.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 7.80, 95% CI 0.36 to 168.52,I 2 = NA) with no di erence in the number of skeletal/limb malformations in children exposed to PB (N = 7) in comparison to control children (N=244).(Analysis 7.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.27 to 0.26; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.2.2"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 3.01, 95% CI 0.56 to 16.07;I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to PB (N = 146) and control children (N = 512) (Analysis 7.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.5.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "7.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "7.5.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PB versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "7.5.4"
            },
            {
                "text": "Despite data being reported in 26 studies, most studies did not investigate dose or report the results of analyses of PB dose with regard to MCM risk or were too limited in terms of the number of included pregnancies.EURAP 2018 included 294 PB monotherapy-exposed cases which is the largest cohort.They found that increasing PB dose was associated with an increasing prevalence of MCM risk.Doses =/< 80 mg/d had a prevalence of 2.7% (95% CI 0.3 to 9.5), doses > 80 to =/< 130 mg/d had a prevalence of 6.2% (95%CI 3.0 to 11. Kaneko 1999 did find an association between PB exposure (N = 79) and increased malformation rate.Other studies were too small or did not investigate an association between PB dose and MCM risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to phenytoin (PHT) (N = 1327), based on data",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenytoin",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews from 26 studies, was 5.4% (95% CI 3.6 to 8.1).The prevalence of major malformations in routine health record studies for children exposed to PHT (N = 103), based on data from one study, was 6.8% (95% CI 0.1 to 91.3).Samren 1997 reported nine cases of major malformation in 141 (6%) PHT-exposed children.Outcomes at centres with a control group in this study were limited to five cases from 33 exposed children, which gave a non-significant di erence (RR 2.2, 95% CI 0.7 to 6.7).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from 15 studies suggested an increased risk with PHT (RR 2.01, 95% CI 1.29 to 3.12; I 2 = 0%), with children exposed to PHT (N = 750) experiencing more major malformations than control children (N = 1588) (Analysis 8.1).The RD also suggested a higher risk for PHT (RD 0.03, 95% CI 0.01 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "8.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "8.1.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "8.1.4"
            },
            {
                "text": "Pooled results from four studies suggested no evidence of a di erence in risk (RR 13.17, 95% CI 0.58 to 299.00,I 2 = NA) with no di erence in the number of neural tube malformations in children exposed to PHT (N = 48) and control children (N = 590) (Analysis 8.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "8.2.1"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.06 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "8.2.1"
            },
            {
                "text": "Pooled results from six studies suggested no evidence of a di erence in risk (RR 2.56, 95% CI 0.64 to 10.17; I 2 = 28%), with no di erence in the number of neural tube malformations in children exposed to PHT (N = 252) and control children (N = 595) (Analysis 8.2).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "8.2.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from four studies suggested no evidence of a di erence in risk (RR 1.56, 95% CI 0.07 to 37.19, I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to PHT (N = 48) and control children (N = 590) (Analysis 8.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy)",
                "sec_num": "8.5.1"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.07 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy)",
                "sec_num": "8.5.1"
            },
            {
                "text": "Pooled results from six studies suggested no evidence of a di erence in risk (RR 1.57, 95% CI 0.31 to 7.95; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to PHT (N = 252) and control children (N = 595) (Analysis 8.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women with epilepsy)",
                "sec_num": "8.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "8.5.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "8.5.4"
            },
            {
                "text": "The majority of included studies did not investigate or formally report on the relationship between the dose of PHT and malformation outcome, with many being limited by included numbers of PHT-exposed pregnancies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenytoin dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to primidone (PRM) (N = 112), based on data from seven studies, was 7.9% (95% CI 2.6 to 21.5).The prevalence of major malformations in routine health record studies for children exposed to PRM (N = 3), was based on data from one study and therefore was not calculated.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primidone",
                "sec_num": null
            },
            {
                "text": "The results from one study (Koch 1992) suggested no evidence of a di erence in risk (RR 0.48, 95% CI 0.03 to 8.43, I 2 = NA) (Analysis 9.1) with no di erence in the number of major malformations in children exposed to PRM (N = 21) and control children (N = 116).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.12 to 0.03; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PRM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "9.1.1"
            },
            {
                "text": "Samren 1997 reported four cases of major malformations out of 43 PRM-exposed children (9%).When limited to centres with control children, there were three cases out of 39 exposed children, which suggested no evidence of di erence from control children (RR 1.0, 95% CI 0.3 to 3.8).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PRM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "9.1.1"
            },
            {
                "text": "Pooled results from six studies suggested an increased risk with PRM (RR 3.61, 95% CI 1.41 to 9.23; I 2 = 8%), with children exposed to PRM (N = 108) experiencing more major malformations than control children (N = 573) (Analysis 9.1).The RD also suggested a higher risk for PRM (RD 0.07, 95% CI 0.00 to 0.14; I 2 = 11%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PRM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "9.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PRM versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "9.1.3"
            },
            {
                "text": "No included studies reported data on this outcome.Specific malformation types were not reviewed due to no reported data on these outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PRM versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "9.1.4"
            },
            {
                "text": "No included studies investigated the dose of PRM and malformation risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primidone dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to topiramate (TPM) (N = 510), based on data from eight studies, was 3.9% (95% CI 2.3 to 6.5).The prevalence of major malformations in routine health record studies for children exposed to TPM (N = 49), based on data from two studies, was 4.1% (95% CI 0.0 to 27,060).Pooled data from three studies suggested an increased risk with TPM (RR 4.07, 95% CI 1.64 to 10.14; I 2 = 0%), with children exposed to TPM (N = 367) experiencing more major malformations than control children (N = 825) (Analysis 10.1).The RD also suggested a higher risk for TPM (RD 0.03, 95% CI 0.01 to 0.06; I 2 = 0).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "There was just one case of MCM in 41 monotherapy cases described by the Israeli Teratogen Service, giving a prevalence of 4.9%, which suggested no di erence in risk to control children (3.4%, P value not reported).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Pooled results from five studies suggested no evidence of a di erence in risk (RR 1.37, 95% CI 0.57 to 3.27; I 2 = 0%), with no di erence in the number of major malformations in children exposed to TPM (N = 139) and control children (N = 1080) (Analysis 10.1).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.03 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "10.1.2"
            },
            {
                "text": "The results from one study suggested no evidence of a di erence in risk (RR 1.65, 95% CI 0.43 to 6.42; I 2 = NA), with children exposed to TPM (N = 48) experiencing comparable rates of major malformations to control children (N = 369,267) (Analysis 10.1).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.04 to 0.07; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "10.1.3"
            },
            {
                "text": "The results from one study suggested no evidence of a di erence in risk (RR 1.62, 95% CI 0.40 to 6.45; I 2 = NA), with children exposed to TPM (N = 48) experiencing comparable rates of major malformations to control children (N = 1900) (Analysis 10.1).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.04 to 0.07; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "10.1.4"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported neural tube malformations in children exposed to TPM (N = 8) or control children (N = 383) (Analysis 10.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "10.2.1"
            },
            {
                "text": "Pooled data from two included studies suggested evidence of a di erence in risk (RR 20.71, 95% CI 2.64 to 162.72,I 2 = 0%), with children exposed to TPM (N = 8) experiencing more cardiac malformations than control children (N = 383) (Analysis 10.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "10.2.1"
            },
            {
                "text": "However, the RD suggested no di erence in the level of risk (RD 0.12, 95% CI -0.16 to 0.39; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "10.2.1"
            },
            {
                "text": "Pooled data from four included studies suggested no evidence of a di erence in risk (RR 2.48, 95% CI 0.49 to 12.49; I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to TPM (N = 60) and control children (N = 510) (Analysis 10.3).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "10.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "10.3.3"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR from two studies due to there being no reported oro-facial cle / craniofacial malformations in children exposed to TPM (N = 8) or control children (N = 383) (Analysis 10.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "10.3.4"
            },
            {
                "text": "Pooled data from three included studies suggested no evidence of a di erence in risk (RR 1.50, 95% CI 0.09 to 24.92;I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to TPM (N = 51) and control children (N = 170) (Analysis 10.4).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.05 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "10.4.2"
            },
            {
                "text": "No included studies reported data on this outcome to be included in the meta-analysis.However, the study by Hernandez-Diaz and colleagues using US Medicaid Registers could not be included in the meta-analysis due to a lack of reporting of specific numbers of oral cle s.In comparison to children born to women without epilepsy (N = 1,322,955), the children exposed to TPM (N = 2425) had higher rates of oral cle s of 4.1 per 1000 live births (RR 3.63, 95% CI 1.95 to 6.76).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "10.4.3"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR from two studies due to there being no reported skeletal/limb malformations in children exposed to TPM (N = 8) or control children (N = 383) (Analysis 10.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "10.4.4"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled data from three included studies suggested no evidence of a di erence in risk (RR 2.06, 95% CI 0.24 to 17.42; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to TPM (N = 59) and control children (N = 502) (Analysis 10.5).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.05 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "10.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "10.5.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "TPM versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "10.5.4"
            },
            {
                "text": "The largest included cohort of TPM-exposed pregnancies came from the study by Hernandez-Diaz using data from the US Medicaid Registers (N = 2425).This register reported the risk of oral cle s for doses \u2264 100 mg/d as 2.4 per 1000 live births, and for doses > 100 mg/d, as 7.3 per 1000 live births.The adjusted values of corresponding adjusted RRs for daily doses \u2264 100 and > 100 mg were 1.64 (95% CI 0.53 to 5.07) and 5.16 (95% CI 1.94 to 13.73) for lower and higher doses, respectively.The data were too limited to provide dose investigations specifically for women with epilepsy, but they did report that higher doses tended to be used for women requiring TPM for the treatment of epilepsy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate dose",
                "sec_num": null
            },
            {
                "text": "North American Epilepsy and Pregnancy Register found no evidence of a di erence in the median dose between TPM-exposed children (N = 359) who had MCM versus those who did not (P value not reported).The Australian Epilepsy and Pregnancy Register (N = 53), did not find a dose association for monotherapy TPM but did see an increase in risk with polytherapy (prevalence not given).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate dose",
                "sec_num": null
            },
            {
                "text": "The UK and Ireland Epilepsy and Pregnancy Register cohort (N = 70) also failed to find an association between the dose of TPM and the risk of overall MCM.However, caution is required due to smaller numbers from the Epilepsy and Pregnancy Register cohorts currently for monotherapy TPM exposure in pregnancy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to valproate (VPA) (N = 3018), based on data from 31 studies, was 9.8% (95% CI 8.1 to 11.9).The prevalence of major malformations in routine health record studies for children exposed to VPA (N = 1364), based on data from six studies, was 9.7% (95% CI 7.1 to 13.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Valproate",
                "sec_num": null
            },
            {
                "text": "Pooled results from eight studies suggested an increased risk with VPA (RR 5.64, 95% CI 1.37 to 23.24;I 2 = 0%), with a higher number of neural tube malformations in children exposed to VPA (N = 814) than in control children (N = 664) (Analysis 11.2).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I 2 = 6%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "11.2.2"
            },
            {
                "text": "Pooled results from 10 studies suggested an increased risk with VPA (RR 2.71, 95% CI 1.42 to 5.17; I 2 = 0%), with a higher number of cardiac malformations in children exposed to VPA (N = 821) than in control children (N = 676) (Analysis 11.3).The RD also suggested a higher risk for VPA (RD 0.03, 95% CI 0.01 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "11.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "11.2.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "11.2.4"
            },
            {
                "text": "Pooled results from four studies suggested no evidence of a di erence in risk (RR 2.76, 95% CI 0.31 to 24.78;I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 104) and control children (N = 836) (Analysis 11.4).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "11.4.1"
            },
            {
                "text": "Pooled results from eight studies suggested an increased risk with VPA (RR 4.44, 95% CI 1.14 to 17.27; I 2 = 2%), with more children exposed to VPA (N = 474) experiencing oro-facial cle /craniofacial malformations than control children (N = 332) (Analysis 11.4).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "11.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "11.4.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "11.4.4"
            },
            {
                "text": "Pooled results from four studies suggested an increased risk with VPA (RR 16.48, 95% CI 2.46 to 110.49;I 2 = 0%), with children exposed to VPA (N = 104) experiencing more skeletal/limb malformations than control children (N = 836) (Analysis 11.5).However, the RD suggested no di erence in the level of risk (RD 0.03, 95% CI -0.01 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "11.5.1"
            },
            {
                "text": "Pooled results from eight studies suggested no evidence of a di erence in risk (RR 2.38, 95% CI 0.93 to 6.12; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 814) and control children (N = 664) (Analysis 11.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "11.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "11.5.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VPA versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "11.5.4"
            },
            {
                "text": "In contrast to the results on dosage for the other AEDs, for VPA there appears to be a consistently documented and clear association between increased dose and the risk for MCM in VPA-exposed children.EURAP 2018 reported evidence that suggested a doserelated MCM risk for VPA exposure.In 1381 exposed pregnancies, the MCM risk ranged from 6.3% (95% CI 4.5 to 8.6%) for doses =/< 650 mg/d, to 11.3% for doses > 650 mg/d to =/< 1450 mg/day and, most concerning, 25",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Valproate dose",
                "sec_num": null
            },
            {
                "text": "The prevalence of major malformations (any type) in cohort studies for children exposed to zonisamide (ZNS) (N = 130), based on data from four studies, was 2.7% (95% CI 0.1 to 47.3).There were no children exposed to ZNS in routine health record studies, therefore, the prevalence of major malformations rated could not be calculated.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Zonisamide",
                "sec_num": null
            },
            {
                "text": "12.1.All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus controls",
                "sec_num": "12"
            },
            {
                "text": "Pooled data from two studies suggested no evidence of a di erence in risk (RR 1.13, 95% CI 0.21 to 6.11; I 2 = 36%), with no di erence in the number of major malformations in children exposed to ZNS (N = 103) and control children (N = 548) (Analysis 12.1).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.03 to 0.02; I 2 = 39%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "12.1.1"
            },
            {
                "text": "Pooled data from two studies suggested an increased risk with ZNS (RR 3.20, 95% CI 1.09 to 9.43; I 2 = 0%), with a higher number of major malformations in children exposed to ZNS (N = 39) than in control children (N = 556) (Analysis 12.1).However, the RD suggested no di erence in the level of risk (RD 0.07, 95% CI -0.03 to 0.18; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "12.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "12.1.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "12.1.4"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported neural tube malformations in children exposed to ZNS (N = 13) or control children (N = 106) (Analysis 12.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "12.2.1"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported neural tube malformations in children exposed to ZNS (N = 13) or control children (N = 15) (Analysis 12.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "12.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "12.2.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "12.2.4"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported cardiac malformations in children exposed to ZNS (N = 13) or control children (N = 106) (Analysis 12.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "12.3.1"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported cardiac malformations in children exposed to ZNS (N = 13) or control children (N = 15) (Analysis 12.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "12.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): routine health record data studies",
                "sec_num": "12.3.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "12.3.4"
            },
            {
                "text": "12.4 Oro-facial cle /craniofacial malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): routine health record data studies",
                "sec_num": "12.3.4"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported oro-facial cle /craniofacial malformations in children exposed to ZNS (N = 13) or control children (N = 106) (Analysis 12.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "12.4.1"
            },
            {
                "text": "We were unable to estimate a RR from one included study due to there being no reported oro-facial cle /craniofacial malformations in children exposed to ZNS (N = 13) or control children (N = 15) (Analysis 12.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ZNS versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "12.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "13.5.2"
            },
            {
                "text": "14.1.All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus GBP",
                "sec_num": "14"
            },
            {
                "text": "Pooled results from four studies suggested no evidence of a di erence in risk(RR 1.55, 95% CI 0.57 to 4.26; I 2 = 47%), with no di erence in the number of major malformations in children exposed to CBZ (N = 3112) and children exposed to GBP (N = 192) (Analysis 14.1).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.00 to 0.04; I 2 = 42%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "14.1.1"
            },
            {
                "text": "Data from one study suggested no evidence of a di erence in risk (RR 1.54, 95% CI 0.10 to 24.27;I 2 = NA), with no di erence in the number of major malformations in children exposed to CBZ (N = 703) and children exposed to GBP (N = 18) (Analysis 14.1).The RD also suggested no di erence in the level of risk (RD 0.04, 95% CI -0.03 to 0.11; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "14.1.2"
            },
            {
                "text": "Data from one included study suggested no evidence of a di erence in risk (RR 0.12, 95% CI 0.01 to 2.93, I 2 = NA) with no di erence in the number of neural tube malformations in children exposed to CBZ (N= 361) and GBP-exposed children (N = 14) (Analysis 14.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.09 to 0.09; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "14.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "14.2.2"
            },
            {
                "text": "Pooled results from two studies suggest n increased in risk (RR 0.13, 95% CI 0.02 to 0.95, I 2 = 0%) with children exposed to GBP (N = 16) being at a higher risk of cardiac malformation than children",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "14.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.The EURAP 2018 collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 2.8% (95% CI 1.7 to 4.5) for children exposed to LEV.No direct statistical comparison was made at the group level, investigations were made across di erent doses of the two ASMs (see Carbamazepine dose and Levetiracetam dose sections).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "14.5.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 1.73, 95% CI 0.78 to 3.83; I 2 = 0%), with no di erence in the number of major malformations in children exposed to CBZ (N = 1000) and children exposed to LEV (N = 248) (Analysis 15.1).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.00 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "15.1.2"
            },
            {
                "text": "Pooled results from 10 studies suggested no evidence of a di erence in risk (RR 1.57, 95% CI 0.41 to 6.08; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 3731) and children exposed to LEV (N = 1148) (Analysis 15.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "15.2.1"
            },
            {
                "text": "EURAP 2018 reported a prevalence of 0.35% (7/1957) for cases of neural tube anomaly in children exposed to CBZ and 0% (0/599) in children exposed to LEV.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "15.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.EURAP 2018 reported a prevalence of 1.4% (28/1957) for cases of a cardiac anomaly in children exposed to CBZ and 0.8% (5/599) in children exposed to LEV.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "15.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "15.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "15.4.2"
            },
            {
                "text": "Pooled results from 10 studies suggested no evidence of a di erence in risk (RR 0.99, 95% CI 0.37 to 2.68; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to CBZ (N = 3731) and children exposed to LEV (N = 1147) (Analysis 15.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "15.5.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "15.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube malformations in those exposed to CBZ was 0.36% (7/1957) and 0.04% for those exposed to LTG (1/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus LTG",
                "sec_num": "16"
            },
            {
                "text": "No included studies reported data on this outcome.3).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.2.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac malformations in those exposed to CBZ was 1.43% (28/1957) and 0.59% (15/2514) for those exposed to lamotrigine.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.2.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from 11 studies suggested no evidence of a di erence in risk (RR 1.22, 95% CI 0.57 to 2.61; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to CBZ (N = 3443) and children exposed to LTG (N = 4357) (Analysis 16.4).However, only three studies contained occurrences of oro-facial cle /craniofacial malformations.The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.3.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.11% for children exposed to LTG (3/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.3.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.4.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews to 0.00, I 2 = 89%).Due to heterogeneity, a random-e ects RD was calculated which upheld similar findings (RD -0.02, 95% CI -0.11 to 0.07; I 2 = 89%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "16.5.2: Routine health record studies",
                "sec_num": null
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 0.93, 95% CI 0.22 to 3.96; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 2403) and children exposed to OXC (N = 364) (Analysis 17.2).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "17.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0% for children exposed to OXC (0/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "17.2.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.3).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "17.2.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 1.2% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "17.2.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "17.3.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 0.52, 95% CI 0.12 to 2.26; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to CBZ (N = 1918) and children exposed to OXC (N = 296) (Analysis 17.4).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "17.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "17.4.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "17.4.2"
            },
            {
                "text": "Pooled results from nine studies suggested no evidence of a di erence in risk (RR 0.53, 95% CI 0.17 to 1.66; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to CBZ (N = 2403) and children exposed to OXC (N = 364) (Analysis 17.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "17.5.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "17.5.2"
            },
            {
                "text": "Pooled results from two routine health record studies suggested no evidence of a di erence in risk (RR 0.35, 95% CI 0.12 to 1.09; I 2 = 0%), with no di erence in the number of major malformations in children exposed to CBZ (N = 1388) and children exposed to PB (N = 34) (Analysis 18.1).The RD also suggested no di erence in the level of risk (RD -0.06, 95% CI -0.15 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "18.1.2"
            },
            {
                "text": "Pooled results from 15 cohort studies suggested no evidence of a di erence in risk (RR 1.28, 95% CI 0.35 to 4.75; I 2 = 32%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 2340) and children exposed to PB (N = 550) (Analysis 18.2).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "18.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0.68% for children exposed to PB (2/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "18.2.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "18.2.2"
            },
            {
                "text": "Pooled results from 15 cohort studies suggested an increased risk with PB (RR 0.26, 95% CI 0.14 to 0.47; I 2 = 0%), with children exposed to CBZ (N = 2340) experiencing fewer cardiac malformations than children exposed to PB (N = 550) (Analysis 18.5).The RD also suggested a higher risk for PB (RD -0.03, 95% CI -0.05 to -0.01;I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "18.3.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 2.7% for children exposed to PB (8/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Included studies did not report any data on this outcome.In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.34% for children exposed to PB (1/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "18.3.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "18.4.2"
            },
            {
                "text": "Pooled results from 15 cohort studies suggested no evidence of a di erence in risk (RR 1.08, 95% CI 0.45 to 2.61; I 2 = 6%), with no di erence in the number of skeletal/limb malformations in children exposed to CBZ (N = 2340) and children exposed to PB (N = 550) (Analysis 18.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "18.5.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "18.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0.80% for children exposed to PB (1/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ versus PHT",
                "sec_num": "19"
            },
            {
                "text": "Included studies did not report any data on this outcome.3).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.2.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 4% for children exposed to PHT (5/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.2.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0% for children exposed to PHT (0/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.3.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.Cochrane Database of Systematic Reviews (Analysis 19.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.4.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "19.5.2"
            },
            {
                "text": "Data from one included study suggested no evidence of a di erence in risk (RR 0.32, 95% CI 0.02 to 4.44, I 2 = NA), with no di erence in the number of major malformations in children exposed to CBZ (N = 703) and children exposed to PRM (N = 3) (Analysis 20.1).The RD also suggested no di erence in the level of risk (RD 0.04, 95% CI -0.28 to 0.36; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "20.1.2"
            },
            {
                "text": "Pooled data from two studies suggested no evidence of a di erence in risk (RR 0.95, 95% CI 0.04 to 22.75, I 2 = NA), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 119) and children exposed to PRM (N = 39) (Analysis 20.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "20.2.1"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.04 to 0.06; I 2 = 0%.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "20.2.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "20.2.2"
            },
            {
                "text": "Pooled data from two studies suggested no evidence of a di erence in risk (RR 0.11, 95% CI 0.00 to 2.53, I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to CBZ (N = 119) and children exposed to PRM (N = 39) (Analysis 20.3).The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.10 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "20.3.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "20.3.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported oro-facial cle /craniofacial malformations in children exposed to CBZ (N = 119) or children exposed to PRM (N = 39) (Analysis 20.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "20.4.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "20.4.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.The EURAP 2018 collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM.No direct statistical comparison was made at the group level; investigations were made across di erent doses of the two ASMs (see Carbamazepine dose and Topiramate dose sections).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "20.5.2"
            },
            {
                "text": "Pooled results from two routine health records suggested no evidence of a di erence in risk (RR 0.59, 95% CI 0.17 to 2.06; I 2 = 12%), with children exposed to CBZ (N = 1388) experiencing more major malformations than children exposed to TPM (N = 49) (Analysis 21.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.07 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "21.1.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 0.91, 95% CI 0.18 to 4.51; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to CBZ (N = 3568) and children exposed to TPM (N = 496) (Analysis 21.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.2.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from eight cohort studies suggested no evidence of a di erence in risk (RR 0.73, 95% CI 0.25 to 2.12; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to CBZ (N = 3573) and children exposed to TPM (N = 497) (Analysis 21.3).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.3.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "21.3.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 0.33, 95% CI 0.13 to 0.82; I 2 = 40%), with children exposed to CBZ (N = 3083) experiencing more oro-facial cle / craniofacial malformations than children exposed to TPM (N = 488) (Analysis 21.4).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.4.1"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "21.4.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 0.34, 95% CI 0.12 to 0.94; I 2 = 0%), with children exposed to CBZ (N = 3568) experiencing more skeletal/limb malformations than children exposed to TPM (N = 496).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "21.5.1"
            },
            {
                "text": "There were no studies that provided data for this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "21.5.2"
            },
            {
                "text": "Pooled results from five routine health record studies suggested an increased risk with VPA (RR 0.42, 95% CI 0.33 to 0.54; I 2 = 14%), with children exposed to CBZ (N = 2806) experiencing fewer major malformations than children exposed to VPA (N = 1351) (Analysis 22.1).The RD also suggested a higher risk for VPA (RD -0.06, 95% CI -0.07 to -0.04;I 2 = 49%).Due to heterogeneity, a random-e ects RD was calculated which found a similar e ect (RD -0.08, 95% CI -0.08 to -0.03,I 2 = 49%).2).The RD also suggested a higher risk for VPA (RD -0.01, 95% CI -0.02 to -0.01;I 2 = 14%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.1.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 1.6% for children exposed to VPA (16/1381).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.1.2"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.19, 95% CI 0.02 to 2.09; I 2 = NA), with children exposed to CBZ (N = 703) experiencing comparable neural tube malformations to children exposed to VPA (N = 268) (Analysis 22.2).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.2.2"
            },
            {
                "text": "Pooled results from 22 cohort studies suggested an increased risk with VPA (RR 0.40, 95% CI 0.28 to 0.58; I 2 = 12%), with children exposed to CBZ (N = 4743) experiencing fewer cardiac malformations than children exposed to VPA (N = 2722) (Analysis 22.3).The RD also suggested a higher risk for VPA (RD -0.02, 95% CI -0.02 to -0.01;I 2 = 20%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "22.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 2.46% for children exposed to VPA (34/1381).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "22.3.1"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0. ).The RD also suggested a higher risk for VPA (RD -0.01, 95% CI -0.02 to -0.00;I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.43% for children exposed to VPA (6/1381).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.3.2"
            },
            {
                "text": "Results from one routine health record study suggested an increased risk with VPA (RR 0.15, 95% CI 0.03 to 0.78; I 2 = NA), with children exposed to CBZ (N = 703) experiencing fewer major malformations than children exposed to VPA (N = 268) (Analysis 22.4).The RD also suggested a higher risk for VPA (RD -0.02, 95% CI -0.03 to 0.01; I 2 = NA).).The RD also suggested a higher risk for VPA (RD -0.01, 95% CI -0.02 to -0.01;I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.4.2"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.38, 95% CI 0.02 to 6.07; I 2 = NA), with children exposed to CBZ (N = 703) experiencing comparable skeletal/limb malformations to children exposed to VPA (N = 268) (Analysis 22.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.03 to 0.03; I 2 = 74%).Due to heterogeneity, a random-e ects RD was calculated which upheld a similar result (RD -0.02, 95% CI -0.15 to 0.12).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "22.5.2"
            },
            {
                "text": "Included studies did not report any data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "23.1.2"
            },
            {
                "text": "Pooled results from three studies suggested evidence of a di erence in risk (RR 0.06, 95% CI 0.01 to 0.54, I 2 = NA), with children exposed to CBZ (N = 1678) experiencing more neural tube malformations than children exposed to ZNS (N = 40) (Analysis 23.2).However, the RD suggested no di erence in the level of risk (RD -0.03, 95% CI -0.10 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "23.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "23.2.2"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 0.47, 95% CI 0.03 to 7.72, I 2 = NA), with no di erence in the number of cardiac malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (Analysis 23.3).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "23.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "23.3.2"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 0.15, 95% CI 0.01 to 2.66, I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (Analysis 23.4).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.06 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "23.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "23.4.2"
            },
            {
                "text": "Pooled results from three studies suggested no evidence of a di erence in risk (RR 0.15, 95% CI 0.01 to 2.66, I 2 = NA), with no di erence in the number of skeletal/limb malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (Analysis 23.5).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.06 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "23.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews (Analysis 24.1).Due to high heterogeneity, a random-e ects RR was calculated which also found no di erence (RR 1.54, 95% CI 0.25 to 9.55, I 2 =85%).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 37%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "23.5.2"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.53, 95% CI 0.03 to 9.48; I 2 = NA), with children exposed to GBP (N = 18) experiencing more major malformations than children exposed to LTG (N = 90) (Analysis 24.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.1.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.13 to 0.01; I 2 = 37%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or in children exposed to LTG (N = 314) (Analysis 24.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "24.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.2.2"
            },
            {
                "text": "Pooled results from two studies suggested evidence of a di erence in risk (RR 9.57, 95% CI 1.69 to 54.15,I 2 = 30%), with children exposed to GBP (N = 16) experiencing more cardiac malformations than children exposed to LTG (N = 352) (Analysis 24.3).However, the RD suggested no di erence in the level of risk (RD 0.05, 95% CI -0.08 to 0.19; I 2 = 76%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "24.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.3.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.92, 95% CI 0.11 to 33.05,I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations between children exposed to GBP (N = 14) and children exposed to LTG (N = 315) (Analysis 24.4).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.11 to 0.08; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "24.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.4.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (N = 14) or children exposed to LTG (N = 315) (Analysis 24.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "24.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "24.5.2"
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 0.53, 95% CI 0.13 to 2.17; I 2 = 0%), with no di erence in the number of major malformations in children exposed to GBP (N = 161) and children exposed to OXC (N = 202) (Analysis 25.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.04 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "25.1.1"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported major malformations in children exposed to GBP (N = 18) or children exposed to OXC (N = 4) (Analysis 25.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "25.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or children exposed to OXC (N = 12) (Analysis 25.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "25.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "25.2.2"
            },
            {
                "text": "Included studies did not reach the threshold for reporting of the meta-analysis (Analysis 25.3).However, available data show that there were 1/15 cases of cardiac malformation in children exposed to GBP and 0/13 in OXC children, based on data from two studies (Australian Epilepsy and Pregnancy Register; Miskov 2016).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "25.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "25.3.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported oro-facial cle /craniofacial malformations in children exposed to GBP (N = 14) or children exposed to OXC (N = 12) (Analysis 25.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "25.4.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 0.30, 95% CI 0.08 to 1.14; I 2 = 75%), with children exposed to GBP (N = 161) experiencing no di erence in major malformations to children exposed to PB (N = 204) (Analysis 26.1).Due to high heterogeneity, a random-e ects RR was calculated which also found no di erence (RR 0.61, 95% CI 0.02 to 19.36,I 2 =85%).However, the RD suggested a higher risk for PB (RD -0.04, 95% CI -0.08 to -0.00;I 2 = 31%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "26.1.1"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.14, 95% CI 0.01 to 3.09; I 2 = NA), with children exposed to GBP (N = 18) experiencing more major malformations than children exposed to PB (N = 1) (Analysis 26.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "26.1.2"
            },
            {
                "text": "The RD also suggested no di erence in the level of risk (RD -0.14, 95% CI -0.42 to 0.14).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "26.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or children exposed to PB (N = 5) (Analysis 26.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "26.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "26.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "30.3.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.70, 95% CI 0.03 to 16.42,I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 63) and children exposed to GBP (N = 14) (Analysis 30.4).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.08 to 0.11; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "30.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to LEV (N = 63) or children exposed to GBP (N = 14) (Analysis 30.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "30.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "30.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.04% for children exposed to LTG (1/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LEV versus LTG",
                "sec_num": "31"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "31.2.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 1.20, 95% CI 0.51 to 2.85; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 1125) and children exposed to LTG (N = 4246) (Analysis 31.3).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.00 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "31.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 0.59% for children exposed to LTG (15/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "31.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0.43% for children exposed to LTG (3/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "31.4.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 1.36, 95% CI 0.45 to 4.13; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to LEV (N = 1128) and children exposed to LTG (N = 4245) (Analysis 31.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "31.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0% for children exposed to OXC (0/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "31.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.2.2"
            },
            {
                "text": "Pooled results from eight cohort studies suggested no evidence of a di erence in risk (RR 0.93, 95% CI 0.31 to 2.76; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 747) and children exposed to OXC (N = 323) (Analysis 32.3).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "32.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 1.2% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "32.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.3.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 0.25, 95% CI 0.03 to 2.12; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to LEV (N = 641) and children exposed to OXC (N = 252) (Analysis 32.4).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "32.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "32.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.4.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 0.80, 95% CI 0.20 to 3.29; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to LEV (N = 738) children exposed to OXC (N = 320) (Analysis 32.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "32.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "32.5.2"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.23, 95% CI 0.03 to 1.55; I 2 = NA), with children exposed to LEV (N = 118) experiencing comparable major malformation rates to children exposed to PB (N = 27).The RD also suggested no di erence in the level of risk (RD -0.06, 95% CI -0.16 to 0.04; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "33.1.2"
            },
            {
                "text": "Results from five cohort studies suggested no evidence of a di erence in risk (RR 0.74, 95% CI 0.08 to 6.51; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to LEV (N = 650) and children exposed to PB (N = 344) (Analysis 33.2).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "33.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.68% for children exposed to PB (2/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "33.2.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "33.2.2"
            },
            {
                "text": "Pooled results from five cohort studies suggested no evidence of a di erence in risk (RR 0.33, 95% CI 0.12 to 0.88; I 2 = 17%), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 650) and PB (N = 344) (Analysis 33.3).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.04 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "33.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 2.72% for children exposed to PB (8/294%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "33.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0.34% for children exposed to PB (1/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "33.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "33.4.2"
            },
            {
                "text": "Pooled results from five cohort studies suggested no evidence of a di erence in risk (RR 0.67, 95% CI 0.15 to 2.94; I 2 = 23%), with no di erence in the number of skeletal/limb malformations in children exposed to LEV (N = 650) and children exposed to PB (N = 344) (Analysis 33.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "33.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.80% for children exposed to PHT (1/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "33.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "34.2.2"
            },
            {
                "text": "Pooled results from four cohort studies suggested no evidence of a di erence in risk (RR 0.43, 95% CI 0.16 to 1.13; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 911) and children exposed to PHT (N = 611) (Analysis 34.3).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "34.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 4.0% for children exposed to PHT (5/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "34.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record data studies",
                "sec_num": "34.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "36.2.2"
            },
            {
                "text": "Pooled results from eight studies suggested no evidence of a di erence in risk (RR 0.72, 95% CI 0.21 to 2.53; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LEV (N = 1039) and children exposed to TPM (N = 497) (Analysis 36.2).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "36.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "36.3.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "36.3.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested an increased risk with TPM (RR 0.19, 95% CI 0.05 to 0.70; I 2 = 48%), with children exposed to LEV (N = 933) experiencing fewer oro-facial/craniofacial malformations than children exposed to TPM (N = 488) (Analysis 36.4).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "36.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0% for children exposed to TPM (0/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "36.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "36.4.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested an increased risk with TPM (RR 0.12, 95% CI 0.02 to 0.98; I 2 = 0%), with children exposed to LEV (N = 1030) experiencing fewer skeletal/limb malformations than children exposed to TPM (N = 496) (Analysis 36.5).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "36.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "36.5.2"
            },
            {
                "text": "Pooled results from four cohort studies suggested no evidence of a di erence in risk (RR 0.66, 95% CI 0.25 to 1.71; I 2 = 79%), with no di erence in the number of major malformations in children exposed to LEV (N = 865) and children exposed to ZNS (N = 130) (Analysis 37.1).Due to high heterogeneity, a random-e ects RR was calculated, which also found no di erence (RD 0.48, 95% CI 0.03 to 7.24, I 2 = 79%).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.04 to 0.03; I 2 = 76%).Due to heterogeneity, a random-e ects RD was calculated, which maintained similar findings (RD -0.03, 95% CI -0.16 to 0.10, I 2 = 76%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "37.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "37.1.2"
            },
            {
                "text": "Pooled results from three included studies suggested evidence of a di erence in risk (RR 0.03, 95% CI 0.00 to 0.71, I 2 = NA), with children exposed to ZNS (N = 40) experiencing more neural tube malformations than children exposed to LEV (N = 415) (Analysis 37.2).However, the RD suggested no di erence in the level of risk (RD -0.03, 95% CI -0.10 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "37.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "37.2.2"
            },
            {
                "text": "Pooled results from three included studies suggested no evidence of a di erence in risk (RR 0.98, 95% CI 0.05 to 17.99, I 2 = NA), with no di erence in cardiac malformations between children exposed to LEV (N = 415) and children exposed to ZNS (N = 40) (Analysis 37.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "37.3.1"
            },
            {
                "text": "The RD suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "37.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR from three studies due to there being no reported oro-facial cle /craniofacial malformations in children exposed to LEV (N = 415) and ZNS (N = 40) (Analysis 37.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "37.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "37.4.2"
            },
            {
                "text": "We were unable to estimate a RR from three studies due to there being no reported skeletal/limb malformations in children exposed to LEV (N = 415) and ZNS (N = 40) (Analysis 37.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "37.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "37.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "39.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 1.2% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG versus OXC",
                "sec_num": "40"
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.64, 95% CI 0.12 to 3.46; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to LTG (N = 1997) and children exposed to OXC (N = 251) (Analysis 40.4).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "40.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "40.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.29, 95% CI 0.06 to 1.56; I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to LTG (N = 2027) and children exposed to OXC (N = 319) (Analysis 40.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "40.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0.68% for children exposed to PB (2/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "40.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "41.2.2"
            },
            {
                "text": "Pooled results from five cohort studies suggested an increased risk with PB (RR 0.21, 95% CI 0.08 to 0.56; I 2 = 0%), with children exposed to LTG (N = 1990) experiencing fewer cardiac malformations than children exposed to PB (N = 411) (Analysis 41.3).The RD also suggested a higher risk for PB (RD -0.02, 95% CI -0.04 to -0.00;I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "41.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 2.72% for children exposed to PB (8/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "41.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "41.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0.80% for children exposed to PHT (1/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "41.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "42.2.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested an increased risk with PHT (RR 0.41, 95% CI 0.17 to 0.98; I 2 = 0%), with children exposed to LTG (N = 4127) experiencing fewer cardiac malformations than children exposed to PHT (N = 718) (Analysis 42.3).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "42.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 4.0% for children exposed to PHT (5/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "42.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0% for children exposed to PHT (0/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "42.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "42.4.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested an increased risk with PHT (RR 0.28, 95% CI 0.09 to 0.86; I 2 = 0%), with children exposed to LTG (N = 4127) experiencing fewer skeletal/limb malformations than children exposed to PHT (N = 718) (Analysis 42.5).However, the RD suggested no di erence in the level of risk (RD -0.01, 95% CI -0.01 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "42.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "42.5.2"
            },
            {
                "text": "One cohort study suggested no evidence of a di erence in risk (RR 0.30, 95% CI 0.02 to 3.93; I 2 = NA), with children exposed to LTG (N = 406) experiencing comparable major malformations to children exposed to PRM (N = 2) (Analysis 43.1).The RD also suggested no di erence in the level of risk (RD 0.05, 95% CI -0.37 to 0.47; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "43.1.1"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 0.40, 95% CI 0.03 to 6.16; I 2 = NA), with children exposed to LTG (N = 90) experiencing comparable major malformations to children exposed to PRM (N = 2) (Analysis 43.1).The RD also suggested no di erence in the level of risk (RD 0.04, 95% CI -0.28 to 0.37; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "43.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "43.5.2"
            },
            {
                "text": "Pooled results from eight cohort studies suggested an increased risk with TPM (RR 0.59, 95% CI 0.36 to 0.96; I 2 = 0%), with children exposed to LTG (N = 4275) experiencing fewer major malformations than children exposed to TPM (N = 505) (Analysis 44.1).However, the RD suggested no di erence in the level of risk (RD -0.02, 95% CI -0.03 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.1.1"
            },
            {
                "text": "The EURAP 2018 collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM.No direct statistical comparison was made at the group level; investigations were made across di erent doses of the two ASMs (see Lamotrigine dose and Topiramate dose sections).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.1.1"
            },
            {
                "text": "Pooled results from two routine health record studies suggested no evidence of a di erence in risk (RR 0.68, 95% CI 0.20 to 2.37; I 2 = 0%), with children exposed to LTG (N = 923) experiencing comparable major malformation rates to children exposed to TPM (N = 49) (Analysis 44.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.07 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "44.1.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 0.62, 95% CI 0.08 to 4.94; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to LTG (N = 4131) and children exposed to TPM (N = 496) (Analysis 44.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "44.2.2"
            },
            {
                "text": "Pooled results from eight cohort studies suggested no evidence of a di erence in risk (RR 0.58, 95% CI 0.19 to 1.81; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LTG (N = 4151) and children exposed to TPM (N = 497) (Analysis 44.3).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "44.3.2"
            },
            {
                "text": "Pooled results from seven cohort studies suggested evidence of a di erence in risk (RR 0.31, 95% CI 0.13 to 0.74; I 2 = 68%), with children exposed to LTG (N = 4101) experiencing less oro-facial cle / craniofacial malformations than children exposed to TPM (N = 488) (Analysis 44.4).Due to high heterogeneity, we undertook a randome ects analysis, which found no di erence (RR 0.22, 95% CI 0.03 to 1.48; I 2 = 68%).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.4.1"
            },
            {
                "text": "No included studies reported data on this outcome that could be included in the meta-analysis.One study by Hernandez-Diaz and colleagues using US Medicaid Registers could not be included in the meta-analysis due to a lack of reporting of specific numbers of oral cle s.In this study, children born to women taking TPM had higher rates of oral cle s (N = 2425, 4.1 per 1000 live births) than the children born to women taking LTG (N = 2796, 1.5 per 1000 live births), but this was not reported to be statistically significant (RR 2.30, 95% CI 0.69 to 7.64).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "44.4.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from seven cohort studies suggested no evidence of a di erence in risk (RR 0.17, 95% CI 0.06 to 0.52; I 2 = 0%), with children exposed to LTG (N = 4131) experiencing fewer skeletal/limb malformations than children exposed to TPM (N = 496) (Analysis 44.5).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "44.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of riskThe RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.04 to 0.02; I 2 = 77%).Due to heterogeneity, a randome ects RD was calculated, which upheld similar findings (RD -0.03, 95% CI -0.16 to 0.11, I 2 = 77%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "44.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "45.1.2"
            },
            {
                "text": "Pooled data from three included studies suggested evidence of a di erence in risk (RR 0.02, 95% CI 0.00 to 0.26, I 2 = NA), with children exposed to ZNS (N = 40) experiencing more neural tube malformations than children exposed to LTG (N = 2230) (Analysis 45.2).However, the RD suggested no di erence in the level of risk (RD -0.03, 95% CI -0.09 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "45.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "45.2.2"
            },
            {
                "text": "Pooled data from two included studies suggested no evidence of a di erence in risk (RR 0.30, 95% CI 0.04 to 2.52, I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to LTG (N = 2211) and children exposed to ZNS (N = 39) (Analysis 45.2).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.04 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "45.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "45.3.2"
            },
            {
                "text": "Pooled data from two included studies suggested no evidence of a di erence in risk (RR 0.06, 95% CI 0.00 to 1.31, I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to LTG (N = 2211) and children exposed to ZNS (N = 39) (Analysis 45.4).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.05 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "45.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "45.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "45.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "46.3.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported oro-facial cle /craniofacial malformations in children exposed to PHT (N = 45) or GBP (N = 16) (Analysis 46.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "46.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "46.4.2"
            },
            {
                "text": "We were unable to estimate a RR due to there being no reported cases of skeletal/limb malformations in children exposed to PHT (N = 45) or GBP (N = 16) (Analysis 46.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "46.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "46.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0% for children exposed to OXC (0/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus OXC",
                "sec_num": "47"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 1.2% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "47.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "47.3.2"
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 0.62, 95% CI 0.10 to 4.05; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to PHT (N = 584) and children exposed to OXC (N = 200) (Analysis 47.4).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "47.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "47.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "47.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from 11 studies suggested no evidence of a di erence in risk (RR 0.79, 95% CI 0.10 to 5.94; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to PHT (N = 707) and children exposed to PB (N = 475) (Analysis 48.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "47.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0.68% for children exposed to PB (2/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus PB",
                "sec_num": "48"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "48.2.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested no evidence of a di erence in risk (RR 0.56, 95% CI 0.29 to 1.07; I 2 = 0%), with children exposed to PHT (N = 707) experiencing no more cardiac malformations than children exposed to PB (N = 475) (Analysis 48.3).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.04 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "48.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 2.72% for children exposed to PB (8/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "48.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "48.3.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested no evidence of a di erence in risk (RR 0.25, 95% CI 0.07 to 0.82; I 2 = 0%), with children exposed to PHT (N = 593) experiencing fewer oro-facial cle /craniofacial malformations than children exposed to PB (N = 347) (Analysis 48.4).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.04 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "48.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0.34% for children exposed to PB (1/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "48.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "48.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "48.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR due to there being no reported cases of oro-facial cle /craniofacial malformations in children exposed to PHT (N = 36) or PRM (N = 39) (Analysis 49.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "49.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "49.4.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 49.5).However, available data showed there were 1/36 cases of skeletal/limb malformations in children exposed to PHT and 0/39 cases in children exposed to PRM, based on data from two studies (Milan Study 1999; Pardi 1982).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "49.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "49.5.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "PHT versus TPM",
                "sec_num": "50"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "50.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 0.37, 95% CI 0.10 to 1.42; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to PHT (N = 542) and children exposed to TPM (N = 474) (Analysis 50.4).The RD also suggested no di erence in the level of risk(RD -0.01, 95% CI -0.02 to 0.00; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "50.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "50.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "50.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "50.5.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.11, 95% CI 0.00 to 2.58, I 2 = NA), with no di erence in the number of neural tube malformations in children exposed to PHT (N = 82) and children exposed to ZNS (N = 26) (Analysis 51.2).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.13 to 0.05; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "51.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "51.2.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.98, 95% CI 0.04 to 23.26,I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to PHT (N = 82) and children exposed to ZNS (N = 26) (Analysis 51.3).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.07; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "51.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "51.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "51.4.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to PHT (N = 82) or ZNS (N = 26) (Analysis 51.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "51.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "51.5.2"
            },
            {
                "text": "Pooled results from two routine health record studies suggested no evidence of a di erence in risk (RR 3.07, 95% CI 0.50 to 18.92; I 2 = 0%), with no di erence in the number of major malformations in children exposed to PB (N = 34) and children exposed to OXC (N = 61) (Analysis 52.1).The RD also suggested no di erence in the level of risk (RD 0.07, 95% CI -0.04 to 0.17; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.1.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 1.57, 95% CI 0.06 to 37.94; I 2 = NA), with no di erence in the number of neural tube malformations in children exposed to PB (N = 349) and children exposed to OXC (N = 305) (Analysis 52.2).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "52.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to PB was 0.68% (2/294) and 0% for children exposed to OXC (0/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "52.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.Cochrane Database of Systematic Reviews 51%).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.01 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.2.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to PB was 2.72% (8/294) and 1.20% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to PB was 0.34% (1/294) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.4.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.98, 95% CI 0.16 to 5.97; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to PB (N = 349) and children exposed to OXC (N = 305) (Analysis 52.5).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "52.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested no di erence in the level of risk (RD -0.05, 95% CI -0.12 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "52.5.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 53.1).However, available data showed there were 1/7 cases of major malformations in children exposed to PB and 0/3 cases in children exposed to PRM, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "53.1.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported no cases of neural tube malformations in children exposed to PB (N = 95) or PRM (N = 39) (Analysis 53.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "53.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "53.2.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "53.3.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported cases of oro-facial cle /craniofacial malformations in children exposed to PB (N = 95) or PRM (N = 39) (Analysis 53.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "53.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "53.4.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 1.29, 95% CI 0.05 to 30.82,I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to PB (N = 95) and children exposed to PRM (N = 39) (Analysis 53.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "53.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to PB was 0.68% (2/294) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "53.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "54.2.2"
            },
            {
                "text": "Pooled results from four cohort studies suggested an increased risk with PB (RR 4.44, 95% CI 0.98 to 20.12;I 2 = 37%), with children exposed to PB (N = 343) experiencing more cardiac malformations than children exposed to TPM (N = 417) (Analysis 54.3).However, the RD suggested no di erence in the level of risk (RD 0.02, 95% CI -0.00 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "54.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to PB was 2.72% (8/294) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "54.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "54.3.2"
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 1.44, 95% CI 0.39 to 5.31; I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to PB (N = 206) and children exposed to TPM (N = 408) (Analysis 54.4).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.02 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "54.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to PB was 0.34% (1/294) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "54.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "54.4.2"
            },
            {
                "text": "Pooled results from four cohort studies suggested no evidence of a di erence in risk (RR 0.36, 95% CI 0.06 to 2.19; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to PB (N = 343) and children exposed to TPM (N = 417) (Analysis 54.5).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "54.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "54.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "55.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of neural tube malformations in children exposed to PB (N = 2) or ZNS (N = 1) (Analysis 55.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "55.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "55.2.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of cardiac malformations in children exposed to PB (N = 2) or ZNS (N = 1) (Analysis 55.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "55.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "55.3.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of skeletal/limb malformations in children exposed to PB (N = 2) or ZNS (N = 1) (Analysis 55.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "55.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "55.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "56.1.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no cases of neural tube malformations in children exposed to TPM (N = 11) or ZNS (N = 14) (Analysis 56.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "56.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "56.2.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 6.00 95% CI 0.28 to 129.16,I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to TPM (N = 81) and children exposed to ZNS (N = 40) (Analysis 56.3).The RD also suggested no di erence in the level of risk (RD 0.03, 95% CI -0.06 to 0.12; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "56.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "56.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "56.4.2"
            },
            {
                "text": "We were unable to estimate a RR from three studies due to there being no cases of skeletal/limb malformations in children exposed to TPM (N = 81) or ZNS (N = 40) (Analysis 56.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "56.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.We were unable to estimate a RR from one cohort study due to there being no major malformations observed in children exposed to TPM (N = 5) or LAC (N = 1) (Analysis 57.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "56.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "57.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of neural tube malformations in children exposed to TPM (N = 5) or LAC (N = 1) (Analysis 57.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "57.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "57.2.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of cardiac malformations in children exposed to TPM (N = 5) or LAC (N = 1) (Analysis 57.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "57.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "57.3.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no cases of oro-facial cle / craniofacial malformations in children exposed to TPM (N = 5) or LAC (N = 1) (Analysis 57.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "57.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "57.4.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from four cohort studies suggested an increased risk with VPA (RR 4.27, 95% CI 1.60 to 11.35;I 2 = 58%), with children exposed to VPA (N = 1839) experiencing more major malformations than children exposed to GBP (N = 192) (Analysis 58.1).Due to high heterogeneity, a random-e ects RR was calculated which found no di erence in the level of risk (RD 2.43, 95% CI 0.40 to 14.64, I 2 = 58%).However, both the fixed-e ect RD analysis (RD 0.08, 95% CI 0.04 to 0.11; I 2 = 60%) and a random-e ects RD also suggested a higher absolute risk for VPA (RD 0.08, 95% CI 0.01 to 0.14, I 2 = 60%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "58.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 3.74, 95% CI 0.24 to 59.08, I 2 = NA), with no di erence in the number of major malformations in children exposed to VPA (N = 268) and children exposed to GBP (N = 18) (Analysis 58.1).However, the RD suggested a di erence in the level of risk (RD 0.10, 95% CI 0.02 to 0.18; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "58.1.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.83, 95% CI 0.05 to 13.81,I 2 = NA), with no di erence in the number of neural tube malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 18) (Analysis 58.2).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.09 to 0.13; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "58.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "58.2.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.46, 95% CI 0.08 to 2.70, I 2 = 4%), with no di erence in the number of cardiac malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16) (Analysis 58.3).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.14 to 0.11; I 2 = 74%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "58.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "58.3.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 1.38, 95% CI 0.09 to 22.19, I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16) (Analysis 58.4).The RD also suggested no di erence in the level of risk (RD 0.04, 95% CI -0.07 to 0.15; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "58.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "58.4.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.72, 95% CI 0.04 to 12.14, I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16) (Analysis 58.5).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.09 to 0.13; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "58.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "58.5.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 59.1).However, available data showed there were 4/17 cases of major malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (Jimenez 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "59.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "59.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 59.3).However, available data showed there were 1/17 cases of neural tube malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (Jimenez 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "59.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "59.2.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 59.4).However, available data showed there were 1/17 cases of cardiac malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (Jimenez 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "59.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "59.3.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 59.5).However, available data showed there were 1/17 cases of oro-facial cle /craniofacial malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (Jimenez 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "59.4.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 59.2).However, available data showed that there were 0/17 cases of skeletal/limb malformations in children exposed to VPA (N = 17) and 0/1 in children exposed to LAC, based on data from one study (Jimenez 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "59.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "59.5.2"
            },
            {
                "text": "Pooled results from two routine health record studies suggested an increased risk with VPA (RR 3.26, 95% CI 1.51 to 7.03; I 2 = 0%), with children exposed to VPA (N = 663) experiencing more major malformations than children exposed to LEV (N = 248) (Analysis 60.1).The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.03 to 0.09; I 2 = 28%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.1.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested an increased risk with VPA (RR 3.76, 95% CI 1.22 to 11.55;I 2 = 0%), with children exposed to VPA (N = 2298) experiencing more neural tube malformations than children exposed to LEV (N = 1048) (Analysis 60.2).The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "60.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to LEV (0/599).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "60.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.2.2"
            },
            {
                "text": "Pooled results from 10 cohort studies suggested an increased risk with VPA (RR 3.04, 95% CI 1.46 to 6.34; I 2 = 0%), with children exposed to VPA (N = 2299) experiencing more cardiac malformations than children exposed to LEV (N = 1057) (Analysis 60.3).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "60.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 0.83% for children exposed to LEV 0.83% (5/599).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "60.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.).The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.3.2"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.16% for children exposed to LEV (1/599).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.4.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested an increased risk with VPA (RR 2.41, 95% CI 0.99 to 5.85; I 2 = 55%), with children exposed to VPA (N = 2298) experiencing more skeletal/ limb malformations than children exposed to LEV (N = 1048) (Analysis 60.5).Due to high heterogeneity, a random-e ects RR was calculated which found no di erence in the level of risk (RR 1.89, 95% CI 0.34 to 10.60, I 2 = 55%).However, both the fixed-e ect RD analysis (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 12%) and the randome ects RD analysis (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 12%) also suggested a higher absolute risk for VPA.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "60.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.3% for children exposed to LTG (1/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "60.5.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "61.2.2"
            },
            {
                "text": "Pooled results from 12 cohort studies suggested an increased risk with VPA (RR 3.39, 95% CI 2.06 to 5.60; I 2 = 0%), with children exposed to VPA (N = 2416) experiencing more neural tube malformations than children exposed to LTG (N = 4313) (Analysis 61.3).The RD also suggested an increased level of risk for VPA (RD 0.02, 95% CI 0.01 to 0.02; I 2 = 3%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "61.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 5.9% for children exposed to LTG (15/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "61.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "61.3.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 4.16, 95% CI 2.14 to 8.08; I 2 = 0%), with children exposed to VPA (N = 2075) experiencing more craniofacial malformations than children exposed to LTG (N = 4263) (Analysis 61.4).The RD also suggested an increased level of risk for VPA (RD 0.01, 95% CI 0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "61.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.11% for children exposed to LTG (3/2514).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "61.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "61.4.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 6.09, 95% CI 2.91 to 12.76; I 2 = 0%), with children exposed to VPA (N = 2415) experiencing more craniofacial malformations than children exposed to LTG (N = 4293) (Analysis 61.5).The RD also suggested an increased level of risk for VPA (RD 0.01, 95% CI 0.01 to 0.02; I 2 = 26%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "61.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "61.5.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 1.27, 95% CI 0.36 to 4.39, I 2 = 0%), with no di erence in the number of major malformations in children exposed to VPA (N = 601) and children exposed to TPM (N = 49) (Analysis 62.1).The RD also suggested no di erence in the level of risk (RD 1.27, 95% CI 0.36 to 4.39; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "62.1.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 2.39, 95% CI 0.73 to 7.80; I 2 = 2%), with no di erence in the number of neural tube malformations in children exposed to VPA (N = 2175) and children exposed to TPM (N = 490) (Analysis 62.2).The RD suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "62.2.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from six cohort studies suggested an increased risk with VPA (RR 3.48, 95% CI 1.16 to 10.48; I 2 = 0%), with children exposed to VPA (N = 2175) experiencing more cardiac malformations than children exposed to TPM (N = 495) (Analysis 62.3).The RD also suggested a higher absolute risk for VPA (RD 0.02, 95% CI 0.01 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "62.3.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.89 95% CI 0.37 to 2.13; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 1835) and children exposed to TPM (N = 482) (Analysis 62.4).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "62.4.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 1.45, 95% CI 0.55 to 3.82; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 2199) and children exposed to TPM (N = 490) (Analysis 62.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.00 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "62.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "62.5.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 2.48, 95% CI 1.42 to 4.31; I 2 = 13%), with children exposed to VPA (N = 1183) experiencing more major malformations than children exposed to OXC (N = 378) (Analysis 63.1).The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.03 to 0.09; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.1.1"
            },
            {
                "text": "The EURAP 2018 collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC.No direct statistical comparison was made at the group level; investigations were made across di erent doses of the two ASMs (see Valproate dose and Oxcarbazepine dose sections).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.1.1"
            },
            {
                "text": "Results from four routine health record studies suggested an increased risk with VPA (RR 1.60, 95% CI 1.11 to 2.29; I 2 = 80%), with children exposed to VPA (N = 1194) experiencing more major malformations than children exposed to OXC (N = 507) (Analysis 63.1).Due to heterogeneity, a random-e ects RR was calculated, which showed no evidence of a di erence in risk (RR 1.80, 95% CI 0.57 to 5.67; I 2 = 80%).The RD suggested a higher risk for VPA (RD 0.04, 95% CI 0.01 to 0.08; I 2 = 65%).Due to heterogeneity, a randome ects RD was calculated which showed no evidence of a di erence in risk (RD 0.04, 95% CI -0.01 to 0.10, I 2 = 65%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "63.1.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 1.55, 95% CI 0.49 to 4.89; I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to VPA (N = 1133) and children exposed to OXC (N = 364) (Analysis 63.2).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to OXC (0/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "63.2.2"
            },
            {
                "text": "Pooled results from 11 cohort studies suggested no evidence of a di erence in risk (RR 1.80, 95% CI 0.84 to 3.88; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to VPA (N = 1140) and children exposed to OXC (N = 457) (Analysis 63.3).The RD suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 1.20% for children exposed to OXC (4/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "63.3.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 2.14, 95% CI 0.76 to 6.06; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 793) and children exposed to OXC (N = 385) (Analysis 63.4).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.00 to 0.04; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.30% for children exposed to OXC (1/333).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.4.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "63.4.2"
            },
            {
                "text": "Pooled results from nine cohort studies suggested no evidence of a di erence in risk (RR 1.37, 95% CI 0.42 to 4.49; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 1133) and children exposed to OXC (N = 364) (Analysis 63.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "63.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.The EURAP 2018 collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 6.5% (95% CI 4.2 to 9.9) for children exposed to PB.No direct statistical comparison was made at the group level; investigations were made across di erent doses of the two ASMs (see Valproate dose and Phenobarbital dose sections).Samren 1997 reported six cases of major malformation out of 184 (9%) VPA-exposed children and five cases from 48 (10%) PB-exposed children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "63.5.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.79, 95% CI 0.26 to 2.42, I 2 = 0%), with no di erence in the number of major malformations in children exposed to VPA (N = 601) and children exposed to PRM (N = 34) (Analysis 64.1).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.12 to 0.08; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "64.1.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested evidence of a di erence in risk (RR 3.04, 95% CI 1.27 to 7.30; I 2 = 1%), with children exposed to VPA (N = 1174) experiencing more neural tube malformations to children exposed to PB (N = 546) (Analysis 64.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.2.1"
            },
            {
                "text": "The RD also suggested a di erence in the level of risk (RD 0.02, 95% CI 0.01 to 0.04; I 2 = 7%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.68% for children exposed to PB (2/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "64.2.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested no evidence of a di erence in risk (RR 0.84, 95% CI 0.50 to 1.43; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to VPA (N = 1174) and children exposed to PB (N = 546) (Analysis 64.3).The RD also suggested no di erence in the level of risk (RD -0.00, 95% CI -0.03 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 2.72% for children exposed to PB (8/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "64.3.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested no evidence of a di erence in risk (RR 0.54, 95% CI 0.23 to 1.27; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 839) and children exposed to PB (N = 418) (Analysis 64.4).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.34% for children exposed to PB (1/294).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "64.4.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested no evidence of a di erence in risk (RR 1.62, 95% CI 0.70 to 3.74; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 1174) and children exposed to PB (N = 546) (Analysis 64.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "64.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "64.5.2"
            },
            {
                "text": "Phenytoin dose sections).Samren 1997 reported six cases of major malformation in 184 (9%) children exposed to VPA and nine in 141 (6%) PHT-exposed children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 1.43, 95% CI 0.64 to 3.19; I 2 = 0%), with no di erence in the number of major malformations in children exposed to VPA (N = 268) and children exposed to PHT (N = 103) (Analysis 65.1).The RD also suggested no di erence in the level of risk (RD 0.03, 95% CI -0.03 to 0.09; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "65.1.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 3.75, 95% CI 1.57 to 8.94; I 2 = 0%), with children exposed to VPA (N = 2419) experiencing more neural tube malformations than children exposed to PHT (N = 974) (Analysis 65.2).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I 2 = 2%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.80% for children exposed to PHT (1/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "65.2.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 1.90, 95% CI 1.07 to 3.36; I 2 = 0%), with children exposed to VPA (N = 2419) experiencing more cardiac malformations than children exposed to PHT (N = 974) (Analysis 65.3).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.3.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 4.0% for children exposed to PHT (5/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "65.3.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested no evidence of a di erence in risk (RR 2.24, 95% CI 0.89 to 5.58; I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 2084) and children exposed to PHT (N = 860) (Analysis 65.4).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.00 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.4.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0% for children exposed to PHT (0/125).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "65.4.2"
            },
            {
                "text": "Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 2.12, 95% CI 1.01 to 4.45; I 2 = 0%), with children exposed to VPA (N = 2419) experiencing more skeletal/limb malformations than children exposed to PHT (N = 975) (Analysis 65.5).The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "65.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "65.5.2"
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 2.34, 95% CI 0.95 to 5.80; I 2 = 77%), with children exposed to VPA (N = 1560) experiencing comparable major malformations to children exposed to ZNS (N = 117) (Analysis 66.1).Due to high heterogeneity, a random-e ects RR analysis was completed which also found no di erence (RR 1.81, 95% CI 0.14 to 22.75; I 2 = 77%).The RD suggested a higher risk for VPA (RD 0.06, 95% CI 0.01 to 0.10; I 2 = 72%).However, due to heterogeneity, a random-e ects RD was calculated which found no di erence in the level of risk (RD 0.04, 95% CI -0.11 to 0.19, I 2 = 72%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "66.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "66.1.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.29, 95% CI 0.06 to 1.51, I 2 = 0%), with no di erence in the number of neural tube malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (Analysis 66.2).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.11 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "66.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "66.2.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.49, 95% CI 0.07 to 3.65, I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (Analysis 66.3).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.08; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "66.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "66.3.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.47, 95% CI 0.06 to 3.49, I 2 = 0%), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (Analysis 66.4).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.05 to 0.08; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "66.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "66.4.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.46, 95% CI 0.03 to 7.72, I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (Analysis 66.5).The RD also suggested no di erence in the level of risk (RD 0.01, 95% CI -0.06 to 0.07; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "66.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "66.5.2"
            },
            {
                "text": "Pooled results from four cohort studies suggested an increased risk with VPA (RR 0.29, 95% CI 0.09 to 0.90; I 2 = 0%), with children exposed to VPA (N = 955) experiencing more major malformations than children exposed to CZP (N = 95) (Analysis 67.1).The RD also suggested a higher risk for VPA (RD -0.09, 95% CI -0.13 to -0.04;I 2 = 30%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "67.1.1"
            },
            {
                "text": "Pooled results from two routine health record studies suggested an increased risk with VPA (RR 0.34, 95% CI 0.13 to 0.94; I 2 = 0%), with children exposed to VPA (N = 601) experiencing more major malformations than children exposed to CZP (N = 161) (Analysis 67.1).The RD suggested no di erence in the level of risk (RD -0.05, 95% CI -0.12 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "67.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 9.77, 95% CI 0.58 to 165.35,I 2 = NA), with no di erence in the number of neural tube malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (Analysis 67.2).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.27 to 0.25; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "67.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "67.2.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.67, 95% CI 0.12 to 23.92,I 2 = NA), with no di erence in the number of cardiac malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (Analysis 67.3).The RD also suggested no di erence in the level of risk (RD -0.06, 95% CI -0.32 to 0.21; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "67.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "67.3.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 7.60, 95% CI 0.47 to 123.14,I 2 = NA), with no di erence in the number of skeletal/limb malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (Analysis 67.4).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.27 to 0.25; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "67.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "67.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "67.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "67.5.2"
            },
            {
                "text": "Pooled results from three cohort studies suggested no evidence of a di erence in risk (RR 1.06, 95% CI 0.32 to 3.44; I 2 = 0%), with children exposed to CZP (N = 94) experiencing more major malformations than children exposed to LEV (N = 695) (Analysis 68.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.05 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "68.1.1"
            },
            {
                "text": "Results from one routine health record study suggested no evidence of a di erence in risk (RR 1.04, 95% CI 0.15 to 7.29; I 2 = NA), with no di erence in the number of major malformations in children exposed to CZP (N = 113) and children exposed to LEV (N = 118) (Analysis 68.1).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.03 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "68.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.The EURAP 2018 collaboration reported the prevalence of MCM was 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM.No direct statistical comparison was made at the group level; investigations were made across di erent doses of the two ASMs (see oxcarbazepine dose and topiramate dose sections).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "69.5.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 70.1).However, available data showed there were 1/61 cases of major malformations in children exposed to OXC and 2/49 cases in children exposed to TPM, based on data from two studies (Norwegian Health Record Registers; Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "70.1.2"
            },
            {
                "text": "We could not estimate a RR from four cohort studies due to there being no reported neural tube malformations in children exposed to OXC (N = 266) or children exposed to TPM (N = 418) (Analysis 70.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "70.2.1"
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of neural tube anomalies in those exposed to OXC was 0% (0/333) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "70.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "70.2.2"
            },
            {
                "text": "Pooled results from five cohort studies suggested no evidence of a di erence in risk (RR 0.80, 95% CI 0.09 to 6.81; I 2 = 0%), with no di erence in the number of cardiac malformations in children exposed to OXC (N = 269) and children exposed to TPM (N = 419) (Analysis 70.3).The RD also suggested no di erence in the level of risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "70.3.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In the EURAP 2018 data, the prevalence of cardiac anomalies in those exposed to OXC was 1.20% (4/333) and 1.97% for children exposed to TPM (3/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "No included studies reported data on this outcome.In the EURAP 2018 data, the prevalence of cle malformations (other oro-facial not specifically reported) in those exposed to OXC was 0.30% (1/333) and 0% for children exposed to TPM (0/152).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "70.3.2"
            },
            {
                "text": "No included studies reported data on this outcome.Pooled results from four cohort studies suggested no evidence of a di erence in risk (RR 0.40, 95% CI 0.07 to 2.44; I 2 = 0%), with no di erence in the number of skeletal/limb malformations in children exposed to OXC (N = 266) and children exposed to TPM (N = 418) (Analysis 70.5).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "70.4.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "70.5.2"
            },
            {
                "text": "Pooled results from two cohort studies suggested no evidence of a di erence in risk (RR 4.48, 95% CI 0.24 to 82.23;I 2 = NA), with no di erence in the number of major malformations in children exposed to OXC (N = 186) and children exposed to ZNS (N = 91) ( Analysis 71.1).The RD also suggested no di erence in the level of risk (RD 0.02, 95% CI -0.01 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "71.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "71.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported cases of neural tube malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (Analysis 71.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "71.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "71.2.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported cases of cardiac malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (Analysis 71.3).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "71.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "71.3.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported cases of oro-facial cle / craniofacial malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (Analysis 71.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "71.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "71.4.2"
            },
            {
                "text": "We were unable to estimate a RR from one study due to there being no reported cases of skeletal/limb malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (Analysis 71.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "71.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "71.5.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 6.00, 95% CI 0.30 to 118.36,I 2 = NA), with no di erence in the number of major malformations in children exposed to PRM (N = 2) and children exposed to TPM (N = 53) (Analysis 72.1).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.44 to 0.41; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "72.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "72.5.2"
            },
            {
                "text": "Pooled results from six cohort studies suggested no evidence of a di erence in risk (RR 0.74, 95% CI 0.39 to 1.40; I 2 = 21%), with no di erence in the number of major malformations in children exposed to PRM (N = 103) and children exposed to VPA (N = 491), (Analysis 73.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.13 to 0.04; I 2 = 1%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "73.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.27, 95% CI 0.09 to 17.39,I 2 = NA), with no di erence in the number of major malformations in children exposed to PRM (N = 3) and children exposed to VPA (N = 268) (Analysis 73.1).The RD also suggested no di erence in the level of risk (RD -0.10, 95% CI -0.42 to 0.23; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "73.1.2"
            },
            {
                "text": "Included studies did not reach the threshold for reporting of the meta-analysis (Analysis 73.2).However, available data showed there were 0/39 cases of neural tube malformations in children exposed to PRM and 5/45 cases in children exposed to VPA, based on data from two studies (Milan Study 1999; Pardi 1982).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "73.2.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "73.2.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 73.3).However, available data showed there were 1/39 cases of cardiac malformations in children exposed to PRM and 0/45 cases in children exposed to VPA, based on data from two studies (Milan Study 1999; Pardi 1982).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "73.3.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "73.3.2"
            },
            {
                "text": "We were unable to estimate a RR from two studies due to there being no reported oro-facial cle /craniofacial malformations in children exposed to PRM (N = 39) or VPA (N = 45).(Analysis 73.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "73.4.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "73.4.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 73.5).However, available data showed there were 0/39 cases of skeletal/limb malformations in children exposed to PRM and 1/45 cases in children exposed to VPA, based on data from two studies (Milan Study 1999; Pardi 1982).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "73.5.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "73.5.2"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to LEV (N = 12) or LAC (N = 1) (Analysis 74.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "74.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "74.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "74.1.2"
            },
            {
                "text": "We could not estimate RR from one cohort study as there were no malformations observed in children exposed to CBZ (N = 7) and children exposed to LAC (N = 1) (Analysis 75.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "75.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "75.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "75.1.2"
            },
            {
                "text": "We were unable to estimate the RR for one cohort study due to there being no major malformations observed in children exposed to OXC (N = 4) or LAC (N = 1) (Analysis 76.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "76.1.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to PB (N = 2) and children exposed to LAC (N = 1) (Analysis 77.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "77.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "77.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "77.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one cohort study due to there being no major malformations observed in children exposed to LAC (N = 1) or ZNS (N = 1) (Analysis 78.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "78.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "78.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "78.1.2"
            },
            {
                "text": "We could not estimate RR from one cohort study as there were no malformations observed in children exposed to GPB (N = 14) and children exposed to PGB (N = 1) (Analysis 79.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "79.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "79.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "79.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 80.1).However, available data showed there were 0/18 cases of major malformations in children exposed to GBP and 2/48 cases in children exposed to CZP from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "80.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "80.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 81.1).However, available data showed there were 4/44 cases of major malformations in children exposed to VPA and 0/5 cases in children exposed to BNZ from two studies (Jimenez 2020; Melikova 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "81.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "81.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "81.1.2"
            },
            {
                "text": "We were unable to estimate a RR from two cohort studies due to there being no malformations observed in children exposed to LTG (N = 26) and children exposed to BNZ (N = 5) (Analysis 82.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "82.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "82.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "82.1.2"
            },
            {
                "text": "We were unable to estimate a RR from two cohort studies due to there being no malformations observed in children exposed to LEV (N = 18) and children exposed to BNZ (N = 5) (Analysis 83.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "83.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "83.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "83.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 84.1).However, available data showed there were 1/43 cases of major malformations in children exposed to CBZ and 0/5 cases in children exposed to BNZ, based on data from two studies (Jimenez 2020; Melikova 2020).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "84.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "84.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "84.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to OXC (N = 4) and children exposed to BNZ (N = 2) (Analysis 85.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "85.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "85.1.2"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to PB (N = 2) or BNZ (N = 2) (Analysis 86.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "86.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "86.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "86.1.2"
            },
            {
                "text": "We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to OXC (N = 4) and children exposed to BNZ (N = 2) (Analysis 87.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "87.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "87.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "87.1.2"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ZNS (N = 1) or BNZ (N = 2) (Analysis 88.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "88.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "88.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "88.1.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.67, 95% CI 0.07 to 1.87, I 2 = NA), with no di erence in the number of major malformations in children exposed to CZP (N = 26) and children exposed to TPM (N = 53) (Analysis 89.1).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.09 to 0.05; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "89.1.1"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.37, 95% CI 0.03 to 15.83,I 2 = 0%), with no di erence in the number of major malformations in children exposed to CZP (N = 26) and children exposed to TPM (N = 53) (Analysis 89.1).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.09 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "89.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "89.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 90.1).However, available data showed there were 0/26 cases of major malformations in children exposed to CZP and 1/19 cases in children exposed to OXC, based on data from one study (Australian Epilepsy and Pregnancy Register).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "90.1.1"
            },
            {
                "text": "Pooled results from two routine health record studies suggested no evidence of a di erence in risk (RR 0.81, 95% CI 0.13 to 5.06; I 2 = 0%), with no di erence between children exposed to CZP (N = 161) and children exposed to OXC (N = 61) (Analysis 90.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.04 to 0.05; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "90.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "90.1.2"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or COZ (N = 2) (Analysis 91.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "91.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "91.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "91.1.2"
            },
            {
                "text": "We were unable to estimate the RR for one cohort study due to there being no reported major malformations observed in children exposed to CZP (N = 48) or ESM (N = 8) (Analysis 92.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "92.1.1"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 92.1).However, available data showed there were 2/48 cases of major malformations in children exposed",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "92.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews to CZP and 0/8 cases in children exposed to ESM, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or children exposed to PRG (N = 1) (Analysis 93.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "93.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "93.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "93.1.2"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or PRM (N = 2) (Analysis 94.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "94.1.1"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 94.1).However, available data showed there were 2/48 cases of major malformations in children exposed to CZP and 0/3 cases in children exposed to PRM, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "94.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "94.1.2"
            },
            {
                "text": "We were unable to estimate RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or VGB (N = 1) (Analysis 95.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "95.1.1"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 95.1).However, available data showed there were 2/48 cases of major malformations in children exposed to CZP and 0/3 cases in children exposed to VGB, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "95.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "95.1.2"
            },
            {
                "text": "We were unable to estimate a RR for two cohort studies due to there being no major malformations observed in children exposed to TPM (N = 7) or BNZ (N = 5) (Analysis 96.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "96.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "96.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "96.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.56, 95% CI 0.04 to 8.03, I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 5) and children exposed to VPA (N = 290) (Analysis 97.1).The RD also suggested no di erence in the level of risk (RD -0.15, 95% CI -0.37 to 0.08; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "97.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.56, 95% CI 0.04 to 8.84, I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 8) and children exposed to VPA (N = 268) (Analysis 97.1).The RD also suggested no di erence in the level of risk (RD -0.10, 95% CI -0.25 to 0.06; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "97.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "97.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.39, 95% CI 0.10 to 20.37,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 4) and children exposed to CBZ (N = 409) (Analysis 98.1).The RD also suggested no di erence in the level of risk (RD -0.06, 95% CI -0.28 to 0.16; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "98.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.37, 95% CI 0.09 to 20.78,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 8) and children exposed to CBZ (N = 703) (Analysis 98.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.19 to 0.11; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "98.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "98.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ESM (N = 5) or PRM (N = 2) (Analysis 99.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "99.1.1"
            },
            {
                "text": "We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or PRM (N = 3) (Analysis 99.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "99.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.We were unable to estimate the RR for one cohort study due to there being no reported major malformations observed in children exposed to ESM (N = 5) or PB (N = 2) (Analysis 100.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "99.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 100.1).However, available data showed there were 0/8 cases of major malformations in children exposed to ESM and 1/7 cases in children exposed to PB, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "100.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "100.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 101.1).However, available data showed there were 0/5 cases of major malformations in children exposed to ESM and 1/44 cases in children exposed to PHT, based on data from one study (Australian Epilepsy and Pregnancy Register).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "101.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.77, 95% CI 0.05 to 12.42, I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 8) and children exposed to PHT (N = 103) (Analysis 101.1).The RD also suggested no di erence in the level of risk (RD -0.07, 95% CI -0.23 to 0.09; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "101.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "101.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 102.1).However, available data showed there were 0/5 cases of major malformations in children exposed to ESM and 1/19 cases in children exposed to OXC, based on data from one study (Australian Epilepsy and Pregnancy Register).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "102.1.1"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no reported no major malformations observed in children exposed to ESM (N = 8) or OXC (N = 4) (Analysis 102.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "102.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "102.1.2"
            },
            {
                "text": "103.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM versus VGB",
                "sec_num": "103"
            },
            {
                "text": "We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ESM (N = 5) or VBG (N = 1) (Analysis 103.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "103.1.1"
            },
            {
                "text": "We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or VGB (N = 3) (Analysis 103.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "103.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "103.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.65, 95% CI 0.11 to 24.30,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 5) and children exposed to LTG (N = 406) (Analysis 104.1).The RD also suggested no di erence in the level of risk (RD -0.05, 95% CI -0.27 to 0.17; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "104.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.12, 95% CI 0.07 to 19.24,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 8) and children exposed to LTG (N = 90) (Analysis 104.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.20 to 0.11; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "104.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "104.1.2"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or TPM (N = 1) (Analysis 105.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "105.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "105.1.2"
            },
            {
                "text": "106.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM vs GBP",
                "sec_num": "106"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "106.1.1"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to ESM (N = 8) or GBP (N = 18) (Analysis 106.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "106.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "106.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.67, 95% CI 0.15 to 18.73, I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 1) and children exposed to VPA (N = 290) (Analysis 107.1).The RD also suggested no di erence in the level of risk (RD -0.15, 95% CI -0.75 to 0.45; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "107.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.27, 95% CI 0.09 to 17.39,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 3) and children exposed to VPA (N = 268) (Analysis 107.1).The RD also suggested no di erence in the level of risk (RD -0.10, 95% CI -0.42 to 0.23; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "107.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "107.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 4.18, 95% CI 0.37 to 47.57, I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 1) and children exposed to CBZ (N = 409) (Analysis 108.1).The RD also suggested no di erence in the level of risk (RD -0.06, 95% CI -0.66 to 0.54; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "108.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 3.09, 95% CI 0.23 to 42.31,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 3) and children exposed to CBZ (N = 703) (Analysis 108.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.36 to 0.28; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "108.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to VGB (N = 1) or PRM (N = 2) (Analysis 109.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "108.1.2"
            },
            {
                "text": "We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to VGB (N = 3) or PRM (N = 3) (Analysis 109.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "109.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "109.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "All major malformations 110.1.1 Cohort studies",
                "sec_num": "110.1"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 110.1).However, available data showed there were 0/3 cases of major malformations in children exposed to VGB and 1/7 cases in children exposed to PB, based on data from one study (Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "110.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "110.1.2"
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 111.1).However, available data showed there were 0/1 cases of major malformations in children exposed to VGB and 1/44 cases in children exposed to PHT, based on data from one study (Australian Epilepsy and Pregnancy Register).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "111.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 1.73, 95% CI 0.13 to 25.35,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 3) and children exposed to PHT (N = 103) (Analysis 111.1).The RD also suggested no di erence in the level of risk (RD -0.07, 95% CI -0.40 to 0.28; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "111.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "111.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Included studies did not meet the threshold for reporting of the meta-analysis (Analysis 112.1).However, available data showed there were 0/1 cases of major malformations in children exposed to VGB and 1/19 cases in children exposed to OXC, based on data from one study (Australian Epilepsy and Pregnancy Register).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "112.1.1"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to VGB (N = 3) or OXC (N = 4) (Analysis 112.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "112.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "112.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 3.31, 95% CI 0.25 to 43.03,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 2) and children exposed to LTG (N = 406) (Analysis 113.1).The RD also suggested no di erence in the level of risk (RD -0.05, 95% CI -0.47 to 0.37; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "113.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 2.53, 95% CI 0.16 to 39.34, I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 3) and children exposed to LTG (N = 90) (Analysis 113.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.37 to 0.28; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "113.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "113.1.2"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 9.00, 95% CI 0.51 to 159.15,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 1) and children exposed to TPM (N = 53) (Analysis 114.1).The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.62 to 0.58; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "114.1.1"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to VGB (N = 3) or TPM (N = 1) (Analysis 114.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "114.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "114.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "115.1.1"
            },
            {
                "text": "We were unable to estimate the RR for one routine health record study due to there being no reported no major malformations observed in children exposed to VGB (N = 3) or GBP (N = 18) (Analysis 115.1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "115.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "115.1.2"
            },
            {
                "text": "116.1 All major malformations",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CZP vs PB",
                "sec_num": "116"
            },
            {
                "text": "Included studies did not meet the threshold for inclusion in the meta-analysis (Analysis 116.1).However, available data showed there were 0/27 cases of major malformations in children exposed to CZP and 1/6 cases in children exposed to PB, based on data from two studies (Australian Epilepsy and Pregnancy Register; D'Souza 1991).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "116.1.1"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.26, 95% CI 0.06 to 1.12, I 2 = 0%), with no di erence in the number of major malformations in children exposed to CZP (N = 161) and children exposed to PB (N = 34) (Analysis 116.1).The RD also suggested no di erence in the level of risk (RD -0.07, 95% CI -0.16 to 0.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "116.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "116.1.2"
            },
            {
                "text": "Pooled results from two studies suggested no evidence of a di erence in risk (RR 0.71, 95% CI 0.10 to 5.11, I 2 = 0%), with no di erence in the number of major malformations in children exposed to CZP (N = 27) and children exposed to PHT (N = 66) (Analysis 117.1).The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.13 to 0.06; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "117.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 0.61, 95% CI 0.13 to 2.48, I 2 = NA), with no di erence in the number of major malformations in children exposed to CZP (N = 48) and children exposed to PHT (N = 103) (Analysis 117.1).The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.10 to 0.05; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "117.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "117.1.2"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 2.12, 95% CI 0.13 to 34.10,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 5) and children exposed to LEV (N = 139) (Analysis 118.1)The RD also suggested no di erence in the level of risk (RD -0.04, 95% CI -0.26 to 0.19; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cohort studies",
                "sec_num": "118.1.1"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "118.1.2"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Routine health record studies",
                "sec_num": "118.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "119.1.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 2.68, 95% CI 0.17 to 43.16,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 5) and control children (N = 176) (Analysis 119.1).The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.25 to 0.19; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "119.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "119.1.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "ESM versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "119.1.4"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "All major malformations 120.1.1 VGB versus no medication (in women without epilepsy): cohort studies",
                "sec_num": "120.1"
            },
            {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 8.05, 95% CI 0.64 to 101.76,I 2 = NA), with no di erence in the number of major malformations in children exposed to VGB (N = 1) and control children (N = 176) (Analysis 120.1).The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.63 to 0.57; I 2 = NA).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VGB versus no medication (in women with epilepsy): cohort studies",
                "sec_num": "120.1.2"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VGB versus no medication (in women without epilepsy): routine health record studies",
                "sec_num": "120.1.3"
            },
            {
                "text": "No included studies reported data on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VGB versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "120.1.4"
            },
            {
                "text": "Due to limited numbers, we did not investigate specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "VGB versus no medication (in women with epilepsy): routine health record studies",
                "sec_num": "120.1.4"
            },
            {
                "text": "The publications of EURAP 2018; Samren 1997 required narrative reporting due to their overlap with other research initiatives.Israeli Teratogen Service showed variability in its reporting and, therefore, required narrative reporting for certain outcomes.Further, studies using US Medicaid Registers also required narrative review due to the format of reporting of the monotherapy TPM and GBP pregnancies in women with epilepsy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Studies not included in the meta-analysis and not narratively reported",
                "sec_num": null
            },
            {
                "text": "We reported results from three study types, meta-analysis of data from cohort studies, data from EURAP 2018 and others, and meta-analysis of data from epidemiological health record studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I S C U S S I O N",
                "sec_num": null
            },
            {
                "text": "Each study design has its inherent methodological strengths and weaknesses.We undertook a stratified approach to evidence synthesis to ensure a sensitive approach to combining data and to allow for the development of evidence groupings; this will allow for replication of findings across di erent study types and will also allow for increased confidence in the evidence .",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I S C U S S I O N",
                "sec_num": null
            },
            {
                "text": "The meta-analyses included 17,964 ASM-exposed pregnancies from cohort studies and 7913 from routine health record studies; additional exposed pregnancies from the EURAP collaboration and other studies were reviewed narratively.Individual ASM prevalence of major malformation ranged from 2.0% to 9.8% for cohort study data and 3.6% to 9.7% for studies utilising routine health record data (Table 1 , Figure 3 ).Summary of findings 1 and Summary of findings 2 along with Table 1 , Table 2 , Table 3 , Table 4 , Table 5 , Table 6 and Table 7 provide a summary of the meta-analysis results for all comparisons for risk of major malformation.This update has included the most recent study data, which strengthens the previously identified risk associations for older ASMs such as CBZ, PB and VPA, where the comparisons include large numbers of exposed pregnancies.For other ASMs, there are some di erences in the results across the comparisons, but the better powered comparisons demonstrate an increased risk for PHT and for an overall major malformation risk with CBZ and for TPM.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 395,
                        "end": 396,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 406,
                        "end": 407,
                        "text": "3",
                        "ref_id": "FIGREF0"
                    },
                    {
                        "start": 475,
                        "end": 476,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 485,
                        "end": 486,
                        "text": "2",
                        "ref_id": null
                    },
                    {
                        "start": 495,
                        "end": 496,
                        "text": "3",
                        "ref_id": "TABREF571"
                    },
                    {
                        "start": 505,
                        "end": 506,
                        "text": "4",
                        "ref_id": null
                    },
                    {
                        "start": 515,
                        "end": 516,
                        "text": "5",
                        "ref_id": "TABREF573"
                    },
                    {
                        "start": 525,
                        "end": 526,
                        "text": "6",
                        "ref_id": "TABREF574"
                    },
                    {
                        "start": 537,
                        "end": 538,
                        "text": "7",
                        "ref_id": "TABREF577"
                    }
                ],
                "eq_spans": [],
                "section": "D I S C U S S I O N",
                "sec_num": null
            },
            {
                "text": "Whilst CBZ, PB, PHT, TPM and VPA are associated with an increase in the risk of major malformation, the level of risk varies between the four ASMs.For example, CBZ showed a lower overall major malformation risk rate than PB and VPA, and a lower risk for specific major malformation types compared to some ASMs (e.g.PB or TPM).All ASMs, regardless of their own association with an increased risk, carried a lower risk than VPA-exposure which had the highest prevalence from both cohort (9.8%) and routine health record data (9.7%).LTG remains the lowest risk ASM with adequate cohort size (N => 4700 pregnancies from cohort studies and N = 2502 from routine health record studies).LTG does appear to have a dose e ect, as do CBZ, PB and VPA.The number of LEVexposed pregnancies remains more limited than LTG but, in direct comparison, there is currently no significant di erence between these two ASMs, and LEV-exposed children have a lower overall",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I S C U S S I O N",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews major malformation risk than CBZ, VPA and PHT.TPM exposure was associated with a higher overall major malformation risk in comparison to LTG, but not other ASMs; this finding may be due to relatively small numbers of participants in the TPM studies and only a few malformation events.TPM exposure, however, was associated with higher specific risks of oro-facial, craniofacial, skeletal and limb malformations in comparison to LTG, LEV, CBZ, but not in comparison to the two control groups; but specific major malformation data were limited for the control cohorts.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "There remains limited information for GBP, OXC, TPM and ZNS and other 'newer' medications.The evidence for each ASM monotherapy is summarised below.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "CBZ was the most frequently investigated ASM both in terms of the number of publications and the number of included pregnancies (over 8220).The pooled major malformation prevalence for CBZ was 4.7% (95% CI, 3.7 to 5.9) from cohort studies, 4.0% (95% CI 3.0 to 5.4) for routine health record studies and 2.9% (95% CI 2.9 to 5.4); these were relatively consistent with the 5.5% (95% CI 4.5 to 6.6) prevalence from EURAP 2018 (Figure 3 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 431,
                        "end": 432,
                        "text": "3",
                        "ref_id": "FIGREF0"
                    }
                ],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "In comparison to both children born to women without epilepsy and children born to women with untreated epilepsy, pooled data from the cohort studies found that children exposed to CBZ in utero had an increased risk of having a major malformation, with the di erence in risk ranging from 1% to 2%, respectively.The findings from routine health record studies are more mixed.In the larger of the two comparisons, CBZ was significantly associated with a higher risk of a major malformation, which was consistent with the cohort study data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "In comparison to unexposed control children (both groups), there was no specific malformation which was increased above the background rate provided by the control children.Data were limited in terms of the specific malformation risk, mainly due to the absence of control data from some large pregnancy and epilepsy registry studies (e.g.North American Epilepsy and Pregnancy Register; UK and Ireland Epilepsy and Pregnancy Register) and reporting of this level of detail from the population datasets (e.g.Denmark Health Record Registers; UK Clinical Research Practice Database; UK Health Record THIN Register).This likely contributed to the non-significant outcomes found for neural tube malformations, which has been an association found by others using di erent methodologies (Jentink 2010b ).",
                "cite_spans": [
                    {
                        "start": 779,
                        "end": 793,
                        "text": "(Jentink 2010b",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "Data from the cohort studies were more numerous for CBZ-exposed pregnancies compared to other monotherapy ASMs.There was a higher risk of major malformation in comparison to children exposed to LEV or LTG in comparisons which included over 500 pregnancies in each arm, with the risk being 1% higher.However, comparisons at the specific malformation level were not significant; this was likely due to fewer data being available at this level of investigation.The increased risk observed in data from cohort studies was not replicated in studies using databases containing routine health records, however, patient/ event numbers in the databases were smaller than the pooled experience from cohort studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "Despite its associated higher risk, CBZ exposure was associated with a lower level of risk than VPA exposure, with a 5% di erence in overall major malformation risk and a lower risk across neural tube, cardiac, oro-facial and skeletal/limb malformations.Further, while CBZ is comparable to the increased risk from PB, PHT or TPM in data from cohort studies for overall major malformation, the specific malformation risk varied.The association of CBZ exposure with cardiac malformations was lower in comparison to PB or to PHT exposure and lower for skeletal/limb or oro-facial/craniofacial malformation risk when compared to TPM exposure.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "There was no significant increase in risk in comparison to OXC, GBP, PRM or CZP exposure from both cohort and health record studies, but data were more limited for these comparator ASMs currently and caution is required.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "Dose is a key feature of teratogenic malformation risk (Brent 2004 ).Data from EURAP 2018 is the most reliable to investigate dose associations due to its large number of CBZ-exposed pregnancies and its low risk of bias on the domain of outcome measurement.It demonstrates a dose-related risk for CBZ with doses over 700 mg/d carrying a higher risk, although even their lower dose group had a high level of risk in comparison to children exposed to LTG (EURAP 2018).",
                "cite_spans": [
                    {
                        "start": 55,
                        "end": 66,
                        "text": "(Brent 2004",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Carbamazepine (CBZ)",
                "sec_num": null
            },
            {
                "text": "Data relating to the use of monotherapy clonazepam during pregnancy and child major malformation risk is substantially limited with fewer than 150 pregnancies reported across both cohort and routine health record studies.The generated prevalence reported here was 2.1% (95% CI 0.2 to 17.3%) to 2.5% (95% CI 0.0 to 131.8) but the confidence intervals were very wide, due to the limited data.When compared to other ASMs, however, a lower risk was identified in comparison to VPA exposure, with a risk di erence of 9%.Due to the current limited data available, no firm conclusion can be made currently whether CZP is associated with an increased risk in comparison to control children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Clonazepam (CZP)",
                "sec_num": null
            },
            {
                "text": "Experience with GBP exposure in pregnancy was also limited.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin (GBP)",
                "sec_num": null
            },
            {
                "text": "Outcomes from only 210 reported pregnancies could be included in our meta-analysis.The pooled prevalence of major malformation was 2.0% (95% CI 0.1 to 32.2) from cohort studies, with too few data being available from studies using routine health records to provide a pooled prevalence rate.We found no di erence between the children exposed to GBP compared with either type of control group, but caution is warranted due to limited numbers.Data which could not be included in meta-analysis, from the US Medicaid Registers, found that children exposed to GBP (N = 347) for the indication of maternal epilepsy were not at a greater risk of major malformation, which matched the wider finding from 3745 GBP-exposed pregnancies (any indication).Whilst this study may o er reassurance, caution is required as the indications were not predominantly epilepsy and, therefore, there may be di erences in typically prescribed doses; replication of this finding is also required in another adequately powered cohort.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin (GBP)",
                "sec_num": null
            },
            {
                "text": "We found no di erence in overall major malformation rate or in the specific malformations investigated for the children exposed to GBP compared to CBZ, LTG, LEV, OXC, PHT, PB, TPM and ZNS, but there was a very limited number of GBP-exposed children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin (GBP)",
                "sec_num": null
            },
            {
                "text": "In comparison to the children exposed to VPA, children exposed",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Gabapentin (GBP)",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews to GBP in utero had a significantly lower risk (8%) of having a malformation than children exposed to VPA, but data were too limited to investigate specific malformation di erences.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Data for GBP dose and malformation rate were limited from cohort studies but data from the US Medicaid Registers failed to find an association between higher doses of GBP and a higher risk of malformation.However, the vast majority of women taking GBP were doing so for conditions other than epilepsy and, therefore, caution is warranted.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The use of LTG has increased over the last decade in women of childbearing age (Ackers 2009; Man 2012; Wen 2015).The pooled prevalence of major malformation for LTG was 2.7% (95% CI 1.9 to 3.8%) from cohort studies, 3.5% (95% CI 2.5 to 4.9) from routine health record studies, and 2.9% (95% CI 2.3 to 3.7) from the EURAP 2018 collaboration.Most of the evidence indicated no di erence in the overall major malformation rate between the children exposed to LTG and either type of control group.However, in comparison to children born to women without epilepsy, there was a significant di erence from the pooled cohort data, with the risk being increased by 1% for the children exposed to LTG.Whilst levels of heterogeneity were not increased overall, one study had a much higher rate of malformation in the LTG group.Further, a larger LTG-exposed group was available for comparison to the women with epilepsy who were not treated, which showed the LTG major malformation risk was not significantly di erent from the control children for overall malformation rate or for the specific malformation types investigated; this was consistent with the non-significant finding from the routine health record studies in comparison to both control groups.Further, no increase in specific malformation types were identified, and data from the US Medicaid Registers failed to find an association with oral cle malformations in over 2000 LTG-exposed children in comparison to control children who were not exposed to ASMs.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine (LTG)",
                "sec_num": null
            },
            {
                "text": "In comparison to LEV, which has also seen a significant increase in use in women of childbearing age in a lot of countries (Meador 2009; Wen 2015), there were no significant di erences for LTG in either the overall major malformation rate or the specific malformation types investigated.Children exposed to LTG also did not di er either in terms of overall major malformation rate or in terms of specific malformations compared with children exposed to OXC, CZP, GBP and ZNS; however, data were limited for all of these comparisons due to small numbers of OXC, CZP, GBP and ZNSexposed pregnancies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine (LTG)",
                "sec_num": null
            },
            {
                "text": "The children exposed to LTG were at a significantly lower risk of overall major malformation compared with children exposed to CBZ, PB, PHT and TPM exposures (see results for specific risk levels) in cohort study data.Routine health record studies did not replicate this, however, were limited in terms of numbers of included LTG-exposed pregnancies in comparison to PB, PHT and TPM and, therefore, were perceived as less reliable.Analyses of cohort study data showed that, at the specific malformation level, children exposed to LTG were at a lower risk of cardiac malformations in comparison to PB and PHT exposures and fewer skeletal malformations than children exposed to TPM and PHT.This latter finding was also observed in the large cohort from the US Medicaid Registers.Finally, children exposed to LTG had a threefold lower risk of overall major malformation when compared to the children exposed to VPA, with a risk di erence showing that the significant reduction in risk was 6% for children exposed to LTG.Neural tube, cardiac, oro-facial cle , craniofacial, skeletal and limb malformations were all significantly lower for the LTG-exposed children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine (LTG)",
                "sec_num": null
            },
            {
                "text": "The large, well-designed EURAP 2018 study has demonstrated a dose relationship between LTG treatment and major malformation risk, with exposures to LTG \u2264 325 mg/d associated with the lowest malformation prevalence.Other studies did not find a dose relationship, however, the EURAP 2018 collaboration is by far the largest and most standardised in their assessment of the malformation, comprising of participants from 42 countries (N = 2514).Therefore, higher doses of LTG may be associated with higher levels of risk and this should be considered when prescribing doses over 325 mg/d.It is possible that this dose association may account, at least in part, for the variation seen in the outcome in one of the control comparisons.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Lamotrigine (LTG)",
                "sec_num": null
            },
            {
                "text": "The frequency of data and the number of included pregnancies exposed to LEV were more limited than for CBZ, LTG or VPA.There were 1242 LEV-exposed pregnancies included from cohort data across all comparisons and just 248 from studies employing routine health record data currently.This delay is likely due in part to the time it takes for adequate numbers of women taking newer ASMs to accumulate, however, it undermines counselling for a now commonly established medication (Meador 2009; Wen 2015).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Levetiracetam (LEV)",
                "sec_num": null
            },
            {
                "text": "The pooled prevalence for major malformation occurrences following LEV-exposure was 2.6% (95% CI 1.6 to 4.4) for cohort study data, 2.8% (95% CI 0.0 to 321.9) for routine health record study data (which had large confidence intervals) and 2.8% (95% CI 1.7 to 4.5) from EURAP 2018.There was no significant di erence between the children exposed to LEV and control children in the meta-analysis for overall major malformation rate; these comparisons also both contained > 1000 pregnancies in each arm.Data pertaining to specific malformation types in comparison to control children were limited, however, and it is not possible to draw conclusions until more data are available.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Levetiracetam (LEV)",
                "sec_num": null
            },
            {
                "text": "In comparison to other ASM treatments, children exposed to LEV were not significantly di erent from children exposed to LTG in terms of overall major malformation prevalence or the specific malformation types investigated.In addition, we found no significant di erence between children exposed to LEV compared with those exposed to GBP, OXC, CZP, TPM ZNS or PRM, although data within these comparisons were somewhat limited.Children exposed to LEV had a lower overall MCM rate than the children exposed to CBZ, PB and PHT exposures, but there was no di erence in terms of the specific malformation types investigated.While the overall major malformation risk was not significantly di erent for the children exposed to LEV versus those exposed to TPM, the children exposed to LEV were at lower risk of having an orofacial/craniofacial, skeletal or limb malformation in comparison to the TPM-exposed children.Additionally, children exposed to LEV had a lower specific risk of developing a cardiac malformation in comparison to PB-exposed children.Finally, the children exposed to LEV had a 7 to 8% lower risk of overall malformations compared with the children exposed to VPA, with a lower risk identified for all investigated specific types of malformations for the children exposed to LEV.Caution is required, therefore, regarding the malformation risk with above average doses of LEV, until more data are available.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Levetiracetam (LEV)",
                "sec_num": null
            },
            {
                "text": "Data for pregnancy outcomes following exposure to OXC were limited to just under 400 pregnancies in cohort studies and 507 pregnancies from routine health record studies.The prevalence of major malformation was 2.8% (95% CI 1.1 to 6.6) versus 4.8% (95% CI 0.7 to 31.5) with routine health record studies containing more OXC-exposed pregnancies across comparisons.The prevalence reported from EURAP 2018 for 333 OXC monotherapy-exposed pregnancies was 3.0% (95% CI 1.4 to 5.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine (OXC)",
                "sec_num": null
            },
            {
                "text": "In comparison to control children, the pooled routine health record study data found no elevated risk for OXC exposure in comparison to controls; these results were similar in the cohort study data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine (OXC)",
                "sec_num": null
            },
            {
                "text": "Given the numbers of included OXC-exposed pregnancies across both study types, further research is required for conclusions to be drawn in regard to OXC exposure and major malformation outcome.While limited comparisons to other ASMs could be made, where evidence was available, there was no significant di erence between the overall major malformation rate or the specific malformations investigated compared with children exposed to CBZ, CZP, LEV, LTG, GBP, PHT, PB, TPM, PRM and ZNS.Children exposed to OXC were at a significantly lower risk of having an major malformation of any type compared with children exposed to VPA, with the risk di erence being 4 to 6% depending on the study type.There were very limited data pertaining to specific malformation types, and caution is required.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine (OXC)",
                "sec_num": null
            },
            {
                "text": "Only EURAP 2018 reported dose and malformation rates for OXCexposed pregnancies.Whilst they did not compare lower versus higher OXC dose, they did report that certain dose levels of OXC were comparable to lower-dose LTG.More studies of OXC-exposed pregnancies are required, however, before it is determined whether a higher level of OXC dose carries a higher malformation risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oxcarbazepine (OXC)",
                "sec_num": null
            },
            {
                "text": "Despite years of use, data from prospective studies investigating PB as monotherapy were surprisingly limited, with only 840 monotherapy-exposed pregnancies across the di erent comparisons and study types.The data pooled from included studies generated a major malformation prevalence of 6.3% (95% CI 4.8 to 8.3) from cohort studies and 8.8% (95% CI 0.0 to 9722.4) from routine health record studies; the latter was limited in cohort size and the prevalence should be interpreted with caution.There was a prevalence of 6.5% (95% CI 4.2 to 9.9) from EURAP 2018.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital (PB)",
                "sec_num": null
            },
            {
                "text": "The results regarding PB-exposure in comparison to control children demonstrated variable results.We found a significantly increased risk of overall major malformation compared with children born to women without epilepsy, with a risk di erence of 4%.However, we found no significant di erence compared with children born to women without epilepsy.However, both comparisons included under 500 PB-exposed pregnancies, which may account for the unstable pattern of the findings.Routine health record data studies included too few PB-exposed pregnancies at this time to provide reliable estimates.Data pertaining to specific malformations were extremely limited or missing and likely contributed to the non-significant di erences found for PB in comparison to the control children.This is certainly the case for cardiac malformations, where rates of cardiac malformations are increased in comparison to numerous other ASMs exposures.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital (PB)",
                "sec_num": null
            },
            {
                "text": "In comparison to other ASMs, children exposed to PB were not at a significantly increased rate of overall major malformation compared with children exposed to CBZ, CZP, GBP, PHT, OXC, TPM, PRM, LEV and ZNS exposures; but the comparison to CBZ exposure was the only one where the PB-exposed group had over 500 pregnancies.PB exposure was significantly associated with an increased risk of oro-facial cle s and craniofacial malformations when compared to LEV or LTG exposures.Children exposed to PB had a higher overall major malformation than the children exposed to LTG, but a lower risk compared with the children exposed to VPA, with the risk being 4% lower.Therefore, despite both PB and VPA being associated with an increased risk of being born with an major malformation, the risk associated with VPA is significantly higher, including for cardiac malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital (PB)",
                "sec_num": null
            },
            {
                "text": "The majority of studies did not investigate or report on a potential relationship between dose of PB and major malformation risk, due to limited included pregnancies.A dose-mediated risk was also apparent for cardiac malformations, with the prevalence increasing from 1% to 8% for doses < 150 mg/d and those \u2265 150 mg/d, respectively (EURAP 2018).Samren 1997 also found a dose e ect for PB.Given the size of the EURAP 2018 cohort and their standardised approach to reviewing, it is concluded that there is likely a strong dose relationship for PB.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenobarbital (PB)",
                "sec_num": null
            },
            {
                "text": "The pooled prevalence of major malformation in the PHT-exposed children was 5.4% (95% CI 3.6 to 8.1%) for cohort studies, 6.8% (95% CI 0.1 to 701.2%) for routine health record studies and 6.4% (95% CI 2.8 to 12.2%) for EURAP 2018.There were 1327 PHT-exposed pregnancies included in the cohort studies, but just 103 children reported from routine health record studies.The children exposed to PHT were at a significantly increased risk in comparison with both types of control group, with the di erence in risk being 3% in the cohort data.However, we found no association between PHT and specific major malformation types; although data were limited in these comparisons due to the limited control data reported in publications from the epilepsy and pregnancy registers.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenytoin (PHT)",
                "sec_num": null
            },
            {
                "text": "In comparison to other ASMs, children exposed to PHT were not at an increased risk of overall major malformation compared with children exposed to CZP, CBZ, GBP, OXC, TPM, PRM, PB or ZNS; however, data comparing PHT with the 'newer' ASMs were limited and caution is needed in the interpretation of these nonsignificant findings.In contrast, compared to studies with a greater number of included children, the children exposed to PHT were at an increased risk of overall major malformation compared with children exposed to LTG or LEV, with the risk di erence indicating a 2% increase in major malformation; however, these RDs were not statistically significant.In contrast, the children exposed to PHT were significantly less likely to have a major malformation than the children exposed to VPA, with the di erence in risk being 5% lower.Further, the children exposed to PHT were also at a lower risk",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Phenytoin (PHT)",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews than those exposed to VPA for their risk of neural tube, cardiac and skeletal/limb malformations.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In terms of specific malformations, children exposed to PHT were less likely than those exposed to PB to have a craniofacial malformation.There was a noted increase in cardiac, skeletal and limb malformations for the PHT-exposed children compared with those exposed to LTG, which was one of the larger comparisons in terms of PHT-exposed pregnancies.Finally, the rates of neural tube, cardiac, skeletal and limb malformations were significantly lower for the children exposed to PHT in comparison to the VPA-exposed children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The majority of studies did not report on whether the risk of being born with a major malformation was associated with dose of PHT; however, those that did investigate such an association did not show a consistent pattern (Kaaja 2003; Kaneko 1999; Motherisk Registry; North American Epilepsy and Pregnancy Register; Samren 1997), therefore, the conclusion around dose e ects is uncertain.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "This is an old ASM with limited utilisation currently.Evidence pertaining to PRM was extremely limited to 112 pregnancies and caution is warranted when interpreting results.Pooled data from included cohort studies gave a malformation prevalence of 7.9% (95% CI 2.6 to 21.5%).There were just 3 PRM-exposed cases reported in the routine health record studies.The children exposed to PRM were at a higher risk of overall major malformation in comparison to the children born to women with an untreated epilepsy, which contained the larger number of PRM-exposed pregnancies.A comparable major malformation risk was found for PRM in comparison to PHT, PB and VPA exposures, but the data were limited.There was either extremely limited or no data available to compare risks to other monotherapy ASMs.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primidone (PRM)",
                "sec_num": null
            },
            {
                "text": "Only one study of 19 PRM cases investigated the dose of PRM and outcome (Kaneko 1999).Therefore, it remains unknown whether there is an association between PRM dose and increased major malformation risk.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primidone (PRM)",
                "sec_num": null
            },
            {
                "text": "Experience with TPM was limited to 510 exposed pregnancies in cohort studies (3.9%, 95% CI 2.3 to 6.5%).There were 49 cases from routine health record investigations which met the criteria for being included in the meta-analyses (4.1%, 95% CI 0.0 to 27,060.0);therefore, caution is required when considering our results.The EURAP 2018 collaboration is also limited currently in its experience with TPM exposures with just 152 exposed pregnancies with a major malformation prevalence of 3.9% (95% CI 1.5 to 8.4%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate (TPM)",
                "sec_num": null
            },
            {
                "text": "In pooled cohort data, in comparison to children born to women without epilepsy, children exposed to TPM had a higher rate of being born with an major malformation with the risk di erence being 3%.We found no significant di erence compared with the no medication control group, but this comparison had even fewer TPM cases.Pooled data were too limited here to allow for the investigation of specific malformation outcomes in comparison to control children.We found no significant di erence in the rate of major malformation compared with children exposed to CBZ, CZP GBP, PHT, PB, PRM, OXC and ZNS.We found a significant increase in the rate of major malformation for the children exposed to TPM compared with the children exposed to LTG, with skeletal/limb and oro-facial cle /craniofacial being specifically increased.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate (TPM)",
                "sec_num": null
            },
            {
                "text": "Data from US Medicaid Registers provides the largest dataset regarding oro-facial cle s and reported an association between topiramate and oral cle s from medical reimbursement databases (4.1 per 1000 live births).This is similar to a retrospective study which was not included in this review (Mines 2014), in a casecontrol study (Margulis 2012) , and in a previous meta-analysis (Alsaad 2015) which were beyond the inclusion criteria of this review.This demonstrates the cohort sizes which are required to investigate very specific rare events, such as specific types of major malformation.",
                "cite_spans": [
                    {
                        "start": 330,
                        "end": 345,
                        "text": "(Margulis 2012)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate (TPM)",
                "sec_num": null
            },
            {
                "text": "The overall major malformation risk was comparable to that for LEV or CBZ-exposed children, but the LEV-exposed children were at a lower risk of skeletal and limb malformations, as were the CBZexposed children.The children exposed to TPM had a lower cardiac risk than the children exposed to PB, and they were less likely to have a malformation of any type compared with the children exposed to VPA, with the di erence in risk being 7%.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate (TPM)",
                "sec_num": null
            },
            {
                "text": "Most studies were too limited to be able to provide reliable investigations into a dose association, however, Hernandez-Diaz, using (US Medicaid Registers) data, found that the adjusted RRs for oro-facial cle s at doses \u2264 100 mg/d and > 100 mg/d were 1.64 (95% CI 0.53 to 5.07) and 5.16 (95% CI 1.94 to 13.73) for lower and higher doses, respectively.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Topiramate (TPM)",
                "sec_num": null
            },
            {
                "text": "In utero exposure to VPA and its possible association with an increased teratological risk has been discussed in the literature since the 1980s, when the first case reports emerged documenting children with a specific constellation of malformations following exposure to VPA (Ardinger 1988 In the meta-analyses reported here a consistent pattern emerged: children exposed to VPA were at an increased risk of both a higher overall major malformation risk and risk of specific malformations including neural tube, cardiac, oro-facial cle , craniofacial, skeletal and limb malformations.The prevalence of major malformation following exposure to VPA in the womb was 9.8% (95% CI 8.1 to 11.9) for cohort studies, with similar rates from routine health record studies (9.7%, 95% CI 7.1 to 13.4) and from EURAP 2018 (10.3, 95% CI 8.8 to 12.0%).Children exposed to VPA were at an increased risk of being born with a major malformation compared with both the children of women without epilepsy and the children of women with untreated epilepsy, with the risk di erence being 7% and 6% compared with the respective control groups.Analysis of the risks associated with VPA treatment at the specific malformation",
                "cite_spans": [
                    {
                        "start": 275,
                        "end": 289,
                        "text": "(Ardinger 1988",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Valproate (VPA)",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews level was limited by a lack of control data; however, children exposed to VPA remained at a significantly increased risk for neural tube, cardiac and skeletal malformations compared with control children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In comparison to other ASMs, in the meta-analyses reported here, children exposed to VPA were at an increased risk of major malformation compared with children exposed to CBZ, CZP, GBP, LEV, LTG, TPM, OXC, PB and PHT, with the ZNS group being nonsignificant but too being small to make a reliable comparison.The increased risk associated with VPA exposure ranged from 4% to 9%, depending on the comparator ASM.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "At the specific malformation level, children exposed to VPA were at an increased risk of neural tube malformation compared with the children exposed to CBZ, LEV, LTG and PHT.We did not note any increase in the specific malformation type analyses compared to children exposed to GBP, OXC, PB or TPM, but this is most likely due to limited data.However, we found an increased rate of cardiac malformation compared to CBZ, LEV, LTG, TPM, PHT and an equal cardiac risk in comparison to the increased risk for PBexposed children.Oro-facial cle and craniofacial malformations were also significantly more common in the children exposed to VPA compared with children exposed to CBZ, LEV and LTG.There was no di erence in the rate of oro-facial cle or craniofacial malformations compared with TPM, PB or PHT, but these are found to carry their own risks of this malformation type (US Medicaid Registers).Finally, skeletal or limb malformations in children exposed to VPA compared with children exposed to CBZ, LEV, LTG or PHT were significantly higher.All specific malformation comparisons that the data compared with CZP, GBP, ZNS and OXC were too limited for conclusions to be made.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "When weighing up the risks and benefits of VPA treatment, the e ects of VPA on other developmental outcomes including the developing brain should also be considered when considering the level of risk posed by VPA.VPA exposure is now also recognised as a neurobehavioural teratogen, with implications for the future cognitive functioning of the exposed child (Bromley 2014) , and an increased risk of neurodevelopmental disorders such as autistic spectrum disorders (Christensen 2013) ",
                "cite_spans": [
                    {
                        "start": 358,
                        "end": 372,
                        "text": "(Bromley 2014)",
                        "ref_id": null
                    },
                    {
                        "start": 465,
                        "end": 483,
                        "text": "(Christensen 2013)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Either no, or very limited numbers, of pregnancies were found for other ASMs from the searches such as ethosuximide, sulthiame, perampanel, lacosamide or vigabatrin.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other antiepileptic drugs",
                "sec_num": null
            },
            {
                "text": "E orts were made to ensure that the evidence presented here was as complete as possible by including the two dominant research study designs for this area of research; cohort study designs and datasets which contain routinely collected health records.However, we did not include case-control congenital anomaly registers.In these registers, children are enrolled when the presence or absence of a malformation is known and, therefore, we classified recruitment as retrospective (e.g.Jentink 2010a; Jentink 2010b).Further, the nature of this data meant that it could not be directly combined into meta-analysis with the data from the prospective observational studies.Additionally, in order to make the results of this review applicable to the treatment of women with epilepsy, included studies were required to include 70% or greater proportions of women taking ASMs for the treatment of epilepsy.This, however, will have reduced the sample size and may not be necessary.Whilst Christensen and colleagues (Denmark Health Record Registers) in 2021 found no di erence in risk estimates in the children of women with epilepsy in comparison to the children born to women with other indications, Hernandez Diaz and colleagues, using US Medicaid Registers, derived data found that, in the context of TPM, the indication did alter the outcome reported.Further investigations are required to answer whether limiting this review to a high proportion of women with epilepsy is required.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "E orts were made to ensure that the most up-to-date information from the longitudinal research initiatives was utilised, which meant that we o en had to take outcomes for di erent ASMs from a number of di erent papers, or that authors investigated malformation types separately over di erent papers, or published updates for certain ASMs only.The largest challenge in terms of the completeness of the evidence came from some studies not reporting specific monotherapy outcomes or reporting monotherapy and polytherapy outcomes for a particular ASM together (e.g.Richmond 2004; Sabers 2004).However, this appeared to be a more frequent finding with older studies and there was a noticeable trend regarding separate reporting for each ASM for monotherapy exposures.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The final challenge to the completeness of the data was in regard to the risk of specific types of malformations, due in a large part to the failure of included studies to publish specific malformation outcomes for all included groups.Whilst this is undoubtedly due to publication space, providing such information is critical for understanding the risks associated with specific malformation types.As demonstrated, in the case of PB or TPM, an ASM exposure may be associated with specific malformations, so reporting only an overall malformation figure may mask important associations.Further, unclear reporting and di erences in the defining of certain malformation types or groups meant that we could not investigate",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews hypospadias or gastrointestinal malformations, which have been linked to certain ASM exposures (EURAP 2018; Sweden Health Record Registers).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "A few points of heterogeneity were found between included studies, which may limit the completeness of the evidence.Studies varied in how they dealt with the inclusion of foetal deaths or interruptions of pregnancy (with and without malformations) and in whether they counted genetic causes of malformation in their overall prevalence.At the outset of this review, we decided to use the author-defined major malformation rate, as the review authors would be unlikely to have all the data required to determine information about reported major malformations.Considering this, however, we cannot confirm that all the studies applied the same criteria for classifying a major malformation.Further, there were di erences between studies in the time at which the outcome was reported.For example, the UK and Ireland Epilepsy and Pregnancy Register has a major malformation reporting time before three months of age, whilst others included malformation presence at birth (e.g.Bozhinov 2009).Data from the EURAP 2018 collaboration and by Christensen and colleagues (2021) using Denmark Health Record Registers demonstrates that the reviewing of major malformation outcome at 12 months of age leads to an increased detection and, therefore, higher prevalence.Thus, data reported from some studies may in fact be an underestimation of the prevalence of major malformation if the assessment of the child occurs prior to 12 months of age.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Finally, major malformation risk is not the only outcome of importance in pregnancy exposures.Beyond the scope of this review, small-for-gestational-age, prematurity, minor congential malformations as well as longer-term child health and neurodevelopmental outcomes can be altered, with life impacting consequences (Bromley 2014 ; Clayton-Smith 2019; Dean 2000) and, therefore, require consideration when understanding the total impact of an ASM exposure on the developing child.Minor malformations, for example, are an important part of the diagnostic criteria for foetal anticonvulsant syndromes, in particular (Clayton-Smith 2019; Dean 2000) and their presence may lead to a more detailed physical examination to check for more severe physical symptoms of exposure or neurodevelopmental impairment.",
                "cite_spans": [
                    {
                        "start": 315,
                        "end": 328,
                        "text": "(Bromley 2014",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Neurodevelopmental impairments are also a more commonly occurring outcome in the general population and, therefore, will occur more frequently in the ASM-exposed populations and can have a significant impact on quality of life (Bromley 2014; Clayton-Smith 2019).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Strengths of this review update include the creation and advance publication of the review protocol, the clear inclusion criteria, extensive searches, the acquisition of unpublished data, the inclusion of articles not written in English, meta-analysis for all possible comparisons, the consideration of specific as well as overall major malformation risk, the balance of both systematic reviewing and content expertise and the assessment of risk of bias and quality in the non-randomised evidence.Further, we improved the quality of the meta-analyses by stratifying by type of control group and importantly study design.The results across the di erent study types were summarised in meta-analysis separately due to the potential overlap in the cases (e.g. a national epilepsy and pregnancy register may contain the same children with a malformation as a population dataset which utilised routine health records for that same region or population).Further, at the start of this review, there were concerns about likely heterogeneity coming from di erent measurement approaches, periods of follow-up and di erent patterns of maternal indications.However, in comparisons with larger numbers of included exposed pregnancies, the prevalences were similar (Table 1 , Figure 3 ).We therefore take the view that cohort studies and studies utilising population level health records o er complimentary evidence which can be viewed as replicating the results of each other, to ensure evidence consistency across the total available data.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 1257,
                        "end": 1258,
                        "text": "1",
                        "ref_id": "TABREF570"
                    },
                    {
                        "start": 1268,
                        "end": 1269,
                        "text": "3",
                        "ref_id": "FIGREF0"
                    }
                ],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Under the Cochrane guidelines, this review will continue to be updated every two years, or following the publication of a significant amount of new data, to ensure it remains up-to-date which adds further strength.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The methodological quality for each individual study is displayed in the Risk of bias in included studies and in Figure 2 . Randomised controlled trials are thought to be unethical in this area due to the permanence of potential adverse e ects for the foetus.Gold standard evidence for this area would, therefore, comprise data coming from a recruitment approach with low selection bias, prospective follow-up, blinded outcome assessment to a standardised protocol and statistical methods to limit the influence of confounding or mediating variables.Obtaining all of these features in a single study is di icult and di erent study designs have a di erent set of strengths and weaknesses.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 120,
                        "end": 121,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "The RoB ratings provided by an adaption of ROBINS-I, for example, showed that the certain routine health record studies scored at a lower risk of bias than the cohort studies for risk of selection biases, yet the routine health record studies were at higher risk for outcome measurement which was completed in a nonstandardised manner by clinicians who were not blinded to the ASM exposure of the child.To balance these strengths and weaknesses which are inherent within these study designs, a complimentary set of pharmacovigilance approaches are required in order to have an accurate understanding of the data pertaining to possible risk associated with ASM exposures.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "It should be considered that ROBINS-I is not optimised for pregnancy pharmacovigilance studies where the person taking the medication (mother) is not the person in which the outcome in is being assessed (child) and it was challenging to adopt the signalling questions and ratings to function for this review.Further, the recommended GRADE framework for rating the certainty of evidence was not used, as it would produce di erential ratings depending on whether there were di erences between the medications or not.For reviews of pregnancy pharmacovigilance data, bespoke risk of bias and certainty of evidence tools are required.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "In conclusion, our risk of bias review indicates that, across the included studies, there are a number of important biases assessed as high risk which should be taken into account when interpreting the results.The biases, however, were thought to be balanced across the ASMs investigated and, therefore, it is not felt that the findings were due solely to these biases.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "Despite many review articles in this area, there are few systematic reviews where meta-analysis has been conducted and, where they have been completed, there are variations in study methodology (i.e.inclusion criteria).For example, the reviews by Veroniki 2017 and Meador 2008, included both prospective and retrospective studies, studies using population-based electronic healthcare records, and data from case-control studies.Whilst such a wide inclusion criteria led to increased numbers of included pregnancies within the meta-analysis, the comparability of data from these di erent methodological types is unclear.Charlton 2008, for example, had demonstrated di erent rates of malformations from the UK Clinical Research Practice Database in comparison to the UK and Ireland Epilepsy and Pregnancy Register.Further, combining data from population studies using healthcare records with national epilepsy and pregnancy registers may lead to cases being represented twice; which, for rare outcomes, could alter the analyses significantly.We took a more cautious approach and did not combine data from cohort studies with data from studies that used population-level routine health records.Whilst our findings were comparable to the more recent Veroniki 2017 review in regard to VPA, PTM, PB, PHT, and CBZ, we did not have enough data to investigate their finding that ethosuximide is associated with an increased risk of major malformation.Overall, our approach of reviewing and undertaking meta-analysis separately for primary and secondary data sources provides internal comparison and validation of the results which, we feel, is a strength.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Agreements and disagreements with other studies or reviews",
                "sec_num": null
            },
            {
                "text": "Further consistent findings were reported by Jentink 2010b who found the prevalence of malformation following CBZ to be 3.3% based on 2680 CBZ children from eight studies.In contrast to our review, however, Jentink 2010b found a significant association between CBZ exposure and spina bifida.However, as in our review, Jentink 2010a found that eight studies (N = 1565 pregnancies) showed a prevalence rate of 7.5% (95% CI 6.3 to 9.0) in those exposed to VPA, and noted an increase in terms of specific malformations.The data reported here pertaining to LEV is consistent with a previous systematic review (Chaudhry 2014) This updated meta-analysis did not consistently replicate the reported association between TPM exposure and oral cle s, but we did narratively review data from the large US Medicaid Registers study, which reported an association.In a previously completed meta-analysis, Alsaad 2015 had wider inclusion criteria which included 3420 patients taking TPM (mixed aetiologies and study design types) and 1,204,981 controls and reported a significant odds ratio (OR 6.26, 95% CI: 3.13 to 12.51).As noted throughout this discussion, data were limited pertaining to the newer ASMs and by the reporting of specific malformations in included studies, therefore, it is possible that the limited data that contributed to this meta-analysis do not consistently uphold this association across all comparisons.",
                "cite_spans": [
                    {
                        "start": 604,
                        "end": 619,
                        "text": "(Chaudhry 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Agreements and disagreements with other studies or reviews",
                "sec_num": null
            },
            {
                "text": "There is an obvious delay between the approval of a medication for use and obtaining comprehensive evidence regarding the potential major malformation risk.Some delay is inevitable, however, a longer delay than necessary will limit evidencebased decision-making regarding optimising the treatment of maternal epilepsy whilst limiting potential foetal risk.A failure to document the first few years' worth of pregnancies to women on newer medications delays knowledge acquisition and new ASMs use in women of childbearing age may be unnecessarily avoided for longer than required.There are numerous medications approved for the treatment of epilepsy around the world, yet we see many without data at this time.The emergence of population level datasets using routine health record databases will likely have a positive impact on this latency, due to their automatic inclusion of large populations (Denmark Health Record Registers).Whilst low in participation selection bias, utilising routine healthcare data has reduced measurement sensitivity though, and disease pregnancy and epilepsy registers or clinical studies which employ blinded, standardised review of the malformation outcome o er a more sensitive approach to outcome measurement.The pharmacovigilance strategy for the ASMs, therefore, should actively include di erent study designs which balance each other's methodological areas of strength and weakness to form a reliable and comprehensive evidence base.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research and pharmacovigilance",
                "sec_num": null
            },
            {
                "text": "The RoB ratings highlight the issue that within-study methodological improvements are required.Few studies, for example, report on how the major malformation was assessed and determined to be major or minor and whether this was done blinded to the ASM history, despite this being the primary study outcome.Therefore, an easily adopted improvement for research is to encourage the use of blinded, standardised assessments of the physical outcomes and use standardised classification approaches, such as those used by clinical geneticists, including the Human Phenotype Ontology (HPO) (http:// human-phenotype-ontology.github.io/about.html)to allow for more accurate comparison across studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research and pharmacovigilance",
                "sec_num": null
            },
            {
                "text": "Whilst research methodologies have become more refined over the years, for example, by reporting individual ASM types, rather than a single monotherapy group or recognising the importance of ASM dose, there are still several limitations in the approach to data reporting.The provision of an overall major malformation risk figure, for example, is unlikely to be reliable, as demonstrated for PB and TPM, and future data collection and analysis should implement automatic reporting at the specific malformation level, including this as supplementary information.To improve the data at this finer level, initiatives will require large cohorts and, therefore, there should be a movement towards standardised protocols and procedural alignment across research initiatives to allow for large enough datasets regarding specific malformation types for specific ASMs and specific doses.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research and pharmacovigilance",
                "sec_num": null
            },
            {
                "text": "Further investigations are also required into the factors which may modify the major malformation risk.This includes further consideration regarding folate supplementation and regarding the optimal dose for women with epilepsy.As cohorts increase in size, more nuanced investigations into dose associations are required by specific malformation types and future work should also consider any family risk factors.Observations have shown that some women who take ASMs, even at a very low dose, appear to be at higher risk of having a child with an ASM-associated malformation.Further research focusing on identification of genomic variants which might modify how di erent women metabolise ASMs is crucial so that those who may be at higher risk of having a child with a major malformation, even when taking a lower dose of a specific ASM, can be identified and ASM treatment selected accordingly.Whilst this has proven di icult in the past, whole exome/genome sequencing, with careful selection of individuals for testing, is likely to make this more achievable (Ku 2011 ).",
                "cite_spans": [
                    {
                        "start": 1060,
                        "end": 1068,
                        "text": "(Ku 2011",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research and pharmacovigilance",
                "sec_num": null
            },
            {
                "text": "Finally, longitudinal work which also investigates the longerterm health outcomes of children with ASM exposures should be undertaken to understand the true impact.Where possible, research initiatives which recruit pregnant women with epilepsy for the purpose of investigating major malformation outcomes should also seek to, where possible, utilise these populations to understand child health and neurodevelopmental outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research and pharmacovigilance",
                "sec_num": null
            },
            {
                "text": "Country India Notes There were 2 spontaneous abortions.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Funding Not reported",
                "sec_num": null
            },
            {
                "text": "Study authors' contact details could not be found.Notes Study authors' contact details could not be found.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Funding Not reported",
                "sec_num": null
            },
            {
                "text": "Protocol requested -protocol received.Data could not be included in the meta-analysis for VPA and TPM as number of women taking these AED for non-epilepsy conditions was > 10%.In the paper on CBZ, data were specifically reported for the women with epilepsy on CBZ and therefore these data could contribute to the meta-analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Protocol requested -no response received.Data reported across two papers.The more recent paper reported outcomes pertaining to heart defects only and therefore the numbers available for metaanalysis for heart defects is substantially higher than that for overall malformation risk and other specific malformation types.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.Total events: Heterogeneity: Chi\u00b2 = 10.74,df = 10 (P = 0.38); I\u00b2 = 7% Test for overall effect: Z = 5.37 (P < 0.00001)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Sweden Health Record Registers Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.36 (P = 0.18) Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P < 0.00001), I\u00b2 = 0% Total events: Heterogeneity: Chi\u00b2 = 1.39, df = 2 (P = 0.50); I\u00b2 = 0% Test for overall effect: Z = 0.14 (P = 0.89)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ vs VPA (database studies)",
                "sec_num": "22.2.2"
            },
            {
                "text": "0 0 0 0 0 0 0 3 0 6 0 1 0 0 0 1 0 3 0 0 4",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "CBZ Events",
                "sec_num": null
            },
            {
                "text": "Norwegian Health Record Registers Sweden Health Record Registers Subtotal (95% CI) Total events: Heterogeneity: Chi\u00b2 = 0.27, df = 1 (P = 0.60); I\u00b2 = 0% Test for overall effect: Z = 0.79 (P = 0.43)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG vs CZP (database studies)",
                "sec_num": "38.1.2"
            },
            {
                "text": "Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P < 0.00001), I\u00b2 = 0%",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LTG vs CZP (database studies)",
                "sec_num": "38.1.2"
            },
            {
                "text": "Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            }
        ],
        "back_matter": [
            {
                "text": "The authors reviewed the Robins-I framework and adpated it for use in this context.The original framework and the signalling questions were reviewed for suitability for classifying quality.Key confounder and mediating variables were determined based on a literature search and author knowledge.The wording of each of the signalling questions was adapted to reflect the issue of exposure to a medication.The criteria for each of the ratings was set by the authors and trialed on three included papers.This framework is available on request from the authors.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Appendix 6. ROBINS-I Adaptation and Rating Framework",
                "sec_num": null
            },
            {
                "text": "RB led the writing of this version of the review with input from SK, MBD, KE, RMcG, R.H, CJ, NA, JG, AJM, CT, JCS, JC, and AM.Data extraction and risk of bias assessments were undertaken by RB, JP, CJ, NA, JCS, AJM, SK,MBD, KE, RMcG.JCS assisted extensively with the classification of malformations within this review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "C O N T R I B U T I O N S O F A U T H O R S",
                "sec_num": null
            },
            {
                "text": "RB's institution has received consultancy fees from UCB Pharma on one occasion due to work undertaken by RB.NA has been sponsored to attend educational meetings and conferences in epilepsy over the last five years by UCB Pharma, GSK and Boehringer Ingelheim, and has participated in regional advisory Board meetings for Eisai on their product eslicarbazepine and zonisamide.AM leads the National Audit of Seizure Management in Hospitals (NASH), which is funded via a grant from UCB Pharma paid to the University of Liverpool.He has also given lectures at educational events sponsored by Sanofi and GSK, with honoraria paid to University of Liverpool.Professor Tony Marson is Theme Leader for Managing Complex Needs at NIHR CLAHRC NWC and an NIHR Senior Investigator.No other conflicts of interest were declared.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D E C L A R A T I O N S O F I N T E R E S T",
                "sec_num": null
            },
            {
                "text": "Firstly, in accordance with the protocol (Pulman 2012) , in the first (Adab 2004 ) and second versions (Weston 2016 ) of this review, where possible, we conducted meta-analysis at the monotherapy group level.However, given the clear di erentiated pattern of risk for specific ASMs in the previous version of the review, we considered that this approach was no longer reliable and could lead to a misrepresentation of the evidence.Therefore, the inclusion criteria for this review were altered at the current update to report outcomes for specific monotherapy ASM types only and not a group of heterogeneous monotherapy exposures.Secondly, in the original protocol, we stated that we would also review outcomes by polytherapy combinations, however, given the already numerous comparisons of monotherapies included in this review, outcomes by polytherapy combinations was not feasible here.A separate piece of work is required to delineate the very limited data currently available for specific polytherapy combinations and infant major congenital malformation outcomes.Thirdly, in the protocol, it was stated that we would look at the specific malformations of a genitourinary and gastrointestinal nature, however, at the point of data extraction, it became apparent that grouping of malformations into this classification was too heterogeneous to do in a way which was worthwhile.A er consideration of the included studies, the four most commonly reported specific malformation types were selected and reported on.This will be considered again at the next update.Finally, due to the small amount of data pertaining to minor malformations identified from the published literature in the second version of this review (Weston 2016), minor malformations were not included in the updated version of the review.",
                "cite_spans": [
                    {
                        "start": 41,
                        "end": 54,
                        "text": "(Pulman 2012)",
                        "ref_id": null
                    },
                    {
                        "start": 70,
                        "end": 80,
                        "text": "(Adab 2004",
                        "ref_id": "BIBREF47"
                    },
                    {
                        "start": 103,
                        "end": 115,
                        "text": "(Weston 2016",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            }
        ],
        "bib_entries": {
            "BIBREF0": {
                "ref_id": "b0",
                "title": "{published data only}",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Jedrzejczak",
                        "suffix": ""
                    }
                ],
                "year": 2022,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF1": {
                "ref_id": "b1",
                "title": "Clinical predictors for breastfeeding initiation among women with epilepsy",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Jedrzejczak",
                        "suffix": ""
                    },
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Majkowska-Zwolinska",
                        "suffix": ""
                    }
                ],
                "year": 2022,
                "venue": "Seizure",
                "volume": "96",
                "issue": "",
                "pages": "59--65",
                "other_ids": {
                    "PMID": [
                        "35123234"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF2": {
                "ref_id": "b2",
                "title": "Pattern of malformations in the children of women treated with carbamazepine during pregnancy",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Jones",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "L"
                        ],
                        "last": "Jones",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "V"
                        ],
                        "last": "Lacro",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "A"
                        ],
                        "last": "Johnson",
                        "suffix": ""
                    },
                    {
                        "first": "J ;",
                        "middle": [],
                        "last": "Adams",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [
                            "G"
                        ],
                        "last": "Rhind",
                        "suffix": ""
                    }
                ],
                "year": 1975,
                "venue": "New England Journal of Medicine",
                "volume": "320",
                "issue": "25",
                "pages": "99--110",
                "other_ids": {
                    "PMID": [
                        "2725616"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF3": {
                "ref_id": "b3",
                "title": "International Lamotrigine Pregnancy Registry Scientific Advisory Committee. E ect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study",
                "authors": [
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Cunnington",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Ferber",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Quartey",
                        "suffix": ""
                    }
                ],
                "year": 2007,
                "venue": "Epilepsia",
                "volume": "48",
                "issue": "6",
                "pages": "1207--1210",
                "other_ids": {
                    "PMID": [
                        "17381445"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF4": {
                "ref_id": "b4",
                "title": "The International Lamotrigine Pregnancy Registry update for the Epilepsy Foundation",
                "authors": [
                    {
                        "first": "M",
                        "middle": [
                            "C"
                        ],
                        "last": "Cunnington",
                        "suffix": ""
                    }
                ],
                "year": 2004,
                "venue": "Epilepsia",
                "volume": "45",
                "issue": "11",
                "pages": "",
                "other_ids": {
                    "PMID": [
                        "15509254"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF5": {
                "ref_id": "b5",
                "title": "Prospective surveillance of Croatian pregnant women on lamotrigine monotherapyaspects of pre-pregnancy counseling and drug monitoring",
                "authors": [
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Tennis",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "R"
                        ],
                        "last": "Eldridge",
                        "suffix": ""
                    }
                ],
                "year": 2002,
                "venue": "Acta Clinica Croatica",
                "volume": "43",
                "issue": "10",
                "pages": "271--281",
                "other_ids": {
                    "PMID": [
                        "12366730"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF6": {
                "ref_id": "b6",
                "title": "Montouris 2003 {published data only} Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry",
                "authors": [
                    {
                        "first": "R",
                        "middle": [
                            "R"
                        ],
                        "last": "Monson ; Only} Monson",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [],
                        "last": "Rosenberg",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "C"
                        ],
                        "last": "Hartz",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Shapiro",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "P"
                        ],
                        "last": "Heinonen",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Slone",
                        "suffix": ""
                    }
                ],
                "year": 1973,
                "venue": "New England Journal of Medicine",
                "volume": "289",
                "issue": "20",
                "pages": "310--317",
                "other_ids": {
                    "PMID": [
                        "4742220"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF7": {
                "ref_id": "b7",
                "title": "Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health",
                "authors": [
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Mostacci",
                        "suffix": ""
                    },
                    {
                        "first": "F",
                        "middle": [],
                        "last": "Bisulli",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Poluzzi",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Cocchi",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Piccinni",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Curti",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "Journal of Neurology, Neurosurgery & Psychiatry",
                "volume": "89",
                "issue": "9",
                "pages": "983--988",
                "other_ids": {
                    "PMID": [
                        "29549194"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF8": {
                "ref_id": "b8",
                "title": "Prevalence of antiepileptic drugs exposure in pregnant women in the Emilia Romagna region (Italy): results from the ESPEA (Emilia Romagna Study on Pregnancy and Exposure to Antiepileptic Drugs)",
                "authors": [
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Mostacci",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Piccinni",
                        "suffix": ""
                    },
                    {
                        "first": "F",
                        "middle": [],
                        "last": "Bisulli",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Poluzzi",
                        "suffix": ""
                    },
                    {
                        "first": "I",
                        "middle": [],
                        "last": "Naldi",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Accetta",
                        "suffix": ""
                    }
                ],
                "year": 2014,
                "venue": "Epilepsia",
                "volume": "55",
                "issue": "Suppl 2",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF9": {
                "ref_id": "b9",
                "title": "{published data only}",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Nakane",
                        "suffix": ""
                    }
                ],
                "year": 1980,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF10": {
                "ref_id": "b10",
                "title": "Reexamination of the teratological e ect of antiepileptic drugs",
                "authors": [
                    {
                        "first": "O",
                        "middle": [],
                        "last": "Murasaki",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [],
                        "last": "Yoshitake",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Tachiki",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Nakane",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Kaneko",
                        "suffix": ""
                    }
                ],
                "year": 1988,
                "venue": "Japanese Journal of Psychiatry and Neurology",
                "volume": "42",
                "issue": "3",
                "pages": "592--593",
                "other_ids": {
                    "PMID": [
                        "3241485"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF11": {
                "ref_id": "b11",
                "title": "Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan",
                "authors": [
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Nakane",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Okuma",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Takahashi",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Sato",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Wada",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Sato",
                        "suffix": ""
                    }
                ],
                "year": 1980,
                "venue": "Epilepsia",
                "volume": "21",
                "issue": "6",
                "pages": "663--680",
                "other_ids": {
                    "PMID": [
                        "7439133"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF12": {
                "ref_id": "b12",
                "title": "Congenital malformation among infants of epileptic mothers treated during pregnancy: the report of a collaborative study group in Japan",
                "authors": [
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Nakane",
                        "suffix": ""
                    }
                ],
                "year": 1979,
                "venue": "Folia Psychiatrica et Neurologica Japonica",
                "volume": "33",
                "issue": "3",
                "pages": "363--369",
                "other_ids": {
                    "PMID": [
                        "520954"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF13": {
                "ref_id": "b13",
                "title": "A pregnancy register of patients receiving carbamazepine in the UK",
                "authors": [
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Pearse",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "B"
                        ],
                        "last": "Pearse",
                        "suffix": ""
                    },
                    {
                        "first": "Garcia",
                        "middle": [],
                        "last": "Rodriguez",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [
                            "A"
                        ],
                        "last": "Hartwell",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Russell",
                        "suffix": ""
                    },
                    {
                        "first": "G ;",
                        "middle": [],
                        "last": "Jr",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Krishnamoorthy",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Andermann",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Benjamin",
                        "suffix": ""
                    }
                ],
                "year": 1992,
                "venue": "American Journal of Obstetrics and Gynecology",
                "volume": "1",
                "issue": "6",
                "pages": "371--379",
                "other_ids": {
                    "DOI": [
                        "10.1002/pds.2630010603"
                    ],
                    "PMID": [
                        "14981376"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF14": {
                "ref_id": "b14",
                "title": "Is valproic acid teratogenic? [L'acide valpro\u00efque est-il t\u00e9ratog\u00e8ne?",
                "authors": [
                    {
                        "first": "Robert",
                        "middle": [],
                        "last": "Robert",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Robert",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "M"
                        ],
                        "last": "Lapras",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 1983,
                "venue": "Revue Neurologique",
                "volume": "139",
                "issue": "6-7",
                "pages": "445--447",
                "other_ids": {
                    "PMID": [
                        "6412342"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF16": {
                "ref_id": "b16",
                "title": "Verification of the fetal valproate syndrome phenotype",
                "authors": [
                    {
                        "first": "H",
                        "middle": [
                            "H"
                        ],
                        "last": "Ardinger",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "F"
                        ],
                        "last": "Atkin",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "D"
                        ],
                        "last": "Blackston",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [
                            "J"
                        ],
                        "last": "Elsas",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "K"
                        ],
                        "last": "Clarren",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Livingstone",
                        "suffix": ""
                    }
                ],
                "year": 1988,
                "venue": "American Journal of Medical Genetics",
                "volume": "29",
                "issue": "1",
                "pages": "171--185",
                "other_ids": {
                    "PMID": [
                        "3125743"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF18": {
                "ref_id": "b18",
                "title": "Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors",
                "authors": [
                    {
                        "first": "R",
                        "middle": [
                            "L"
                        ],
                        "last": "Brent",
                        "suffix": ""
                    }
                ],
                "year": 2004,
                "venue": "Pediatrics",
                "volume": "113",
                "issue": "4",
                "pages": "957--968",
                "other_ids": {
                    "PMID": [
                        "15060188"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF20": {
                "ref_id": "b20",
                "title": "Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child",
                "authors": [
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Bromley",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Weston",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Adab",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Greenhalgh",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Sanniti",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "J"
                        ],
                        "last": "Mckay",
                        "suffix": ""
                    }
                ],
                "year": 2014,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "10",
                "pages": "",
                "other_ids": {
                    "DOI": [
                        "10.1002/14651858.CD010236.pub2]Charlton2008"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF21": {
                "ref_id": "b21",
                "title": "Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries",
                "authors": [
                    {
                        "first": "R",
                        "middle": [
                            "A"
                        ],
                        "last": "Charlton",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "C"
                        ],
                        "last": "Cunnington",
                        "suffix": ""
                    },
                    {
                        "first": "De",
                        "middle": [],
                        "last": "Vries",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "S"
                        ],
                        "last": "Weil",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "G"
                        ],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2008,
                "venue": "Drug Safety",
                "volume": "31",
                "issue": "1",
                "pages": "39--51",
                "other_ids": {
                    "PMID": [
                        "18095745"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF23": {
                "ref_id": "b23",
                "title": "The fetal safety of levetiracetam: a systematic review",
                "authors": [
                    {
                        "first": "S",
                        "middle": [
                            "A"
                        ],
                        "last": "Chaudhry",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Jong",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Koren",
                        "suffix": ""
                    }
                ],
                "year": 2014,
                "venue": "Reproductive Toxicology",
                "volume": "46",
                "issue": "",
                "pages": "40--45",
                "other_ids": {
                    "PMID": [
                        "24602560"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF25": {
                "ref_id": "b25",
                "title": "Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Christensen",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [
                            "K"
                        ],
                        "last": "Gr\u00f8nborg",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "J"
                        ],
                        "last": "S\u00f8rensen",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Schendel",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [
                            "T"
                        ],
                        "last": "Parner",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [
                            "H"
                        ],
                        "last": "Pedersen",
                        "suffix": ""
                    }
                ],
                "year": 2013,
                "venue": "JAMA",
                "volume": "309",
                "issue": "16",
                "pages": "1696--1703",
                "other_ids": {
                    "PMID": [
                        "23613074"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF27": {
                "ref_id": "b27",
                "title": "Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/ hyperactivity disorder in o spring",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Christensen",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [],
                        "last": "Pedersen",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Sun",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "W"
                        ],
                        "last": "Dreier",
                        "suffix": ""
                    },
                    {
                        "first": "I",
                        "middle": [],
                        "last": "Brikell",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Dalsgaard",
                        "suffix": ""
                    }
                ],
                "year": 2019,
                "venue": "JAMA Network Open",
                "volume": "2",
                "issue": "1",
                "pages": "",
                "other_ids": {
                    "PMID": [
                        "30646190"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF29": {
                "ref_id": "b29",
                "title": "Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Clayton-Smith",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Bromley",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Dean",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Journel",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Odent",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Wood",
                        "suffix": ""
                    }
                ],
                "year": 2019,
                "venue": "Orphanet Journal of Rare Diseases",
                "volume": "14",
                "issue": "1",
                "pages": "",
                "other_ids": {
                    "PMID": [
                        "31324220"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF31": {
                "ref_id": "b31",
                "title": "Developing diagnostic criteria for the fetal anticonvulsant syndromes",
                "authors": [
                    {
                        "first": "J",
                        "middle": [
                            "C"
                        ],
                        "last": "Dean",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "J"
                        ],
                        "last": "Moore",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "D"
                        ],
                        "last": "Turnpenny",
                        "suffix": ""
                    }
                ],
                "year": 2000,
                "venue": "Seizure",
                "volume": "9",
                "issue": "3",
                "pages": "233--234",
                "other_ids": {
                    "PMID": [
                        "10775521"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF32": {
                "ref_id": "b32",
                "title": "The fetal valproate syndrome",
                "authors": [
                    {
                        "first": "J",
                        "middle": [
                            "H"
                        ],
                        "last": "Diliberti",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "A"
                        ],
                        "last": "Farndon",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [
                            "R"
                        ],
                        "last": "Dennis",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "J"
                        ],
                        "last": "Curry",
                        "suffix": ""
                    }
                ],
                "year": 1984,
                "venue": "American Journal of Medical Genetics",
                "volume": "19",
                "issue": "3",
                "pages": "473--481",
                "other_ids": {
                    "PMID": [
                        "6439041"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF34": {
                "ref_id": "b34",
                "title": "Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies",
                "authors": [
                    {
                        "first": "K",
                        "middle": [
                            "M"
                        ],
                        "last": "Fiest",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "M"
                        ],
                        "last": "Sauro",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Wiebe",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "B"
                        ],
                        "last": "Patten",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "S"
                        ],
                        "last": "Kwon",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Dykeman",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "Neurology",
                "volume": "88",
                "issue": "3",
                "pages": "296--303",
                "other_ids": {
                    "PMID": [
                        "27986877"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF36": {
                "ref_id": "b36",
                "title": "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations",
                "authors": [
                    {
                        "first": "G",
                        "middle": [
                            "H"
                        ],
                        "last": "Guyatt",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "D"
                        ],
                        "last": "Oxman",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Vist",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Kunz",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Falck-Ytter",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Alonso-Coello",
                        "suffix": ""
                    }
                ],
                "year": 2008,
                "venue": "BMJ",
                "volume": "336",
                "issue": "7650",
                "pages": "924--926",
                "other_ids": {
                    "PMID": [
                        "18436948"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF38": {
                "ref_id": "b38",
                "title": "Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0",
                "authors": [],
                "year": 2011,
                "venue": "The Cochrane Collaboration",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF39": {
                "ref_id": "b39",
                "title": "Valproic acid monotherapy in pregnancy and major congenital malformations",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Jentink",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Loane",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Dolk",
                        "suffix": ""
                    },
                    {
                        "first": "I",
                        "middle": [],
                        "last": "Barisic",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Garne",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "K"
                        ],
                        "last": "Morris",
                        "suffix": ""
                    }
                ],
                "year": 2010,
                "venue": "New England Journal of Medicine",
                "volume": "362",
                "issue": "23",
                "pages": "2185--2193",
                "other_ids": {
                    "PMID": [
                        "20558369"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF41": {
                "ref_id": "b41",
                "title": "Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Jentink",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Dolk",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Loane",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "K"
                        ],
                        "last": "Morris",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Wellesley",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Garne",
                        "suffix": ""
                    }
                ],
                "year": 2010,
                "venue": "BMJ",
                "volume": "341",
                "issue": "",
                "pages": "",
                "other_ids": {
                    "PMID": [
                        "21127116"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF43": {
                "ref_id": "b43",
                "title": "Studying the epigenome using next generation sequencing",
                "authors": [
                    {
                        "first": "C",
                        "middle": [
                            "S"
                        ],
                        "last": "Ku",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Naidoo",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Wu",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Soong",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "Journal of Medical Genetics",
                "volume": "48",
                "issue": "11",
                "pages": "721--730",
                "other_ids": {
                    "PMID": [
                        "21825079"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF44": {
                "ref_id": "b44",
                "title": "Antiepileptic drugs during pregnancy in primary care: a UK population based study",
                "authors": [
                    {
                        "first": "S",
                        "middle": [
                            "L"
                        ],
                        "last": "Man",
                        "suffix": ""
                    },
                    {
                        "first": "I",
                        "middle": [],
                        "last": "Petersen",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Thompson",
                        "suffix": ""
                    },
                    {
                        "first": "I",
                        "middle": [],
                        "last": "Nazareth",
                        "suffix": ""
                    }
                ],
                "year": 2012,
                "venue": "PLOS One",
                "volume": "7",
                "issue": "",
                "pages": "",
                "other_ids": {
                    "PMID": [
                        "23272239"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF46": {
                "ref_id": "b46",
                "title": "National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral cle s",
                "authors": [
                    {
                        "first": "A",
                        "middle": [
                            "V"
                        ],
                        "last": "Margulis",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "A"
                        ],
                        "last": "Mitchell",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "M"
                        ],
                        "last": "Gilboa",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "M"
                        ],
                        "last": "Werler",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Mittleman",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "J"
                        ],
                        "last": "Glynn",
                        "suffix": ""
                    }
                ],
                "year": 2012,
                "venue": "American Journal of Obstetrics and Gynecology",
                "volume": "207",
                "issue": "5",
                "pages": "1--7",
                "other_ids": {
                    "PMID": [
                        "22917484"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF47": {
                "ref_id": "b47",
                "title": "Common antiepileptic drugs in pregnancy in women with epilepsy",
                "authors": [
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Adab",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "C"
                        ],
                        "last": "Tudur",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Vinten",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Williamson",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Winterbottom",
                        "suffix": ""
                    }
                ],
                "year": 2004,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "3",
                "pages": "",
                "other_ids": {
                    "DOI": [
                        "10.1002/14651858.CD004848"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF49": {
                "ref_id": "b49",
                "title": "Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Pulman",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Bromley",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Adab",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Greenhalgh",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "J"
                        ],
                        "last": "Mckay",
                        "suffix": ""
                    },
                    {
                        "first": "Tudur",
                        "middle": [],
                        "last": "Smith",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2012,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "11",
                "pages": "",
                "other_ids": {
                    "DOI": [
                        "10.1002/14651858.CD010224"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF51": {
                "ref_id": "b51",
                "title": "Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Weston",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Bromley",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "F"
                        ],
                        "last": "Jackson",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Adab",
                        "suffix": ""
                    },
                    {
                        "first": "Clayton",
                        "middle": [
                            "-"
                        ],
                        "last": "Smith",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Greenhalgh",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2016,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "11",
                "pages": "",
                "other_ids": {
                    "DOI": [
                        "10.1002/14651858.CD010224.pub2"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF52": {
                "ref_id": "b52",
                "title": "Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 17.1.1 CBZ vs OXC (cohort studies) 11 2877 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF53": {
                "ref_id": "b53",
                "title": "1.2 CBZ vs OXC (database studies) 4 3015 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "0",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF54": {
                "ref_id": "b54",
                "title": "2 CBZ vs OXC: Neural Tube Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 17.2.1 CBZ vs OXC (cohort studies) 9 2767 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed",
                "volume": "95",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF55": {
                "ref_id": "b55",
                "title": "3 CBZ vs OXC: Cardiac Malformations 11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 17.3.1 CBZ vs OXC (cohort studies) 11 2789",
                "authors": [],
                "year": null,
                "venue": "Risk Ratio (M-H, Fixed, 95% CI)",
                "volume": "0",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF56": {
                "ref_id": "b56",
                "title": "4 CBZ vs OXC: Oro-Facial Cle / Craniofacial Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 17.4.1 CBZ vs OXC (cohort studies) 9 2214 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed",
                "volume": "95",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF57": {
                "ref_id": "b57",
                "title": "5 CBZ vs OXC: Skeletal/Limb Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 17.5.1 CBZ vs OXC (cohort studies) 9 2767 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "0",
                "issue": "",
                "pages": "1--66",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF58": {
                "ref_id": "b58",
                "title": "Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 31.1.1 LEV vs LTG (cohort studies) 10 5612 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "0",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF59": {
                "ref_id": "b59",
                "title": "1.2 LEV vs LTG (database studies) 2 2316 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed",
                "volume": "95",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF60": {
                "ref_id": "b60",
                "title": "Neural Tube Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 31.2.1 LEV vs LTG (cohort studies) 9 5373 Risk Ratio",
                "authors": [
                    {
                        "first": "Ltg",
                        "middle": [],
                        "last": "Lev",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF61": {
                "ref_id": "b61",
                "title": "Cardiac Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 31.3.1 LEV vs LTG (cohort studies) 9 5371 Risk Ratio",
                "authors": [
                    {
                        "first": "Ltg",
                        "middle": [],
                        "last": "Lev",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF62": {
                "ref_id": "b62",
                "title": "Oro-Facial Cle / Craniofacial Malformations 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 31.4.1 LEV vs LTG (cohort studies) 8 5215 Risk Ratio",
                "authors": [
                    {
                        "first": "Ltg",
                        "middle": [],
                        "last": "Lev",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "0",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF63": {
                "ref_id": "b63",
                "title": "Skeletal/Limb Malformation 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 31.5.1 LEV vs LTG (cohort studies) 9 5373 Risk Ratio",
                "authors": [
                    {
                        "first": "Ltg",
                        "middle": [],
                        "last": "Lev",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "4--13",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF64": {
                "ref_id": "b64",
                "title": "Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 60.1.1 VPA vs LEV (cohort studies) 10 3485 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "3",
                "issue": "",
                "pages": "5--74",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF65": {
                "ref_id": "b65",
                "title": "1.2 VPA vs LEV (database studies) 2 911 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed",
                "volume": "3",
                "issue": "",
                "pages": "7--10",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF66": {
                "ref_id": "b66",
                "title": "2 VPA vs LEV: Neural Tube Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 60.2.1 VPA vs LEV (cohort studies) 9 3346 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "3",
                "issue": "",
                "pages": "11--55",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF67": {
                "ref_id": "b67",
                "title": "3 VPA vs LEV: Cardiac Malformations 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 60.3.1 VPA vs LEV (cohort studies) 10 3356 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "3",
                "issue": "",
                "pages": "6--34",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF68": {
                "ref_id": "b68",
                "title": "4 VPA vs LEV: Oro-Facial Cle / Craniofacial Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 60.4.1 VPA vs LEV (cohort studies) 9 2909",
                "authors": [],
                "year": null,
                "venue": "Risk Ratio (M-H, Fixed, 95% CI)",
                "volume": "3",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF69": {
                "ref_id": "b69",
                "title": "5 VPA vs LEV: Skeletal/Limb Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "60",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF70": {
                "ref_id": "b70",
                "title": "1 VPA vs LEV (cohort studies) 9 3346 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed",
                "volume": "95",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF71": {
                "ref_id": "b71",
                "title": "1.1 VPA vs OXC (cohort studies) 11 1561 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "2",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF72": {
                "ref_id": "b72",
                "title": "1.2 VPA vs OXC (database studies) 4 1701 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF73": {
                "ref_id": "b73",
                "title": "2 VPA vs OXC: Neural Tube Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 63.2.1 VPA vs OXC (cohort studies) 9 1497 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "4--89",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF74": {
                "ref_id": "b74",
                "title": "3 VPA vs OXC: Cardiac Malformations 11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 63.3.1 VPA vs OXC (cohort studies) 11 1597 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "3--88",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF75": {
                "ref_id": "b75",
                "title": "4 VPA vs OXC: Oro-Facial Cle / Craniofacial Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 63.4.1 VPA vs OXC (cohort studies) 9 1178 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "2",
                "issue": "",
                "pages": "6--06",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF76": {
                "ref_id": "b76",
                "title": "5 VPA vs OXC: Skeletal/Limb Malformations 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only 63.5.1 VPA vs OXC (cohort studies) 9 1497 Risk Ratio",
                "authors": [],
                "year": null,
                "venue": "M-H, Fixed, 95% CI)",
                "volume": "1",
                "issue": "",
                "pages": "4--49",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF77": {
                "ref_id": "b77",
                "title": "Prenatal Exposure Delayed E ects Explode All AND INSEGMENT 4. fetal or foetal or fetus or foetus or prenatal or pregnant or pregnanc* AND INSEGMENT 5. newborn or infant AND INSEGMENT 6. MeSH DESCRIPTOR Teratogens Explode All AND INSEGMENT 7. teratogen* AND INSEGMENT 8. in NEXT utero AND INSEGMENT 9",
                "authors": [],
                "year": null,
                "venue": "MeSH DESCRIPTOR Pregnancy Explode All AND INSEGMENT 2. MeSH DESCRIPTOR Pregnancy Complications Explode All AND INSEGMENT 3",
                "volume": "12",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF78": {
                "ref_id": "b78",
                "title": "Congenital Abnormalities EXPLODE ALL AND INSEGMENT 14. congenital NEAR2 defec* AND INSEGMENT 15. congenital NEAR2 malformation* AND INSEGMENT",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Mesh Descriptor",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF79": {
                "ref_id": "b79",
                "title": "congenital NEAR2 (anomal* or abnormal*) AND INSEGMENT",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF80": {
                "ref_id": "b80",
                "title": "birth NEAR2 defec* AND INSEGMENT",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF81": {
                "ref_id": "b81",
                "title": "minor NEAR2 (anomal* or abnormal* or malformation*) AND INSEGMENT",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF82": {
                "ref_id": "b82",
                "title": "AND INSEGMENT",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF83": {
                "ref_id": "b83",
                "title": ") NEAR2 (defec* or malformation* or anomal* or abnormal",
                "authors": [],
                "year": null,
                "venue": "neural tube AND INSEGMENT 21",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF85": {
                "ref_id": "b85",
                "title": "philtrum",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF86": {
                "ref_id": "b86",
                "title": "28 OR #29 OR #30 AND INSEGMENT 32. #12 AND #31 AND INSEGMENT Cochrane Library Trusted evidence. Informed decisions. Better health",
                "authors": [],
                "year": 2015,
                "venue": "#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22",
                "volume": "33",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF88": {
                "ref_id": "b88",
                "title": "MeSH DESCRIPTOR Pregnancy Complications Explode All AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF89": {
                "ref_id": "b89",
                "title": "prenatal or pregnant or pregnanc* AND CENTRAL:TARGET 39. newborn or infant AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "MeSH DESCRIPTOR Prenatal Exposure Delayed E ects Explode All AND CENTRAL:TARGET 38. fetal or foetal or fetus or foetus or",
                "volume": "40",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF92": {
                "ref_id": "b92",
                "title": "intra uterine\" or intrauterine AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "44",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF94": {
                "ref_id": "b94",
                "title": "MeSH DESCRIPTOR Infant",
                "authors": [],
                "year": null,
                "venue": "#35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 AND CENTRAL",
                "volume": "46",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF95": {
                "ref_id": "b95",
                "title": "MESH DESCRIPTOR Congenital Abnormalities",
                "authors": [],
                "year": null,
                "venue": "EXPLODE ALL AND CENTRAL",
                "volume": "48",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF96": {
                "ref_id": "b96",
                "title": "congenital NEAR2 defec* AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF97": {
                "ref_id": "b97",
                "title": "congenital NEAR2 malformation* AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF98": {
                "ref_id": "b98",
                "title": "*) AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "congenital NEAR2 (anomal* or abnormal",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF99": {
                "ref_id": "b99",
                "title": "NEAR2 defec* AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF100": {
                "ref_id": "b100",
                "title": "minor NEAR2 (anomal* or abnormal* or malformation*) AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF102": {
                "ref_id": "b102",
                "title": "neural tube AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF103": {
                "ref_id": "b103",
                "title": "*) AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "cardiac or cardiovasc*) NEAR2 (defec* or malformation* or anomal* or abnormal",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF104": {
                "ref_id": "b104",
                "title": "orofac* or craniofac*)",
                "authors": [],
                "year": null,
                "venue": "NEAR",
                "volume": "2",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF106": {
                "ref_id": "b106",
                "title": "eye* or ear* or nose",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF108": {
                "ref_id": "b108",
                "title": "philtrum or microstomia AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF109": {
                "ref_id": "b109",
                "title": "digit* or finger* or toe",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF110": {
                "ref_id": "b110",
                "title": "hypoplasia or arachnodactyly AND CENTRAL:TARGET",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF111": {
                "ref_id": "b111",
                "title": "hernia* or sacral dimple* AND CENTRAL:TARGET 65",
                "authors": [],
                "year": null,
                "venue": "#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 AND CENTRAL:TARGET",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF112": {
                "ref_id": "b112",
                "title": "MeSH DESCRIPTOR Epilepsy Explode All WITH QUALIFIER DT AND CENTRAL:TARGET Cochrane Database of Systematic Reviews 67",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF114": {
                "ref_id": "b114",
                "title": "antiepilep* or anti-epilep* or anticonvulsant* or anti-convulsant* or antiseizure* or anti-seizure* or AED or AEDs):AB",
                "authors": [
                    {
                        "first": "K",
                        "middle": [
                            "Y"
                        ],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "TI AND CENTRAL:TARGET",
                "volume": "70",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF115": {
                "ref_id": "b115",
                "title": "MeSH DESCRIPTOR Midazolam Explode All AND CENTRAL",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF124": {
                "ref_id": "b124",
                "title": "OR Pentothal OR Sodipental OR Thiomebumal OR Thionembutal OR Thiopent",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Bomathal",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Farmotal",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Nesdonal",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Penthiobarbit",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "TI AND CENTRAL:TARGET",
                "volume": "85",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF125": {
                "ref_id": "b125",
                "title": "TI AND CENTRAL:TARGET 88",
                "authors": [
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Acemit Or Acetamide Or Acetazolamid",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Avva",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Azm",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Azol",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diacarb",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diamox",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diazomid",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diluran",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Edemox",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Glaupax",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF126": {
                "ref_id": "b126",
                "title": "TI AND CENTRAL:TARGET 90",
                "authors": [
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Beclamid",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Chloracon",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Hibicon",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Posedrine",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Nydrane",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Seclar",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF127": {
                "ref_id": "b127",
                "title": "SPD417 OR \"Apo-Carbamazepine",
                "authors": [
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Carbamazepin",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or Carbamazepen",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or Carbamezepin",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Or",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Or",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "OR Atretol OR Biston OR Calepsin OR Carbagen OR Carbatrol OR Carbazepin* OR Carbelan OR Epitol OR Equetro OR Finlepsin OR Karbamazepin OR Lexin OR Neurotop OR \"Novo-Carbamaz",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF128": {
                "ref_id": "b128",
                "title": "Carisbamat* OR Comfyde OR",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF129": {
                "ref_id": "b129",
                "title": "Cenobamat* OR Xcopri OR YKP3089",
                "authors": [
                    {
                        "first": "K",
                        "middle": [
                            "W"
                        ],
                        "last": "Ab",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF130": {
                "ref_id": "b130",
                "title": "TARGET Cochrane Library Trusted evidence. Informed decisions. Better health",
                "authors": [
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Chlormethiazol",
                        "suffix": ""
                    },
                    {
                        "first": "):",
                        "middle": [],
                        "last": "Or Distraneurin",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Central",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "96",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF131": {
                "ref_id": "b131",
                "title": "Clonex OR Clonopin OR Iktorivil OR Klonopin OR Kriadex OR Landsen OR Paxam OR Petril OR Ravotril OR Rivatril OR Rivotril OR \"ro 5-4023",
                "authors": [
                    {
                        "first": "Antelepsin Or Antilepsin Or",
                        "middle": [],
                        "last": "Chlonazepam",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Cloazepam",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Clonazepam",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF132": {
                "ref_id": "b132",
                "title": "Novo-Clopate",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Calner",
                        "suffix": ""
                    },
                    {
                        "first": "* Or Justum Or",
                        "middle": [],
                        "last": "Clorazepat",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Mendon",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "OR Tranxene OR Tranxilium)",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF133": {
                "ref_id": "b133",
                "title": "TARGET 100",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diapam",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Diastat",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Diazemuls",
                        "suffix": ""
                    },
                    {
                        "first": "* Or",
                        "middle": [],
                        "last": "Diazepam",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Nervium",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Relanium",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Valium",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Central",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "101",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF134": {
                "ref_id": "b134",
                "title": "TI AND CENTRAL:TARGET 103",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Esilgan",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Estazolam",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Eurodin Or Nuctalon",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Prosom Or Tasedan",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF135": {
                "ref_id": "b135",
                "title": "TARGET 105",
                "authors": [
                    {
                        "first": "* Or",
                        "middle": [],
                        "last": "Aethosuximid",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Emeside",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Ethosucci",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Ethosuxide",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Ethosuximid",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or Etosuximid",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Or Zarontin",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Central",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "106",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF136": {
                "ref_id": "b136",
                "title": "Neogab OR Neurontin OR \"Novo-Gabapentin",
                "authors": [
                    {
                        "first": "* Or",
                        "middle": [],
                        "last": "Gabapentin",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Aclonium",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Fanatrex",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Gabapetin",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Gabarone",
                        "suffix": ""
                    },
                    {
                        "first": "Or ;",
                        "middle": [],
                        "last": "Gbp Or Gralise",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "CCD-1042",
                "volume": "111",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF137": {
                "ref_id": "b137",
                "title": "GW 273293",
                "authors": [
                    {
                        "first": "* Or Elmendos Or",
                        "middle": [],
                        "last": "Lamotrigin",
                        "suffix": ""
                    },
                    {
                        "first": "Or ;",
                        "middle": [],
                        "last": "Epilepax",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "OR Lamictal OR Lamictin OR Lamitor OR Lamitrin OR Lamogine OR Lamotrine OR LTG",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF138": {
                "ref_id": "b138",
                "title": "Magnesium sulfat*\" OR \"Magnesium sulphat*",
                "authors": [
                    {
                        "first": "Ativan Or Intensl Or",
                        "middle": [],
                        "last": "Loraz",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Lorazepam",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or Lormetazepam",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Or Temesta",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Central",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "116",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF139": {
                "ref_id": "b139",
                "title": "TARGET 120",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Dapaz",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Equanil",
                        "suffix": ""
                    },
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Meprobamat",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Meprospan Or Miltown",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Tranmep",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Visano",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Central",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF141": {
                "ref_id": "b141",
                "title": "GP 47680",
                "authors": [
                    {
                        "first": "* Or",
                        "middle": [],
                        "last": "Oxcarbazepin",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Actinium",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Barzepin",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Carbox",
                        "suffix": ""
                    },
                    {
                        "first": "Or ;",
                        "middle": [],
                        "last": "Deprectal",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "146",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF142": {
                "ref_id": "b142",
                "title": "TI AND CENTRAL:TARGET 150",
                "authors": [
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Avugane",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Baceca",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Convulex",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Delepsine",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Depacon",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Depakene",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Depakine",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Depakote",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Deproic",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Divalprax",
                        "suffix": ""
                    },
                    {
                        "first": "* Or Dpa Or",
                        "middle": [],
                        "last": "Divalproex",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Encorate",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Epiject",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Epilex",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Epilim",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Episenta",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Epival",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Ergenyl",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Mylproin",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Orfiril",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Orlept",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Selenica",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Stavzor",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Valance",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Valcote",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Valparin",
                        "suffix": ""
                    },
                    {
                        "first": "* Or",
                        "middle": [],
                        "last": "Valpro",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Vpa Or Zalkote",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "151",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF143": {
                "ref_id": "b143",
                "title": "101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114 OR #115 OR #116 OR #117 OR #118 OR #119 OR #120 OR #121 OR #122 OR #123 OR #124 OR #125 OR #126 OR #127 OR #128 OR #129 OR #130 OR #131 OR #132 OR #133 OR #134 OR #135 OR #136 OR #137 OR #138 OR #139 OR #140 OR #141 OR #142 OR #143 OR #144 OR #145 OR #146 OR #147 OR #148 OR #149 OR #150 OR #151 OR #",
                "authors": [
                    {
                        "first": "*",
                        "middle": [],
                        "last": "Zonisamid",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Or Exceglan",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Excegram",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [
                            "R"
                        ],
                        "last": "Excegran",
                        "suffix": ""
                    },
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Zns Or Zonegran",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ab",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Kw",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ky",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "H"
                        ],
                        "last": "Mc",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "#86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95",
                "volume": "153",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF144": {
                "ref_id": "b144",
                "title": "intrauterine).mp. 10. exp Fetal Development/ 11. exp Infant",
                "authors": [],
                "year": null,
                "venue": "Congenital Abnormalities",
                "volume": "14",
                "issue": "",
                "pages": "1--11",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF145": {
                "ref_id": "b145",
                "title": "congenital adj2 malformation",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF146": {
                "ref_id": "b146",
                "title": "congenital adj2 (anomal$ or abnormal",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF147": {
                "ref_id": "b147",
                "title": "Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors",
                "authors": [],
                "year": null,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "19",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF148": {
                "ref_id": "b148",
                "title": "neural tube",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF149": {
                "ref_id": "b149",
                "title": "cardiac or cardiovasc$) adj2 (defec$ or malformation$ or anomal$ or abnormal",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF150": {
                "ref_id": "b150",
                "title": "orofac$ or craniofac$) adj2 (defec$ or malformation$ or anomal$ or abnormal",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF151": {
                "ref_id": "b151",
                "title": "skelet$ or limb$ or hip$ or joint$) adj2 (defec$ or malformation$ or anomal",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF152": {
                "ref_id": "b152",
                "title": "eye$ or ear$ or nose$ or nasal or nostril or mouth or lip$) adj2 (defec$ or malformation$ or anomal",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF154": {
                "ref_id": "b154",
                "title": "philtrum or microstomia",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF155": {
                "ref_id": "b155",
                "title": "digit$ or finger$ or toe$ or nail$) adj2 (defec",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF156": {
                "ref_id": "b156",
                "title": "hypoplasia or arachnodactyly",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF157": {
                "ref_id": "b157",
                "title": "hernia* or sacral dimple*)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "31",
                "issue": "",
                "pages": "13--30",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF160": {
                "ref_id": "b160",
                "title": "antiepilep$ or anti-epilep$ or anticonvulsant$ or anti-convulsant$ or antiseizure$ or anti-seizure$ or AED or AEDs)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF161": {
                "ref_id": "b161",
                "title": "exp Midazolam",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF162": {
                "ref_id": "b162",
                "title": "Dalam or Dormicum or Dormire or Epistatus or Fulsed or Garen or Hypnovel or Ipnovel or Midazolam* or Nocturna or Setam or Terap or Versed)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF163": {
                "ref_id": "b163",
                "title": "exp Methazolamide/ 39",
                "authors": [],
                "year": null,
                "venue": "Methazolamid* or Methylacetazolamide or Neptazane)",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF164": {
                "ref_id": "b164",
                "title": "Anepol or Diprivan or Disoprivan or Disoprofol or Fresofol or Hypro or Lipuro or Plofed or Profol or Propofil or Propofol* or Propolipid or Propovan or Propoven or Provive or Recofol)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF165": {
                "ref_id": "b165",
                "title": "Dasuen or Euhypnos or Hydroxydiazepam or Levanxol or Methyloxazepam or Nocturne or Norkotral or Normison or Normitab or Nortem or Oxydiazepam or Planum or Pronervon or Remestan or Restoril or Signopam or Temaze or Temazep* or Temtabs or Tenox)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF166": {
                "ref_id": "b166",
                "title": "Bomathal or Farmotal or Nesdonal or Penthiobarbit* or Pentothal or Sodipental or Thiomebumal or Thionembutal or Thiopent* or Tiobarbital or Tiopental* or Trapanal)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF167": {
                "ref_id": "b167",
                "title": "Acemit or Acetamide or Acetazolamid* or Avva or Azm or Azol or Diacarb or Diamox or Diazomid or Diluran or Edemox or Glaupax)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF169": {
                "ref_id": "b169",
                "title": "Beclamid* or Chloracon or Hibicon or Posedrine or Nydrane or Seclar)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF171": {
                "ref_id": "b171",
                "title": "* or CBZ or SPD417 or \"Apo-Carbamazepine\" or Atretol or Biston or Calepsin or Carbagen or Carbatrol or Carbazepin* or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotop or \"Novo-Carbamaz\" or \"Nu-Carbamazepine\" or Sirtal or Stazepin* or \"Taro-Carbamazepine\" or Tegretal or Tegretol or Telesmin or Teril or Timonil)",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Bromide",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF172": {
                "ref_id": "b172",
                "title": "Carisbamat* or Comfyde or \"RWJ-333369",
                "authors": [],
                "year": null,
                "venue": "YKP",
                "volume": "509",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF173": {
                "ref_id": "b173",
                "title": "cenobamat* or Xcopri or YKP3089",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF175": {
                "ref_id": "b175",
                "title": "Aedon or Anxirloc or Castilium or Chlorepin or Clarmyl or Clobam or Clobamax or Clobator or Clobazam* or Clofritis or Clopax or Clorepin or Frisium or Grifoclobam or Karidium or Lucium or Mystan or Noiafren or Onfi or Sederlona or Sentil or Urbadan or Urbanil or Urbanol or Urbanyl)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF176": {
                "ref_id": "b176",
                "title": "Antelepsin or Antilepsin or Chlonazepam or Cloazepam or Clonazepam* or Clonex or Clonopin or Iktorivil or Klonopin or Kriadex or Landsen or Paxam or Petril or Ravotril or Rivatril or Rivotril or \"ro 5-4023",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF177": {
                "ref_id": "b177",
                "title": "Calner or Clorazepat* or Justum or Mendon or \"Novo-Clopate\" or Tranxene or Tranxilium)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF178": {
                "ref_id": "b178",
                "title": "Diapam or Diastat or Diazemuls or Diazepam* or Nervium or Relanium or Valium)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF179": {
                "ref_id": "b179",
                "title": "Dimethadion* or Dimethyloxazolidinedione",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF180": {
                "ref_id": "b180",
                "title": "Eslicarbazepin* or Exalief or Stedesa or Zebinix",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF181": {
                "ref_id": "b181",
                "title": "Esilgan or Estazolam* or Eurodin or Nuctalon or Prosom or Tasedan)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF183": {
                "ref_id": "b183",
                "title": "Aethosuximid* or Emeside or Ethosucci* or Ethosuxide or Ethosuximid* or Etosuximid* or Zarontin",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF185": {
                "ref_id": "b185",
                "title": "Felbamat* or Felbatol or Felbamyl or Taloxa)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF187": {
                "ref_id": "b187",
                "title": "Cerebyx or Fosphenytoin* or Prodilantin)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF188": {
                "ref_id": "b188",
                "title": "Gabapentin* or Aclonium or Fanatrex or Gabapetin or Gabarone or GBP or Gralise or Neogab or Neurontin or",
                "authors": [],
                "year": null,
                "venue": "Novo-Gabapentin",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF189": {
                "ref_id": "b189",
                "title": "CCD-1042\" or Ganaxolon*)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF190": {
                "ref_id": "b190",
                "title": "Erlosamide or Harkoseride or Lacosamid* or Vimpat",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF191": {
                "ref_id": "b191",
                "title": "GW 273293\" or Lamictal or Lamictin or Lamitor or Lamitrin or Lamogine or Lamotrine or LTG)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF192": {
                "ref_id": "b192",
                "title": "Levetiracetam* or Keppra or LEV or Levitiracetam)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF193": {
                "ref_id": "b193",
                "title": "Ativan or Intensl or Loraz or Lorazepam* or Lormetazepam* or Temesta)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF195": {
                "ref_id": "b195",
                "title": "Magnesium sulfat*\" or",
                "authors": [],
                "year": null,
                "venue": "Magnesium sulphat",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF196": {
                "ref_id": "b196",
                "title": "Nobrium or Rudotel or Rusedal",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Medazepam",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF198": {
                "ref_id": "b198",
                "title": "Dapaz or Equanil or Meprobamat* or Meprospan or Miltown or Tranmep or Visano)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF199": {
                "ref_id": "b199",
                "title": "Celontin or Mesuximid* or Methsuximide or Petinutin",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF200": {
                "ref_id": "b200",
                "title": "Tiletamin*.mp. 105. (Topiramat* or Qudexy or Tipiramate or Topamax or \"Topiramic acid\" or TPM).mp. 106. (Tridione or Trimethadion*).mp. 107. Valnoctamid*.mp. 108. (Avugane or Baceca or Convulex or Delepsine or Depacon or Depakene or Depakine or Depakote or Deproic or Divalprax or DPA or Encorate or Epiject 109. (Depamide or Valpromid*.mp. 110. (GVG or Sabril or Vigabatrin*).mp. 111. (Zonisamid* or Exceglan or Excegram or Excegran or ZNS or Zonegran).mp. 112. or/32-111 113. 12 and 31 and 112 114. exp animals/ not humans.sh. 115. (animal or animals or mouse or mice or murine or rat or rats or rodent or rodents or zebrafish).ti. 116. 114 or 115 117. 113 not 116 118",
                "authors": [],
                "year": null,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            }
        },
        "ref_entries": {
            "FIGREF0": {
                "text": "Figure 2. (Continued)",
                "fig_num": "3",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF1": {
                "text": "All major malformations 4.1.1LEV versus no medication (in women without epilepsy): cohort studies",
                "fig_num": "1",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF2": {
                "text": "All major malformations 10.1.1 TPM versus no medication (in women without epilepsy): cohort studies",
                "fig_num": "1",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF11": {
                "text": "Pooled results from nine studies suggested an increased risk with VPA (RR 3.75, 95% CI 1.19 to 11.77;I 2 = 0%), with children exposed to VPA (N = 1958) experiencing more oro-facial cle /craniofacial malformations than children exposed to LEV (N = 951) (Analysis 60.4",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF12": {
                "text": "All Cohort studiesPooled results from five cohort studies suggested no evidence of a di erence in risk (RR 0.71, 95% CI 0.28 to 1.77; I 2 = 0%), with no di erence in the number of major malformations in children exposed to OXC (N = 279) and children exposed to TPM (N = 427) (Analysis 70.1).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.04 to 0.02; I 2 = 0%).",
                "fig_num": "17011",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF13": {
                "text": "Pooled results from four studies suggested no evidence of a di erence in risk (RR 0.39, 95% CI 0.05 to 3.35, I 2 = NA), with no di erence in the number of oro-facial cle /craniofacial malformations in children exposed to OXC (N = 198) and children exposed to TPM (N = 410) (Analysis 70.4).The RD also suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 0%).",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF16": {
                "text": "Results from one study suggested no evidence of a di erence in risk (RR 3.00, 95% CI 0.14 to 65.77,I 2 = NA), with no di erence in the number of major malformations in children exposed to ESM (N = 8) and children exposed to TPM (N = 53) (Analysis 105.1)The RD also suggested no di erence in the level of risk (RD -0.02, 95% CI -0.24 to 0.21; I 2 = NA).",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF18": {
                "text": "women on AED monotherapy or polytherapy Control group: women with epilepsy not taking AEDs Interventions Intervention groups (monotherapy): treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Personal communication received regarding number of specific malformations by monotherapy Australian Epilepsy and Pregnancy Register (Continued)",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF19": {
                "text": "Prospective cohort study Participants Intervention group: Women on AED monotherapy or polytherapy Control group: Women with epilepsy not taking AEDs Interventions Intervention groups (monotherapy): Protocol requested -no response received.Barqawi 2005 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy not taking AEDs 2) Non-epileptic women taking AED 3) Healthy women without epilepsy Interventions Intervention group (monotherapy, with known malformation outcomes, limited to women with epileptreatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.authors unable to provide protocol but description of study plan given D'Souza 1991 (Continued) Women with epilepsy not taking any AEDs (N = 10) Intervention group: Women on AED monotherapy or polytherapy Denmark Health Record Registers Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration., GlaxoSmithKline, Janssen-Cilag, Novartis, Pfizer, Sanofi-Aventis, UCB, the Netherlands Epilepsy Foundation, Stockholm County Council Country 42 countries Notes Protocol requested -no response received.Not included in meta-analysis due to overlap with other studies (e.g.UK Epilepsy and Pregnancy Register) treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.author could not provide protocol but summarised the aims of the study.",
                "fig_num": "11",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF20": {
                "text": "treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF21": {
                "text": "(N = 56) 4) PRG (N = 63) Italian Lombardy Region Health Register Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy who were not taking AEDs (N = 237) Women on AED monotherapy or polytherapy Control group: Women with epilepsy not taking AEDs Interventions Intervention group (monotherapy): Women with epilepsy not taking any AEDs (N = 340)",
                "fig_num": "11",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF22": {
                "text": "Women without epilepsy not taking AEDs (N = 116) Women with epilepsy not taking AEDs (N = 28) Outcomes Congenital malformations Funding Ciba-Geigy, Sanofi, Chemische Industrie Katwijk Lindhout 1992 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy not taking AEDs (N = 46) 2) Women without epilepsy not taking AEDs (N = 315) Outcomes Major congenital malformations Funding Epilepsy Research UK, US National Institutes of Health, Sanofi Aventis, UK National Institute of Health Research Country UK Notes Protocol requested -protocol received.Overlap in data with NEAD study.Data combined in metaanalysis along with NEAD data were non-NEAD data from this study.treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women on AED monotherapy or polytherapy Control group: Women without epilepsy not taking AEDs Interventions Intervention groups (monotherapy): Intervention group: Women on AED monotherapy or polytherapy Control group: Women with epilepsy not taking AEDs Milan Study 1999 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy not taking AEDs (N = 25) Outcomes Malformations specific to a) cardiac, b) gastrointestinal, c) neural tube defects Funding Not reported Country Italy Notes 58 pregnancies that had ended with early spontaneous (N = 38) or early voluntary (N = 20) abortions were excluded from the analysis.Linked to Battino 1992 and Battino 1999 Study authors' contact details count not be found.Women on AED monotherapy or polytherapy Control group: Women without epilepsy not taking AEDs Interventions Intervention groups (monotherapy): Women without epilepsy (N = 128) Miskov 2016 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women on AED monotherapy or polytherapy Control group: 1) Women with epilepsy not taking AEDs 2) Women without epilepsy not taking Women with epilepsy not taking AEDs (N = 15) 2) Women without epilepsy not taking AEDs (N = 106) Participants Intervention group: Women on AED monotherapy or polytherapy Montreal Series Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy not taking any AEDs (N = 9) 2) Women without epilepsy not taking medication (N = 79) Protocol requested -no response received.Data not included in meta-analysis as non-epilepsy cases > 10% Motherisk Registry Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women without epilepsy not taking AEDs (N = 442) Major congenital malformations, most commonly: hypospadias, neural tube defects, cardiovascular anomalies and oral cle s Funding Country USA Notes Protocol requested -no response received.Data not available for specific malformations for GBP or ZNS , PB, CZP, LTG, LEV, OXC, TPM Outcomes Major congenital malformations and specific congenital malformations Norwegian Health Record Registers Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.MCM came from Veiby and colleagues 2009 paper as specific numbers with MCM were not reported in the 2014 paper.Norwegian Health Record Registers (Continued) treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Onderzoek/Nationaal Epilepsie Fonds, and the International League Against Epilepsy through a grant from the Klingenstein Foundation Country Finland, Germany, Netherlands Notes Study authors' contact details could not be found.Not included in meta-analysis due to overlap with other included studies; reviewed narratively Women with epilepsy not taking AEDs 2) Women without epilepsy who were not taking any medication.Women with epilepsy not taking any AEDs (N = 126) 2) no medication (in women without epilepsy) (N Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.and KA Wallenbergs Stiftelse to BK, Swedish Medical Research Council, the Pediatric Research Foundation of the Free-masons in Sweden, and the May Flower Foundation to Women on AED monotherapy or polytherapy Control group: Women without epilepsy not taking AEDs Interventions Intervention groups (monotherapy): (N = 2098) 4) PHT (N = 106) UK and Ireland Epilepsy and Pregnancy Register Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Women with epilepsy who were not taking AEDs (N = 541) Outcomes Congenital malformations Funding Epilepsy Research Foundation, Parke Davis, Glaxo Smith Kline, Eisai, Novartis, Sanofi-Aventis, Pfizer, Janssen-Cilag and UCB Country UK Notes Personal communication from the authors provided up-to-date figures for PHT and controls.Protocol requested -protocol received UK and Ireland Epilepsy and Pregnancy Register (Continued) overlap in database coverage with the THIN Network.Narrative review only Intervention group: Women on AED monotherapy or polytherapy Control group: Women without epilepsy UK Health Record THIN Register Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Intervention group: Women on AED monotherapy or polytherapy Control group: Women with epilepsy not taking AEDs Waters 1994 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "fig_num": "111111111111",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF23": {
                "text": "MethodsProspective, observational, single-centre study (Serbia) Participants 21 women with juvenile myoclonic epilepsy (25 pregnancies, mean age 26.4,ranged 22to AEDs during pregnancy were involved in the study.Interventions 1) Valproic acid (N = 7) 2) Carbamazepine (N = 5) Kaabi 2013 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.83 women with epilepsy: 1) focal onset with secondary generalised seizures (N = 52) 2) generalised seizures (N = 31) treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.(49 in 1998 and 113 in 2013) with: Focal epilepsy (N = 124; 38 in 1998 and 86 in 2013) 2) Ideopathic generalised epilepsy (N = 31; 6 in 1998 and 25 in 2013) 3) Undetermined epilepsy (N = 7; 5 in 1998 and 2 in 2013) Interventions 1) Carbamazepine (N = 48) 2) Valproate (N = 26) Vlasov 2014 Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review) Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "fig_num": "1",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF24": {
                "text": "= 2.21, df = 2 (P = 0.33); I\u00b2 = 10% Test for overall effect: Z = 3.01 (P = 0.003) = 2.44, df = 3 (P = 0.49); I\u00b2 = 0% Test for overall effect: Z = 0.02 (P = 0.99) Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P < 0.00001), I\u00b2 = 0%",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF25": {
                "text": "125. (Paraldehyd*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 126.(Paramethadion*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 127.(E2007 OR Fycompa OR Perampanel*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 128.(Phenacemid*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 129. (Ethylphenacemid* OR Pheneturid*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 130. (Adonal OR Aephenal OR Agrypnal OR Amylofene OR Aphenylbarbit OR Aphenyletten OR Barbenyl OR Barbinal OR Barbiphen* OR Barbipil OR Barbita OR Barbivis OR Barbonal OR Barbophen OR Bardorm OR Bartol OR Bialminal OR \"Blu-Phen\" OR Cabronal OR Calmetten OR Calminal OR Cardenal OR Chinoin OR Codibarbita OR Coronaletta OR Cratecil OR Damoral OR Dezibarbitur OR Dormina OR Dormiral OR Dormital OR Doscalun OR Duneryl OR Ensobarb OR Ensodorm OR Epanal OR Epidorm OR Epilol OR Episedal OR Epsylone OR Eskabarb OR Etilfen OR Euneryl OR Fenbital OR Fenemal OR Fenobarbital OR Fenosed OR Fenylettae OR Gardenal OR Gardepanyl OR Glysoletten OR Haplopan OR Haplos OR Helional OR Hennoletten OR Henotal OR Hypnaletten OR Hypnette OR \"Hypno-Tablinetten\" OR Hypnogen OR Hypnolone OR Hypnoltol OR Hysteps OR Lefebar OR Leonal OR Lephebar OR Lepinal OR Lepinaletten OR Linasen OR Liquital OR Lixophen OR Lubergal OR Lubrokal OR Lumen OR Lumesettes OR Lumesyn OR Luminal OR Lumofridetten OR Luphenil OR Luramin OR Molinal OR Neurobarb OR Nirvonal OR Noptil OR \"Nova-Pheno\" OR Nunol OR Parkotal OR PB OR Pharmetten OR \"Phen-Bar\" OR Phenaemal OR Phenemal* OR Phenobal OR Phenobarbit* OR Phenobarbyl OR Phenoluric OR Phenolurio OR Phenomet OR Phenonyl OR Phenoturic OR Phenylethylbarbit* OR Phenylethylmalonylurea OR Phenyletten OR Phenyral OR Phob OR Polcominal OR Prominal OR Promptonal OR \"Seda-Tablinen\" OR Sedabar OR Sedicat OR Sedizorin OR Sedlyn OR Sedofen OR Sedonal OR Sedonettes OR Sevenal OR Sinoratox OR Solfoton OR \"Solu-Barb\" OR Sombutol OR Somnolens OR Somnoletten OR Somnosan OR Somonal OR Spasepilin OR Starifen OR Starilettae OR Stental OR Talpheno OR Teolaxin OR Teoloxin OR Thenobarbital OR Theoloxin OR Triabarb OR Tridezibarbitur OR Triphenatol OR Versomnal OR Zadoletten OR Zadonal):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 131.(Phensuximid*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 132.(Aleviatin OR Antisacer OR Auranile OR Causoin OR Citrullamon OR Citrulliamon OR Comital OR Comitoina OR Convul OR Danten OR Dantinal OR Dantoin* OR Denyl OR \"Di-Hydan\" OR \"Di-Lan\" OR \"Di-Phetine\" OR Didan OR Difenilhidantoin* OR Difenin OR Difetoin OR Difhydan OR Dihycon OR Dihydantoin OR Dilabid OR Dilantin* OR Dillantin OR Dintoin* OR Diphantoin OR Diphedal OR Diphedan OR Diphenat OR Diphenin* OR Diphentoin OR Diphentyn OR Diphenylan OR Diphenylhydantoin* OR Diphenylhydatanoin OR Ditoinate OR Ekko OR Elepsindon OR Enkelfel OR Epamin OR Epanutin OR Epasmir OR Epdantoin* OR Epelin OR Epifenyl OR Epihydan OR Epilan OR Epilantin OR Epinat OR Epised OR Eptal OR Eptoin OR Fenantoin OR Fenidantoin OR Fenitoin* OR Fentoin OR Fenylepsin OR Fenytoin* OR \"Gerot-epilan-D\" OR Hidan OR Hidant* OR Hindatal OR Hydant* OR Ictalis OR Idantoi* OR Iphenylhydantoin OR Kessodanten OR Labopal OR Lehydan OR Lepitoin OR Lepsin OR Mesantoin OR Minetoin OR \"Neos-Hidantoina\" OR Neosidantoina OR Novantoina OR Novophenytoin OR \"Om-hidantoina\" OR \"Om-Hydantoine\" OR Oxylan OR Phanantin* OR Phenatine OR Phenatoine OR Phenhydan* OR Phenitoin OR Phentoin OR Phentytoin OR Phenytek OR Phenytex OR Phenytoin* OR PHT OR Ritmenal OR Saceril OR Sanepil OR Silantin OR Sinergina OR Sodanthon OR Sodanto* OR Solantin OR Solantoin OR Solantyl OR Sylantoic OR Tacosal OR Thilophenyl OR TOIN OR Zentronal OR Zentropil):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 133.(Lyrica OR Pregabalin*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 134.(Mysoline OR Primidon* OR Sertan):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 135.(Gabrene OR Garene OR Halogabide OR Halogenide OR Progabid*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 136.(Ecovia OR Remacemid*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 137.(\"D-23129\" OR \"D23129\" OR EZG OR Ezogabin* OR Retigabin* OR RTG OR Trobalt OR Potiga):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 138.(Rilutek OR Riluzol* OR Trifluoromethoxybenzothiazol*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 139.(Inovelon OR Rufinamid* OR Xilep):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 140.(Seletracetam*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 141.(Diacomit OR Stiripentol*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 142. (Sulthiam* OR Sultiam* OR Ospolot):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 143.(Talampanel*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 144.(Tiagabin* OR Gabitril):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET 145.(Tiletamin*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET Erimin or Nimetazepam*).mp.82.(Alodorm or Arem or Insoma or Mogadon or Nitrados or Nitrazadon or Nitrazepam* or Ormodon or Paxadorm or Remnos or Somnite or Pacisyn).mp.83.(Oxcarbazepin* or Actinium or Barzepin or Carbox or Deprectal or \"GP 47680\" or Lonazet or OCBZ or Oxalepsy or OXC or Oxcarbamazepine or Oxetol or Oxpin or Oxrate or Oxtellar or Oxypine or Pharozepine or Prolepsi or Timox or Trexapin or Trileptal or Trileptin).mp.84.Paraldehyd*.mp.85. Paramethadion*.mp.86.(E2007 or Fycompa or Perampanel*).mp.87.Phenacemid*.mp.88. (Ethylphenacemid* or Pheneturid*).mp.89.(Adonal or Aephenal or Agrypnal or Amylofene or Aphenylbarbit or Aphenyletten or Barbenyl or Barbinal or Barbiphen* or Barbipil or Barbita or Barbivis or Barbonal or Barbophen or Bardorm or Bartol or Bialminal or \"Blu-Phen\" or Cabronal or Calmetten or Calminal or Cardenal or Chinoin or Codibarbita or Coronaletta or Cratecil or Damoral or Dezibarbitur or Dormina or Dormiral or Dormital or Doscalun or Duneryl or Ensobarb or Ensodorm or Epanal or Epidorm or Epilol or Episedal or Epsylone or Eskabarb or Etilfen or Euneryl or Fenbital or Fenemal or Fenobarbital or Fenosed or Fenylettae or Gardenal or Gardepanyl or Glysoletten or Haplopan or Haplos or Helional or Hennoletten or Henotal or Hypnaletten or Hypnette or \"Hypno-Tablinetten\" or Hypnogen or Hypnolone or Hypnoltol or Hysteps or Lefebar or Leonal or Lephebar or Lepinal or Lepinaletten or Linasen or Liquital or Lixophen or Lubergal or Lubrokal or Lumen or Lumesettes or Lumesyn or Luminal or Lumofridetten or Luphenil or Luramin or Molinal or Neurobarb or Nirvonal or Noptil or \"Nova-Pheno\" or Nunol or Parkotal or PB or Pharmetten or \"Phen-Bar\" or Phenaemal or Phenemal* or Phenobal or Phenobarbit* or Phenobarbyl or Phenoluric or Phenolurio or Phenomet or Phenonyl or Phenoturic or Phenylethylbarbit* or Phenylethylmalonylurea or Phenyletten or Phenyral or Phob or Polcominal or Prominal or Promptonal or \"Seda-Tablinen\" or Sedabar or Sedicat or Sedizorin or Sedlyn or Sedofen or Sedonal or Sedonettes or Sevenal or Sinoratox or Solfoton or \"Solu-Barb\" or Sombutol or Somnolens or Somnoletten or Somnosan or Somonal or Spasepilin or Starifen or Starilettae or Stental or Talpheno or Teolaxin or Teoloxin or Thenobarbital or Theoloxin or Triabarb or Tridezibarbitur or Triphenatol or Versomnal or Zadoletten or Zadonal).mp.90.Phensuximid*.mp.91.(Aleviatin or Antisacer or Auranile or Causoin or Citrullamon or Citrulliamon or Comital or Comitoina or Convul or Danten or Dantinal or Dantoin* or Denyl or \"Di-Hydan\" or \"Di-Lan\" or \"Di-Phetine\" or Didan or Difenilhidantoin* or Difenin or Difetoin or Difhydan or Dihycon or Dihydantoin or Dilabid or Dilantin* or Dillantin or Dintoin* or Diphantoin or Diphedal or Diphedan or Diphenat or Diphenin* or Diphentoin or Diphentyn or Diphenylan or Diphenylhydantoin*",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "TABREF1": {
                "text": "and Table7.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/></tr><tr><td colspan=\"2\">11,695 records identified from searches for previous version of review</td><td>1067 records identified through updated database searching</td><td>50 records identified through other sources</td></tr><tr><td/><td/><td>12,296 records</td></tr><tr><td/><td/><td>after duplicates</td></tr><tr><td/><td/><td>removed</td></tr><tr><td/><td/><td>12,296 abstracts</td><td>12,013 records</td></tr><tr><td/><td/><td>screened</td><td>excluded</td></tr><tr><td/><td/><td>283 full-text articles assessed for eligibility*</td><td>155 full-text articles excluded</td></tr><tr><td/><td/><td>128 records (49</td></tr><tr><td/><td/><td>studies) included</td></tr><tr><td/><td/><td>113 records (45</td></tr><tr><td/><td/><td>studies) included in</td></tr><tr><td/><td/><td>meta analysis**</td></tr></table>",
                "type_str": "table"
            },
            "TABREF3": {
                "text": "UK Health Record THIN Register; US Medicaid Registers; Waters 1994) and three studies were rated as critical due to the risk of selection biases (Fr\u00f6scher 1991; Mawer 2010; Meischenguiser 2004).There was not su icient information to rate five studies (Al Bunyan 1999; Bag 1989; D'Souza 1991; Delmi\u0161 1991; Montreal Series).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>AlSheikh 2020; Australian Epilepsy and Pregnancy</td></tr><tr><td>Register; Barqawi 2005; Cassina 2013; Eroglu 2008; EURAP 2018;</td></tr><tr><td>Fairgrieve 2000; Fr\u00f6scher 1991; Garza-Morales 1996; Hosny 2021;</td></tr><tr><td>Israeli Teratogen Service; Italian Lombardy Region Health Register;</td></tr><tr><td>Jimenez 2020; Kaaja 2003; Kaneko 1999; Kaur 2020; Kelly 1984;</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry; Koch 1992; Martinez Ferri</td></tr><tr><td>2018; Mawer 2010; Meador 2006; Melikova 2020; Milan Study</td></tr><tr><td>1999</td></tr></table>",
                "type_str": "table"
            },
            "TABREF7": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight studies suggested an increased risk with</td></tr><tr><td>PHT (RR 3.81, 95% CI 1.91 to 7.57; I 2 = 35%), with children exposed to</td></tr><tr><td>PHT (N = 496) experiencing more major malformations than control</td></tr><tr><td>children (N = 1397) (Analysis 8.1). The RD also suggested a higher</td></tr><tr><td>risk for PHT (RD 0.03, 95% CI 0.01 to 0.06; I 2 = 44%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF9": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF10": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Data from the Israeli Teratogen Service study, including women</td></tr><tr><td>treated with VPA for epilepsy and other indications (restricted to</td></tr><tr><td>monotherapy), reported major congenital malformations (MCM)</td></tr><tr><td>in 3/89 (3.4%) VPA-treated cases compared with 31/1236 (2.5%)</td></tr><tr><td>of control children. Samren 1997 reported 16 cases of major</td></tr><tr><td>malformations out of 184 (9%) VPA-exposed children. When limited</td></tr><tr><td>to the two sites with control children, investigators reported six</td></tr><tr><td>cases with malformation out of 21 children exposed to VPA, which</td></tr><tr><td>was higher than control children (RR 4.9, 95% CI 1.6 to 15.0).</td></tr><tr><td>11.1.2 VPA versus no medication (in women with epilepsy): cohort</td></tr><tr><td>studies</td></tr><tr><td>Pooled results from 17 studies suggested an increased risk with VPA</td></tr><tr><td>(RR 2.77, 95% CI 2.03 to 3.79; I 2 = 0%), with children exposed to VPA</td></tr><tr><td>(N = 2288) experiencing more major malformations than control</td></tr><tr><td>children (N = 1710) (Analysis 11.1). The RD also suggested a higher</td></tr><tr><td>risk for VPA (RD 0.06, 95% CI 0.04 to 0.07; I 2 = 32%).</td></tr><tr><td>11.1.3</td></tr><tr><td>Pooled results from 10 studies suggested an increased risk with VPA</td></tr><tr><td>(RR 5.53, 95% CI 3.29 to 9.29; I 2 = 0%), with children exposed to</td></tr></table>",
                "type_str": "table"
            },
            "TABREF11": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF12": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 6.05, 95% CI 0.94 to 38.81; I 2 = 20%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to VPA (N = 104) and control children (N = 836) (Analysis</td></tr><tr><td>11.2). The RD also suggested no di erence in the level of risk (RD</td></tr><tr><td>0.01, 95% CI -0.02 to 0.04; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF13": {
                "text": "Data from one study suggested an increased risk with VPA (RR 8.02, 95% CI 1.48 to 43.50,I 2 = NA), with a higher number of neural tube malformations in children exposed to VPA (N = 225) than in control children (N = 902) (Analysis 11.2).The RD also suggested a higher risk for VPA (RD 0.02, 95% CI -0.00 to 0.03; I 2 = NA).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Trusted evidence.</td><td/></tr><tr><td>Informed decisions.</td><td/></tr><tr><td>Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>11.2.4 11.3 Cardiac malformations</td><td/></tr><tr><td>11.3.1 VPA versus no medication (in women without epilepsy): cohort</td><td/></tr><tr><td>studies</td><td/></tr><tr><td>Pooled results from four studies suggested an increased risk with</td><td/></tr><tr><td>VPA (RR 11.89 95% CI 2.88 to 49.08; I 2 = 0%), with children</td><td/></tr><tr><td>exposed to VPA (N = 104) experiencing more cardiac malformations</td><td/></tr><tr><td>than control children (N = 836) (Analysis 11.3). However, the RD</td><td/></tr><tr><td>suggested no di erence in the level of risk (RD 0.04, 95% CI -0.00 to</td><td/></tr><tr><td>0.09; I 2 = 28%).</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF14": {
                "text": "Investigations from studies using population health record data are fewer, due to the lack of dose information available for the Norwegian Health Record Registers, Sweden Health Record Registers, and the absence of dose information for the Denmark Health Record Registers or UK Clinical Research Practice Database; UK Health Record THIN Register at this time.Putignano and colleagues 2019, using the Italian Lombardy Region Health Register, reported that children with MCMs had a higher dose of VPA.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">exposed children with a malformation to be 1000 mg/d compared</td><td/></tr><tr><td colspan=\"2\">with children exposed to VPA without an MCM (750 mg/d). The</td><td/></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry reported a prevalence of</td><td/></tr><tr><td colspan=\"2\">MCM of 3.0% for doses of VPA =/&lt; 400 mg/d, 9.5% for doses</td><td/></tr><tr><td colspan=\"2\">between &gt; 400 to 800 mg/d, and 28.6% for doses over 800 mg/</td><td/></tr><tr><td colspan=\"2\">d. Smaller studies including VPA-exposed children also reported</td><td/></tr><tr><td colspan=\"2\">data showing an association between VPA dose or serum levels</td><td/></tr><tr><td colspan=\"2\">and increased MCM rate (Israeli Teratogen Service; Kaneko 1999;</td><td/></tr><tr><td colspan=\"2\">Lindhout 1992; Meador 2006; Milan Study 1999; Samren 1997).</td><td/></tr><tr><td colspan=\"2\">Kaaja 2003 was the only smaller study that investigated a dose-</td><td/></tr><tr><td colspan=\"2\">response association without finding a positive correlation (N = 61</td><td/></tr><tr><td>VPA-exposed pregnancies).</td><td/><td/></tr><tr><td/><td/><td>52, 95% CI 7.73</td></tr><tr><td/><td colspan=\"2\">to 23.64, P = 0.0002) were all associated with higher risk than LTG</td></tr><tr><td/><td colspan=\"2\">exposure at doses &lt; 325 mg/d. Similarly, doses of &gt; 650 mg/d to =/</td></tr><tr><td/><td colspan=\"2\">&lt; 1450 mg/day (OR 2.81, 95% CI 1.70 to 4.65, P = 0.0002) had higher</td></tr><tr><td/><td colspan=\"2\">risk than LTG &gt; 325 mg/d. The highest level of VPA exposure was</td></tr><tr><td/><td colspan=\"2\">not statistically compared to LTG doses &gt; 325 mg/d, but there was a</td></tr><tr><td/><td colspan=\"2\">large di erence in prevalence (25.2% vs 4.3%). The lowest doses of</td></tr><tr><td/><td colspan=\"2\">VPA investigated (=/&lt; 650 mg/d) were not associated with a lower</td></tr><tr><td/><td colspan=\"2\">MCM risk than higher doses (&gt; 325 mg/d) of LTG (OR 0.62, 95% CI</td></tr><tr><td/><td>0.36 to 1.09, P = 0.0959).</td><td/></tr><tr><td/><td colspan=\"2\">In the UK and Ireland Epilepsy and Pregnancy Register (N = 1220),</td></tr><tr><td/><td colspan=\"2\">an increase in malformation from 5.0% at doses &lt; 600 mg/d to</td></tr><tr><td/><td colspan=\"2\">10.4% for doses &gt; 1000 mg/d (OR 2.20 95% CI 1.26 to 3.82, P</td></tr></table>",
                "type_str": "table"
            },
            "TABREF16": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF17": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF18": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 13 cohort studies suggested an increased risk</td></tr><tr><td>with CBZ (RR 1.37, 95% CI 1.06 to 1.77; I 2 = 0%), with children</td></tr><tr><td>exposed to CBZ (N = 4018) experiencing more major malformations</td></tr><tr><td>than children exposed to LTG (N = 4550) (Analysis 16.1). The RD also</td></tr><tr><td>suggested a higher risk for CBZ (RD 0.01, 95% CI 0.00 to 0.02; I 2 =</td></tr><tr><td>0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 2.9%</td></tr><tr><td>(95% CI 2.3 to 3.7) for children exposed to LTG. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Carbamazepine dose</td></tr><tr><td>and Lamotrigine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF21": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF24": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF27": {
                "text": "Analysis 19.1).The RD also suggested no di erence in the level of risk (RD -0.03, 95% CI -0.08 to 0.02; I 2 = 0%).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 6.4%</td></tr><tr><td>(95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Carbamazepine dose</td></tr><tr><td>and Phenytoin dose sections). Samren 1997 reported 22 cases of</td></tr><tr><td>major malformation out of 280 (8%) CBZ-exposed children and 9</td></tr><tr><td>cases from 141 PHT-exposed children (9%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF28": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 16 cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 1.12, 95% CI 0.45 to 2.83; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to CBZ (N = 4341) and children exposed to PHT (N = 1005)</td></tr><tr><td>(Analysis 19.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF29": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF30": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF31": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF32": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from seven cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.59, 95% CI 0.23 to 1.56; I 2 = 40%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to CBZ (N = 1076) and children with PRM (N = 112) (Analysis</td></tr><tr><td>20.1). The RD also suggested no di erence in the level of risk (RD</td></tr><tr><td>-0.02, 95% CI -0.09 to 0.05; I 2 = 8%).</td></tr><tr><td>Samren 1997 reported 22 cases of major malformation out of 280</td></tr><tr><td>(8%) CBZ-exposed children and 4 cases out of 43 (9%) PRM-exposed</td></tr><tr><td>children.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF34": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF35": {
                "text": "doses of the two ASMs (see Carbamazepine dose and Valproate dose sections).Samren 1997 reported 22 cases of major malformation out of 280 (8%) CBZ-exposed children and six cases out of 184 (9%) VPA-exposed children.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 29 cohort studies suggested an increased risk</td></tr><tr><td>with VPA (RR 0.44, 95% CI 0.37 to 0.53; I 2 = 0%), with children</td></tr><tr><td>exposed to CBZ (N = 5133) experiencing fewer major malformations</td></tr><tr><td>than children exposed to VPA (N = 2957) (Analysis 22.1). The RD also</td></tr><tr><td>suggested a higher risk for VPA (RD -0.05, 95% CI -0.06 to -0.04; I 2</td></tr><tr><td>= 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF38": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF39": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.94, 95% CI 0.36 to 2.44; I 2 = 75%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to CBZ (N = 2711) and children exposed to ZNS (N = 130)</td></tr><tr><td>(Analysis 23.1). Due to high heterogeneity, a random-e ects RR was</td></tr><tr><td>calculated which also found no di erence (RR 0.86, 95% CI 0.07 to</td></tr><tr><td>10.35, I 2 =75%</td></tr></table>",
                "type_str": "table"
            },
            "TABREF40": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF41": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Included studies did not reach the threshold for reporting of the</td></tr><tr><td>meta-analysis (Analysis 26.3). However, available data show that</td></tr><tr><td>there were 1/16 cases of cardiac malformation in children exposed</td></tr><tr><td>to GBP and 0/8 in children exposed to PB, based on data from two</td></tr><tr><td>studies (Australian Epilepsy and Pregnancy Register; Miskov 2016).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF42": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF43": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 10 cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.90, 95% CI 0.58 to 1.39; I 2 = 16%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to LEV (N = 1223) and children exposed to LTG (N = 4389)</td></tr><tr><td>(Analysis 31.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 10%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 2.9%</td></tr><tr><td>(95% CI 2.3 to 3.7) for children exposed to LTG. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Levetiracetam dose and</td></tr><tr><td>Lamotrigine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF44": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two routine health record studies suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 0.79, 95% CI 0.37 to 1.69; I 2 =</td></tr><tr><td>0%), with no di erence in the number of major malformations in</td></tr><tr><td>children exposed to LEV (N = 248) and children exposed to LTG (N</td></tr><tr><td>= 2068) (Analysis 31.1). The RD also suggested no di erence in the</td></tr><tr><td>level of risk (RD -0.01, 95% CI -0.03 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF45": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from nine cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.59, 95% CI 0.24 to 10.38; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LEV (N = 1128) and children exposed to LTG (N = 4245)</td></tr><tr><td>(Analysis 31.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF46": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk (RR 0.63, 95% CI 0.15 to 2.68; I 2 = 0%),</td></tr><tr><td>with no di erence in the number of oro-facial cle /craniofacial</td></tr><tr><td>malformations in children exposed to LEV (N = 1019) and children</td></tr><tr><td>exposed to LTG (N = 4196) (Analysis 31.4</td></tr></table>",
                "type_str": "table"
            },
            "TABREF47": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.04, 95% CI 0.51 to 2.09; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to LEV (N = 833) and children exposed to OXC (N = 333)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF48": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>(Analysis 32.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.02 to 0.03; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 3.0%</td></tr><tr><td>(95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Levetiracetam dose and</td></tr><tr><td>Oxcarbazepine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF49": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two routine health record studies suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 1.17, 95% CI 0.45 to 3.06; I 2 =</td></tr><tr><td>0%), with no di erence in the number of major malformations in</td></tr><tr><td>children exposed to LEV (N = 248) and children exposed to OXC (N =</td></tr><tr><td>373) (Analysis 32.1). The RD also suggested no di erence in the level</td></tr><tr><td>of risk (RD 0.00, 95% CI -0.02 to 0.03; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF50": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from seven cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.22, 95% CI 0.05 to 29.74; I 2 = NA), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LEV (N = 738) and children exposed to OXC (N = 320)</td></tr><tr><td>(Analysis 32.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF51": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from five cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.54, 95% CI 0.29 to 1.02; I 2 = 0%), with</td></tr><tr><td>children exposed to LEV (N = 726) experiencing comparable major</td></tr><tr><td>malformations to children exposed to PB (N = 341) (Analysis 33.1).</td></tr><tr><td>The RD also suggested no di erence in the level of risk (RD -0.02,</td></tr><tr><td>95% CI -0.05 to 0.01; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 6.5%</td></tr><tr><td>(95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Levetiracetam dose and</td></tr><tr><td>Phenobarbital dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF52": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested an increased risk</td></tr><tr><td>with PB (RR 0.08, 95% CI 0.01 to 0.67; I 2 = 0%), with children exposed</td></tr><tr><td>to LEV (N = 544) experiencing fewer oro-facial cle /craniofacial</td></tr><tr><td>malformations than children exposed to PB (N = 207) (Analysis</td></tr><tr><td>33.4). The RD suggested no di erence in the level of risk (RD -0.02,</td></tr><tr><td>95% CI -0.04 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF53": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>level of risk (RD -0.02, 95% CI -0.04 to -0.00; I 2 = 52%). Due to high</td></tr><tr><td>heterogeneity, we undertook a random-e ects analysis, which also</td></tr><tr><td>found no di erence (RD -0.02, 95% CI -0.05 to 0.02; I 2 = 52%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 6.4%</td></tr><tr><td>(95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Levetiracetam dose and</td></tr><tr><td>Phenytoin dose sections).</td></tr><tr><td>Pooled results from five cohort studies suggested an increased risk</td></tr><tr><td>with PHT (RR 0.58, 95% CI 0.34 to 0.97; I 2 = 58%), with children</td></tr><tr><td>exposed to LEV (N = 1018) experiencing fewer major malformations</td></tr><tr><td>than children exposed to PHT (N = 687) (Analysis 34.1). Due to</td></tr><tr><td>high heterogeneity, we undertook a random-e ects analysis, which</td></tr><tr><td>changed found no evidence of a di erence in risk (RR 0.46, 95% CI</td></tr><tr><td>0.17 to 1.28; I 2 = 58%). The RD also suggested no di erence in the</td></tr></table>",
                "type_str": "table"
            },
            "TABREF54": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>No included studies reported data on this outcome.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF55": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.68, 95% CI 0.13 to 3.44; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LEV (N = 913) and children exposed to PHT (N = 661)</td></tr><tr><td>(Analysis 34.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF56": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.57, 95% CI 0.32 to 1.04; I 2 = 0%), with</td></tr><tr><td>children exposed to LEV (N = 1124) experiencing comparable major</td></tr><tr><td>malformations to children exposed to TPM (N = 505) (Analysis 36.1).</td></tr><tr><td>The RD also suggested no di erence in the level of risk (RD -0.02,</td></tr><tr><td>95% CI -0.04 to 0.00; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 3.9%</td></tr><tr><td>(95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Levetiracetam dose and</td></tr><tr><td>Topiramate dose sections).</td></tr><tr><td>Pooled results from three studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.37, 95% CI 0.09 to 1.61; I 2 = 4%),</td></tr><tr><td>with no di erence in the number of oro-facial cle /craniofacial</td></tr><tr><td>malformations in children exposed to LEV (N = 807) and children</td></tr><tr><td>exposed to PHT (N = 542) (Analysis 34.4). The RD also suggested no</td></tr><tr><td>di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr><tr><td>In the EURAP 2018 data, the prevalence of cle malformations</td></tr><tr><td>(other oro-facial not specifically reported) in those exposed to LEV</td></tr><tr><td>was 0.16% (1/599) and 0% for children exposed to PHT (0/125).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF57": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one routine health record study suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 0.41, 95% CI 0.06 to 2.81; I 2 = NA),</td></tr><tr><td>with children exposed to LEV (N = 118) experiencing comparable</td></tr><tr><td>major malformation rate to children exposed to TPM (N = 48)</td></tr><tr><td>(Analysis 36.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.02, 95% CI -0.09 to 0.04; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF58": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from seven cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 2.39, 95% CI 0.10 to 58.61; I 2 = NA), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LEV (N = 1030) and children exposed to TPM (N = 496)</td></tr><tr><td>(Analysis 36.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF59": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from three cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk (RR 0.92, 95% CI 0.29 to 2.91; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to LTG (N = 2018) and children exposed to CZP (N = 94)</td></tr><tr><td>(Analysis 38.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.01, 95% CI -0.03 to 0.04; I 2 = 33%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF60": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two routine health record studies suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 1.54, 95% CI 0.53 to 4.54; I 2 =</td></tr><tr><td>0%), with no di erence in the number of major malformations in</td></tr><tr><td>children exposed to LTG (N = 923) and children exposed to CZP (N =</td></tr><tr><td>161) (Analysis 38.1). The RD also suggested no di erence in the level</td></tr><tr><td>of risk (RD 0.01, 95% CI -0.01 to 0.04; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF61": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk(RR 0.73, 95% CI 0.33 to 1.62; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to LTG (N = 2208) and children exposed to OXC (N = 333)</td></tr><tr><td>(Analysis 40.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 3.0%</td></tr><tr><td>(95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Lamotrigine dose and</td></tr><tr><td>Oxcarbazepine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF62": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from three routine health record studies suggested</td></tr><tr><td>no evidence of a di erence in risk (RR 1.24, 95% CI 0.67 to 2.30; I 2</td></tr><tr><td>= 0%), with no di erence in the number of major malformations in</td></tr><tr><td>children exposed to LTG (N = 2158) and children exposed to OXC (N =</td></tr><tr><td>377) (Analysis 40.1). The RD also suggested no di erence in the level</td></tr><tr><td>of risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF63": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.59, 95% CI 0.03 to 12.15; I 2 = NA), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LTG (N = 2027) and children exposed to OXC (N = 319)</td></tr><tr><td>(Analysis 40.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr><tr><td>In the EURAP 2018 data, the prevalence of neural tube anomalies</td></tr><tr><td>in those exposed to LTG was 0.3% (1/2514) and 0% for children</td></tr><tr><td>exposed to OXC (0/333).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF64": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.59, 95% CI 0.15 to 2.30; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of cardiac malformations in children</td></tr><tr><td>exposed to LTG (N = 2084) and children exposed to OXC (N = 323)</td></tr><tr><td>(Analysis 40.3</td></tr></table>",
                "type_str": "table"
            },
            "TABREF65": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>across di erent doses of the two ASMs (see Lamotrigine dose and</td></tr><tr><td>Phenobarbital dose sections).</td></tr><tr><td>Pooled results from seven cohort studies suggested an increased</td></tr><tr><td>risk with PB (RR 0.32, 95% CI 0.17 to 0.59; I 2 = 0%), with children</td></tr><tr><td>exposed to LTG (N = 2156) experiencing fewer major malformations</td></tr><tr><td>than children exposed to PB (N = 421) (Analysis 41.1). The RD also</td></tr><tr><td>suggested a higher risk for PB (RD -0.04, 95% CI -0.07 to -0.01; I 2</td></tr><tr><td>= 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 6.5%</td></tr><tr><td>(95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr></table>",
                "type_str": "table"
            },
            "TABREF66": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two routine health record studies suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 0.41, 95% CI 0.13 to 1.28; I 2 = 0%),</td></tr><tr><td>with children exposed to LTG (N = 923) experiencing comparable</td></tr><tr><td>major malformations to children exposed to PB (N = 34) (Analysis</td></tr><tr><td>41.1). The RD also suggested no di erence in the level of risk (RD</td></tr><tr><td>-0.05, 95% CI -0.15 to 0.04; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF67": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.76, 95% CI 0.09 to 6.88; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LTG (N = 2009) and children exposed to PB (N = 412)</td></tr><tr><td>(Analysis 41.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF68": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested an increased risk</td></tr><tr><td>with PB (RR 0.22, 95% CI 0.07 to 0.68; I 2 = 0%), with fewer oro-</td></tr><tr><td>facial cle /craniofacial malformations in children exposed to LTG (N</td></tr><tr><td>= 1940) compared to PB (N = 274) (Analysis 41.4). However, the RD</td></tr><tr><td>suggested no di erence in the level of risk (RD -0.01, 95% CI -0.03</td></tr><tr><td>to 0.01; I 2 = 0%).</td></tr><tr><td>In the EURAP 2018 data, the prevalence of cle malformations</td></tr><tr><td>(other oro-facial not specifically reported) in those exposed to LTG</td></tr><tr><td>was 0.11% (3/2514) and 0.34% for children exposed to PB (1/294).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF69": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.38, 95% CI 0.06 to 2.58; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of skeletal/limb malformations in children</td></tr><tr><td>exposed to LTG (N = 2009) and children exposed to PB (N = 413)</td></tr><tr><td>(Analysis 41.5</td></tr></table>",
                "type_str": "table"
            },
            "TABREF70": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested an increased risk</td></tr><tr><td>with PHT (RR 0.55, 95% CI 0.35 to 0.87; I 2 = 24%), with children</td></tr><tr><td>exposed to LTG (N = 4251) experiencing fewer major malformations</td></tr><tr><td>than children exposed to PHT (N = 742) (Analysis 42.1). The RD also</td></tr><tr><td>suggested a higher risk for PHT (RD -0.02, 95% CI -0.03 to -0.00; I 2</td></tr><tr><td>= 31%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 6.4%</td></tr><tr><td>(95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Lamotrigine dose and</td></tr><tr><td>Phenytoin dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF71": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>One routine health record study suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.65, 95% CI 0.20 to 2.16; I 2 = NA%), with</td></tr><tr><td>children exposed to LTG (N = 90) experiencing comparable major</td></tr><tr><td>malformations to children exposed to PHT (N = 103) (Analysis 42.1).</td></tr><tr><td>The RD also suggested no di erence in the level of risk (RD -0.02,</td></tr><tr><td>95% CI -0.09 to 0.04; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF72": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.40, 95% CI 0.11 to 1.51; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to LTG (N = 4127) and children exposed to PHT (N = 718)</td></tr><tr><td>(Analysis 42.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF73": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from five cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk (RR 0.73, 95% CI 0.23 to 2.28; I 2 = 45%),</td></tr><tr><td>with no di erence in the number of oro-facial cle /craniofacial</td></tr><tr><td>malformations in children exposed to LTG (N = 4077) and children</td></tr><tr><td>exposed to PHT (N = 599) (Analysis 42.4). The RD also suggested no</td></tr><tr><td>di erence in the level of risk (RD -0.00, 95% CI -0.01 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF74": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.66, 95% CI 0.26 to 1.65; I 2 = 66%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to LTG (N = 3792) and children exposed to ZNS (N = 130)</td></tr><tr><td>(Analysis 45.1). Due to high heterogeneity, a random-e ects RR was</td></tr><tr><td>calculated which also found no di erence (RD 0.57, 95% CI 0.09 to</td></tr><tr><td>3.81, I 2 = 66%</td></tr></table>",
                "type_str": "table"
            },
            "TABREF75": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled data from three included studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.22, 95% CI 0.03 to 1.93, I 2 = 0%, with no</td></tr><tr><td>di erence in the number of skeletal/limb malformations in children</td></tr><tr><td>exposed to LTG (N = 2230) and children exposed to ZNS (N = 40)</td></tr><tr><td>(Analysis 45.5). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.05 to 0.06; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF76": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 2.15, 95% CI 0.69 to 6.73; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 567) and children exposed to GBP (N = 192)</td></tr><tr><td>(Analysis 46.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.02, 95% CI -0.00 to 0.04; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF77": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one routine health record study suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 2.74, 95% CI 0.16 to 46.00;</td></tr><tr><td>I 2 = 0%), with children exposed to PHT (N = 103) experiencing</td></tr><tr><td>comparable major malformations to children exposed to GBP (N =</td></tr><tr><td>18) (Analysis 46.1). The RD also suggested no di erence in the level</td></tr><tr><td>of risk (RD 0.07, 95% CI -0.02 to 0.16; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF78": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Included studies did not meet the threshold for reporting of the</td></tr><tr><td>meta-analysis (Analysis 46.2). However, available data showed</td></tr><tr><td>there were 1/45 cases of neural tube malformations in children</td></tr><tr><td>exposed to PHT and 0/16 cases in children exposed to GBP, based</td></tr><tr><td>on data from two studies (Australian Epilepsy and Pregnancy</td></tr><tr><td>Register; Miskov 2016).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF79": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>No included studies reported data on this outcome.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF80": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Included studies did not meet the threshold for reporting of the</td></tr><tr><td>meta-analysis (Analysis 46.3). However, available data showed</td></tr><tr><td>there were 1/45 cases of cardiac malformations in children exposed</td></tr><tr><td>to PHT and 1/16 cases in children exposed to GBP, based on</td></tr><tr><td>data from two studies (Australian Epilepsy and Pregnancy Register;</td></tr><tr><td>Miskov 2016).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF81": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.94, 95% CI 0.48 to 1.85; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 706) and children exposed to OXC (N = 283)</td></tr><tr><td>(Analysis 47.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.03 to 0.03; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>6.4% (95% CI 2.8 to 12.2) for children exposed to PHT and 3.0%</td></tr><tr><td>(95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Phenytoin dose and</td></tr><tr><td>Oxcarbazepine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF82": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one routine health record study suggested an</td></tr><tr><td>increased risk with PHT (RR 0.72, 95% CI 0.05 to 0.93; I 2 = NA),</td></tr><tr><td>with children exposed to PHT (N = 103) experiencing more major</td></tr><tr><td>malformations than children exposed to OXC (N = 4) (Analysis 47.1).</td></tr><tr><td>However, the RD suggested no di erence in the level of risk (RD 0.07,</td></tr><tr><td>95% CI -0.20 to 0.34; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF83": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.16, 95% CI 0.13 to 10.29; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to PHT (N = 703) and children exposed to OXC (N = 271)</td></tr><tr><td>(Analysis 47.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF84": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from five cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.33, 95% CI 0.43 to 14.17; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of cardiac malformations in children</td></tr><tr><td>exposed to PHT (N = 704) and children exposed to OXC (N = 272)</td></tr><tr><td>(Analysis 47.3). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.01, 95% CI -0.01 to 0.03; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF85": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.20, 95% CI 0.23 to 6.35; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of skeletal/limb malformations in children</td></tr><tr><td>exposed to PHT (N = 703) and children exposed to OXC (N = 271)</td></tr><tr><td>(Analysis 47.5). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.01 to 0.02; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF86": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF87": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 20 cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.84, 95% CI 0.57 to 1.23; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 1095) and children exposed to PB (N = 634)</td></tr><tr><td>(Analysis 48.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.01, 95% CI -0.03 to 0.02; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>6.4% (95% CI 2.8 to 12.2) for children exposed to PHT and 6.5%</td></tr><tr><td>(95% CI 4.2 to 9.9) for children exposed to PHT. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Phenytoin dose and</td></tr><tr><td>Phenobarbital dose sections). Samren 1997 reported nine cases of</td></tr><tr><td>major malformation in 141 (6%) PHT cases and five cases in 48</td></tr><tr><td>(10%) PB-exposed children.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF88": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one routine health record study suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 0.48, 95% CI 0.07 to 3.35; I 2 = NA),</td></tr><tr><td>with children exposed to PHT (N = 103) experiencing comparable</td></tr><tr><td>major malformations to children exposed to PB (N = 7) (Analysis</td></tr><tr><td>48.1). The RD also suggested no di erence in the level of risk (RD</td></tr><tr><td>-0.07, 95% CI -0.34 to 0.19; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF89": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF90": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 11 cohort studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 1.31, 95% CI 0.39 to 4.39; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of skeletal/limb malformations in children</td></tr><tr><td>exposed to PHT (N = 707) and children exposed to PB (N = 475)</td></tr><tr><td>(Analysis 48.5</td></tr></table>",
                "type_str": "table"
            },
            "TABREF91": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.78, 95% CI 0.39 to 1.56; I 2 = 19%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 360) and children exposed to PRM (N = 103)</td></tr><tr><td>(Analysis 49.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.02, 95% CI -0.09 to 0.06; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF92": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one routine health record study suggested no</td></tr><tr><td>evidence of a di erence in risk (RR 0.58, 95% CI 0.04 to 8.44; I 2 = NA),</td></tr><tr><td>with children exposed to PHT (N = 103) experiencing no more major</td></tr><tr><td>malformations than children exposed to PRM (N = 3) (Analysis 49.1).</td></tr><tr><td>The RD also suggested no di erence in the level of risk (RD 0.07, 95%</td></tr><tr><td>CI -0.26 to 0.40; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF93": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Included studies did not meet the threshold for reporting of the</td></tr><tr><td>meta-analysis (Analysis 49.3). However, available data showed</td></tr><tr><td>there were 0/36 cases of cardiac malformations in children exposed</td></tr><tr><td>to PHT and 1/39 cases in children exposed to PRM, based on data</td></tr><tr><td>from two studies (Milan Study 1999; Pardi 1982).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF94": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies showed no evidence of</td></tr><tr><td>a di erence in risk (RR 0.88, 95% CI 0.48 to 1.61; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 685) and children exposed to TPM (N = 491)</td></tr><tr><td>(Analysis 50.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.03 to 0.02; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM was</td></tr><tr><td>2.9% (95% CI 2.3 to 3.7%) for children exposed to PHT and 3.9%</td></tr><tr><td>(95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Phenytoin dose and</td></tr><tr><td>Topiramate dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF95": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one study suggested no evidence of a di erence in</td></tr><tr><td>risk (RR 0.29, 95% CI 0.02 to 3.51, I 2 = NA), with no di erence in the</td></tr><tr><td>number of major malformations in children exposed to PHT (N =</td></tr><tr><td>103) and children exposed to PRM (N = 1) (Analysis 50.1). The RD also</td></tr><tr><td>suggested no di erence in the level of risk (RD 0.07, 95% CI -0.53 to</td></tr><tr><td>0.67; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF96": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.23, 95% CI 0.17 to 8.87; I 2 = 24%), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to PHT (N = 661) and children exposed to TPM (N = 483)</td></tr><tr><td>(Analysis 50.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF97": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 2.46, 95% CI 0.65 to 9.36; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of cardiac malformations in children</td></tr><tr><td>exposed to PHT (N = 661) and children exposed to TPM (N = 483)</td></tr><tr><td>(Analysis 50.3). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.01, 95% CI -0.00 to 0.02; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF98": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.63, 95% CI 0.19 to 2.09; I 2 = 0%), with no</td></tr><tr><td>di erence in the number of skeletal/limb malformations in children</td></tr><tr><td>exposed to PHT (N = 661) and children exposed to TPM (N = 483)</td></tr><tr><td>(Analysis 50.5). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.00, 95% CI -0.02 to 0.01; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF99": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF100": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.28, 95% CI 0.42 to 3.93; I 2 = 61%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PHT (N = 522) and children exposed to ZNS (N = 116)</td></tr><tr><td>(Analysis 51.1). Due to high heterogeneity, a random-e ects RR was</td></tr><tr><td>calculated which found a similar e ect (RR 1.28, 95% CI 0.42 to 3.93,</td></tr><tr><td>I 2 = 61%). The RD also suggested no di erence in the level of risk</td></tr><tr><td>(RD 0.01, 95% CI -0.02 to 0.05; I 2 = 68%). Due to heterogeneity, a</td></tr><tr><td>random-e ects RD was calculated which also found no di erence</td></tr><tr><td>in risk (RD 0.00, 95% CI -0.11 to 0.11, I 2 = 68%)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF101": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF102": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Results from one study suggested no evidence of a di erence in risk</td></tr><tr><td>(RR 0.98, 95% CI 0.04 to 23.26, I 2 = NA), with no di erence in the</td></tr><tr><td>number of oro-facial cle /craniofacial malformations in children</td></tr><tr><td>exposed to PHT (N = 82) and children exposed to ZNS (N = 26)</td></tr><tr><td>(Analysis 51.4). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.01, 95% CI -0.05 to 0.07; I 2 = NA).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF103": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from eight cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.61, 95% CI 0.83 to 3.14; I 2 = 19%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PB (N = 354) and children exposed to OXC (N = 322)</td></tr><tr><td>(Analysis 52.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.02, 95% CI -0.02 to 0.06; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM</td></tr><tr><td>was 6.5% (95% CI 4.2 to 9.9) for children exposed to PB and 3.0%</td></tr><tr><td>(95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr><tr><td>across di erent doses of the two ASMs (see Phenobarbital dose and</td></tr><tr><td>Oxcarbazepine dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF104": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from seven cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 2.58, 95% CI 0.94 to 7.09; I 2 = 51%), with</td></tr><tr><td>children exposed to PB (N = 352) experiencing comparable cardiac</td></tr><tr><td>malformations to children exposed to OXC (N = 306) (Analysis 52.3).</td></tr><tr><td>Due to high heterogeneity, a random-e ects RR was calculated</td></tr><tr><td>which also found no di erence (RR 3.84, 95% CI 0.54 to 27.19, I 2 =</td></tr></table>",
                "type_str": "table"
            },
            "TABREF105": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF106": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from five cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk (RR 3.66, 95% CI 0.41 to 32.43; I 2 = NA),</td></tr><tr><td>with no di erence in the number of oro-facial cle /craniofacial</td></tr><tr><td>malformations in children exposed to PB (N = 212) and children</td></tr><tr><td>exposed to TPM (N = 234) (Analysis 52.4). The RD also suggested no</td></tr><tr><td>di erence in the level of risk (RD 0.01, 95% CI -0.01 to 0.04; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF107": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from six cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.50, 95% CI 0.21 to 1.16; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PB (N = 241) and children exposed to PRM (N = 110)</td></tr><tr><td>(Analysis 53.1</td></tr></table>",
                "type_str": "table"
            },
            "TABREF108": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 0.42, 95% CI 0.03 to 6.55, I 2 = NA), with</td></tr><tr><td>no di erence in the number of cardiac malformations in children</td></tr><tr><td>exposed to PB (N = 95) and children exposed to PRM (N = 39)</td></tr><tr><td>(Analysis 53.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD -0.01, 95% CI -0.08 to 0.05; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF109": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.38, 95% CI 0.68 to 2.81; I 2 = 0%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to PB (N = 340) and children exposed to TPM (N = 426)</td></tr><tr><td>(Analysis 54.1). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.02, 95% CI -0.02 to 0.05; I 2 = 0%).</td></tr><tr><td>The EURAP 2018 collaboration reported the prevalence of MCM</td></tr><tr><td>was 6.5% (95% CI 4.2 to 9.9) for children exposed to PB and 3.9%</td></tr><tr><td>(95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical</td></tr><tr><td>comparison was made at the group level; investigations were made</td></tr></table>",
                "type_str": "table"
            },
            "TABREF110": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>across di erent doses of the two ASMs (see Phenobarbital dose and</td></tr><tr><td>Topiramate dose sections).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF111": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Included studies did not meet the threshold for reporting of the</td></tr><tr><td>meta-analysis (Analysis 54.1). However, available data showed</td></tr><tr><td>there were 3/34 cases of major malformations in children exposed</td></tr><tr><td>to PB and 2/49 cases in children exposed to TPM, based on data</td></tr><tr><td>from two studies (Norwegian Health Record Registers; Sweden</td></tr><tr><td>Health Record Registers).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF112": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 0.22, 95% CI 0.01 to 5.00; I 2 = NA), with no</td></tr><tr><td>di erence in the number of neural tube malformations in children</td></tr><tr><td>exposed to PB (N = 343) and children exposed to TPM (N = 417)</td></tr><tr><td>(Analysis 54.2). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.00, 95% CI -0.02 to 0.02; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF113": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two cohort studies suggested no evidence</td></tr><tr><td>of a di erence in risk (RR 10.46, 95% CI 0.62 to 175.67; I 2 =</td></tr><tr><td>NA), with no di erence in the number of major malformations in</td></tr><tr><td>children exposed to PB (N = 201) and children exposed to ZNS</td></tr><tr><td>(N = 91) (Analysis 55.1). The RD suggested a higher rate of major</td></tr><tr><td>malformation observed in the PB-exposed group (RD 0.05, 95% CI</td></tr><tr><td>0.02 to 0.09; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF114": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from four cohort studies suggested no evidence of</td></tr><tr><td>a di erence in risk (RR 1.59, 95% CI 0.54 to 4.66; I 2 = 58%), with</td></tr><tr><td>no di erence in the number of major malformations in children</td></tr><tr><td>exposed to TPM (N = 440) and children exposed to ZNS (N = 130)</td></tr><tr><td>(Analysis 56.1). Due to high heterogeneity, a random-e ects RR was</td></tr><tr><td>calculated which also found no di erence (RD 1.44, 95% CI 0.19 to</td></tr><tr><td>10.82, I 2 =58%). The RD also suggested no di erence in the level of</td></tr><tr><td>risk (RD 0.02, 95% CI -0.02 to 0.06; I 2 = 35%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF115": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from two studies suggested no evidence of a</td></tr><tr><td>di erence in risk (RR 1.90 95% CI 0.09 to 38.34, I 2 = NA),</td></tr><tr><td>with no di erence in the number of oro-facial cle /craniofacial</td></tr><tr><td>malformations in children exposed to TPM (N = 81) and children</td></tr><tr><td>exposed to ZNS (N = 40) (Analysis 56.4). The RD also suggested no</td></tr><tr><td>di erence in the level of risk (RD 0.02, 95% CI -0.06 to 0.10; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF116": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 10 cohort studies suggested an increased risk</td></tr><tr><td>with VPA (RR 3.77, 95% CI 2.48 to 5.74; I 2 = 17%), with children</td></tr><tr><td>exposed to VPA (N = 2342) experiencing more major malformations</td></tr></table>",
                "type_str": "table"
            },
            "TABREF117": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Pooled results from 12 cohort studies suggested an increased risk with VPA (RR 3.50, 95% CI 2.76 to 4.46; I 2 = 0%), with children exposed to VPA (N = 2459) experiencing more major malformations than children exposed to LTG (N = 4437) (Analysis 61.1). The RD suggested an increased risk for VPA (RD 0.06, 95% CI 0.05 to 0.08; I 2 = 34%). The EURAP 2018 collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 2.9% (95% CI 2.3 to 3.Cochrane Trusted evidence. Informed decisions. Library Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF118": {
                "text": "Pooled results from four routine health record studies suggested an increased risk with VPA (RR 2.49, 95% CI 1.86 to 3.35; I 2 = 0%), with children exposed to VPA (N = 1088) experiencing more major malformations than children exposed to LTG (N = 2502) (Analysis 61.1).The RD also suggested an increased level of risk for VPA (RD 0.05, 95% CI 0.03 to 0.07; I 2 = 42%).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>61.2 Neural tube malformations</td></tr><tr><td>61.2.1 Cohort studies</td></tr><tr><td>Pooled results from 11 cohort studies suggested an increased</td></tr><tr><td>risk with VPA (RR 7.48, 95% CI 3.27 to 17.13; I 2 = 0%), with</td></tr><tr><td>children exposed to VPA (N = 2415) experiencing more neural tube</td></tr><tr><td>malformations than children exposed to LTG (N = 4293) (Analysis</td></tr><tr><td>61.2). The RD also suggested an increased level of risk for VPA (RD</td></tr><tr><td>0.01, 95% CI 0.01 to 0.02; I 2 = 0%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF119": {
                "text": "Pooled results from seven cohort studies suggested an increased risk with VPA (RR 2.47, 95% CI 1.50 to 4.08; I",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF120": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF121": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr><tr><td/><td>Pooled results from 21 cohort studies suggested an increased risk</td></tr><tr><td/><td>with VPA (RR 1.92, 95% CI 1.44 to 2.56; I 2 = 0%), with children</td></tr><tr><td/><td>exposed to VPA (N = 2650) experiencing more major malformations</td></tr><tr><td/><td>than children exposed to PHT (N = 1247) (Analysis 65.1). The RD also</td></tr><tr><td/><td>suggested a higher risk for VPA (RD 0.05, 95% CI 0.03 to 0.07; I 2 = 4%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF122": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF123": {
                "text": "Cochrane Database of Systematic ReviewsInvestigation between dose of LEV and major malformation outcome was limited by numbers included within the individual studies (i.e.Denmark Health Record Registers; Kerala Epilepsy and Pregnancy Registry; North American Epilepsy and Pregnancy Register; UK and Ireland Epilepsy and Pregnancy Register), including the EURAP 2018 study.In 599 LEV-exposed pregnancies, EURAP 2018 did not investigate lower versus higher-dose LEV.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Trusted evidence.</td></tr><tr><td>Informed decisions.</td></tr><tr><td>Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF125": {
                "text": "Epilepsy and Pregnancy Register; UK and Ireland Epilepsy and Pregnancy Register), therefore, it is not possible to draw conclusions at this time.Further e orts are needed to develop experience with this medication in pregnancy, as it has been in use for a long period in certain parts of the world (Oommen 1999).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>and attention</td></tr><tr><td>deficit hyperactivity disorder (Christensen 2019).</td></tr><tr><td>More than any other ASM, studies have reported dose associations</td></tr><tr><td>with level of major malformation risk for VPA (Australian Epilepsy</td></tr><tr><td>and Pregnancy Register; EURAP 2018; Fairgrieve 2000; Israeli</td></tr><tr><td>Teratogen Service; Kaneko 1999; Lindhout 1992; Milan Study</td></tr><tr><td>1999; North American Epilepsy and Pregnancy Register; Samren</td></tr><tr><td>1997; UK and Ireland Epilepsy and Pregnancy Register). The</td></tr><tr><td>largest data set with clear dose comparisons is the EURAP 2018</td></tr><tr><td>collaboration, which found that the prevalence of major congenital</td></tr><tr><td>malformations increased from 6.3% at doses &lt; 650 mg daily to</td></tr><tr><td>25.2% for doses \u2265 1450 mg daily. Interestingly, pregnancy registers</td></tr><tr><td>have reported a decrease in the mean dose for new registrations</td></tr><tr><td>(UK and Ireland Epilepsy and Pregnancy Register) and have noted</td></tr><tr><td>that this is associated with a reduction in the number of observed</td></tr><tr><td>cases of neural tube malformations and hypospadias (Australian</td></tr><tr><td>Epilepsy and Pregnancy Register).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF127": {
                "text": "Cochrane Database of Systematic Reviews dataset, but this is only possible with the support of referring clinicians and the women who participate.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr><tr><td/><td>There is consistent evidence, across di erent study designs, that</td></tr><tr><td/><td>prenatal exposure to VPA increases the risk of having a child with</td></tr><tr><td/><td>a major malformation with the risk including neural tube, cardiac,</td></tr><tr><td/><td>skeletal, limb, oro-facial cle and craniofacial malformations.</td></tr><tr><td/><td>Whilst the prevalence of major malformation is 9.8%, this outcome</td></tr><tr><td/><td>is only one of a constellation of symptoms associated with VPA</td></tr><tr><td/><td>exposure in utero (Clayton-Smith 2019; Dean 2000; Yerby 1992)</td></tr><tr><td/><td>and which constitute the condition, foetal valproate spectrum</td></tr><tr><td/><td>disorder (ICD 11 LD2F.03) (Clayton-Smith 2019). The impact of VPA</td></tr><tr><td/><td>on the developing foetus is clearly dose-related (EURAP 2018) and</td></tr><tr><td/><td>this should be considered when counselling regarding the risks</td></tr><tr><td/><td>associated with in utero exposure to VPA. The evidence reported</td></tr><tr><td/><td>here therefore supports regulatory limitations on VPA's use, unless</td></tr><tr><td/><td>clinically necessary, to treat maternal epilepsy (NICE 2022) and</td></tr><tr><td/><td>where clear counselling has been given to the patient. There are</td></tr><tr><td/><td>other ASMs, however, which also require careful patient counselling</td></tr><tr><td/><td>and these include CBZ, PB, TPM and PHT.</td></tr><tr><td/><td>Given the variance in major malformation risk associated with</td></tr><tr><td/><td>individual ASM treatments and at di erent doses, preconceptual</td></tr><tr><td/><td>counselling should be tailored to the individual patient. Although</td></tr><tr><td/><td>traditional counselling has been that 90% of children born to</td></tr><tr><td/><td>women with epilepsy have healthy children, this oversimplifies</td></tr><tr><td/><td>a complex set of data. The ASM type, but also dose and</td></tr><tr><td/><td>considerations regarding specific malformation types, should also</td></tr><tr><td/><td>be central to counselling. It is also important to note that major</td></tr><tr><td/><td>malformation risk is just one aspect and that minor malformations</td></tr><tr><td/><td>and longer-term child health and neurodevelopmental outcome</td></tr><tr><td/><td>risks should also feature in counselling.</td></tr><tr><td/><td>Finally, every e ort should be made by clinicians to inform women</td></tr><tr><td/><td>about local initiatives collecting data on ASM use in pregnancy</td></tr></table>",
                "type_str": "table"
            },
            "TABREF128": {
                "text": "Sabers A, Dam M, A-Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, et al.Epilepsy and pregnancy: lamotrigine as main drug used.Acta Neurologica Scandinavica 2004;109(1):9-13.Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al, EURAP study group.Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.Lancet Neurology 2011;10(7):609-17.[PMID: 21652013]",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">REFERENCES Tomson T, Battino D, Bonizzoni E, Craig JJ, Lindhout D, population-based cohort study. British Journal of Obstetrics and * Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth Cassina 2013 {published data only} UK Epilepsy and Pregnancy Register as tools for postmarketing Baermig 1973 {published data only} EMPiRE Study {published data only} Sabers 2004 {published data only} References to studies awaiting assessment Tomson 2011</td></tr><tr><td colspan=\"3\">References to studies included in this review Al Bunyan 1999 {published data only} Al Bunyan M, Abo-Talib Z. Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure 1999;8(1):26-9. [PMID: 10091844] AlSheikh 2020 {published data only} AlSheikh MH. Prevalence of epilepsy in Saudi pregnant women and possible e ects of anti-epileptic drugs on pregnancy outcomes. Neurosciences 2020;25(1):32-7. [PMID: 31982897] Australian Epilepsy and Pregnancy Register {published and unpublished data} Jazayeri D, Graham J, Hitchcock A, O'Brien TJ, Vajda FJ. Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure 2018;56:111-4. [PMID: 29471258] Cassina M, Dilaghi A, Di Gianantonio E, Cesari E, De Santis M, Mannaioni G, et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology 2013;39:50-7. [PMID: 23591043] D'Souza 1991 {published data only} D'Souza SW, Robertson IG, Donnai D, Mawer G. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood 1991;65(3):320-4. [PMID: 2025009] Delmi\u0161 1991 {published data only} \u0110elmi\u0161 J, Dra\u017ean\u010di\u0107 A, Tkal\u010devi\u0107 T, Ivani\u0161evi\u0107 M. Epilepsy in pregnancy [Epilepsija i trudno\u0107a]. Jugoslavenska Ginekologija i Perinatologija 1991;31(1-2):23-6. [PMID: 1875716] Denmark Health Record Registers {published and unpublished data} anomalies: an Italian prospective, controlled study. Neurology 1992;42(4 Suppl 5):89-93. [PMID: 1574184] UK and Ireland Epilepsy and Pregnancy Register {published and unpublished data} Campbell E, Devenney E, Morrow J, Russell A, Smithson WH, Parsons L, et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013;54(1):165-71. [PMID: 23167802] * Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry 2014;85(9):1029-34. [PMID: 24444855] Hunt S, Craig J, Russell A, Guthrie E, Parsons L, Robertson I, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006;67(10):1876-9. [PMID: 17130430] Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in women with epilepsy: population-based cohort study. BJOG 2009;116(13):1736-42. [PMID: 19781049] 2009;48(1):16-21. [PMID: 19496458] Bozhinova S, Bozhinov P. The course of pregnancy and labor in patients with epilepsy [Protichane na bremennostta i razhdaneto pri bremenni s epilepsiia]. Akusherstvo i Ginekologiia 1998;37(4):12-4. [PMID: 10360042] development of birth defects. Lancet 1976;1(7954):272-5. [PMID: 55587] Shapiro S, Hartz SC, Siskind V, Mitchell AA, Slone D, Rosenberg L, et al. Anticonvulsants and parental epilepsy in the in women with epilepsy]. Akusherstvo i Ginekologiia Shapiro 1976 {published data only} * Bozhinov P, Bozhinova C, Markova C. [Fetal malformations [PMID: 31124321] Bozhinov 2009 {published data only} Scheuerle AE, Holmes LB, Albano JD, Badalamenti V, Battino D, results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. Birth Defects Research 2019;111(13):872-87. Covington D, et al. Levetiracetam Pregnancy Registry: final B\u00e4rmig H. Epilepsy and pregnancy [Epilepsie und schwangerscha ]. Geburtshilfe und Frauenheilkunde 1973;33(3):203-4. [PMID: 4692245] Borthen 2009 {published data only} Participants Intervention group: Women on AED monotherapy or polytherapy Vajda FJ, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Is carbamazepine a human teratogen? Journal of Clinical Neuroscience 2016;23:34-7. [PMID: 26521756] Vajda FJ, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research 2014;108(6):1013-7. [PMID: 24880523] Vajda FJ, O'Brien TJ, Graham JE, Hitchcock AA, Lander CM, Eadie MJ. Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica 2017;135(3):360-5. [PMID: 27573510] Vajda FJ, O'Brien TJ, Graham JE, Hitchcock AA, Lander CM, Eadie MJ. Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior 2020;103(Pt A):106481. [PMID: 31711866] Perucca E, et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology 2015;85(7):580-8. [PMID: 26187231] Fairgrieve 2000 {published data only} Fairgrieve SD, Jackson M, Jonas P, Walshaw D, White K, Montgomery TL, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal 2000;321(7262):674-5. [PMID: 10987772] Finland Health Record Registers {published data only} * Artama M, Auvinen A, Raudaskoski T, Isoj\u00e4rvi I, Isoj\u00e4rvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in o spring. Neurology 2005;64(11):1874-8. [PMID: 15955936] Artama M, Ritvanen A, Gissler M, Isoj\u00e4rvi J, Auvinen A. Congenital structural anomalies in o spring of women with epilepsy -a population-based cohort study in Finland. International Journal of Epidemiology 2006;35(2):280-7. [PMID: 16280367] Fr\u00f6scher 1991 {published data only} Gynecology 2009;116(13):1736-42. [PMID: 19781049] * Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology 2014;261(13):579-88. [PMID: 24449062] Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009;50(9):2130-9. [PMID: 19490036] Omtzigt 1992 {published data only} * Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta a er first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(4 Suppl 5):119-25. [PMID: 1574165] Omtzigt JG, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta a er first-trimester valproate exposure. Prenatal Diagnosis 1992;12(11):893-7. [PMID: 1283633] teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety 2011;34(2):157-71. [PMID: 21247222] UK Health Record THIN Register {published data only} et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One 2015;10(7):e0131130. [PMID: 26147467] * Petersen I, Collings S-L, McCrea RL, Nazareth I, Osborn DP, Cowen PJ, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology 2017;9:95-103. [PMID: 28243149] US Medicaid Registers {published data only} Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, et al. Topiramate use early in pregnancy and the risk of oral cle s: a pregnancy cohort study. Neurology 2018;90(4):e342-51. [PMID: 29282333] in utero a farmaci. Analisi di un campione di neonati pretrattati 2015;84(9):944-50. [PMID: 25653296] [PMID: 3702846] pregnant women enrolled in Florida Medicaid. Neurology con anticonvulsivanti]. Minerva Pediatrica 1986;38(3-4):75-81. Wen X, Meador KJ, Hartzema A. Antiepileptic drug use by 1990;5(3):217-22. [PMID: 2384077] newborn infants pretreated with anticonvulsants [Esposizione Wen 2015 of drug exposure and genetic background. Epilepsy Research phenytoin exposure: results of a controlled anthropometric study. American Journal of Medical Genetics 1990;35(4):574-8. Gaily EK, Granstr\u00f6m ML, Hiilesmaa VK, Bardy AH. Head circumference in children of epileptic mothers: contributions Siena G. Intrauterine exposure to drugs: analysis of a sample of Medicine 2017;15(1):95. [PMID: 28472982] Lazzaroni Fossati F, De Toni T, Magnani M, Repetto E, Calvi A, Di of congenital malformations and prenatal outcomes. BMC Lazzaroni Fossati 1986 {published data only} pregnancy: a systematic review and network meta-analysis [PMID: 2333888] et al. Comparative safety of anti-epileptic drugs during 2013;54(Suppl 3):127-8, Abstract no: P399. Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, treatment of women with epilepsy during pregnancy. Epilepsia Gaily E. Distal phalangeal hypoplasia in children with prenatal Kutlu G, Erdal A, Aydogan S, Gomceli YB, Inan LE. Follow up and Veroniki 2017 1988;112(4):520-9. [PMID: 3351676] Kutlu 2013 {published data only} 25851171] 2018. [DOI: 10.3310/hta22230] [PMID: 29737274] Finland Cohort Study {published data only} Gaily E, Granstr\u00f6m ML, Hiilesmaa V, Bardy A. Minor anomalies in o spring of epileptic mothers. Journal of Pediatrics of childbearing potential. Epilepsia 2015;56(7):1006-19. [PMID: Safety 2013;36(9):844, Abstract no: ISP3556-47. et al. Valproate in the treatment of epilepsy in girls and women Pregnancy outcomes in women using antiepileptic drugs. Drug Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, Kaabi W, El Aidli S, Kastalli S, Lakhoua G, Zaiem A, Srairi S, et al. Tomson 2015 Kaabi 2013 {published data only} Ban L, Fleming KM, Doyle P, Smeeth L, Hubbard RB, Fiaschi L, Thangaratinam S, Marlin N, Newton S, Weckesser A, Bagary M, Babic 2014 {published data only} Greenhill L, et al. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on e ectiveness and Babic N, Jovic M. Postnatal concerns in children born to women Control group: Women with epilepsy not taking AEDs with juvenile myoclonic epilepsy. Epilepsia 2014;55(Suppl acceptability of monitoring strategies. Southampton (UK): NIHR Journals Library (Health Technology Assessment, No. 22.23), Scheuerle 2019 {published data only} 2):128, Abstract no: p389. Interventions Intervention groups (monotherapy):</td></tr><tr><td/><td/><td>Midi 2014 {published data only}</td></tr><tr><td>Oommen 1999</td><td/><td/></tr><tr><td colspan=\"2\">Oommen KJ, Mathews S. Zonisamide: a new antiepileptic</td><td/></tr><tr><td colspan=\"2\">Ginecologia y Obstetricia de Mexico 1995;63:282-6. [PMID: drug. Clinical Neuropharmacology 1999;22(4):192-200. [PMID:</td><td/></tr><tr><td>7665113] 10442247]</td><td/><td/></tr><tr><td colspan=\"2\">Wide 2000 {published data only} Sterne 2016</td><td/></tr><tr><td colspan=\"2\">Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND,</td><td>Galappatty 2018 {published data only}</td></tr><tr><td colspan=\"2\">Psychomotor development and minor anomalies in children Viswanathan M, et al. ROBINS-I: a tool for assessing risk</td><td>Galappatthy P, Liyanage CK, Lucas MN, Jayasekara DTLM,</td></tr><tr><td colspan=\"2\">exposed to antiepileptic drugs in utero: a prospective of bias in non-randomised studies of interventions. BMJ</td><td>Abhayaratna SA, Weeraratne C, et al. Obstetric outcomes and</td></tr><tr><td colspan=\"3\">Seizure Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. 2010;19(9):558-61. [PMID: 20739196] The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology 2007;47(6):468-74. [PMID: 17991111] Vajda FJ, Lander CM, Hitchcock A, Graham J, Solinas C, O'Brien T, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience 2007;14(7):611-7. [PMID: 17400456] population-based study. Developmental Medicine and Child 2016;355:i4919. [PMID: 27733354] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology 2019;93(9):e831-40. [PMID: 31391249] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Dose-dependent teratogenicity of valproate in mono-and polytherapy: an observational study. Neurology 2015;85(10):866-72. [PMID: 26085607] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17. [PMID: 21652013] Seizure 2021;91:311-5. [PMID: 34273670] Neurology 2000;42(2):87-92. [PMID: 10698324] Tetro 2017 Yeh 2017 {published data only} Tetro N, Moushaev S, Shmuel M, Eyal S. Antiseizure medications 2017;109(15Holmes LB, Rosenberger PB, Harvey EA, Khoshbin S, Ryan L. e ects on babies born to women treated for epilepsy during 27265509] Vajda FJ, O'Brien TJ, Lander CM, Graham J, Roten A, Eadie MJ. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013;54(1):181-6. [PMID: 22882134] Bag 1989 {published data only} Bag S, Behari M, Ahuja GK, Karmarkar MG. Pregnancy and epilepsy. Journal of Neurology 1989;236(5):311-3. [PMID: 2760652] Barqawi 2005 {published data only} Barqawi R. Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal : 2005;11(4):601-5. [PMID: 16700374] Israeli Teratogen Service {published data only} Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001;57(2):321-4. [PMID: 11468320] * Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome a er in utero exposure to valproate: evidence of dose relationship in teratogenic e ect. CNS Drugs 2008;22(4):325-34. [PMID: 18336060] Diav-Citrin O, Shechtman S, Zvi N, Finkel-Pekarsky V, Ornoy A. Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research pregnancy in a resource limited setting: a comparative cohort study. BMC Pregnancy &amp; Childbirth 2018;18(1):230. [PMID: 29898689] Intelligence and physical features of children of women with epilepsy. Teratology 2000;61(3):196-202. [PMID: 10661909] Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry. Epilepsia 2004;45(11):1465. [PMID: 15509251] Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, et al. Increased rate of major malformations in o spring exposed to valproate during pregnancy. Neurology 2005;64(6):961-5. [PMID: 15781808] Norwegian Health Record Registers {published data only} Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in women with epilepsy: K\u00e4ll\u00e9n B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica 1986;73(3):253-9. [PMID: 3716762] * Wide K, Winbladh B, K\u00e4ll\u00e9n B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica 2004;93(2):174-6. [PMID: 15046269] Tanganelli 1992 {published data only} Regesta G, Tanganelli P. The risk of malformations and Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(2):193-8. [PMID: 16157661] UK Clinical Research Practice Database {published data only} Charlton RA, Weil JG, Cunnington MC, De Vries CS. Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety 2010;33(9):741-50. [PMID: 20701407] Arteaga-Vazques 2012 {published data only} Arteaga-Vazquez J, Luna-Munoz L, Mutchinick OM. Congenital malformations in the o spring of epileptic mothers with and without anticonvulsant treatment [Malformaciones congenitas en hijos de madres epilepticas con y sin tratmiento con anticonvulsivantes]. Salud Publica Mexico 2012;54(6):579-86. [PMID: 23318894] Arulmozhi 2006 {published data only} Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A. Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India 2006;54(1):42-6; 1971;115(33):1371-5. [PMID: 5565182] 2015;53:45-50. [PMID: 25797654] discussion 47. [PMID: 16679642] Dravet 1992 {published data only} Dravet C, Julian C, Legras C, Magaudda A, Guerrini R, Genton P, et al. Epilepsy, antiepileptic drugs, and malformations in Elshove 1971 {published data only} and cle palate in particular, in children of epileptic mothers systematic review and meta-analysis. Reproductive Toxicology met epilepsie]. Nederlands Tijdschri voor Geneeskunde 1974;127(5):645-53. [PMID: 4825584] to topiramate and the risk of oral cle s in the o spring: a of zonder gespleten verhemelte, bij kinderen van moeders prospective study. American Journal of Diseases of Children Suppl 5):132-40. [PMID: 1574169] Alsaad AM, Chaudhry SA, Koren G. First trimester exposure [Aangeboren misvormingen, met name gespleten lip met Hill RM, Verniaud WM, Horning MG, McCulley LB, Morgan NF. Infants exposed in utero to antiepileptic drugs: a development of congenital anomalies. Neurology 1992;42(4 Alsaad 2015 Loewenson RB, Sells CJ, et al. Antiepileptics and the Elshove J, Van Eck JH. Congenital abnormalities, cle lip Yerby MS, Leavitt A, Erickson DM, McCormick KB, [PMID: 19307197] Hill 1974 {published data only} potential. Archives of Disease in Childhood 2009;94(6):443-7. Yerby 1992 {published data only} la Reproduction 1974;3(6):831-42. [PMID: 4470757] trends in antiepileptic drug prescribing in girls of child-bearing study. Neurology 1992;42(4 Suppl 5):75-82. [PMID: 1574181] congenitales]. Journal de Gyn \u0301ecologie, Obst \u0301etrique et Biologie de [PMID: 29253023] Ackers R, Besag FM, Wade A, Murray ML, Wong IC. Changing children of women with epilepsy: a French prospective cohort Yeh CC, Lussier EC, Sun YT, Lan TY, Yu HY, Chang TY. Antiepileptic and fetal nutrients: e ects on choline transporters in a Goujard 1974 {published data only} Goujard J, Huel G, Rumeau-Rouquette C. Antiepileptics and congenital malformations [Antiepileptiques et malformations drug use among women from the Taiwanese Registry of Epilepsy and Pregnancy: obstetric complications and fetal malformation outcomes. PLOS One 2017;12(12):e0189497. human placental cell line. Epilepsia 2021;62(6):1451-9. [PMID: Additional references Ackers 2009 33890297]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF130": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">1.4.1 CBZ vs Women Without Epilepsy (co-</td><td>7</td><td>2070</td><td>Risk Ratio (M-H, Fixed,</td><td>9.04 [2.16, 37.87]</td></tr><tr><td>hort studies) Cassina 2013</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.4.2 CBZ vs WWE -No Medication (cohort D'Souza 1991 Israeli Teratogen Service</td><td>9</td><td>1056</td><td>Risk Ratio (M-H, Fixed,</td><td>0.99 [0.27, 3.62]</td></tr><tr><td>studies) Kaur 2020</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>Koch 1992</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.5 CBZ vs Controls: Skeletal/Limb Malfor-mations Mawer 2010 Melikova 2020 Miskov 2016</td><td>13</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.5.1 CBZ vs Woment Without Epilepsy Motherisk Registry</td><td>7</td><td>2070</td><td>Risk Ratio (M-H, Fixed,</td><td>5.13 [0.52, 50.67]</td></tr><tr><td colspan=\"2\">(cohort studies) North American Epilepsy and Pregnancy Register Steegers-Theunissen 1994</td><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.5.2 CBZ vs WWE -No Medication (cohort Tanganelli 1992 Subtotal (95% CI)</td><td>9</td><td>1873</td><td>Risk Ratio (M-H, Fixed,</td><td>0.96 [0.33, 2.82]</td></tr><tr><td>studies) Total events:</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 5.54, df = 11 (P = 0.90); I\u00b2 = 0%</td><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 3.66 (P = 0.0003)</td><td/><td/><td/></tr><tr><td colspan=\"2\">1.1.2 CBZ vs WWE -No Medication (cohort studies)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title AlSheikh 2020</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register Barqawi 2005</td><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">1.1 CBZ vs Controls: All Major Malforma-D'Souza 1991 Delmi\u0161 1991</td><td>33</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions Fairgrieve 2000</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>Garza-Morales 1996</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.1.1 CBZ vs Women Without Epilepsy (co-hort studies) Hosny 2021 Kaaja 2003 Kaneko 1999</td><td>13</td><td>5047</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>2.30 [1.47, 3.59]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td/><td/></tr><tr><td colspan=\"2\">1.1.2 CBZ vs WWE -No Medication (cohort Koch 1992</td><td>20</td><td>5289</td><td>Risk Ratio (M-H, Fixed,</td><td>1.44 [1.05, 1.96]</td></tr><tr><td>studies) Lindhout 1992 Mawer 2010</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>Milan Study 1999</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.1.3 CBZ vs Women Without Epilepsy Miskov 2016</td><td>2</td><td>373094</td><td>Risk Ratio (M-H, Fixed,</td><td>1.14 [0.80, 1.64]</td></tr><tr><td>(database studies) MONEAD 2020</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>Montreal Series</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.1.4 CBZ vs WWE -No Medication (data-base studies) UK and Ireland Epilepsy and Pregnancy Register Waters 1994 Subtotal (95% CI)</td><td>4</td><td>14334</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.42 [1.10, 1.83]</td></tr><tr><td>Total events:</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.2 CBZ vs Controls: Neural Tube Malfor-mations Heterogeneity: Chi\u00b2 = 8.67, df = 17 (P = 0.95); I\u00b2 = 0% Test for overall effect: Z = 2.26 (P = 0.02)</td><td>13</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>1.1</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.2.1 CBZ vs Women Without Epilepsy (co-</td><td>7</td><td>2070</td><td>Risk Ratio (M-H, Fixed,</td><td>3.09 [0.38, 25.40]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.2.2 CBZ vs WWE -No Medication (cohort</td><td>9</td><td>1873</td><td>Risk Ratio (M-H, Fixed,</td><td>2.54 [0.63, 10.20]</td></tr><tr><td>studies)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.3 CBZ vs Controls: Cardiac Malforma-</td><td>14</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.3.1 CBZ vs Women Without Epilepsy (co-</td><td>7</td><td>2070</td><td>Risk Ratio (M-H, Fixed,</td><td>1.46 [0.43, 4.99]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.3.2 CBZ vs WWE -No Medication (cohort</td><td>11</td><td>1903</td><td>Risk Ratio (M-H, Fixed,</td><td>0.87 [0.41, 1.84]</td></tr><tr><td>studies)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.4 CBZ vs Controls: Oro-Facial Cle /</td><td>13</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF131": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>5</td><td>88</td><td>25</td><td>867</td><td>19.6%</td><td>1.97 [0.77 , 5.02]</td></tr><tr><td/><td>1</td><td>3</td><td>0</td><td>62</td><td>0.3%</td><td>47.25 [2.27 , 984.68]</td></tr><tr><td/><td>6</td><td>108</td><td>22</td><td>828</td><td>21.6%</td><td>2.09 [0.87 , 5.04]</td></tr><tr><td/><td>0</td><td>7</td><td>5</td><td>197</td><td>1.8%</td><td>2.25 [0.14 , 37.28]</td></tr><tr><td/><td>0</td><td>9</td><td>5</td><td>116</td><td>3.7%</td><td>1.06 [0.06 , 17.88]</td></tr><tr><td/><td>2</td><td>74</td><td>6</td><td>315</td><td>9.7%</td><td>1.42 [0.29 , 6.89]</td></tr><tr><td/><td>1</td><td>36</td><td>3</td><td>277</td><td>2.9%</td><td>2.56 [0.27 , 24.00]</td></tr><tr><td/><td>0</td><td>13</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td/><td>1</td><td>14</td><td>2</td><td>106</td><td>2.0%</td><td>3.79 [0.37 , 39.10]</td></tr><tr><td/><td>1</td><td>15</td><td>0</td><td>31</td><td>1.4%</td><td>6.00 [0.26 , 139.16]</td></tr><tr><td/><td>31</td><td>1033</td><td>5</td><td>442</td><td>29.7%</td><td>2.65 [1.04 , 6.78]</td></tr><tr><td/><td>1</td><td>39</td><td>2</td><td>106</td><td>4.6%</td><td>1.36 [0.13 , 14.57]</td></tr><tr><td/><td>0</td><td>9</td><td>4</td><td>124</td><td>2.8%</td><td>1.39 [0.08 , 24.01]</td></tr><tr><td/><td/><td>1448</td><td/><td>3599</td><td>100.0%</td><td>2.30 [1.47 , 3.59]</td></tr><tr><td/><td>49</td><td/><td>79</td><td/><td/></tr><tr><td/><td>2</td><td>5</td><td>1</td><td>8</td><td>1.2%</td><td>3.20 [0.38 , 26.78]</td></tr><tr><td/><td>24</td><td>409</td><td>5</td><td>176</td><td>10.5%</td><td>2.07 [0.80 , 5.33]</td></tr><tr><td/><td>0</td><td>16</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td/><td>1</td><td>3</td><td>1</td><td>8</td><td>0.8%</td><td>2.67 [0.23 , 30.40]</td></tr><tr><td/><td>4</td><td>18</td><td>0</td><td>10</td><td>0.9%</td><td>5.21 [0.31 , 87.93]</td></tr><tr><td/><td>4</td><td>109</td><td>3</td><td>48</td><td>6.2%</td><td>0.59 [0.14 , 2.52]</td></tr><tr><td/><td>0</td><td>24</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td/><td>1</td><td>8</td><td>1</td><td>21</td><td>0.8%</td><td>2.63 [0.19 , 37.14]</td></tr><tr><td/><td>10</td><td>363</td><td>2</td><td>239</td><td>3.6%</td><td>3.29 [0.73 , 14.89]</td></tr><tr><td/><td>9</td><td>158</td><td>3</td><td>98</td><td>5.5%</td><td>1.86 [0.52 , 6.71]</td></tr><tr><td/><td>23</td><td>490</td><td>16</td><td>340</td><td>28.2%</td><td>1.00 [0.54 , 1.86]</td></tr><tr><td/><td>0</td><td>9</td><td>1</td><td>25</td><td>1.2%</td><td>0.87 [0.04 , 19.56]</td></tr><tr><td/><td>5</td><td>50</td><td>2</td><td>28</td><td>3.8%</td><td>1.40 [0.29 , 6.75]</td></tr><tr><td/><td>2</td><td>74</td><td>1</td><td>46</td><td>1.8%</td><td>1.24 [0.12 , 13.33]</td></tr><tr><td/><td>12</td><td>113</td><td>0</td><td>25</td><td>1.2%</td><td>5.70 [0.35 , 93.24]</td></tr><tr><td/><td>1</td><td>13</td><td>0</td><td>4</td><td>1.1%</td><td>1.07 [0.05 , 22.25]</td></tr><tr><td/><td>1</td><td>14</td><td>1</td><td>15</td><td>1.4%</td><td>1.07 [0.07 , 15.54]</td></tr><tr><td/><td>5</td><td>32</td><td>0</td><td>8</td><td>1.2%</td><td>3.00 [0.18 , 49.32]</td></tr><tr><td/><td>43</td><td>1657</td><td>13</td><td>541</td><td>29.3%</td><td>1.08 [0.59 , 1.99]</td></tr><tr><td/><td>1</td><td>33</td><td>0</td><td>15</td><td>1.0%</td><td>1.41 [0.06 , 32.78]</td></tr><tr><td/><td/><td>3598</td><td/><td>1691</td><td>100.0%</td><td>1</td></tr><tr><td/><td>148</td><td/><td>50</td><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>9309</td><td>369267</td><td>67.9%</td></tr><tr><td>UK Health Record THIN Register</td><td>10</td><td>298</td><td>86</td><td>2844</td><td>32.1%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>983</td><td/><td>372111</td><td>100.0%</td></tr><tr><td>Total events:</td><td>30</td><td/><td>9395</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.01, df = 1 (P = 0.91); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.73 (P = 0.47)</td><td/><td/><td/><td/><td/></tr><tr><td>1.1.4 CBZ vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>21</td><td>315</td><td>361</td><td>8477</td><td>29.7%</td></tr><tr><td>Finland Health Record Registers</td><td>32</td><td>805</td><td>26</td><td>939</td><td>27.6%</td></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>49</td><td>1900</td><td>29.8%</td></tr><tr><td>UK Clinical Research Practice Database</td><td>13</td><td>311</td><td>22</td><td>902</td><td>12.9%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2116</td><td/><td>12218</td><td>100.0%</td></tr><tr><td>Total events:</td><td>86</td><td/><td>458</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.25, df = 3 (P = 0.74); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.69 (P = 0.007)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF132": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 1.1. (Continued)</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td>0.01</td><td colspan=\"3\">M-H, Fixed, 95% CI 0.1 1 10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours Controls</td></tr><tr><td>Analysis 1.2.</td><td/><td/><td/><td/></tr><tr><td/><td/><td>1.16 [0.75 , 1.78]</td><td/><td/></tr><tr><td/><td/><td>1.11 [0.58 , 2.11]</td><td/><td/></tr><tr><td/><td/><td>1.14 [0.80 , 1.64]</td><td/><td/></tr><tr><td/><td/><td>1.57 [1.02 , 2.40]</td><td/><td/></tr><tr><td/><td/><td>1.44 [0.86 , 2.39]</td><td/><td/></tr><tr><td/><td/><td>1.13 [0.68 , 1.89]</td><td/><td/></tr><tr><td/><td/><td>1.71 [0.87 , 3.36]</td><td/><td/></tr><tr><td/><td/><td>1.42 [1.10 , 1.83]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr></table>",
                "type_str": "table"
            },
            "TABREF133": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 1.3.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">1.2.1 CBZ vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Israeli Teratogen Service</td><td/><td>0</td><td>108</td><td>0</td><td>828</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>116</td><td/><td>Not estimable</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>1</td><td>315</td><td>63.3%</td><td>1.40 [0.06 , 34.14]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td>Motherisk Registry</td><td/><td>1</td><td>15</td><td>0</td><td>31</td><td>36.7%</td><td>6.00 [0.26 , 139.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>269</td><td/><td>1801</td><td>100.0%</td><td>3.09 [0.38 , 25.40]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.41, df = 1 (P = 0.52); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.05 (P = 0.29)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.2.2 CBZ vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>361</td><td>0</td><td>147</td><td>24.1%</td><td>1.23 [0.05 , 29.94]</td></tr><tr><td>Barqawi 2005</td><td/><td>0</td><td>16</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td/><td>0</td><td>109</td><td>0</td><td>48</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>0</td><td>340</td><td>20.0%</td><td>9.03 [0.51 , 159.73]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>1</td><td>25</td><td>28.3%</td><td>0.87 [0.04 , 19.56]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>1</td><td>113</td><td>0</td><td>25</td><td>27.6%</td><td>0.68 [0.03 , 16.32]</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1194</td><td/><td>679</td><td>100.0%</td><td>2.54 [0.63 , 10.20]</td></tr><tr><td>Total events:</td><td/><td>8</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.06, df = 3 (P = 0.56); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.31 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF134": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Israeli Teratogen Service</td><td/><td>1</td><td>108</td><td>9</td><td>828</td><td>57.5%</td><td>0.85 [0.11 , 6.66]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>1</td><td>116</td><td>6.5%</td><td>3.90 [0.17 , 89.64]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>1</td><td>315</td><td>15.9%</td><td>1.40 [0.06 , 34.14]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>1</td><td>277</td><td>9.8%</td><td>2.50 [0.10 , 60.36]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>1</td><td>106</td><td>10.2%</td><td>2.38 [0.10 , 55.75]</td></tr><tr><td>Motherisk Registry</td><td/><td>0</td><td>15</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>269</td><td/><td>1801</td><td>100.0%</td><td>1.46 [0.43 , 4.99]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>13</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.85, df = 4 (P = 0.93); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.60 (P = 0.55)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.3.2 CBZ vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td/><td>1</td><td>5</td><td>0</td><td>8</td><td>2.9%</td><td>4.50 [0.22 , 93.07]</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>3</td><td>361</td><td>1</td><td>147</td><td>10.1%</td><td>1.22 [0.13 , 11.65]</td></tr><tr><td>Barqawi 2005</td><td/><td>0</td><td>16</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td/><td>3</td><td>109</td><td>0</td><td>48</td><td>4.9%</td><td>3.12 [0.16 , 59.22]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>1</td><td>21</td><td>6.2%</td><td>0.81 [0.04 , 18.18]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>9</td><td>340</td><td>75.8%</td><td>0.54 [0.20 , 1.44]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>113</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1212</td><td/><td>691</td><td>100.0%</td><td>0.87 [0.41 , 1.84]</td></tr><tr><td>Total events:</td><td colspan=\"2\">14</td><td/><td>11</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.85, df = 4 (P = 0.58); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.37 (P = 0.71)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF135": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 1.5. Israeli Teratogen Service Analysis 2.1</td><td colspan=\"2\">CBZ Events 0</td><td>Total 108</td><td colspan=\"2\">Controls Events 0 Total 828</td><td>Weight Weight</td><td>Risk Ratio M-H, Fixed, 95% CI Risk Ratio M-H, Fixed, 95% CI Not estimable</td><td>Risk Ratio M-H, Fixed, 95% CI Risk Ratio M-H, Fixed, 95% CI</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>1</td><td>828 116</td><td>13.5% 41.5%</td><td>38.03 [1.84 , 786.90] 3.90 [0.17 , 89.64]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>0</td><td>116 315</td><td>64.2%</td><td>1.67 [0.09 , 30.13] Not estimable</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>315 277</td><td>22.3%</td><td>12.64 [0.52 , 307.22] Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>277 128</td><td/><td>Not estimable Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>128 106</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Motherisk Registry</td><td/><td>1</td><td>15</td><td>0</td><td>106 31</td><td>58.5%</td><td>Not estimable 6.00 [0.26 , 139.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>269</td><td/><td>31 1801</td><td>100.0%</td><td>Not estimable 5.13 [0.52 , 50.67]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>1</td><td>1801</td><td>100.0%</td><td>9.04 [2.16 , 37.87]</td></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.04, df = 1 (P = 0.84); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.40 (P = 0.16)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">1.5.2 CBZ vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>2</td><td>361</td><td>1</td><td>147</td><td>21.3%</td><td>0.81 [0.07 , 8.91]</td></tr><tr><td>Barqawi 2005</td><td/><td>0</td><td>16</td><td>0</td><td>8 18</td><td>25.9%</td><td>0.50 [0.02 , 10.34] Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td/><td>0</td><td>109</td><td>1</td><td>147 48</td><td>15.3% 31.1%</td><td>3.68 [0.20 , 67.92] 0.15 [0.01 , 3.58]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>18 21</td><td/><td>Not estimable Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>2</td><td>48 340</td><td>44.8% 35.4%</td><td>0.15 [0.01 , 3.58] 1.39 [0.26 , 7.53]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>21 25</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>74</td><td>0</td><td>25 40</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>4</td><td>113</td><td>0</td><td>40 25</td><td>14.0% 12.2%</td><td>1.64 [0.07 , 39.35] 2.05 [0.11 , 36.95]</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>25 15</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1194</td><td/><td>15 679</td><td>100.0%</td><td>Not estimable 0.96 [0.33 , 2.82]</td></tr><tr><td>Total events:</td><td/><td>10</td><td/><td>4</td><td>347</td><td>100.0%</td><td>0.99 [0.27 , 3.62]</td></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.79, df = 3 (P = 0.62); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.07 (P = 0.94)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>0.01 Favours CBZ 0.1</td><td>1</td><td>10 Favours Controls 100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Comparison 2. CZP vs Controls</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">2.1 CZP vs Controls: All Major Malforma-</td><td>5</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1.1 CZP vs Women Without Epilepsy (co-</td><td>2</td><td/><td/><td>569</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>2.76 [0.55, 13.94]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1.2 CZP vs WWE -No Medication (cohort</td><td>3</td><td/><td/><td>555</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.08 [0.21, 5.42]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1.3 CZP vs Women Without Epilepsy</td><td>1</td><td/><td/><td colspan=\"2\">369380</td><td>Risk Ratio (M-H, Fixed,</td><td>0.70 [0.18, 2.77]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1.4 CZP vs WWE -No Medication (data-</td><td>1</td><td/><td/><td>2013</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>0.69 [0.17, 2.79]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF136": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td colspan=\"2\">CZP</td><td/><td colspan=\"3\">Controls pants</td><td/><td colspan=\"2\">Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td/><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">3.3.1 GBP vs Women Without Epilepsy</td><td>1</td><td/><td/><td colspan=\"2\">130</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>129.00 [6.49,</td></tr><tr><td>D'Souza 1991 (cohort studies)</td><td/><td>)</td><td>0</td><td>1</td><td/><td>0</td><td>62</td><td/><td>CI)</td><td>Not estimable</td><td>2562.48]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register Subtotal (95% CI) 3.3.2 GBP vs WWE -No Medication (co-</td><td>1</td><td>2</td><td>64 65</td><td>6</td><td>5</td><td>442 504</td><td>100.0% 100.0%</td><td colspan=\"2\">2.76 [0.55 , 13.94] 2.76 [0.55 , 13.94] Risk Ratio (M-H, Fixed, 95%</td><td>5.00 [0.29, 87.54]</td></tr><tr><td>Total events: hort studies)</td><td/><td/><td>2</td><td/><td/><td>5</td><td/><td/><td>CI)</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.23 (P = 0.22) 3.4 GBP vs Controls: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">2.1.2 CZP vs WWE -No Medication (cohort studies) Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td/><td>0</td><td>26</td><td/><td>5</td><td>176</td><td>58.7%</td><td colspan=\"2\">0.60 [0.03 , 10.48]</td></tr><tr><td colspan=\"2\">D'Souza 1991 3.4.1 GBP vs Women Without Epilepsy</td><td>1</td><td>0</td><td>1</td><td>0</td><td>1</td><td>8</td><td>22.0%</td><td colspan=\"2\">1.50 [0.09 , 24.92] Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry (cohort studies)</td><td/><td>0</td><td>4</td><td colspan=\"2\">16</td><td>340</td><td>19.2%</td><td colspan=\"2\">2.07 [0.14 , 29.88] CI)</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>31</td><td/><td/><td>524</td><td>100.0%</td><td colspan=\"2\">1.08 [0.21 , 5.42]</td></tr><tr><td colspan=\"2\">Total events: Heterogeneity: Chi\u00b2 = 0.45, df = 2 (P = 0.80); I\u00b2 = 0% 3.5 GBP vs Controls: Skeletal/Limb Mal-</td><td>1</td><td>0</td><td/><td colspan=\"2\">22</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.09 (P = 0.93) formations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">2.1.3 CZP vs Women Without Epilepsy (database studies) Norwegian Health Record Registers Subtotal (95% CI) (cohort studies) 3.5.1 GBP vs Women Without Epilepsy 1</td><td>2</td><td>113 113</td><td colspan=\"2\">9309 0</td><td>369267 369267</td><td>100.0% 100.0%</td><td colspan=\"2\">0.70 [0.18 , 2.77] CI) 0.70 [0.18 , 2.77] Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td/><td>2</td><td/><td colspan=\"2\">9309</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.50 (P = 0.61)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">2.1.4 CZP vs WWE -No Medication (database studies) Norwegian Health Record Registers Analysis 3.1</td><td>2</td><td>113</td><td colspan=\"2\">49</td><td>1900</td><td>100.0%</td><td colspan=\"2\">0.69 [0.17 , 2.79]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>113</td><td/><td/><td>1900</td><td>100.0%</td><td colspan=\"2\">0.69 [0.17 , 2.79]</td></tr><tr><td>Total events:</td><td/><td/><td>2</td><td/><td colspan=\"2\">49</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.53 (P = 0.60)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours CZP</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Comparison 3. GBP vs Controls</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"3\">pants</td><td/><td/></tr><tr><td colspan=\"2\">3.1 GBP vs Controls: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.1.1 GBP vs Women Without Epilepsy</td><td>2</td><td/><td/><td colspan=\"2\">717</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.78 [0.50, 6.29]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.1.2 GBP vs WWE -No Medication (co-</td><td>3</td><td/><td/><td colspan=\"2\">768</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.77 [0.46, 6.90]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.2 GBP vs Controls: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.2.1 GBP vs Women Without Epilepsy</td><td>1</td><td/><td/><td>0</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.3 GBP vs Controls: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF137": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>128</td><td>0.9%</td><td>129.00 [6.49 , 2562.48]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>5</td><td>442</td><td>99.1%</td><td>0.61 [0.07 , 5.18]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>147</td><td/><td>570</td><td>100.0%</td><td>1.78 [0.50 , 6.29]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 8.85, df = 1 (P = 0.003); I\u00b2 = 89%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.90 (P = 0.37)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.1.2 GBP vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>5</td><td>176</td><td>32.5%</td><td>1.07 [0.06 , 18.48]</td></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>4</td><td>14.2%</td><td>5.00 [0.29 , 87.54]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>31</td><td>13</td><td>541</td><td>53.3%</td><td>1.34 [0.18 , 9.93]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>47</td><td/><td>721</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>2</td><td/><td>18</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.70, df = 2 (P = 0.71); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.83 (P = 0.41)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF138": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 3.2.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours GBP</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF139": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Miskov 2016</td><td>0</td><td>2</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours Controls</td></tr><tr><td>Analysis 3.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF140": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>128</td><td>100.0%</td><td>129.00 [6.49 , 2562.48]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2</td><td/><td>128</td><td>100.0%</td><td>129.00 [6.49 , 2562.48]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 3.19 (P = 0.001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">3.3.2 GBP vs WWE -No Medication (cohort studies)</td><td/><td/><td/></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>4</td><td>100.0%</td><td>5.00 [0.29 , 87.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2</td><td/><td>4</td><td>100.0%</td><td>5.00 [0.29 , 87.54]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.10 (P = 0.27)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours Controls</td></tr><tr><td/><td colspan=\"2\">Analysis 3.</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF141": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 3.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>GBP</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Miskov 2016</td><td>0</td><td>2</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF142": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td>GBP</td><td/><td colspan=\"2\">Control</td><td/><td>pants</td><td colspan=\"2\">Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events 4.4.1 LEV vs Women Without Epilepsy Total</td><td/><td>Events 2</td><td colspan=\"2\">Total</td><td>Weight 0</td><td colspan=\"2\">M-H, Fixed, 95% CI Risk Ratio (M-H, Fixed, 95% M-H, Fixed, 95% CI Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Miskov 2016 Subtotal (95% CI) Total events: hort studies) 4.4.2 LEV vs WWE -No Medication (co-0 0</td><td>2 0</td><td>3</td><td>0 0</td><td>128 0</td><td>230</td><td colspan=\"2\">Not estimable CI) Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>0.14 [0.01, 3.18]</td></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable formations Test for overall effect: Not applicable 4.5 LEV vs Controls: Skeletal/Limb Mal-</td><td/><td>4</td><td/><td/><td/><td/><td>CI) Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable (cohort studies) 4.5.1 LEV vs Women Without Epilepsy</td><td>2</td><td/><td/><td>0</td><td/><td>0.01 Favours GBP 0.1 Risk Ratio (M-H, Fixed, 95% 1 CI)</td><td>10 Favours Controls 100 Not estimable</td></tr><tr><td colspan=\"2\">4.5.2 LEV vs WWE -No Medication (co-</td><td/><td>3</td><td/><td/><td>648</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.21 [0.46, 22.50]</td></tr><tr><td colspan=\"2\">Comparison 4. LEV vs Controls hort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">4.1 LEV vs Controls: All Major Malforma-Analysis 4.1</td><td/><td>11</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.1.1 LEV vs Women Without Epilepsy</td><td/><td>4</td><td/><td/><td>1596</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.20 [0.98, 4.93]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.1.2 LEV vs WWE -No Medication (co-</td><td/><td>6</td><td/><td/><td>1825</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.71 [0.39, 1.28]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.1.3 LEV vs Women Without Epilepsy</td><td/><td>1</td><td/><td/><td colspan=\"2\">369385</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.67 [0.17, 2.66]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.1.4 LEV vs WWE -No Medication (data-</td><td/><td>2</td><td/><td/><td>10625</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.82 [0.39, 1.71]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.2 LEV vs Controls: Neural Tube Malfor-</td><td/><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.2.1 LEV vs Women Without Epilepsy</td><td/><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.2.2 LEV vs WWE -No Medication (co-</td><td/><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.3 LEV vs Controls: Cardiac Malforma-</td><td/><td>5</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.3.1 LEV vs Women Without Epilepsy</td><td/><td>2</td><td/><td/><td>488</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.92 [0.57, 27.07]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.3.2 LEV vs WWE -No Medication (co-</td><td/><td>4</td><td/><td/><td>665</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.90 [0.31, 2.60]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.4 LEV vs Controls: Oro-Facial Cle /</td><td/><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF143": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 4.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LEV</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>19</td><td>5</td><td>197</td><td>12.4%</td><td>0.90 [0.05 , 15.69]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>6</td><td>3</td><td>277</td><td>2.1%</td><td>5.67 [0.32 , 99.73]</td></tr><tr><td>MONEAD 2020</td><td/><td>5</td><td>99</td><td>2</td><td>106</td><td>23.7%</td><td>2.68 [0.53 , 13.48]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>5</td><td>442</td><td>61.8%</td><td>2.16 [0.76 , 6.17]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>574</td><td/><td>1022</td><td>100.0%</td><td>2.20 [0.98 , 4.93]</td></tr><tr><td>Total events:</td><td/><td>16</td><td/><td>15</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.85, df = 3 (P = 0.84); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.92 (P = 0.06)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.1.2 LEV vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>9</td><td>1</td><td>8</td><td>6.0%</td><td>0.30 [0.01 , 6.47]</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>5</td><td>176</td><td>16.8%</td><td>1.27 [0.37 , 4.29]</td></tr><tr><td>Hosny 2021</td><td/><td>2</td><td>67</td><td>1</td><td>21</td><td>5.8%</td><td>0.63 [0.06 , 6.57]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>106</td><td>16</td><td>340</td><td>29.0%</td><td>1.00 [0.38 , 2.67]</td></tr><tr><td>MONEAD 2020</td><td/><td>5</td><td>99</td><td>1</td><td>15</td><td>6.6%</td><td>0.76 [0.09 , 6.05]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>13</td><td>541</td><td>35.7%</td><td>0.27 [0.06 , 1.21]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>724</td><td/><td>1101</td><td>100.0%</td><td>0.71 [0.39 , 1.28]</td></tr><tr><td>Total events:</td><td/><td>19</td><td/><td>37</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 3.25, df = 5 (P = 0.66); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.15 (P = 0.25)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.1.3 LEV vs Women Without Epilepsy (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>2</td><td>118</td><td>9309</td><td>369267</td><td>100.0%</td><td>0.67 [0.17 , 2.66]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>118</td><td/><td>369267</td><td>100.0%</td><td>0.67 [0.17 , 2.66]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>9309</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.57 (P = 0.57)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.1.4 LEV vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Denmark Health Record Registers</td><td>5</td><td>130</td><td>361</td><td>8477</td><td>65.6%</td><td>0.90 [0.38 , 2.15]</td></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>2</td><td>118</td><td>49</td><td>1900</td><td>34.4%</td><td>0.66 [0.16 , 2.67]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>248</td><td/><td>10377</td><td>100.0%</td><td>0.82 [0.39 , 1.71]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>410</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.14, df = 1 (P = 0.70); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.53 (P = 0.59)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LEV</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF144": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">4.2.1 LEV vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>277</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>106</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.2.2 LEV vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>67</td><td>0</td><td>21</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>0</td><td>340</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours Controls</td></tr><tr><td>Analysis 4.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF145": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"2\">Analysis 4.4.</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LEV</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>6</td><td>1</td><td>277</td><td>7.1%</td><td>13.24 [0.59 , 297.25]</td></tr><tr><td>MONEAD 2020</td><td/><td>3</td><td>99</td><td>1</td><td>106</td><td>92.9%</td><td>3.21 [0.34 , 30.37]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>105</td><td/><td>383</td><td>100.0%</td><td>3.92 [0.57 , 27.07]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>2</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.62, df = 1 (P = 0.43); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.39 (P = 0.17)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.3.2 LEV vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>9</td><td>0</td><td>8</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>1</td><td>67</td><td>1</td><td>21</td><td>22.9%</td><td>0.31 [0.02 , 4.80]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>9</td><td>340</td><td>64.2%</td><td>1.07 [0.29 , 3.88]</td></tr><tr><td>MONEAD 2020</td><td/><td>3</td><td>99</td><td>0</td><td>15</td><td>12.9%</td><td>1.12 [0.06 , 20.68]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>281</td><td/><td>384</td><td>100.0%</td><td>0.90 [0.31 , 2.60]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>10</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.66, df = 2 (P = 0.72); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.19 (P = 0.85)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LEV</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF146": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">4.4.2 LEV vs WWE -No Medication (cohort studies)</td><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>1</td><td>8</td><td>100.0%</td><td>0.14 [0.01 , 3.18]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>67</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td colspan=\"2\">186</td><td/><td>44</td><td>100.0%</td><td>0.14 [0.01 , 3.18]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.23 (P = 0.22)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">4.5.1 LEV vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>4.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF147": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Analysis 5.1.</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">5.1.1 LTG vs Women Without Epilepsy (co-</td><td>7</td><td/><td/><td>4862</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.99 [1.16, 3.39]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.1.2 LTG vs WWE -No Medication (cohort</td><td>8</td><td/><td/><td>3918</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.04 [0.66, 1.63]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.1.3 LTG vs Women Without Epilepsy</td><td>2</td><td/><td/><td colspan=\"2\">373288</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.19 [0.86, 1.64]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.1.4 LTG vs WWE -No Medication (data-</td><td>3</td><td/><td/><td colspan=\"2\">13445</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.00 [0.79, 1.28]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.2 LTG vs Controls: Neural Tube Malfor-</td><td>8</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.2.1 LTG vs Women Without Epilepsy (co-</td><td>5</td><td/><td/><td>1967</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>7.55 [1.05, 54.09]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.2.2 LTG vs WWE -No Medication (cohort</td><td>5</td><td/><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.3 LTG vs Controls: Cardiac Malforma-</td><td>9</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.3.1 LTG vs Women Without Epilepsy (co-</td><td>5</td><td/><td/><td>2006</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>2.71 [1.05, 6.98]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"3\">LEV Events 5.3.2 LTG vs WWE -No Medication (cohort 6</td><td>Total</td><td colspan=\"2\">Control Events Total 1112</td><td>Weight</td><td colspan=\"2\">Risk Ratio M-H, Fixed, 95% CI Risk Ratio (M-H, Fixed, M-H, Fixed, 95% CI Risk Ratio 0.97 [0.28, 3.32]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.4 LTG vs Controls: Oro-Facial Cle /</td><td>0 7</td><td>6</td><td>0</td><td>277</td><td/><td/><td>Not estimable Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Crainofacial Malformations</td><td>0</td><td>99 0</td><td>0</td><td>106 0</td><td/><td/><td>Not estimable Not estimable 95% CI)</td></tr><tr><td colspan=\"2\">5.4.1 LTG vs Women Without Epilepsy (co-</td><td>0 4</td><td/><td>0</td><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.4.2 LTG vs WWE -No Medication (cohort</td><td>5</td><td/><td/><td>813</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.37 [0.29, 6.56]</td></tr><tr><td>Hosny 2021 studies)</td><td/><td>0</td><td>67</td><td>0</td><td>21</td><td/><td/><td>Not estimable 95% CI)</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>2</td><td>340</td><td>100.0%</td><td/><td>3.21 [0.46 , 22.50]</td></tr><tr><td colspan=\"2\">MONEAD 2020 Subtotal (95% CI) Total events: mations 5.5 LTG vs Controls: Skeletal/Limb Malfor-</td><td>0 2 8</td><td>99 272</td><td>0 2</td><td>15 376</td><td>100.0%</td><td/><td>Not estimable 95% CI) 3.21 [0.46 , 22.50] Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.17 (P = 0.24) 5.5.1 LTG vs Women Without Epilepsy (co-</td><td>5</td><td/><td/><td>1965</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>11.29 [2.37,</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td><td>53.91]</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">5.5.2 LTG vs WWE -No Medication (cohort</td><td>5</td><td/><td/><td>1084</td><td/><td/><td>Favours LEV Risk Ratio (M-H, Fixed,</td><td>Favours Controls 0.75 [0.20, 2.89]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">Comparison 5. LTG vs Controls</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">5.1 LTG vs Controls: All Major Malforma-</td><td>16</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF148": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 5.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LTG</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>26</td><td>25</td><td>867</td><td>8.4%</td><td>0.63 [0.04 , 10.08]</td></tr><tr><td>Israeli Teratogen Service</td><td/><td>7</td><td>114</td><td>22</td><td>828</td><td>29.1%</td><td>2.31 [1.01 , 5.29]</td></tr><tr><td>Mawer 2010</td><td/><td>2</td><td>40</td><td>6</td><td>315</td><td>7.4%</td><td>2.63 [0.55 , 12.57]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>7</td><td>3</td><td>277</td><td>1.1%</td><td>4.96 [0.28 , 88.31]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>37</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>5</td><td>113</td><td>2</td><td>106</td><td>11.3%</td><td>2.35 [0.46 , 11.83]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>31</td><td>1562</td><td>5</td><td>442</td><td>42.7%</td><td>1.75 [0.69 , 4.49]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1899</td><td/><td>2963</td><td>100.0%</td><td>1.99 [1.16 , 3.39]</td></tr><tr><td>Total events:</td><td/><td>45</td><td/><td>63</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.40, df = 5 (P = 0.92); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.52 (P = 0.01)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">5.1.2 LTG vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>20</td><td>1</td><td>8</td><td>5.7%</td><td>0.14 [0.01 , 3.18]</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>20</td><td>406</td><td>5</td><td>176</td><td>18.9%</td><td>1.73 [0.66 , 4.55]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>3</td><td>1</td><td>21</td><td>1.2%</td><td>1.83 [0.09 , 37.50]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>16</td><td>340</td><td>11.1%</td><td>0.42 [0.06 , 3.14]</td></tr><tr><td>Mawer 2010</td><td/><td>2</td><td>40</td><td>1</td><td>46</td><td>2.5%</td><td>2.30 [0.22 , 24.43]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>37</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>5</td><td>113</td><td>1</td><td>15</td><td>4.8%</td><td>0.66 [0.08 , 5.30]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>49</td><td>2098</td><td>13</td><td>541</td><td>55.9%</td><td>0.97 [0.53 , 1.78]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2767</td><td/><td>1151</td><td>100.0%</td><td>1.04 [0.66 , 1.63]</td></tr><tr><td>Total events:</td><td/><td>77</td><td/><td>38</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 4.22, df = 6 (P = 0.65); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.16 (P = 0.87)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">5.1.3 LTG vs Women Without Epilepsy (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>28</td><td>833</td><td>9309</td><td>369267</td><td>69.3%</td><td>1.33 [0.93 , 1.92]</td></tr><tr><td colspan=\"2\">UK Health Record THIN Register</td><td>9</td><td>344</td><td>86</td><td>2844</td><td>30.7%</td><td>0.87 [0.44 , 1.70]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1177</td><td/><td>372111</td><td>100.0%</td><td>1.19 [0.86 , 1.64]</td></tr><tr><td>Total events:</td><td/><td>37</td><td/><td>9395</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.22, df = 1 (P = 0.27); I\u00b2 = 18%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.06 (P = 0.29)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">5.1.4 LTG vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Denmark Health Record Registers</td><td>47</td><td>1235</td><td>361</td><td>8477</td><td>72.9%</td><td>0.89 [0.66 , 1.20]</td></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>28</td><td>833</td><td>49</td><td>1900</td><td>23.7%</td><td>1.30 [0.83 , 2.06]</td></tr><tr><td colspan=\"2\">UK Clinical Research Practice Database</td><td>3</td><td>98</td><td>22</td><td>902</td><td>3.4%</td><td>1.26 [0.38 , 4.12]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2166</td><td/><td>11279</td><td>100.0%</td><td>1.00 [0.79 , 1.28]</td></tr><tr><td>Total events:</td><td/><td>78</td><td/><td>432</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.97, df = 2 (P = 0.37); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.03 (P = 0.98)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LTG</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF149": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Israeli Teratogen Service</td><td>1</td><td>114</td><td>0</td><td>828</td><td>26.1%</td><td>21.63 [0.89 , 527.72]</td></tr><tr><td>Mawer 2010</td><td>0</td><td>40</td><td>1</td><td>315</td><td>73.9%</td><td>2.57 [0.11 , 62.03]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>115</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>313</td><td/><td>1654</td><td>100.0%</td><td>7.55 [1.05 , 54.09]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.86, df = 1 (P = 0.35); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.01 (P = 0.04)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.2.2 LTG vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>315</td><td>0</td><td>147</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>0</td><td>340</td><td/><td>Not estimable</td></tr><tr><td>Mawer 2010</td><td>0</td><td>40</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.3.1 LTG vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Israeli Teratogen Service</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Mawer 2010</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td/><td/><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.49, df = 3 (P = 0.69); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.06 (P = 0.04)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.3</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF150": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>4</td><td>114</td><td>9</td><td>828</td><td>59.9%</td><td>3.23 [1.01 , 10.31]</td></tr><tr><td/><td>0</td><td>40</td><td>1</td><td>315</td><td>9.5%</td><td>2.57 [0.11 , 62.03]</td></tr><tr><td/><td>0</td><td>7</td><td>1</td><td>277</td><td>2.3%</td><td>11.58 [0.51 , 262.97]</td></tr><tr><td/><td>0</td><td>37</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>37</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td/><td>1</td><td>113</td><td>1</td><td>106</td><td>28.4%</td><td>0.94 [0.06 , 14.81]</td></tr><tr><td/><td/><td>348</td><td/><td>1658</td><td>100.0%</td><td>2.</td></tr><tr><td/><td>5</td><td/><td>12</td><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>8</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>3</td><td>315</td><td>1</td><td>147</td><td>27.2%</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>1</td><td>21</td><td>9.2%</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>9</td><td>340</td><td>46.1%</td></tr><tr><td>Mawer 2010</td><td>0</td><td>40</td><td>0</td><td>40</td><td/></tr><tr><td>MONEAD 2020</td><td>1</td><td>113</td><td>0</td><td>15</td><td>17.5%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>541</td><td/><td>571</td><td>100.0%</td></tr><tr><td>Total events:</td><td>5</td><td/><td>11</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.60, df = 3 (P = 0.90); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.05 (P = 0.96)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF151": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>Analysis 5.4.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>1.40 [0.15 , 13.35]</td><td/><td/><td/></tr><tr><td/><td>1.83 [0.09 , 37.50]</td><td/><td/><td/></tr><tr><td/><td>0.76 [0.10 , 5.84]</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>0.42 [0.02 , 9.90]</td><td/><td/><td/></tr><tr><td/><td>0.97 [0.28 , 3.32]</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF152": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Mawer 2010</td><td>0</td><td>40</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.4.2 LTG vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>1</td><td>8</td><td>75.5%</td><td>0.14 [0.01 , 3.18]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>315</td><td>0</td><td>147</td><td>24.5%</td><td>5.15 [0.29 , 92.56]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Mawer 2010</td><td>0</td><td>40</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>491</td><td/><td>322</td><td>100.0%</td><td>1.37 [0.29 , 6.56]</td></tr><tr><td>Total events:</td><td>5</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.85, df = 1 (P = 0.09); I\u00b2 = 65%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.39 (P = 0.69)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.5.1 LTG vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Israeli Teratogen Service</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Mawer 2010</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td/><td/><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.49, df = 2 (P = 0.48); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.04 (P = 0.002)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF153": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">Controls</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>2</td><td>114</td><td>0</td><td>828</td><td>16.2%</td><td>36.04 [1.74 , 746.07]</td></tr><tr><td/><td>1</td><td>40</td><td>0</td><td>315</td><td>15.3%</td><td>23.12 [0.96 , 558.25]</td></tr><tr><td/><td>0</td><td>7</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>37</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td/><td>1</td><td>113</td><td>0</td><td>106</td><td>68.5%</td><td>2.82 [0.12 , 68.37]</td></tr><tr><td/><td/><td>311</td><td/><td>1654</td><td>100.0%</td></tr><tr><td/><td>4</td><td/><td>0</td><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>315</td><td>1</td><td>147</td><td>50.2%</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>21</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>2</td><td>340</td><td>16.0%</td></tr><tr><td>Mawer 2010</td><td>1</td><td>40</td><td>0</td><td>40</td><td>12.3%</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>113</td><td>0</td><td>15</td><td>21.5%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>521</td><td/><td>563</td><td>100.0%</td></tr><tr><td>Total events:</td><td>2</td><td/><td>3</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.93, df = 3 (P = 0.59); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.42 (P = 0.68)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF154": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 6. OXC vs Controls Analysis 6.1.</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">6.1 OXC vs Controls: All Major Malforma-</td><td>11</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.1.1 OXC vs Women Without Epilepsy</td><td>3</td><td>951</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.20 [0.67, 7.27]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.1.2 OXC vs WWE -No Medication (co-</td><td>6</td><td>922</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.40 [0.68, 2.91]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.1.3 OXC vs Women Without Epilepsy</td><td>1</td><td>369324</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.70 [0.10, 4.86]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.1.4 OXC vs WWE -No Medication (data-</td><td>3</td><td>11819</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.75 [1.22, 2.52]</td></tr><tr><td>base studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.2 OXC vs Controls: Neural Tube Malfor-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.2.1 OXC vs WWE -No Medication (co-</td><td>2</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.3 OXC vs Controls: Cardiac Malforma-</td><td>4</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.3.1 OXC vs Women Without Epilepsy</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td>CI)</td><td>Risk Ratio M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">6.3.2 OXC vs WWE -No Medication (co-</td><td>4</td><td>479</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.10 [0.36, 3.35]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.4 OXC vs Controls: Oro-Facial Cle /</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.4.1 OXC vs WWE -No Medication (co-</td><td>2</td><td>63</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.75 [0.04, 14.71]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">6.5 OXC vs Controls: Skeletal/Limb Mal-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td>0.16 [0.01 , 3.81] CI)</td></tr><tr><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">6.5.1 OXC vs WWE -No Medication (co-</td><td>2</td><td>463</td><td colspan=\"2\">1.34 [0.07 , 27.46] Risk Ratio (M-H, Fixed, 95%</td><td>2.39 [0.22, 26.05]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>3.00 [0.13 , 71.51] CI)</td></tr><tr><td/><td/><td/><td/><td>0.42 [0.02 , 9.90]</td></tr><tr><td/><td/><td/><td/><td>0.75 [0.20 , 2.89]</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF155": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Kaur 2020</td><td>0</td><td>1</td><td>5</td><td>197</td><td>3.6%</td><td>9.00 [0.71 , 113.88]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>182</td><td>5</td><td>442</td><td>96.4%</td><td>1.94 [0.53 , 7.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>184</td><td/><td>767</td><td>100.0%</td><td>2.20 [0.67 , 7.27]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>10</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.22, df = 1 (P = 0.27); I\u00b2 = 18%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.29 (P = 0.20)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>6.1.2 OXC vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>3</td><td>1</td><td>8</td><td>9.9%</td><td>0.75 [0.04 , 14.71]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>19</td><td>5</td><td>176</td><td>10.4%</td><td>1.85 [0.23 , 15.04]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>31</td><td>1</td><td>21</td><td>19.0%</td><td>0.23 [0.01 , 5.37]</td></tr><tr><td>Kaaja 2003</td><td>1</td><td>9</td><td>2</td><td>239</td><td>1.6%</td><td>13.28 [1.32 , 133.28]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>71</td><td>16</td><td>340</td><td>59.1%</td><td>1.50 [0.57 , 3.95]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>134</td><td/><td>788</td><td>100.0%</td><td>1.40 [0.68 , 2.91]</td></tr><tr><td>Total events:</td><td>7</td><td/><td>25</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 5.17, df = 4 (P = 0.27); I\u00b2 = 23%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.91 (P = 0.36)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>6.1.3 OXC vs Women Without Epilepsy (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>1</td><td>57</td><td>9309</td><td>369267</td><td>100.0%</td><td>0.70 [0.10 , 4.86]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>57</td><td/><td>369267</td><td>100.0%</td><td>0.70 [0.10 , 4.86]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>9309</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.37 (P = 0.71)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>6.1.4 OXC vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>10</td><td>316</td><td>361</td><td>8477</td><td>73.9%</td><td>0.74 [0.40 , 1.38]</td></tr><tr><td>Finland Health Record Registers</td><td>23</td><td>130</td><td>26</td><td>939</td><td>18.0%</td><td>6.39 [3.76 , 10.86]</td></tr><tr><td>Norwegian Health Record Registers</td><td>1</td><td>57</td><td>49</td><td>1900</td><td>8.1%</td><td>0.68 [0.10 , 4.84]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>503</td><td/><td>11316</td><td>100.0%</td><td>1.75 [1.22 , 2.52]</td></tr><tr><td>Total events:</td><td>34</td><td/><td>436</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 31.14, df = 2 (P &lt; 0.00001); I\u00b2 = 94%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.04 (P = 0.002)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours Controls</td></tr><tr><td>Analysis 6.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF156": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H</td></tr><tr><td>Hosny 2021</td><td>0</td><td>31</td><td>0</td><td>21</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>71</td><td>0</td><td>340</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF157": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 6.3.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours OXC</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF158": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">6.3.1 OXC vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">6.3.2 OXC vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>3</td><td>0</td><td>8</td><td/><td>Not estimable</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>31</td><td>1</td><td>21</td><td>36.4%</td><td>0.23 [0.01 , 5.37]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>71</td><td>9</td><td>340</td><td>63.6%</td><td>1.60 [0.44 , 5.75]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>106</td><td/><td>373</td><td>100.0%</td><td>1.10 [0.36 , 3.35]</td><td/></tr><tr><td>Total events:</td><td>3</td><td/><td>10</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.27, df = 1 (P = 0.26); I\u00b2 = 22%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.17 (P = 0.87)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Analysis 6.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF159": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>3</td><td>1</td><td>8</td><td>100.0%</td><td>0.75 [0.04 , 14.71]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>31</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>34</td><td/><td>29</td><td>100.0%</td><td>0.75 [0.04 , 14.71]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.19 (P = 0.85)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours Controls</td></tr><tr><td>Analysis 6.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF160": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 7. PB vs Controls Analysis 7.1.</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td></tr><tr><td colspan=\"2\">7.1 PB vs Controls: All Major Malforma-</td><td colspan=\"2\">19</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.1.1 PB vs Women Without Epilepsy</td><td>8</td><td/><td/><td colspan=\"2\">2395</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.22 [1.84, 5.65]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.1.2 PB vs WWE -No Medication (cohort</td><td colspan=\"2\">13</td><td/><td colspan=\"2\">1437</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.64 [0.94, 2.83]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.1.3 PB vs Women Without Epilepsy</td><td>1</td><td/><td/><td colspan=\"2\">369294</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.94 [0.77, 11.15]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.1.4 PB vs WWE -No Medication (data-</td><td>1</td><td/><td/><td colspan=\"2\">1927</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.87 [0.74, 11.21]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.2 PB vs Controls: Neural Tube Malfor-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.2.1 PB vs Women Without Epilepsy</td><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.2.2 PB vs WWE -No Medication (cohort</td><td>3</td><td/><td/><td colspan=\"2\">658</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.85 [0.47, 31.26]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.3 PB vs Controls: Cardiac Malforma-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.3.1 PB vs Women Without Epilepsy</td><td>2</td><td/><td/><td colspan=\"2\">251</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>7.80 [0.36,</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td><td>168.52]</td></tr><tr><td colspan=\"2\">7.3.2 PB vs WWE -No Medication (cohort</td><td>4</td><td/><td/><td colspan=\"2\">665</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.80 [0.69, 4.71]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.4 PB vs Controls: Oro-Facial Cle /</td><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.4.1 PB vs Women Without Epilepsy</td><td>2</td><td/><td/><td colspan=\"2\">251</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.34 [0.20, 56.35]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">7.4.2 PB vs WWE -No Medication (cohort</td><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>Study or Subgroup studies)</td><td colspan=\"3\">OXC Events Total</td><td colspan=\"3\">Control Events Total</td><td>Weight</td><td>Risk Ratio M-H, Fixed, 95% CI CI)</td><td>Risk Ratio M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"3\">Hosny 2021 formations 6.5.1 OXC vs WWE -No Medication (cohort studies) 7.5 PB vs Controls: Skeletal/Limb Mal-4</td><td>0</td><td>31</td><td>0</td><td>21</td><td>Not estimable CI) Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td>1</td><td>71</td><td>2</td><td>340</td><td>100.0%</td><td>2.39 [0.22 , 26.05]</td></tr><tr><td colspan=\"2\">Subtotal (95% CI) 7.5.1 PB vs Women Without Epilepsy</td><td>2</td><td colspan=\"2\">102</td><td colspan=\"2\">361 251</td><td>100.0%</td><td>2.39 [0.22 , 26.05] Risk Ratio (M-H, Fixed, 95%</td><td>7.80 [0.36,</td></tr><tr><td>Total events: (cohort studies)</td><td/><td/><td>1</td><td/><td>2</td><td/><td>CI)</td><td>168.52]</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.72 (P = 0.47) 7.5.2 PB vs WWE -No Medication (cohort</td><td>3</td><td/><td/><td colspan=\"2\">658</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.01 [0.56, 16.07]</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable studies)</td><td/><td/><td/><td/><td/><td>CI)</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours OXC</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF161": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cassina 2013</td></tr><tr><td>D'Souza 1991</td></tr><tr><td>Kaur 2020</td></tr><tr><td>Koch 1992</td></tr><tr><td>Miskov 2016</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>Steegers-Theunissen 1994</td></tr><tr><td>Tanganelli 1992</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Chi\u00b2 = 5.30, df = 6 (P = 0.51); I\u00b2 = 0%</td></tr><tr><td>Test for overall effect: Z = 4.09 (P &lt; 0.0001)</td></tr><tr><td>7.1.2 PB vs WWE -No Medication (cohort studies)</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td></tr><tr><td>D'Souza 1991</td></tr><tr><td>Delmi\u0161 1991</td></tr><tr><td>Kaaja 2003</td></tr><tr><td>Kaneko 1999</td></tr><tr><td>Kelly 1984</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td></tr><tr><td>Koch 1992</td></tr><tr><td>Lindhout 1992</td></tr><tr><td>Milan Study 1999</td></tr><tr><td>Miskov 2016</td></tr><tr><td>Montreal Series</td></tr><tr><td>Waters 1994</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.38, df = 11 (P = 0.96); I\u00b2 = 0%</td></tr><tr><td>Test for overall effect: Z = 1.75 (P = 0.08)</td></tr><tr><td>7.1.3 PB vs Women Without Epilepsy (database studies)</td></tr><tr><td>Norwegian Health Record Registers</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Not applicable</td></tr><tr><td>Test for overall effect: Z = 1.58 (P = 0.11)</td></tr><tr><td>7.1</td></tr></table>",
                "type_str": "table"
            },
            "TABREF162": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>5</td><td>67</td><td>25</td><td>867</td><td>34.0%</td><td>2.59 [1.02 , 6.54]</td></tr><tr><td/><td>1</td><td>4</td><td>0</td><td>62</td><td>0.7%</td><td>37.80 [1.76 , 812.92]</td></tr><tr><td/><td>0</td><td>1</td><td>5</td><td>197</td><td>1.0%</td><td>9.00 [0.71 , 113.88]</td></tr><tr><td/><td>0</td><td>4</td><td>5</td><td>116</td><td>4.3%</td><td>2.13 [0.14 , 33.38]</td></tr><tr><td/><td>0</td><td>3</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">11</td><td>199</td><td>5</td><td>442</td><td>29.4%</td><td>4.89 [1.72 , 13.88]</td></tr><tr><td/><td>0</td><td>12</td><td>2</td><td>106</td><td>5.1%</td><td>1.65 [0.08 , 32.45]</td></tr><tr><td/><td>3</td><td>63</td><td>4</td><td>124</td><td>25.5%</td><td>1.48 [0.34 , 6.39]</td></tr><tr><td/><td/><td>353</td><td/><td>2042</td><td>100.0%</td><td>3.22 [1.84 , 5.65]</td></tr><tr><td colspan=\"2\">20</td><td/><td>46</td><td/><td/><td/></tr><tr><td/><td>0</td><td>2</td><td>5</td><td>176</td><td>1.0%</td><td>5.36 [0.37 , 76.73]</td></tr><tr><td/><td>1</td><td>4</td><td>1</td><td>8</td><td>3.6%</td><td>2.00 [0.16 , 24.33]</td></tr><tr><td/><td>4</td><td>58</td><td>0</td><td>10</td><td>4.5%</td><td>1.68 [0.10 , 29.01]</td></tr><tr><td/><td>0</td><td>5</td><td>2</td><td>239</td><td>0.7%</td><td>8.00 [0.43 , 149.27]</td></tr><tr><td/><td>4</td><td>79</td><td>3</td><td>98</td><td>14.3%</td><td>1.65 [0.38 , 7.17]</td></tr><tr><td/><td>0</td><td>6</td><td>1</td><td>23</td><td>3.6%</td><td>1.14 [0.05 , 25.06]</td></tr><tr><td/><td>8</td><td>137</td><td>16</td><td>340</td><td>49.2%</td><td>1.24 [0.54 , 2.83]</td></tr><tr><td/><td>0</td><td>4</td><td>1</td><td>25</td><td>2.6%</td><td>1.73 [0.08 , 36.75]</td></tr><tr><td/><td>1</td><td>26</td><td>2</td><td>28</td><td>10.3%</td><td>0.54 [0.05 , 5.59]</td></tr><tr><td/><td>4</td><td>83</td><td>0</td><td>25</td><td>4.1%</td><td>2.79 [0.16 , 50.05]</td></tr><tr><td/><td>0</td><td>3</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td/><td>2</td><td>10</td><td>0</td><td>8</td><td>2.9%</td><td>4.09 [0.22 , 74.78]</td></tr><tr><td/><td>3</td><td>21</td><td>0</td><td>15</td><td>3.1%</td><td>5.09 [0.28 , 91.82]</td></tr><tr><td/><td/><td>438</td><td/><td>999</td><td>100.0%</td><td>1.64 [0.94 , 2.83]</td></tr><tr><td colspan=\"2\">27</td><td/><td>31</td><td/><td/><td/></tr><tr><td/><td>2</td><td>27</td><td>9309</td><td>369267</td><td>100.0%</td><td>2.94 [0.77 , 11.15]</td></tr><tr><td/><td/><td>27</td><td/><td>369267</td><td>100.0%</td><td>2.94 [0.77 , 11.15]</td></tr><tr><td/><td>2</td><td/><td>9309</td><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>27</td><td>49</td><td>1900</td><td>100.0%</td><td>2.87 [0.74 , 11.21]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>27</td><td/><td>1900</td><td>100.0%</td><td>2.</td></tr><tr><td>Total events:</td><td>2</td><td/><td>49</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.52 (P = 0.13)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF163": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 7.2.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td>Favours PB</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF164": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">7.2.1 PB vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>0</td><td>116</td><td/><td>Not estimable</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>128</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">7.2.2 PB vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>147</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>137</td><td>0</td><td>340</td><td>37.3%</td><td>7.41 [0.30 , 180.86]</td><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>1</td><td>25</td><td>62.7%</td><td>1.73 [0.08 , 36.75]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>146</td><td/><td>512</td><td>100.0%</td><td>3.85 [0.47 , 31.26]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.42, df = 1 (P = 0.51); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.26 (P = 0.21)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours Controls</td></tr><tr><td>Analysis 7.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF165": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">7.3.1 PB vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>1</td><td>116</td><td>100.0%</td><td>7.80 [0.36 , 168.52]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>7</td><td/><td>244</td><td>100.0%</td><td>7.80 [0.36 , 168.52]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.31 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">7.3.2 PB vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>1</td><td>147</td><td>2.2%</td><td>8.22 [0.37 , 181.57]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>137</td><td>9</td><td>340</td><td>97.8%</td><td>1.65 [0.60 , 4.56]</td></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>149</td><td/><td>516</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>6</td><td/><td>10</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.95, df = 1 (P = 0.33); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.20 (P = 0.23)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF166": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 7.4.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td>Favours PB</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF167": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">7.4.1 PB vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>3</td><td>116</td><td>100.0%</td><td>3.34 [0.20 , 56.35]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>128</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>7</td><td/><td>244</td><td>100.0%</td><td>3.34 [0.20 , 56.35]</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.84 (P = 0.40)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">7.4.2 PB vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>147</td><td/><td>Not estimable</td><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>0</td><td>25</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours Controls</td></tr><tr><td>Analysis 7.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF168": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">7.5.1 PB vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>1</td><td>116</td><td>100.0%</td><td>7.80 [0.36 , 168.52]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>7</td><td/><td>244</td><td>100.0%</td><td>7.80 [0.36 , 168.52]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.31 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">7.5.2 PB vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>1</td><td>147</td><td>9.2%</td><td>8.22 [0.37 , 181.57]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>137</td><td>2</td><td>340</td><td>90.8%</td><td>2.48 [0.35 , 17.44]</td></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>146</td><td/><td>512</td><td>100.0%</td><td>3</td></tr><tr><td>Total events:</td><td>2</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.44, df = 1 (P = 0.51); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.29 (P = 0.20)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF169": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Analysis 8.2.</td><td colspan=\"3\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>PHT</td><td/><td colspan=\"3\">pants Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">8.2 PHT vs Controls: Neural Tube Malfor-</td><td>8</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td>6</td><td>22</td><td>0</td><td/><td>62</td><td>3.5%</td><td>95% CI) 35.61 [2.09 , 607.36]</td></tr><tr><td colspan=\"2\">8.2.1 PHT vs Women Without Epilepsy</td><td>4</td><td>1 2</td><td>2 24</td><td colspan=\"2\">638 5 5</td><td>197 116</td><td>1.3% 22.4%</td><td>Risk Ratio (M-H, Fixed, 19.70 [3.84 , 100.94] 1.93 [0.40 , 9.38]</td><td>13.17 [0.58,</td></tr><tr><td>(cohort studies)</td><td/><td/><td>0</td><td>7</td><td>6</td><td/><td>315</td><td>4.2%</td><td>95% CI) 3.04 [0.19 , 49.45]</td><td>299.00]</td></tr><tr><td/><td/><td/><td>0</td><td>1</td><td>0</td><td/><td>128</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">8.2.2 PHT vs WWE -No Medication (cohort studies)</td><td>6</td><td>0 12 0</td><td>16 416 8</td><td colspan=\"2\">847 0 5 2</td><td>31 442 106</td><td>63.5% 5.1%</td><td>Risk Ratio (M-H, Fixed, Not estimable 2.55 [0.91 , 7.18] 95% CI) 2.38 [0.12 , 45.85]</td><td>2.56 [0.64, 10.17]</td></tr><tr><td/><td/><td/><td/><td>496</td><td/><td colspan=\"2\">1397</td><td>100.0%</td><td>3.81 [1.91 , 7.57]</td></tr><tr><td colspan=\"2\">8.3 PHT vs Controls: Cardiac Malforma-</td><td>8</td><td>21</td><td/><td>23</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">8.3.1 PHT vs Women Without Epilepsy</td><td>4</td><td/><td/><td colspan=\"2\">638</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>6.31 [0.75, 52.91]</td></tr><tr><td>(cohort studies)</td><td/><td/><td>1</td><td>44</td><td>5</td><td/><td>176</td><td>7.4%</td><td>95% CI) 0.80 [0.10 , 6.67]</td></tr><tr><td/><td/><td/><td>6</td><td>22</td><td>1</td><td/><td>8</td><td>5.5%</td><td>2.18 [0.31 , 15.43]</td></tr><tr><td colspan=\"2\">8.3.2 PHT vs WWE -No Medication (cohort studies)</td><td>7</td><td>0 3 12</td><td>27 124 132</td><td colspan=\"2\">852 0 2 3</td><td>18 239 98</td><td>5.1% 12.8%</td><td>Risk Ratio (M-H, Fixed, Not estimable 2.89 [0.49 , 17.08] 95% CI) 2.97 [0.86 , 10.24]</td><td>1.86 [0.72, 4.80]</td></tr><tr><td/><td/><td/><td>1</td><td>24</td><td>1</td><td/><td>23</td><td>3.8%</td><td>0.96 [0.06 , 14.43]</td></tr><tr><td colspan=\"2\">8.4 PHT vs Controls: Oro-Facial Cle /</td><td>7</td><td>7</td><td>119</td><td>16</td><td/><td>340</td><td>30.9%</td><td>Risk Ratio (M-H, Fixed, 1.25 [0.53 , 2.96]</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td>2 1</td><td>24 17</td><td>1 2</td><td/><td>25 28</td><td>3.6% 5.6%</td><td>2.08 [0.20 , 21.50] 95% CI) 0.82 [0.08 , 8.41]</td></tr><tr><td colspan=\"2\">8.4.1 PHT vs Women Without Epilepsy</td><td>4</td><td>0 3</td><td>7 31</td><td colspan=\"2\">638 1 0</td><td>40 25</td><td>1.8% 2.1%</td><td>Risk Ratio (M-H, Fixed, 1.71 [0.08 , 38.29] 5.69 [0.31 , 105.21]</td><td>Risk Ratio 0.67 [0.04, 12.54]</td></tr><tr><td>(cohort studies)</td><td/><td/><td>0</td><td>1</td><td>0</td><td/><td>4</td><td/><td>95% CI) Not estimable</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td>6</td><td>44</td><td>0</td><td/><td>8</td><td>3.1%</td><td>2.60 [0.16 , 42.16]</td></tr><tr><td colspan=\"2\">8.4.2 PHT vs WWE -No Medication (cohort studies)</td><td>5</td><td>7 3</td><td>106 28 750</td><td>0 13 0</td><td colspan=\"2\">541 15 1588</td><td>15.9% 2.4% 100.0%</td><td>Risk Ratio (M-H, Fixed, 2.75 [1.12 , 6.73] 3.86 [0.21 , 70.16] 95% CI) 2.01 [1.29 , 3.12]</td><td>Not estimable</td></tr><tr><td/><td/><td/><td>52</td><td/><td>45</td><td/><td/><td/></tr><tr><td colspan=\"2\">8.5 PHT vs Controls: Skeletal/Limb Mal-</td><td>8</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"5\">8.5.1 PHT vs Women Without Epilepsy Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0% 4</td><td colspan=\"2\">638</td><td/><td/><td>Risk Ratio (M-H, Fixed, 0.01 0.1 Favours PHT</td><td>1</td><td>10 1.56 [0.07, 37.19] 100 Favours Controls</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">8.5.2 PHT vs WWE -No Medication (cohort</td><td>6</td><td/><td/><td colspan=\"2\">847</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.57 [0.31, 7.95]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Comparison 8. PHT vs Controls</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"3\">pants</td><td/></tr><tr><td colspan=\"2\">8.1 PHT vs Controls: All Major Malforma-</td><td>19</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">8.1.1 PHT vs Women Without Epilepsy</td><td>8</td><td/><td/><td colspan=\"2\">1893</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>3.81 [1.91, 7.57]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">8.1.2 PHT vs WWE -No Medication (cohort</td><td>15</td><td/><td/><td colspan=\"2\">2338</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>2.01 [1.29, 3.12]</td></tr><tr><td>studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF170": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">8.2.1 PHT vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>0</td><td>116</td><td/><td>Not estimable</td><td/></tr><tr><td>Mawer 2010</td><td>0</td><td>7</td><td>1</td><td>315</td><td>100.0%</td><td>13.17 [0.58 , 299.00]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td><td/></tr><tr><td>Motherisk Registry</td><td>0</td><td>16</td><td>0</td><td>31</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>590</td><td>100.0%</td><td>13.17 [0.58 , 299.00]</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.62 (P = 0.11)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">8.2.2 PHT vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>147</td><td>11.9%</td><td>9.87 [0.41 , 238.01]</td><td/></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>27</td><td>0</td><td>18</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>0</td><td>340</td><td>13.3%</td><td>8.53 [0.35 , 207.86]</td><td/></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>1</td><td>25</td><td>74.9%</td><td>0.35 [0.01 , 8.12]</td><td/></tr><tr><td>Mawer 2010</td><td>0</td><td>7</td><td>0</td><td>40</td><td/><td>Not estimable</td><td/></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>0</td><td>25</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>252</td><td/><td>595</td><td>100.0%</td><td>2.56 [0.64 , 10.17]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.78, df = 2 (P = 0.25); I\u00b2 = 28%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.34 (P = 0.18)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">8.3.1 PHT vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Mawer 2010</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Motherisk Registry</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.25, df = 1 (P = 0.62); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.70 (P = 0.09)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>8.3</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF171": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"2\">Analysis 8.4.</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PHT</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>1</td><td>24</td><td>1</td><td>116</td><td>82.2%</td><td>4.83 [0.31 , 74.61]</td></tr><tr><td/><td/><td>0</td><td>7</td><td>1</td><td>315</td><td>17.8%</td><td>13.17 [0.58 , 299.00]</td></tr><tr><td/><td/><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>0</td><td>16</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td>48</td><td/><td>590</td><td>100.0%</td><td>6.31 [0.75 , 52.91]</td></tr><tr><td/><td/><td>1</td><td/><td>2</td><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>1</td><td>147</td><td>8.2%</td><td>3.34 [0.21 , 52.33]</td></tr><tr><td>Garza-Morales 1996</td><td/><td>0</td><td>27</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>119</td><td>9</td><td>340</td><td>83.1%</td><td>1.59 [0.54 , 4.64]</td></tr><tr><td>Koch 1992</td><td/><td>1</td><td>24</td><td>0</td><td>25</td><td>8.7%</td><td>3.12 [0.13 , 73.04]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>7</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>31</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>253</td><td/><td>599</td><td>100.0%</td><td>1.86 [0.72 , 4.80]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>10</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.36, df = 2 (P = 0.83); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.29 (P = 0.20)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PHT</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF172": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>3</td><td>116</td><td>100.0%</td><td>0.67 [0.04 , 12.54]</td></tr><tr><td>Mawer 2010</td><td>0</td><td>7</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Motherisk Registry</td><td>0</td><td>16</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>590</td><td>100.0%</td><td>0.67 [0.04 , 12.54]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.27 (P = 0.79)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>8.4.2 PHT vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>147</td><td/><td>Not estimable</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>27</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Mawer 2010</td><td>0</td><td>7</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/></tr><tr><td>8.5.1 PHT vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Koch 1992</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Mawer 2010</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Miskov 2016</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Motherisk Registry</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.27 (P = 0.78)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>8.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF173": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>0</td><td>24</td><td>1</td><td>116</td><td>100.0%</td><td>1.56 [0.07 , 37.19]</td></tr><tr><td/><td>0</td><td>7</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>1</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>16</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>48</td><td/><td>590</td><td>100.0%</td><td>1</td></tr><tr><td/><td>0</td><td/><td>1</td><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>1</td><td>147</td><td>30.6%</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>27</td><td>0</td><td>18</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>2</td><td>340</td><td>45.3%</td></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>0</td><td>25</td><td/></tr><tr><td>Mawer 2010</td><td>0</td><td>7</td><td>0</td><td>40</td><td/></tr><tr><td>Milan Study 1999</td><td>1</td><td>31</td><td>0</td><td>25</td><td>24.1%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>252</td><td/><td>595</td><td>100.0%</td></tr><tr><td>Total events:</td><td>2</td><td/><td>3</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.13, df = 2 (P = 0.94); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.55 (P = 0.59)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF174": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 9. PRM vs Controls</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">9.1 PRM vs Controls: All Major Malforma-</td><td>6</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">9.1.1 PRM vs Women Without Epilepsy</td><td>1</td><td>137</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.48 [0.03, 8.43]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">9.1.2 PRM vs WWE -No Medication (co-</td><td>6</td><td>681</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>3.61 [1.41, 9.23]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 9.1. Comparison 9:</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>1.10 [0.05 , 26.45]</td></tr><tr><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>1.43 [0.13 , 15.61]</td></tr><tr><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>2.44 [0.10 , 57.37]</td></tr><tr><td/><td/><td/><td/><td>1.57 [0.31 , 7.95]</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF175": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Analysis 10.1.</td><td colspan=\"4\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"3\">pants</td><td/></tr><tr><td colspan=\"2\">10.1.4 TPM vs WWE -No Medication (data-</td><td>1</td><td/><td/><td/><td colspan=\"3\">1948</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.62 [0.40, 6.45]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.2 TPM vs Controls: Neural Tube Malfor-</td><td>4</td><td/><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.2.1 TPM vs Women Without Epilepsy</td><td>2</td><td/><td/><td/><td>0</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.2.2 TPM vs WWE -No Medication (co-</td><td>3</td><td/><td/><td/><td>0</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.3 TPM vs Controls: Cardiac Malforma-</td><td>5</td><td/><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.3.1 TPM vs Women Without Epilepsy</td><td>2</td><td colspan=\"2\">PRM</td><td colspan=\"3\">Control 391</td><td/><td/><td>Risk Ratio Risk Ratio (M-H, Fixed,</td><td>Risk Ratio 20.71 [2.64,</td></tr><tr><td>(cohort studies)</td><td colspan=\"3\">Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td colspan=\"2\">Weight</td><td>M-H, Fixed, 95% CI 95% CI)</td><td>M-H, Fixed, 95% CI 162.72]</td></tr><tr><td colspan=\"2\">Koch 1992 Subtotal (95% CI) hort studies) 10.3.2 TPM vs WWE -No Medication (co-</td><td>4</td><td>0</td><td>21 21</td><td>5</td><td colspan=\"3\">116 116 570</td><td>100.0% 100.0%</td><td>0.48 [0.03 , 8.43] 95% CI) 0.48 [0.03 , 8.43] Risk Ratio (M-H, Fixed,</td><td>2.48 [0.49, 12.49]</td></tr><tr><td>Total events:</td><td/><td/><td>0</td><td/><td>5</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable 10.4 TPM vs Controls: Oro-Facial Cle /</td><td>4</td><td/><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.50 (P = 0.62) Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">9.1.2 PRM vs WWE -No Medication (cohort studies) Australian Epilepsy and Pregnancy Register Delmi\u0161 1991 (cohort studies) 10.4.1 TPM vs Women Without Epilepsy</td><td>2</td><td>0 0</td><td>2 9</td><td>5 0</td><td>0</td><td colspan=\"2\">176 10</td><td>4.8%</td><td>Not estimable 95% CI) 5.36 [0.37 , 76.73] Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td/><td>1</td><td>6</td><td>2</td><td/><td colspan=\"2\">239</td><td>2.6%</td><td>19.92 [2.08 , 190.79]</td></tr><tr><td colspan=\"2\">Kaneko 1999 10.4.2 TPM vs WWE -No Medication (co-</td><td>3</td><td>5</td><td>35</td><td>3</td><td colspan=\"2\">221</td><td>98</td><td>41.4%</td><td>4.67 [1.18 , 18.52] Risk Ratio (M-H, Fixed,</td><td>1.50 [0.09, 24.92]</td></tr><tr><td>Koch 1992 hort studies)</td><td/><td/><td>0</td><td>21</td><td>1</td><td/><td/><td>25</td><td>36.0%</td><td>0.39 [0.02 , 9.19] 95% CI)</td></tr><tr><td>Milan Study 1999</td><td/><td/><td>3</td><td>35</td><td>0</td><td/><td/><td>25</td><td>15.2%</td><td>5.06 [0.27 , 93.73]</td></tr><tr><td colspan=\"2\">Subtotal (95% CI) Total events: Heterogeneity: Chi\u00b2 = 4.36, df = 4 (P = 0.36); I\u00b2 = 8% formations 10.5 TPM vs Controls: Skeletal/Limb Mal-</td><td>4</td><td>9</td><td>108</td><td>11</td><td/><td colspan=\"2\">573</td><td>100.0%</td><td>95% CI) 3.61 [1.41 , 9.23] Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.68 (P = 0.007)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">10.5.1 TPM vs Women Without Epilepsy</td><td>2</td><td/><td/><td/><td>0</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td colspan=\"5\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0% (cohort studies)</td><td/><td/><td/><td/><td/><td>95% CI)</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PRM</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">10.5.2 TPM vs WWE -No Medication (co-</td><td>3</td><td/><td/><td/><td colspan=\"2\">561</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>2.06 [0.24, 17.42]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">Comparison 10. TPM vs Controls</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"4\">No. of studies</td><td colspan=\"4\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"3\">pants</td><td/></tr><tr><td colspan=\"2\">10.1 TPM vs Controls: All Major Malforma-</td><td>8</td><td/><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.1.1 TPM vs Women Without Epilepsy</td><td>3</td><td/><td/><td/><td colspan=\"3\">1192</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>4.07 [1.64, 10.14]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.1.2 TPM vs WWE -No Medication (co-</td><td>5</td><td/><td/><td/><td colspan=\"3\">1219</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.37 [0.57, 3.27]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">10.1.3 TPM vs Women Without Epilepsy</td><td>1</td><td/><td/><td/><td colspan=\"3\">369315</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.65 [0.43, 6.42]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF176": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">TPM</td><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Melikova 2020</td><td>0</td><td>2</td><td>3</td><td>277</td><td>1.6%</td><td>13.24 [0.86 , 204.22]</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>2</td><td>106</td><td>4.5%</td><td>8.83 [0.93 , 84.24]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>15</td><td>359</td><td>5</td><td>442</td><td>93.9%</td><td>3.69 [1.36 , 10.07]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>367</td><td/><td>825</td><td>100.0%</td><td>4.07 [1.64 , 10.14]</td></tr><tr><td>Total events:</td><td>16</td><td/><td>10</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.20, df = 2 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.02 (P = 0.003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>10.1.2 TPM vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>1</td><td>8</td><td>7.4%</td><td>1.50 [0.09 , 24.92]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>5</td><td>176</td><td>31.5%</td><td>0.66 [0.08 , 5.56]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>9</td><td>16</td><td>340</td><td>12.8%</td><td>1.03 [0.07 , 16.04]</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>1</td><td>15</td><td>7.8%</td><td>2.50 [0.18 , 33.83]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>70</td><td>13</td><td>541</td><td>40.5%</td><td>1.78 [0.52 , 6.10]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>139</td><td/><td>1080</td><td>100.0%</td><td>1.37 [0.57 , 3.27]</td></tr><tr><td>Total events:</td><td>5</td><td/><td>36</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.87, df = 4 (P = 0.93); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.71 (P = 0.48)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>10.1.3 TPM vs Women Without Epilepsy (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>48</td><td>9309</td><td>369267</td><td>100.0%</td><td>1.65 [0.43 , 6.42]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>369267</td><td>100.0%</td><td>1.65 [0.43 , 6.42]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>9309</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.73 (P = 0.47)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>10.1.4 TPM vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>48</td><td>49</td><td>1900</td><td>100.0%</td><td>1.62 [0.40 , 6.45]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>1900</td><td>100.0%</td><td>1.62 [0.40 , 6.45]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>49</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.68 (P = 0.50)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours Controls</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF177": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H</td></tr><tr><td>Melikova 2020</td><td>0</td><td>2</td><td>0</td><td>277</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>6</td><td>0</td><td>106</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>10.2.2 TPM vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>147</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>9</td><td>0</td><td>340</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>6</td><td>0</td><td>15</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF178": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 10.3.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours TPM</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF179": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">TPM</td><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">10.3.1 TPM vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>2</td><td>1</td><td>277</td><td>23.0%</td><td>30.89 [1.55 , 615.22]</td><td/></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>1</td><td>106</td><td>77.0%</td><td>17.67 [1.25 , 249.30]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>8</td><td/><td>383</td><td>100.0%</td><td>20.71 [2.64 , 162.72]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.08, df = 1 (P = 0.77); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.88 (P = 0.004)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">10.3.2 TPM vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>8</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>1</td><td>147</td><td>45.3%</td><td>1.10 [0.05 , 26.45]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>9</td><td>9</td><td>340</td><td>35.0%</td><td>1.79 [0.11 , 28.74]</td><td/></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>0</td><td>15</td><td>19.7%</td><td>6.86 [0.32 , 148.44]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>60</td><td/><td>510</td><td>100.0%</td><td>2.48 [0.49 , 12.49]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>10</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.72, df = 2 (P = 0.70); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.10 (P = 0.27)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">10.4.1 TPM vs Women Without Epilepsy (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Melikova 2020</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>10.4</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF180": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>0</td><td>2</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>6</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>1</td><td>8</td><td>100.0%</td><td>1.50 [0.09 , 24.92]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>147</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>6</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>51</td><td/><td>170</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.28 (P = 0.78)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF181": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 10.5.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours TPM</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF182": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Analysis 11.1.</td><td colspan=\"3\">No. of studies</td><td/><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td colspan=\"2\">TPM</td><td colspan=\"3\">Control pants</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td/><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">11.3.1 VPA vs Women without Medication</td><td>4</td><td/><td/><td/><td>940</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>11.89 [2.88,</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td><td>49.08]</td></tr><tr><td>Melikova 2020</td><td/><td/><td>0</td><td>2</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">MONEAD 2020 Subtotal (95% CI) Total events: hort studies) 11.3.2 VPA vs WWE -No Medication (co-</td><td>10</td><td>0 0</td><td>6 0</td><td>0 0</td><td>106 0 1497</td><td/><td colspan=\"2\">Not estimable 95% CI) Not estimable Risk Ratio (M-H, Fixed,</td><td>2.71 [1.42, 5.17]</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable 11.4 VPA vs Controls: Oro-Facial Cle /</td><td>10</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"3\">10.5.2 TPM vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register Kerala Epilepsy and Pregnancy Registry MONEAD 2020 (cohort studies) 11.4.1 VPA vs Women Without Epilepsy</td><td>4</td><td>0 0 0</td><td>44 9 6</td><td>1 2 0</td><td>147 340 15 940</td><td>83.1% 16.9%</td><td colspan=\"2\">1.10 [0.05 , 26.45] Not estimable 95% CI) 6.82 [0.35 , 133.01] Risk Ratio (M-H, Fixed,</td><td>2.76 [0.31, 24.78]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>59</td><td/><td>502</td><td>100.0%</td><td>2.06 [0.24 , 17.42]</td></tr><tr><td colspan=\"2\">Total events: 11.4.2 VPA vs WWE -No Medication (co-</td><td>8</td><td>0</td><td/><td>3</td><td>806</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>4.44 [1.14, 17.27]</td></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.77, df = 1 (P = 0.38); I\u00b2 = 0% hort studies)</td><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.67 (P = 0.51)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable formations 11.5 VPA vs Controls: Skeletal/Limb Mal-</td><td>10</td><td/><td/><td/><td/><td/><td colspan=\"2\">0.01 Favours TPM 0.1 Risk Ratio (M-H, Fixed, 95% CI)</td><td>1</td><td>10 Favours Controls 100 Subtotals only</td></tr><tr><td colspan=\"2\">11.5.1 VPA vs Women Without Epilepsy</td><td>4</td><td/><td/><td/><td>940</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>16.48 [2.46,</td></tr><tr><td>(cohort study)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td><td>110.49]</td></tr><tr><td colspan=\"2\">Comparison 11. VPA vs Controls</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.5.2 VPA vs WWE -No Medication (co-</td><td>8</td><td/><td/><td/><td>1478</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>2.38 [0.93, 6.12]</td></tr><tr><td colspan=\"2\">Outcome or subgroup title hort study)</td><td colspan=\"3\">No. of studies</td><td/><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method 95% CI)</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">11.1 VPA vs Controls: All Major Malforma-</td><td>29</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.1.1 VPA vs Women Without Epilepsy</td><td>10</td><td/><td/><td/><td>3135</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>5.53 [3.29, 9.29]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.1.2 VPA vs WWE -No Med Controls (co-</td><td>17</td><td/><td/><td/><td>3998</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>2.77 [2.03, 3.79]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.1.3 VPA vs Women Without Epilepsy</td><td>3</td><td/><td/><td/><td>373649</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>2.29 [1.71, 3.08]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.1.4 VPA vs WWE -No Med Controls</td><td>4</td><td/><td/><td/><td>13369</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>3.01 [2.42, 3.75]</td></tr><tr><td>(database studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.2 VPA vs Controls: Neural Tube Malfor-</td><td>11</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.2.1 VPA vs Women Without Epilepsy</td><td>4</td><td/><td/><td/><td>940</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>6.05 [0.94, 38.81]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.2.2 VPA vs WWE -No Medication (co-</td><td>8</td><td/><td/><td/><td>1478</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>5.64 [1.37, 23.24]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.2.3 VPA vs WWE -No Medication (data-</td><td>1</td><td/><td/><td/><td>1127</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>8.02 [1.48, 43.50]</td></tr><tr><td>base studies)</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">11.3 VPA vs Controls: Cardiac Malforma-</td><td>11</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF183": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 11.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Cassina 2013</td><td/><td>3</td><td>45</td><td>25</td><td>867</td><td>21.4%</td><td>2.31 [0.73 , 7.37]</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>1</td><td>0</td><td>62</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>5</td><td>197</td><td>1.9%</td><td>4.50 [0.30 , 68.35]</td></tr><tr><td>Koch 1992</td><td/><td>3</td><td>14</td><td>5</td><td>116</td><td>9.3%</td><td>4.97 [1.33 , 18.60]</td></tr><tr><td>Mawer 2010</td><td/><td>6</td><td>57</td><td>6</td><td>315</td><td>15.9%</td><td>5.53 [1.85 , 16.53]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>3</td><td>277</td><td>5.5%</td><td>1.42 [0.08 , 26.77]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>5</td><td>442</td><td>36.6%</td><td>8.21 [3.22 , 20.93]</td></tr><tr><td>Steegers-Theunissen 1994</td><td/><td>3</td><td>19</td><td>2</td><td>106</td><td>5.3%</td><td>8.37 [1.50 , 46.79]</td></tr><tr><td>Tanganelli 1992</td><td/><td>0</td><td>6</td><td>4</td><td>124</td><td>4.1%</td><td>1.98 [0.12 , 33.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>501</td><td/><td>2634</td><td>100.0%</td><td>5.53 [3.29 , 9.29]</td></tr><tr><td>Total events:</td><td/><td>45</td><td/><td>55</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 4.46, df = 7 (P = 0.73); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 6.45 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.1.2 VPA vs WWE -No Med Controls (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>1</td><td>1</td><td>8</td><td>1.0%</td><td>1.50 [0.09 , 24.92]</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>5</td><td>176</td><td>11.3%</td><td>5.22 [2.11 , 12.93]</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>1</td><td>0</td><td>62</td><td/><td>Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td/><td>4</td><td>74</td><td>3</td><td>48</td><td>6.6%</td><td>0.86 [0.20 , 3.70]</td></tr><tr><td>Garza-Morales 1996</td><td/><td>0</td><td>5</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>1</td><td>21</td><td>1.6%</td><td>0.81 [0.04 , 18.18]</td></tr><tr><td>Kaaja 2003</td><td/><td>4</td><td>61</td><td>2</td><td>239</td><td>1.5%</td><td>7.84 [1.47 , 41.79]</td></tr><tr><td>Kaneko 1999</td><td/><td>9</td><td>81</td><td>3</td><td>98</td><td>4.9%</td><td>3.63 [1.02 , 12.96]</td></tr><tr><td>Kelly 1984</td><td/><td>0</td><td>4</td><td>1</td><td>23</td><td>0.9%</td><td>1.60 [0.08 , 33.86]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>27</td><td>341</td><td>16</td><td>340</td><td>29.0%</td><td>1.68 [0.92 , 3.07]</td></tr><tr><td>Koch 1992</td><td/><td>3</td><td>14</td><td>1</td><td>25</td><td>1.3%</td><td>5.36 [0.61 , 46.76]</td></tr><tr><td>Lindhout 1992</td><td/><td>5</td><td>66</td><td>2</td><td>28</td><td>5.1%</td><td>1.06 [0.22 , 5.14]</td></tr><tr><td>Mawer 2010</td><td/><td>6</td><td>57</td><td>1</td><td>46</td><td>2.0%</td><td>4.84 [0.60 , 38.80]</td></tr><tr><td>Milan Study 1999</td><td/><td>8</td><td>44</td><td>0</td><td>25</td><td>1.1%</td><td>9.82 [0.59 , 163.31]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Montreal Series</td><td/><td>4</td><td>15</td><td>0</td><td>8</td><td>1.2%</td><td>5.06 [0.31 , 83.69]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>82</td><td>1220</td><td>13</td><td>541</td><td>32.6%</td><td>2.80 [1.57 , 4.98]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2288</td><td/><td>1710</td><td>100.0%</td><td>2.77 [2.03 , 3.79]</td></tr><tr><td>Total events:</td><td/><td>195</td><td/><td>49</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 12.57, df = 13 (P = 0.48); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 6.40 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.1.3 VPA vs Women Without Epilepsy (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Italian Lombardy Region Health Register</td><td>15</td><td>131</td><td>49</td><td>917</td><td>32.2%</td><td>2.14 [1.24 , 3.71]</td></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>21</td><td>333</td><td>9309</td><td>369267</td><td>44.1%</td><td>2.50 [1.65 , 3.79]</td></tr><tr><td colspan=\"2\">UK Health Record THIN Register</td><td>10</td><td>157</td><td>86</td><td>2844</td><td>23.7%</td><td>2.11 [1.12 , 3.97]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>621</td><td/><td>373028</td><td>100.0%</td><td>2.29 [1.71 , 3.08]</td></tr><tr><td>Total events:</td><td/><td>46</td><td/><td>9444</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.30, df = 2 (P = 0.86); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 5.53 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.1.4 VPA vs WWE -No Med Controls (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Denmark Health Record Registers</td><td>39</td><td>330</td><td>361</td><td>8477</td><td>43.8%</td><td>2.78 [2.03 , 3.79]</td></tr><tr><td>Finland Health Record Registers</td><td/><td>37</td><td>263</td><td>26</td><td>939</td><td>18.4%</td><td>5.08 [3.14 , 8.23]</td></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>21</td><td>333</td><td>49</td><td>1900</td><td>23.6%</td><td>2.45 [1.49 , 4.02]</td></tr><tr><td colspan=\"2\">UK Clinical Research Practice Database</td><td>11</td><td>225</td><td>22</td><td>902</td><td>14.2%</td><td>2.00 [0.99 , 4.07]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1151</td><td/><td>12218</td><td>100.0%</td><td>3.01 [2.42 , 3.75]</td></tr><tr><td>Total events:</td><td/><td>108</td><td/><td>458</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 6.72, df = 3 (P = 0.08); I\u00b2 = 55%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 9.82 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 3 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF184": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 11.3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">VPA</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Koch 1992</td><td/><td>1</td><td>14</td><td>0</td><td>116</td><td>19.6%</td><td>23.40 [1.00 , 548.88]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>57</td><td>1</td><td>315</td><td>80.4%</td><td>1.82 [0.07 , 44.04]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>104</td><td/><td>836</td><td>100.0%</td><td>6.05 [0.94 , 38.81]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.25, df = 1 (P = 0.26); I\u00b2 = 20%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.90 (P = 0.06)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.2.2 VPA vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>7</td><td>271</td><td>0</td><td>147</td><td>25.9%</td><td>8.16 [0.47 , 141.91]</td></tr><tr><td>Fairgrieve 2000</td><td/><td>0</td><td>74</td><td>0</td><td>48</td><td/><td>Not estimable</td></tr><tr><td>Garza-Morales 1996</td><td/><td>0</td><td>5</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>0</td><td>340</td><td>20.0%</td><td>6.98 [0.36 , 134.61]</td></tr><tr><td>Koch 1992</td><td/><td>1</td><td>14</td><td>1</td><td>25</td><td>28.7%</td><td>1.79 [0.12 , 26.40]</td></tr><tr><td>Mawer 2010</td><td/><td>0</td><td>57</td><td>0</td><td>40</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>5</td><td>44</td><td>0</td><td>25</td><td>25.4%</td><td>6.36 [0.37 , 110.37]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>814</td><td/><td>664</td><td>100.0%</td><td>5.64 [1.37 , 23.24]</td></tr><tr><td>Total events:</td><td colspan=\"2\">16</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.79, df = 3 (P = 0.85); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.39 (P = 0.02)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">11.2.3 VPA vs WWE -No Medication (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">UK Clinical Research Practice Database</td><td>4</td><td>225</td><td>2</td><td>902</td><td>100.0%</td><td>8.02 [1.48 , 43.50]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>225</td><td/><td>902</td><td>100.0%</td><td>8.02 [1.48 , 43.50]</td></tr><tr><td>Total events:</td><td/><td>4</td><td/><td>2</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.41 (P = 0.02)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 2 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF185": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>1</td><td>116</td><td>27.0%</td><td>8.29 [0.55 , 125.25]</td></tr><tr><td>Mawer 2010</td><td>4</td><td>57</td><td>1</td><td>315</td><td>38.5%</td><td>22.11 [2.52 , 194.20]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>1</td><td>277</td><td>34.5%</td><td>3.31 [0.14 , 79.34]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>104</td><td/><td>836</td><td>100.0%</td><td>11.89 [2.88 , 49.08]</td></tr><tr><td>Total events:</td><td>5</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.00, df = 2 (P = 0.61); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.42 (P = 0.0006)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>11.3.2 VPA vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>8</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>10</td><td>271</td><td>1</td><td>147</td><td>10.2%</td><td>5.42 [0.70 , 41.96]</td></tr><tr><td>Fairgrieve 2000</td><td>1</td><td>74</td><td>0</td><td>48</td><td>4.7%</td><td>1.96 [0.08 , 47.15]</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>1</td><td>21</td><td>6.8%</td><td>0.81 [0.04 , 18.18]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>9</td><td>340</td><td>70.8%</td><td>2.22 [1.02 , 4.80]</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>25</td><td>2.9%</td><td>5.20 [0.23 , 119.77]</td></tr><tr><td>Mawer 2010</td><td>4</td><td>57</td><td>0</td><td>40</td><td>4.6%</td><td>6.36 [0.35 , 114.96]</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>0</td><td>25</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>821</td><td/><td>676</td><td>100.0%</td><td>2.71 [1.42 , 5.17]</td></tr><tr><td>Total events:</td><td>36</td><td/><td>11</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.82, df = 5 (P = 0.87); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.02 (P = 0.003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Analysis 11.4.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF186": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>3</td><td>116</td><td>100.0%</td><td>2.76 [0.31 , 24.78]</td></tr><tr><td>Mawer 2010</td><td>0</td><td>57</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>277</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>128</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>104</td><td/><td>836</td><td>100.0%</td><td>2</td></tr><tr><td>Total events:</td><td>1</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.91 (P = 0.36)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>11.4.2 VPA vs WWE -No Medication (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>1</td><td>8</td><td>19.7%</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>12</td><td>271</td><td>0</td><td>147</td><td>23.4%</td><td/></tr><tr><td>Fairgrieve 2000</td><td>1</td><td>74</td><td>1</td><td>48</td><td>43.8%</td><td/></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>18</td><td/><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>21</td><td/><td/></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>25</td><td>13.2%</td><td/></tr><tr><td>Mawer 2010</td><td>0</td><td>57</td><td>0</td><td>40</td><td/><td/></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>0</td><td>25</td><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>474</td><td/><td>332</td><td>100.0%</td><td/></tr><tr><td>Total events:</td><td>14</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.07, df = 3 (P = 0.38); I\u00b2 = 2%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.15 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF187": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 11.5.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td>1.50 [0.09 , 24.92]</td><td/><td/><td/></tr><tr><td/><td>13.60 [0.81 , 228.12]</td><td/><td/><td/></tr><tr><td/><td>0.65 [0.04 , 10.13]</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>5.20 [0.23 , 119.77]</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>Not estimable</td><td/><td/><td/></tr><tr><td/><td>4.44 [1.14 , 17.27]</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VPA</td><td colspan=\"2\">Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF188": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"4\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">Study or Subgroup (cohort study) 12.3.1 ZNS vs Women Without Epilepsy</td><td colspan=\"3\">VPA Events 1</td><td>Total</td><td colspan=\"3\">Controls Events Total 119</td><td>Weight</td><td>Risk Ratio M-H, Fixed, 95% CI 95% CI) Risk Ratio (M-H, Fixed, M-H, Fixed, 95% CI Risk Ratio 2.55 [0.11, 59.56]</td></tr><tr><td colspan=\"3\">11.5.1 VPA vs Women Without Epilepsy (cohort study) Koch 1992 Mawer 2010 hort study) 12.3.2 ZNS vs WWE -No Medication (co-</td><td>1</td><td>2 1</td><td>14 57</td><td>1 0</td><td>0</td><td>116 315</td><td>58.1% 41.9%</td><td>16.34 [0.67 , 396.33] 95% CI) 16.57 [1.60 , 171.26] Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Melikova 2020 Miskov 2016 12.4 ZNS vs Controls: Oro-Facial Cle /</td><td/><td>1</td><td>0 0</td><td>27 6</td><td>0 0</td><td/><td>277 128</td><td/><td>Not estimable Not estimable Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Subtotal (95% CI) Craniofacial Malformations</td><td/><td/><td/><td>104</td><td/><td/><td>836</td><td>100.0%</td><td>16.48 [2.46 , 110.49] 95% CI)</td></tr><tr><td>Total events:</td><td/><td/><td/><td>3</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 0.99); I\u00b2 = 0% (cohort study) Test for overall effect: Z = 2.89 (P = 0.004) 12.4.1 ZNS vs Women Without Epilepsy</td><td/><td>1</td><td/><td/><td/><td>0</td><td/><td/><td>95% CI) Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td colspan=\"3\">11.5.2 VPA vs WWE -No Medication (cohort study)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register 12.4.2 ZNS vs WWE -No Medication (co-</td><td/><td>1</td><td>6</td><td>271</td><td>1</td><td>0</td><td>147</td><td>21.3%</td><td>3.25 [0.40 , 26.78] Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>Fairgrieve 2000 hort study)</td><td/><td/><td/><td>1</td><td>74</td><td>1</td><td/><td>48</td><td>19.9%</td><td>0.65 [0.04 , 10.13] 95% CI)</td></tr><tr><td>Garza-Morales 1996</td><td/><td/><td/><td>0</td><td>5</td><td>0</td><td/><td>18</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Hosny 2021 Kerala Epilepsy and Pregnancy Registry Koch 1992 formations 12.5 ZNS vs Controls: Skeletal/Limb Mal-</td><td/><td>1</td><td>0 4 2</td><td>8 341 14</td><td>0 2 0</td><td/><td>21 340 25</td><td>32.8% 6.0%</td><td>Not estimable 8.67 [0.45 , 168.78] 95% CI) 1.99 [0.37 , 10.81] Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>Mawer 2010</td><td/><td/><td/><td>1</td><td>57</td><td>0</td><td/><td>40</td><td>9.6%</td><td>2.12 [0.09 , 50.77]</td></tr><tr><td colspan=\"2\">Milan Study 1999 12.5.1 ZNS vs Women without Epilepsy</td><td/><td>1</td><td>1</td><td>44</td><td>0</td><td>0</td><td>25</td><td>10.4%</td><td>1.73 [0.07 , 41.02] Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI) (cohort study)</td><td/><td/><td/><td/><td>814</td><td/><td/><td>664</td><td>100.0%</td><td>2.38 [0.93 , 6.12] 95% CI)</td></tr><tr><td>Total events:</td><td/><td/><td/><td>15</td><td/><td>4</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.76, df = 5 (P = 0.88); I\u00b2 = 0% hort study) Test for overall effect: Z = 1.80 (P = 0.07) 12.5.2 ZNS vs WWE -No Medication (co-</td><td/><td>1</td><td/><td/><td/><td>0</td><td/><td/><td>95% CI) Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td colspan=\"6\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Comparison 12. ZNS vs Controls Analysis 12.1.</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"4\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">12.1 ZNS vs Controls: All Major Malforma-</td><td/><td>3</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.1.1 ZNS vs Women Without Epilepsy</td><td/><td>2</td><td/><td/><td/><td colspan=\"2\">651</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>1.13 [0.21, 6.11]</td></tr><tr><td>(cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.1.2 ZNS vs WWE -No Medication (co-</td><td/><td>2</td><td/><td/><td/><td colspan=\"2\">595</td><td/><td>Risk Ratio (M-H, Fixed,</td><td>3.20 [1.09, 9.43]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.2 ZNS vs Controls: Neural Tube Malfor-</td><td/><td>1</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.2.1 ZNS vs Women Without Epilepsy</td><td/><td>1</td><td/><td/><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>(cohort study)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.2.2 ZNS vs WWE -No Medication (co-</td><td/><td>1</td><td/><td/><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Not estimable</td></tr><tr><td>hort study)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">12.3 ZNS vs Controls: Cardiac Malforma-</td><td/><td>1</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF189": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>MONEAD 2020</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.57, df = 1 (P = 0.21); I\u00b2 = 36%</td></tr><tr><td>Test for overall effect: Z = 0.14 (P = 0.89)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF190": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 12.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">ZNS</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td/><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>1</td><td>13</td><td>2</td><td>106</td><td>18.9%</td><td>4.08 [0.40 , 41.92]</td></tr><tr><td/><td/><td>0</td><td>90</td><td>5</td><td>442</td><td>81.1%</td><td>0.44 [0.02 , 7.93]</td></tr><tr><td/><td/><td colspan=\"2\">103</td><td/><td>548</td><td>100.0%</td><td>1.13 [0.21 , 6.11]</td></tr><tr><td/><td/><td>1</td><td/><td>7</td><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td>1</td><td>13</td><td>1</td><td>15</td><td>43.8%</td><td>1.15 [0.08 , 16.67]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>26</td><td>13</td><td>541</td><td>56.2%</td><td>4.80 [1.46 , 15.82]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>39</td><td/><td>556</td><td>100.0%</td><td>3.20 [1.09 , 9.43]</td></tr><tr><td>Total events:</td><td/><td>4</td><td/><td>14</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.00, df = 1 (P = 0.32); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.11 (P = 0.03)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours ZNS</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF191": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>ZNS</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"4\">12.2.1 ZNS vs Women Without Epilepsy (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>0</td><td>106</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">12.2.2 ZNS vs WWE -No Medication (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>0</td><td>15</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ZNS</td><td>Favours Controls</td></tr><tr><td>Analysis 12.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF192": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"3\">Analysis 12.4.</td><td/><td/><td/><td/></tr><tr><td/><td>ZNS</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"4\">12.3.1 ZNS vs Women Without Epilepsy (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>1</td><td>106</td><td>100.0%</td><td>2.55 [0.11 , 59.56]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>13</td><td/><td>106</td><td>100.0%</td><td>2.55 [0.11 , 59.56]</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for overall effect: Z = 0.58 (P = 0.56)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">12.3.2 ZNS vs WWE -No Medication (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>0</td><td>15</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ZNS</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF193": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>ZNS</td><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"4\">12.4.1 ZNS vs Women Without Epilepsy (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>0</td><td>106</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">12.4.2 ZNS vs WWE -No Medication (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>13</td><td>0</td><td>15</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ZNS</td><td>Favours Controls</td></tr><tr><td>Study or Subgroup</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">12.5.1 ZNS vs Women without Epilepsy (cohort study)</td><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Total events:</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>12.5</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF194": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td></tr><tr><td colspan=\"2\">13.1.2 CBZ vs CZP (database stud-</td><td/><td>2</td><td/><td colspan=\"2\">1549</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.29 [0.47, 3.51]</td></tr><tr><td>ies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Analysis 13.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>ZNS</td><td/><td/><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>0</td><td/><td>13</td><td>0</td><td>106</td><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td/><td/><td>0</td><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td/><td>13</td><td>0</td><td>15</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours ZNS</td><td>Favours Controls</td></tr><tr><td colspan=\"2\">Comparison 13. CBZ vs CZP</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td></tr><tr><td colspan=\"3\">13.1 CBZ vs CZP: All Major Malforma-</td><td>6</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">13.1.1 CBZ vs CZP (cohort studies)</td><td/><td>4</td><td/><td colspan=\"2\">1406</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.82 [0.63, 5.26]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF195": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">14.4 CBZ vs GBP: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.4.1 CBZ vs GBP (cohort studies)</td><td>1</td><td/><td/><td>375</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.37 [0.02, 6.62]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.5 CBZ vs GBP: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td>CBZ</td><td/><td>CZP</td><td/><td/><td>CI)</td><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Study or Subgroup 14.5.1 CBZ vs GBP (cohort studies)</td><td>1</td><td>Events</td><td>Total</td><td>Events 375</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI Risk Ratio (M-H, Fixed, 95% M-H, Fixed, 95% CI 0.21 [0.01, 4.13]</td></tr><tr><td colspan=\"2\">13.1.1 CBZ vs CZP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td/><td>24</td><td>409</td><td>0</td><td>26</td><td>15.5%</td><td>3.23 [0.20 , 51.64]</td></tr><tr><td>D'Souza 1991</td><td/><td/><td>1</td><td>3</td><td>0</td><td>1</td><td>11.0%</td><td>1.50 [0.10 , 22.62]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td>23</td><td>490</td><td>0</td><td>4</td><td>16.4%</td><td>0.48 [0.03 , 6.84]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td/><td>24</td><td>409</td><td>2</td><td>64</td><td>57.1%</td><td>1.88 [0.45 , 7.75]</td></tr><tr><td colspan=\"2\">Subtotal (95% CI) Total events: Analysis 14.1.</td><td/><td>72</td><td>1311</td><td>2</td><td>95</td><td>100.0%</td><td>1.82 [0.63 , 5.26]</td></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 1.15, df = 3 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.10 (P = 0.27)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">13.1.2 CBZ vs CZP (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td/><td>20</td><td>685</td><td>2</td><td>113</td><td>47.8%</td><td>1.65 [0.39 , 6.96]</td></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td/><td>28</td><td>703</td><td>2</td><td>48</td><td>52.2%</td><td>0.96 [0.23 , 3.89]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>1388</td><td/><td>161</td><td>100.0%</td><td>1.29 [0.47 , 3.51]</td></tr><tr><td>Total events:</td><td/><td/><td>48</td><td/><td>4</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.29, df = 1 (P = 0.59); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.49 (P = 0.62)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours CZP</td></tr><tr><td colspan=\"2\">Comparison 14. CBZ vs GBP</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">14.1 CBZ vs GBP: All Major Malforma-</td><td>5</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.1.1 CBZ vs GBP (cohort studies)</td><td>4</td><td/><td/><td>3304</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.55 [0.57, 4.26]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.1.2 CBZ vs GBP (database studies)</td><td>1</td><td/><td/><td>721</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.54 [0.10, 24.27]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.2 CBZ vs GBP: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.2.1 CBZ vs GBP (cohort studies)</td><td>1</td><td/><td/><td>375</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.12 [0.01, 2.93]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.3 CBZ vs GBP: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">14.3.1 CBZ vs GBP (cohort studies)</td><td>2</td><td/><td/><td>390</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.13 [0.02, 0.95]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF196": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>14.1.1 CBZ vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>0</td><td>14</td><td>13.5%</td><td>1.79 [0.11 , 28.10]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>1</td><td>2</td><td>34.5%</td><td>0.07 [0.00 , 1.36]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>1</td><td>145</td><td>24.5%</td><td>4.35 [0.60 , 31.63]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>1</td><td>31</td><td>27.4%</td><td>0.80 [0.11 , 5.66]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>3112</td><td/><td>192</td><td>100.0%</td><td>1.55 [0.57 , 4.26]</td><td/></tr><tr><td>Total events:</td><td>98</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 5.68, df = 3 (P = 0.13); I\u00b2 = 47%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.86 (P = 0.39)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>14.1.2 CBZ vs GBP (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>0</td><td>18</td><td>100.0%</td><td>1.54 [0.10 , 24.27]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>703</td><td/><td>18</td><td>100.0%</td><td>1.54 [0.10 , 24.27]</td><td/></tr><tr><td>Total events:</td><td>28</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.31 (P = 0.76)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF197": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 14.3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">14.2.1 CBZ vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>361</td><td>0</td><td>14</td><td>100.0%</td><td>0.12 [0.01 , 2.93]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>361</td><td/><td>14</td><td>100.0%</td><td>0.12 [0.01 , 2.93]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.29 (P = 0.20)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF198": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>14.3.1 CBZ vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>3</td><td>361</td><td>0</td><td>14</td><td>28.0%</td><td>0.29 [0.02 , 5.37]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>1</td><td>2</td><td>72.0%</td><td>0.07 [0.00 , 1.36]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>374</td><td/><td>16</td><td>100.0%</td><td>0.13 [0.02 , 0.95]</td><td/></tr><tr><td>Total events:</td><td>3</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.45, df = 1 (P = 0.50); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.01 (P = 0.04)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours GBP</td></tr><tr><td>Analysis 14.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF199": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>14.4.1 CBZ vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>361</td><td>0</td><td>14</td><td>100.0%</td><td>0.37 [0.02 , 6.62]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>361</td><td/><td>14</td><td>100.0%</td><td>0.37 [0.02 , 6.62]</td><td/></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.67 (P = 0.50)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours GBP</td></tr><tr><td>Analysis 14.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF200": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>14.5.1 CBZ vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>2</td><td>361</td><td>0</td><td>14</td><td>100.0%</td><td>0.21 [0.01 , 4.13]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>361</td><td/><td>14</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.03 (P = 0.30)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF201": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">15.2 CBZ vs LEV: Neural Tube Malfor-</td><td>10</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.2.1 CBZ vs LEV (cohort studies)</td><td>10</td><td>4879</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.57 [0.41, 6.08]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.3 CBZ vs LEV: Cardiac Malforma-</td><td>11</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.3.1 CBZ vs LEV (cohort studies)</td><td>11</td><td>4892</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.20 [0.57, 2.52]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.4 CBZ vs LEV: Oro-Facial Cle /</td><td>10</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.4.1 CBZ vs LEV (cohort studies)</td><td>10</td><td>4296</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.79 [0.43, 7.41]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.5 CBZ vs LEV: Skeletal/Limb Mal-</td><td>10</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.5.1 CBZ vs LEV (cohort studies)</td><td>10</td><td>4878</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.99 [0.37, 2.68]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours GBP</td></tr><tr><td colspan=\"2\">Comparison 15. CBZ vs LEV</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">15.1 CBZ vs LEV: All Major Malforma-</td><td>13</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.1.1 CBZ vs LEV (cohort studies)</td><td>11</td><td>5056</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.51 [1.01, 2.26]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">15.1.2 CBZ vs LEV (database studies)</td><td>2</td><td>1248</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.73 [0.78, 3.83]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF202": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 15.2.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CBZ</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>2</td><td>5</td><td>0</td><td>9</td><td>0.9%</td><td>8.33 [0.48 , 145.91]</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>5</td><td>139</td><td>18.4%</td><td>1.63 [0.63 , 4.19]</td></tr><tr><td>Hosny 2021</td><td/><td>1</td><td>8</td><td>2</td><td>67</td><td>1.1%</td><td>4.19 [0.43 , 41.18]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>5</td><td>106</td><td>20.3%</td><td>1.00 [0.39 , 2.56]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>5</td><td>148</td><td>2</td><td>31</td><td>8.2%</td><td>0.52 [0.11 , 2.58]</td></tr><tr><td>Melikova 2020</td><td/><td>1</td><td>36</td><td>0</td><td>6</td><td>2.1%</td><td>0.57 [0.03 , 12.56]</td></tr><tr><td>MONEAD 2020</td><td/><td>1</td><td>14</td><td>5</td><td>99</td><td>3.1%</td><td>1.41 [0.18 , 11.24]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>11</td><td>450</td><td>37.8%</td><td>1.23 [0.62 , 2.42]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>2</td><td>304</td><td>8.3%</td><td>3.94 [0.96 , 16.20]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>3814</td><td/><td>1242</td><td>100.0%</td><td>1.51 [1.01 , 2.26]</td></tr><tr><td>Total events:</td><td/><td>131</td><td/><td>32</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 7.13, df = 8 (P = 0.52); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.01 (P = 0.04)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">15.1.2 CBZ vs LEV (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Denmark Health Record Registers</td><td>21</td><td>315</td><td>5</td><td>130</td><td>67.5%</td><td>1.73 [0.67 , 4.50]</td></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>20</td><td>685</td><td>2</td><td>118</td><td>32.5%</td><td>1.72 [0.41 , 7.27]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1000</td><td/><td>248</td><td>100.0%</td><td>1.73 [0.78 , 3.83]</td></tr><tr><td>Total events:</td><td/><td>41</td><td/><td>7</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 0.99); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.35 (P = 0.18)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours LEV</td></tr></table>",
                "type_str": "table"
            },
            "TABREF203": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>15.2.1 CBZ vs LEV (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>331</td><td>0</td><td>53</td><td/><td>Not estimable</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>12</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>0</td><td>106</td><td>21.2%</td><td>2.83 [0.16 , 49.91]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>1</td><td>148</td><td>0</td><td>32</td><td>21.1%</td><td>0.66 [0.03 , 15.95]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>6</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>99</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>1</td><td>450</td><td>35.9%</td><td>1.31 [0.14 , 12.53]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>304</td><td>21.8%</td><td>1.66 [0.09 , 30.67]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>3731</td><td/><td>1148</td><td>100.0%</td><td>1.57 [0.41 , 6.08]</td><td/></tr><tr><td>Total events:</td><td>14</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.47, df = 3 (P = 0.93); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.65 (P = 0.51)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours LEV</td></tr><tr><td>Analysis 15.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF204": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>1</td><td>5</td><td>0</td><td>9</td><td>3.1%</td><td>5.00 [0.24 , 104.15]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>1</td><td>53</td><td>14.1%</td><td>0.64 [0.07 , 5.62]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>1</td><td>67</td><td>2.9%</td><td>2.52 [0.11 , 57.27]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>3</td><td>106</td><td>40.5%</td><td>0.50 [0.13 , 1.92]</td></tr><tr><td>Martinez Ferri 2018</td><td>3</td><td>148</td><td>1</td><td>31</td><td>13.6%</td><td>0.63 [0.07 , 5.84]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>3</td><td>99</td><td>7.5%</td><td>0.95 [0.05 , 17.54]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>1</td><td>450</td><td>11.4%</td><td>1.31 [0.14 , 12.53]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1657</td><td>0</td><td>304</td><td>6.9%</td><td>5.33 [0.32 , 89.19]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3736</td><td/><td>1156</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>32</td><td/><td>10</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.42, df = 7 (P = 0.73); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.47 (P = 0.64)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF205": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 15.4.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours LEV</td></tr></table>",
                "type_str": "table"
            },
            "TABREF206": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>5</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>1</td><td>53</td><td>52.8%</td><td>0.64 [0.07 , 5.62]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>148</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>99</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>0</td><td>450</td><td>21.3%</td><td>4.80 [0.27 , 86.58]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>304</td><td>25.9%</td><td>1.66 [0.09 , 30.67]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3246</td><td/><td>1050</td><td>100.0%</td><td>1.79 [0.43 , 7.41]</td></tr><tr><td>Total events:</td><td>13</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.31, df = 2 (P = 0.52); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.80 (P = 0.42)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours LEV</td></tr><tr><td>Analysis 15.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF207": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td>CBZ</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>331</td><td>0</td><td>53</td><td>11.7%</td><td>0.49 [0.02 , 11.82]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>2</td><td>106</td><td>44.8%</td><td>0.43 [0.08 , 2.33]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>148</td><td>1</td><td>31</td><td>22.5%</td><td>0.42 [0.04 , 4.48]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>99</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>0</td><td>450</td><td>9.5%</td><td>4.80 [0.27 , 86.58]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>304</td><td>11.5%</td><td>1.66 [0.09 , 30.67]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>3731</td><td/><td>1147</td><td>100.0%</td><td>0.99 [0.37 , 2.68]</td></tr><tr><td>Total events:</td><td/><td>16</td><td/><td>3</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 2.89, df = 4 (P = 0.58); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.02 (P = 0.99)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours LEV</td></tr><tr><td colspan=\"2\">Comparison 16. CBZ vs LTG</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">16.1 CBZ vs LTG: All Major Malforma-</td><td>17</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">16.1.1 CBZ vs LTG (cohort studies)</td><td>13</td><td/><td>8568</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.37 [1.06, 1.77]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">16.1.2 CBZ vs LTG (database studies)</td><td>4</td><td/><td>4503</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.21 [0.88, 1.67]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF208": {
                "text": "Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>2</td><td>5</td><td>0</td><td>20</td><td>0.2%</td><td>17.50 [0.97 , 317.30]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>20</td><td>406</td><td>20.7%</td><td>1.19 [0.67 , 2.12]</td></tr><tr><td>Cassina 2013</td><td>5</td><td>88</td><td>0</td><td>26</td><td>0.8%</td><td>3.34 [0.19 , 58.44]</td></tr><tr><td>Hosny 2021</td><td>1</td><td>8</td><td>0</td><td>3</td><td>0.7%</td><td>1.33 [0.07 , 26.15]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>1</td><td>50</td><td>1.9%</td><td>2.35 [0.32 , 17.01]</td></tr><tr><td>Martinez Ferri 2018</td><td>5</td><td>148</td><td>2</td><td>111</td><td>2.4%</td><td>1.88 [0.37 , 9.49]</td></tr><tr><td>Meador 2006 (1)</td><td>5</td><td>110</td><td>1</td><td>98</td><td>1.1%</td><td>4.45 [0.53 , 37.47]</td></tr><tr><td>Melikova 2020</td><td>1</td><td>36</td><td>0</td><td>7</td><td>0.8%</td><td>0.65 [0.03 , 14.51]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>14</td><td>5</td><td>113</td><td>1.1%</td><td>1.61 [0.20 , 12.84]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>31</td><td>1562</td><td>25.5%</td><td>1.51 [0.92 , 2.47]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>49</td><td>2098</td><td>44.7%</td><td>1.11 [0.74 , 1.66]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4018</td><td/><td>4550</td><td>100.0%</td><td>1.37 [1.06 , 1.77]</td></tr><tr><td>Total events:</td><td>141</td><td/><td>109</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.59, df = 10 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.38 (P = 0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>16.1.2 CBZ vs LTG (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>21</td><td>315</td><td>47</td><td>1235</td><td>31.9%</td><td>1.75 [1.06 , 2.89]</td></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>28</td><td>833</td><td>42.2%</td><td>0.87 [0.49 , 1.53]</td></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>4</td><td>90</td><td>11.9%</td><td>0.90 [0.32 , 2.50]</td></tr><tr><td>UK Health Record THIN Register</td><td>10</td><td>298</td><td>9</td><td>344</td><td>14.0%</td><td>1.28 [0.53 , 3.11]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2001</td><td/><td>2502</td><td>100.0%</td><td>1.21 [0.88 , 1.67]</td></tr><tr><td>Total events:</td><td>79</td><td/><td>88</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.78, df = 3 (P = 0.29); I\u00b2 = 21%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.16 (P = 0.24)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours LTG</td></tr><tr><td>Footnotes</td><td/><td/><td/><td/><td/><td/></tr><tr><td>(1)</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF209": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>331</td><td>0</td><td>282</td><td/></tr><tr><td>Cassina 2013</td><td>0</td><td>88</td><td>0</td><td>26</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>19</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>0</td><td>50</td><td>18.7%</td></tr><tr><td>Martinez Ferri 2018</td><td>1</td><td>148</td><td>0</td><td>111</td><td>11.8%</td></tr><tr><td>Meador 2006</td><td>0</td><td>110</td><td>0</td><td>98</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>7</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>37</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>113</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>2</td><td>1562</td><td>32.9%</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>2</td><td>2098</td><td>36.5%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3935</td><td/><td>4406</td><td>100.0%</td></tr><tr><td>Total events:</td><td>14</td><td/><td>4</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.14, df = 3 (P = 0.99); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.45 (P = 0.15)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF210": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 16.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>1.35 [0.08 , 23.62]</td><td/><td/></tr><tr><td/><td/><td>2.26 [0.09 , 54.84]</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>2.27 [0.38 , 13.55]</td><td/><td/></tr><tr><td/><td/><td>2.53 [0.46 , 13.81]</td><td/><td/></tr><tr><td/><td/><td>2.19 [0.76 , 6.33]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF211": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>1</td><td>5</td><td>0</td><td>20</td><td>1.0%</td><td>10.50 [0.49 , 226.04]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>4</td><td>282</td><td>19.9%</td><td>0.85 [0.22 , 3.38]</td></tr><tr><td>Cassina 2013</td><td>3</td><td>88</td><td>0</td><td>26</td><td>3.5%</td><td>2.12 [0.11 , 39.84]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>1</td><td>50</td><td>8.4%</td><td>0.71 [0.09 , 5.69]</td></tr><tr><td>Martinez Ferri 2018</td><td>3</td><td>148</td><td>2</td><td>111</td><td>10.5%</td><td>1.13 [0.19 , 6.62]</td></tr><tr><td>Meador 2006</td><td>0</td><td>110</td><td>1</td><td>98</td><td>7.3%</td><td>0.30 [0.01 , 7.21]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>1</td><td>113</td><td>1.6%</td><td>2.53 [0.11 , 59.42]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>3</td><td>1562</td><td>11.0%</td><td>1.51 [0.31 , 7.48]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1657</td><td>9</td><td>2098</td><td>36.6%</td><td>1.97 [0.85 , 4.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3933</td><td/><td>4407</td><td>100.0%</td><td>1.48 [0.87 , 2.51]</td></tr><tr><td>Total events:</td><td>35</td><td/><td>21</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.34, df = 8 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.46 (P = 0.14)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours LTG</td></tr><tr><td>Analysis 16.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF212": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>5</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>4</td><td>282</td><td>37.1%</td><td>0.85 [0.22 , 3.38]</td></tr><tr><td>Cassina 2013</td><td>0</td><td>88</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>148</td><td>0</td><td>111</td><td/><td>Not estimable</td></tr><tr><td>Meador 2006</td><td>0</td><td>110</td><td>0</td><td>98</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>113</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>7</td><td>1562</td><td>47.8%</td><td>1.08 [0.34 , 3.39]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>2</td><td>2098</td><td>15.1%</td><td>2.53 [0.46 , 13.81]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3443</td><td/><td>4357</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>13</td><td/><td>13</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.02, df = 2 (P = 0.60); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.50 (P = 0.62)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF213": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 16.5.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF214": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td>CBZ</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>331</td><td>2</td><td>282</td><td>26.3%</td><td>0.43 [0.04 , 4.67]</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>88</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>0</td><td>50</td><td>11.0%</td><td>0.93 [0.05 , 17.12]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>148</td><td>0</td><td>111</td><td>6.9%</td><td>3.76 [0.18 , 77.51]</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>110</td><td>0</td><td>98</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>1</td><td>113</td><td>4.2%</td><td>2.53 [0.11 , 59.42]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>2</td><td>1562</td><td>19.4%</td><td>3.78 [0.73 , 19.45]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>3</td><td>2098</td><td>32.2%</td><td>1.69 [0.38 , 7.53]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>3935</td><td/><td>4406</td><td>100.0%</td><td>1.86 [0.82 , 4.22]</td></tr><tr><td>Total events:</td><td/><td>16</td><td/><td>8</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 2.65, df = 5 (P = 0.75); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.48 (P = 0.14)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours LTG</td></tr><tr><td colspan=\"2\">Comparison 17. CBZ vs OXC</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">17.1 CBZ vs OXC: All Major Malfor-</td><td/><td/><td/><td/><td/></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF215": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>17.1.1 CBZ vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>2</td><td>5</td><td>0</td><td>3</td><td>2.8%</td><td>3.33 [0.21 , 52.68]</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>1</td><td>19</td><td>8.9%</td><td>1.11 [0.16 , 7.81]</td><td/></tr><tr><td>Hosny 2021</td><td>1</td><td>8</td><td>0</td><td>31</td><td>1.0%</td><td>10.67 [0.47 , 240.12]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaaja 2003</td><td>10</td><td>363</td><td>1</td><td>9</td><td>9.1%</td><td>0.25 [0.04 , 1.74]</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>5</td><td>71</td><td>40.8%</td><td>0.67 [0.26 , 1.70]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>5</td><td>148</td><td>0</td><td>22</td><td>4.0%</td><td>1.70 [0.10 , 29.70]</td><td/></tr><tr><td>Meischenguiser 2004</td><td>2</td><td>16</td><td>0</td><td>35</td><td>1.5%</td><td>10.59 [0.54 , 208.68]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>4</td><td>182</td><td>31.8%</td><td>1.37 [0.49 , 3.82]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2499</td><td/><td>378</td><td>100.0%</td><td>1.26 [0.74 , 2.15]</td><td/></tr><tr><td>Total events:</td><td>98</td><td/><td>11</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 8.78, df = 7 (P = 0.27); I\u00b2 = 20%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.84 (P = 0.40)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>17.1.2 CBZ vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>21</td><td>315</td><td>10</td><td>316</td><td>19.0%</td><td>2.11 [1.01 , 4.40]</td><td/></tr><tr><td>Finland Health Record Registers</td><td>32</td><td>805</td><td>23</td><td>130</td><td>75.5%</td><td>0.22 [0.14 , 0.37]</td><td/></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>1</td><td>57</td><td>3.5%</td><td>1.66 [0.23 , 12.18]</td><td/></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>0</td><td>4</td><td>1.9%</td><td>0.40 [0.03 , 5.75]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2508</td><td/><td>507</td><td>100.0%</td><td>0.64 [0.44 , 0.91]</td><td/></tr><tr><td>Total events:</td><td>101</td><td/><td>34</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 27.64, df = 3 (P &lt; 0.00001); I\u00b2 = 89%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.45 (P = 0.01)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours OXC</td></tr><tr><td>Analysis 17.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF216": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 17.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>331</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>3</td><td>363</td><td>0</td><td>9</td><td>27.3%</td><td>0.19 [0.01 , 3.48]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>0</td><td>71</td><td>24.5%</td><td>1.91 [0.11 , 33.48]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>1</td><td>148</td><td>0</td><td>22</td><td>24.3%</td><td>0.46 [0.02 , 11.03]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>0</td><td>182</td><td>23.9%</td><td>1.24 [0.06 , 23.88]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2403</td><td/><td>364</td><td>100.0%</td><td>0.93 [0.22 , 3.96]</td></tr><tr><td>Total events:</td><td colspan=\"2\">13</td><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.60, df = 3 (P = 0.66); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.10 (P = 0.92)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF217": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>1</td><td>5</td><td>0</td><td>3</td><td>6.3%</td><td>2.00 [0.11 , 37.83]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>0</td><td>9</td><td>10.2%</td><td>0.27 [0.02 , 4.70]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>2</td><td>363</td><td>0</td><td>9</td><td>10.2%</td><td>0.14 [0.01 , 2.68]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>3</td><td>71</td><td>55.2%</td><td>0.34 [0.09 , 1.28]</td></tr><tr><td>Martinez Ferri 2018</td><td>3</td><td>148</td><td>0</td><td>22</td><td>9.1%</td><td>1.08 [0.06 , 20.25]</td></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>16</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>0</td><td>182</td><td>8.9%</td><td>1.24 [0.06 , 23.88]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2421</td><td/><td>368</td><td>100.0%</td><td>0.56 [0.23 , 1.38]</td></tr><tr><td>Total events:</td><td>20</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.86, df = 5 (P = 0.72); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.26 (P = 0.21)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours OXC</td></tr><tr><td>Analysis 17.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF218": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 17.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>5</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>0</td><td>9</td><td>26.6%</td><td>0.27 [0.02 , 4.70]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>2</td><td>363</td><td>0</td><td>9</td><td>26.7%</td><td>0.14 [0.01 , 2.68]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>0</td><td>148</td><td>0</td><td>22</td><td/><td>Not estimable</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>1</td><td>182</td><td>46.7%</td><td>0.88 [0.10 , 7.50]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1918</td><td/><td>296</td><td>100.0%</td><td>0.52 [0.12 , 2.26]</td></tr><tr><td>Total events:</td><td colspan=\"2\">11</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.20, df = 2 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.87 (P = 0.38)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF219": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td>CBZ</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>331</td><td>0</td><td>9</td><td>15.5%</td><td>0.09 [0.00 , 2.08]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>1</td><td>363</td><td>0</td><td>9</td><td>15.6%</td><td>0.08 [0.00 , 1.90]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>1</td><td>71</td><td>27.9%</td><td>0.58 [0.07 , 5.11]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>148</td><td>0</td><td>22</td><td>13.8%</td><td>0.77 [0.04 , 15.57]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>1</td><td>182</td><td>27.2%</td><td>0.88 [0.10 , 7.50]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2403</td><td/><td>364</td><td>100.0%</td><td>0.53 [0.17 , 1.66]</td></tr><tr><td>Total events:</td><td/><td>13</td><td/><td>2</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 2.87, df = 4 (P = 0.58); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.08 (P = 0.28)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours OXC</td></tr><tr><td colspan=\"2\">Comparison 18. CBZ vs PB</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">18.1 CBZ vs PB: All Major Malforma-</td><td>26</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.1.1 CBZ vs PB (cohort studies)</td><td>24</td><td/><td>4067</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.83 [0.61, 1.13]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.1.2 CBZ vs PB (database studies)</td><td>2</td><td/><td>1422</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.35 [0.12, 1.09]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.2 CBZ vs PB: Neural Tube Malfor-</td><td>15</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.2.1 CBZ vs PB (cohort studies)</td><td>15</td><td/><td>2890</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.28 [0.35, 4.75]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.3 CBZ vs PB: Cardiac Malforma-</td><td>15</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.3.1 CBZ vs PB (cohort studies)</td><td>15</td><td/><td>2890</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.26 [0.14, 0.47]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.4 CBZ vs PB: Oro-Facial Cle /Cran-</td><td>15</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.4.1 CBZ vs PB (cohort studies)</td><td>15</td><td/><td>2279</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.18 [0.07, 0.48]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.5 CBZ vs PB: Skeletal/Limb Malfor-</td><td>15</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mation</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">18.5.1 CBZ vs PB (cohort studies)</td><td>15</td><td/><td>2890</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.08 [0.45, 2.61]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF220": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 18.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CBZ</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">18.1.1 CBZ vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>0</td><td>2</td><td>1.4%</td><td>0.36 [0.03 , 4.63]</td></tr><tr><td>Cassina 2013</td><td/><td>5</td><td>88</td><td>5</td><td>67</td><td>7.8%</td><td>0.76 [0.23 , 2.52]</td></tr><tr><td>D'Souza 1991</td><td/><td>1</td><td>3</td><td>1</td><td>4</td><td>1.2%</td><td>1.33 [0.13 , 13.74]</td></tr><tr><td>Delmi\u0161 1991</td><td/><td>4</td><td>18</td><td>4</td><td>58</td><td>2.6%</td><td>3.22 [0.89 , 11.60]</td></tr><tr><td>Eroglu 2008</td><td/><td>3</td><td>46</td><td>1</td><td>5</td><td>2.5%</td><td>0.33 [0.04 , 2.57]</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>2</td><td>31</td><td>1</td><td>5</td><td>2.4%</td><td>0.32 [0.04 , 2.93]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>10</td><td>363</td><td>0</td><td>5</td><td>1.3%</td><td>0.35 [0.02 , 5.25]</td></tr><tr><td>Kaneko 1999</td><td/><td>9</td><td>158</td><td>4</td><td>79</td><td>7.3%</td><td>1.13 [0.36 , 3.54]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>8</td><td>137</td><td>17.1%</td><td>0.80 [0.37 , 1.76]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Lindhout 1992</td><td/><td>5</td><td>50</td><td>1</td><td>26</td><td>1.8%</td><td>2.60 [0.32 , 21.11]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>5</td><td>148</td><td>1</td><td>11</td><td>2.5%</td><td>0.37 [0.05 , 2.91]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>2</td><td>16</td><td>1</td><td>5</td><td>2.1%</td><td>0.63 [0.07 , 5.53]</td></tr><tr><td>Milan Study 1999</td><td/><td>12</td><td>113</td><td>4</td><td>83</td><td>6.3%</td><td>2.20 [0.74 , 6.59]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Montreal Series</td><td/><td>5</td><td>32</td><td>2</td><td>10</td><td>4.2%</td><td>0.78 [0.18 , 3.43]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>11</td><td>199</td><td>25.2%</td><td>0.54 [0.28 , 1.06]</td></tr><tr><td>Omtzigt 1992</td><td/><td>4</td><td>114</td><td>3</td><td>18</td><td>7.1%</td><td>0.21 [0.05 , 0.86]</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Steegers-Theunissen 1994</td><td/><td>1</td><td>39</td><td>0</td><td>12</td><td>1.0%</td><td>0.97 [0.04 , 22.50]</td></tr><tr><td>Tanganelli 1992</td><td/><td>0</td><td>9</td><td>3</td><td>63</td><td>1.3%</td><td>0.91 [0.05 , 16.41]</td></tr><tr><td>Waters 1994</td><td/><td>1</td><td>33</td><td>3</td><td>21</td><td>5.0%</td><td>0.21 [0.02 , 1.91]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>3235</td><td/><td>832</td><td>100.0%</td><td>0.83 [0.61 , 1.13]</td></tr><tr><td>Total events:</td><td/><td>147</td><td/><td>53</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 18.56, df = 18 (P = 0.42); I\u00b2 = 3%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.20 (P = 0.23)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">18.1.2 CBZ vs PB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>20</td><td>685</td><td>2</td><td>27</td><td>66.0%</td><td>0.39 [0.10 , 1.60]</td></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>28</td><td>703</td><td>1</td><td>7</td><td>34.0%</td><td>0.28 [0.04 , 1.77]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1388</td><td/><td>34</td><td>100.0%</td><td>0.35 [0.12 , 1.09]</td></tr><tr><td>Total events:</td><td/><td>48</td><td/><td>3</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.09, df = 1 (P = 0.77); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.81 (P = 0.07)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF221": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 18.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>361</td><td>0</td><td>5</td><td>24.8%</td><td>0.05 [0.00 , 1.10]</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>88</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>3</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>49</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>0</td><td>31</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>1</td><td>137</td><td>39.5%</td><td>1.68 [0.20 , 13.82]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>1</td><td>113</td><td>0</td><td>83</td><td>14.5%</td><td>2.21 [0.09 , 53.59]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>0</td><td>199</td><td>21.2%</td><td>1.35 [0.07 , 26.11]</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>114</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2340</td><td/><td>550</td><td>100.0%</td><td>1.28 [0.35 , 4.75]</td></tr><tr><td>Total events:</td><td colspan=\"2\">11</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 4.41, df = 3 (P = 0.22); I\u00b2 = 32%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.37 (P = 0.71)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PB</td></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">18.3.1 CBZ vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>3</td><td>361</td><td>0</td><td>5</td><td>3.0%</td><td>0.12 [0.01 , 2.01]</td></tr><tr><td>Cassina 2013</td><td/><td>3</td><td>88</td><td>2</td><td>67</td><td>7.0%</td><td>1.14 [0.20 , 6.64]</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>3</td><td>1</td><td>4</td><td>4.1%</td><td>0.42 [0.02 , 7.71]</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>49</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>1</td><td>31</td><td>1</td><td>5</td><td>5.3%</td><td>0.16 [0.01 , 2.18]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>6</td><td>137</td><td>29.0%</td><td>0.33 [0.11 , 0.95]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>1</td><td>5</td><td>6.9%</td><td>0.12 [0.01 , 2.51]</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>113</td><td>1</td><td>83</td><td>5.3%</td><td>0.25 [0.01 , 5.95]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>5</td><td>199</td><td>26.0%</td><td>0.12 [0.03 , 0.48]</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>114</td><td>2</td><td>18</td><td>13.3%</td><td>0.03 [0.00 , 0.66]</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2340</td><td/><td>550</td><td>100.0%</td><td>0.26 [0.14 , 0.47]</td></tr><tr><td>Total events:</td><td colspan=\"2\">17</td><td/><td>19</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 6.75, df = 8 (P = 0.56); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 4.43 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF222": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 19. CBZ vs PHT</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">CBZ Events No. of studies Total</td><td colspan=\"4\">PB pants Events No. of partici-Total Weight</td><td>Risk Ratio M-H, Fixed, 95% CI Statistical method</td><td>Risk Ratio M-H, Fixed, 95% CI Effect size</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register 19.1 CBZ vs PHT: All Major Malforma-</td><td>24</td><td>4</td><td>361</td><td/><td>0</td><td>5</td><td>8.1%</td><td>0.15 [0.01 , 2.47] Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>Cassina 2013 tions</td><td/><td/><td>0</td><td>88</td><td/><td>0</td><td>67</td><td/><td>CI)</td><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td/><td>0</td><td>3</td><td/><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Eroglu 2008 Fr\u00f6scher 1991 Jimenez 2020 19.1.1 CBZ vs PHT (cohort studies)</td><td>23</td><td>0 0 0</td><td>49 31 7</td><td colspan=\"2\">1 0 0 6046</td><td>5 5 2</td><td>22.1%</td><td>0.04 [0.00 , 0.88] Not estimable Not estimable Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.83 [0.62, 1.11]</td></tr><tr><td>Kaur 2020</td><td/><td/><td>0</td><td>7</td><td/><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry 19.1.2 CBZ vs PHT (database studies)</td><td>1</td><td>0</td><td>7</td><td>806</td><td>0</td><td>9</td><td/><td>Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>0.59 [0.26, 1.31]</td></tr><tr><td>Koch 1992 Meischenguiser 2004</td><td/><td/><td>0 0</td><td>9 16</td><td/><td>0 0</td><td>4 5</td><td/><td>CI)</td><td>Not estimable Not estimable</td></tr><tr><td colspan=\"2\">Milan Study 1999 Miskov 2016 19.2 CBZ vs PHT: Neural Tube Malfor-</td><td>16</td><td>0 0</td><td>113 13</td><td/><td>0 0</td><td>83 3</td><td/><td>Not estimable Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register mations</td><td/><td>5</td><td>1033</td><td/><td>4</td><td>199</td><td>55.4%</td><td>CI)</td><td>0.24 [0.07 , 0.89]</td></tr><tr><td>Omtzigt 1992</td><td/><td/><td>1</td><td>114</td><td/><td>1</td><td>18</td><td>14.3%</td><td>0.16 [0.01 , 2.41]</td></tr><tr><td colspan=\"2\">Pardi 1982 Subtotal (95% CI) Total events: 19.2.1 CBZ vs PHT (cohort studies)</td><td>16</td><td>0 10</td><td>6 1857</td><td colspan=\"2\">0 6 5346</td><td>12 422</td><td>100.0%</td><td>Not estimable 0.18 [0.07 , 0.48] Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.12 [0.45, 2.83]</td></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 1.13, df = 3 (P = 0.77); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 3.40 (P = 0.0007) 19.3 CBZ vs PHT: Cardiac Malforma-</td><td>16</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">19.3.1 CBZ vs PHT (cohort studies)</td><td>16</td><td/><td/><td colspan=\"2\">5346</td><td/><td/><td>Favours CBZ Risk Ratio (M-H, Fixed, 95%</td><td>Favours PB 0.44 [0.23, 0.84]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">19.4 CBZ vs PHT: Oro-Facial Cle /</td><td>16</td><td/><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td>CBZ</td><td/><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Study or Subgroup 19.4.1 CBZ vs PHT (cohort studies)</td><td>16</td><td>Events</td><td>Total</td><td colspan=\"2\">Events 4749</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI Risk Ratio (M-H, Fixed, 95% M-H, Fixed, 95% CI 0.81 [0.32, 2.08]</td></tr><tr><td colspan=\"2\">18.5.1 CBZ vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td/><td>2</td><td>361</td><td/><td>0</td><td>5</td><td>11.9%</td><td>0.08 [0.00 , 1.55]</td></tr><tr><td colspan=\"2\">Cassina 2013 19.5 CBZ vs PHT: Skeletal/Limb Mal-</td><td>16</td><td>0</td><td>88</td><td/><td>0</td><td>67</td><td/><td>Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>D'Souza 1991 formation</td><td/><td/><td>1</td><td>3</td><td/><td>0</td><td>4</td><td>5.4%</td><td>CI)</td><td>3.75 [0.20 , 69.40]</td></tr><tr><td>Eroglu 2008</td><td/><td/><td>0</td><td>49</td><td/><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Fr\u00f6scher 1991 Jimenez 2020 Kaur 2020 19.5.1 CBZ vs PHT (cohort studies)</td><td>16</td><td>0 0 0</td><td>31 7 7</td><td colspan=\"2\">0 0 0 5346</td><td>5 2 1</td><td/><td>Not estimable Not estimable Not estimable Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.88 [0.43, 1.82]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td>4</td><td>490</td><td/><td>2</td><td>137</td><td>37.9%</td><td>0.56 [0.10 , 3.02]</td></tr><tr><td>Koch 1992</td><td/><td/><td>0</td><td>9</td><td/><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Meischenguiser 2004</td><td/><td/><td>0</td><td>16</td><td/><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td/><td>4</td><td>113</td><td/><td>1</td><td>83</td><td>14.0%</td><td>2.94 [0.33 , 25.81]</td></tr><tr><td>Miskov 2016</td><td/><td/><td>0</td><td>13</td><td/><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td/><td>5</td><td>1033</td><td/><td>1</td><td>199</td><td>20.3%</td><td>0.96 [0.11 , 8.20]</td></tr><tr><td>Omtzigt 1992</td><td/><td/><td>1</td><td>114</td><td/><td>0</td><td>18</td><td>10.4%</td><td>0.50 [0.02 , 11.72]</td></tr><tr><td>Pardi 1982</td><td/><td/><td>0</td><td>6</td><td/><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>2340</td><td/><td/><td>550</td><td>100.0%</td><td>1.08 [0.45 , 2.61]</td></tr><tr><td>Total events:</td><td/><td/><td>17</td><td/><td/><td>4</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 5.30, df = 5 (P = 0.38); I\u00b2 = 6%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.18 (P = 0.86)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF223": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td>CBZ</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>1</td><td>44</td><td>2.0%</td><td>2.58 [0.36 , 18.63]</td></tr><tr><td>Bag 1989</td><td/><td>0</td><td>4</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td>1</td><td>3</td><td>6</td><td>22</td><td>1.6%</td><td>1.22 [0.21 , 6.96]</td></tr><tr><td>Eroglu 2008</td><td/><td>3</td><td>46</td><td>2</td><td>14</td><td>3.3%</td><td>0.46 [0.08 , 2.46]</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>2</td><td>31</td><td>0</td><td>3</td><td>1.0%</td><td>0.63 [0.04 , 10.84]</td></tr><tr><td>Garza-Morales 1996</td><td/><td>0</td><td>24</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>10</td><td>363</td><td>3</td><td>124</td><td>4.9%</td><td>1.14 [0.32 , 4.07]</td></tr><tr><td>Kaneko 1999</td><td/><td>9</td><td>158</td><td>12</td><td>132</td><td>14.2%</td><td>0.63 [0.27 , 1.44]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>1</td><td>2</td><td>2.4%</td><td>0.13 [0.01 , 2.30]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>7</td><td>119</td><td>12.3%</td><td>0.80 [0.35 , 1.82]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>2</td><td>24</td><td>1.6%</td><td>0.50 [0.03 , 9.52]</td></tr><tr><td>Lindhout 1992</td><td/><td>5</td><td>50</td><td>1</td><td>17</td><td>1.6%</td><td>1.70 [0.21 , 13.54]</td></tr><tr><td>Meador 2006 (1)</td><td/><td>5</td><td>110</td><td>4</td><td>56</td><td>5.8%</td><td>0.64 [0.18 , 2.28]</td></tr><tr><td>Milan Study 1999</td><td/><td>12</td><td>113</td><td>3</td><td>31</td><td>5.1%</td><td>1.10 [0.33 , 3.65]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Montreal Series</td><td/><td>5</td><td>32</td><td>6</td><td>44</td><td>5.5%</td><td>1.15 [0.38 , 3.43]</td></tr><tr><td>Motherisk Registry</td><td/><td>1</td><td>15</td><td>0</td><td>16</td><td>0.5%</td><td>3.19 [0.14 , 72.69]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>12</td><td>416</td><td>18.6%</td><td>1.04 [0.54 , 2.01]</td></tr><tr><td>Omtzigt 1992</td><td/><td>4</td><td>114</td><td>0</td><td>28</td><td>0.9%</td><td>2.27 [0.13 , 40.97]</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Steegers-Theunissen 1994</td><td/><td>1</td><td>39</td><td>0</td><td>8</td><td>0.9%</td><td>0.68 [0.03 , 15.25]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>7</td><td>106</td><td>14.3%</td><td>0.39 [0.18 , 0.85]</td></tr><tr><td>Waters 1994</td><td/><td>1</td><td>33</td><td>3</td><td>28</td><td>3.5%</td><td>0.28 [0.03 , 2.57]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4759</td><td/><td>1287</td><td>100.0%</td><td>0.83 [0.62 , 1.11]</td></tr><tr><td>Total events:</td><td/><td>180</td><td/><td>70</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 11.71, df = 18 (P = 0.86); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.26 (P = 0.21)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">19.1.2 CBZ vs PHT (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>28</td><td>703</td><td>7</td><td>103</td><td>100.0%</td><td>0.59 [0.26 , 1.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>703</td><td/><td>103</td><td>100.0%</td><td>0.59 [0.26 , 1.31]</td></tr><tr><td>Total events:</td><td/><td>28</td><td/><td>7</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.31 (P = 0.19)</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td>Footnotes</td><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours PHT</td></tr><tr><td colspan=\"5\">(1) Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF224": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 19.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CBZ</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>331</td><td>1</td><td>44</td><td>33.3%</td><td>0.05 [0.00 , 1.09]</td></tr><tr><td>Bag 1989</td><td/><td>0</td><td>4</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>3</td><td>0</td><td>22</td><td/><td>Not estimable</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>49</td><td>0</td><td>14</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>0</td><td>31</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td/><td>3</td><td>363</td><td>0</td><td>124</td><td>9.4%</td><td>2.40 [0.13 , 46.21]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>1</td><td>119</td><td>20.3%</td><td>1.46 [0.18 , 11.99]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>0</td><td>24</td><td/><td>Not estimable</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>110</td><td>0</td><td>56</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>1</td><td>113</td><td>0</td><td>31</td><td>9.9%</td><td>0.84 [0.04 , 20.18]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Motherisk Registry</td><td/><td>1</td><td>15</td><td>0</td><td>16</td><td>6.1%</td><td>3.19 [0.14 , 72.69]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>0</td><td>416</td><td>9.0%</td><td>2.82 [0.15 , 54.53]</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>114</td><td>0</td><td>28</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>82</td><td>12.0%</td><td>0.45 [0.02 , 8.30]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4341</td><td/><td>1005</td><td>100.0%</td><td>1.12 [0.45 , 2.83]</td></tr><tr><td>Total events:</td><td/><td>18</td><td/><td>2</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 5.43, df = 6 (P = 0.49); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.25 (P = 0.81)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PHT</td></tr><tr><td/><td/><td>CBZ</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">19.3.1 CBZ vs PHT (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>1</td><td>44</td><td>7.7%</td><td>0.53 [0.06 , 4.65]</td></tr><tr><td>Bag 1989</td><td/><td>0</td><td>4</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>3</td><td>2</td><td>22</td><td>3.2%</td><td>1.15 [0.07 , 19.78]</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>49</td><td>1</td><td>14</td><td>10.1%</td><td>0.10 [0.00 , 2.33]</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>1</td><td>31</td><td>0</td><td>3</td><td>3.9%</td><td>0.38 [0.02 , 7.74]</td></tr><tr><td>Kaaja 2003</td><td/><td>2</td><td>363</td><td>0</td><td>124</td><td>3.2%</td><td>1.72 [0.08 , 35.52]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>5</td><td>119</td><td>35.0%</td><td>0.34 [0.11 , 1.05]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>1</td><td>24</td><td>3.7%</td><td>0.83 [0.04 , 18.79]</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>110</td><td>0</td><td>56</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>113</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Motherisk Registry</td><td/><td>0</td><td>15</td><td>0</td><td>16</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>4</td><td>416</td><td>24.8%</td><td>0.30 [0.07 , 1.34]</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>114</td><td>0</td><td>28</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1657</td><td>1</td><td>82</td><td>8.3%</td><td>0.69 [0.09 , 5.20]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4341</td><td/><td>1005</td><td>100.0%</td><td>0.44 [0.23 , 0.84]</td></tr><tr><td>Total events:</td><td/><td>31</td><td/><td>15</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.91, df = 8 (P = 0.94); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.50 (P = 0.01)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF225": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 20. CBZ vs PRM</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">CBZ Events No. of studies Total</td><td colspan=\"3\">PHT Events pants Total No. of partici-Weight</td><td colspan=\"2\">Risk Ratio M-H, Fixed, 95% CI Statistical method</td><td>Risk Ratio M-H, Fixed, 95% CI Effect size</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register 20.1 CBZ vs PRM: All Major Malforma-</td><td>8</td><td>4</td><td>331</td><td>0</td><td>44</td><td>10.5%</td><td colspan=\"2\">1.22 [0.07 , 22.28] Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>Bag 1989 tions</td><td/><td/><td>0</td><td>4</td><td>0</td><td>20</td><td/><td>CI)</td><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td/><td>0</td><td>3</td><td>1</td><td>22</td><td>5.3%</td><td colspan=\"2\">1.92 [0.09 , 39.25]</td></tr><tr><td colspan=\"2\">Eroglu 2008 Fr\u00f6scher 1991 Kaaja 2003 20.1.1 CBZ vs PRM (cohort studies)</td><td>7</td><td>0 0 2</td><td>49 31 363</td><td>0 0 1 1188</td><td>14 3 124</td><td>17.8%</td><td colspan=\"2\">Not estimable 0.68 [0.06 , 7.47] Not estimable Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.78 [0.41, 1.48]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td>0</td><td>7</td><td>0</td><td>5</td><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Koch 1992 20.1.2 CBZ vs PRM (database studies)</td><td>1</td><td>0</td><td>9</td><td>0 706</td><td>24</td><td/><td colspan=\"2\">Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>0.32 [0.02, 4.44]</td></tr><tr><td>Meador 2006 Milan Study 1999</td><td/><td/><td>0 0</td><td>110 113</td><td>0 0</td><td>56 31</td><td/><td>CI)</td><td>Not estimable Not estimable</td></tr><tr><td colspan=\"2\">Miskov 2016 Motherisk Registry 20.2 CBZ vs PRM: Neural Tube Malfor-</td><td>2</td><td>0 0</td><td>13 15</td><td>0 0</td><td>1 16</td><td/><td colspan=\"2\">Not estimable Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register mations</td><td/><td>5</td><td>1033</td><td>2</td><td>416</td><td>34.1%</td><td>CI)</td><td>1.01 [0.20 , 5.17]</td></tr><tr><td>Omtzigt 1992</td><td/><td/><td>1</td><td>114</td><td>0</td><td>28</td><td>9.5%</td><td colspan=\"2\">0.76 [0.03 , 18.09]</td></tr><tr><td colspan=\"2\">Pardi 1982 UK and Ireland Epilepsy and Pregnancy Register Subtotal (95% CI) 20.2.1 CBZ vs PRM (cohort studies)</td><td>2</td><td>0 4</td><td>6 1657 3858</td><td>0 1 158</td><td>5 82 891</td><td>22.8% 100.0%</td><td colspan=\"2\">Not estimable 0.81 [0.32 , 2.08] 0.20 [0.02 , 1.75] Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.95 [0.04, 22.75]</td></tr><tr><td>Total events:</td><td/><td/><td>16</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.08, df = 5 (P = 0.84); I\u00b2 = 0% 20.3 CBZ vs PRM: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.43 (P = 0.66) tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable 20.3.1 CBZ vs PRM (cohort studies)</td><td>2</td><td/><td/><td>158</td><td/><td/><td colspan=\"2\">0.01 Favours CBZ 0.1 Risk Ratio (M-H, Fixed, 95%</td><td>1</td><td>10 Favours PHT 100 0.11 [0.00, 2.53]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">20.4 CBZ vs PRM: Oro-Facial Cle /Cran-</td><td>2</td><td/><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Study or Subgroup 20.4.1 CBZ vs PRM (cohort studies)</td><td>2</td><td>CBZ Events</td><td>Total</td><td>PHT Events 0</td><td>Total</td><td>Weight</td><td colspan=\"2\">Risk Ratio M-H, Fixed, 95% CI CI) Risk Ratio (M-H, Fixed, 95% Risk Ratio M-H, Fixed, 95% CI Not estimable</td></tr><tr><td colspan=\"2\">19.5.1 CBZ vs PHT (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register 20.5 CBZ vs PRM: Skeletal/Limb Malfor-</td><td>2</td><td>1</td><td>331</td><td>0</td><td>44</td><td>6.7%</td><td colspan=\"2\">0.41 [0.02 , 9.83] Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>Bag 1989 mations</td><td/><td/><td>0</td><td>4</td><td>0</td><td>20</td><td/><td>CI)</td><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td/><td/><td>1</td><td>3</td><td>2</td><td>22</td><td>3.6%</td><td colspan=\"2\">3.67 [0.46 , 29.21]</td></tr><tr><td colspan=\"2\">Eroglu 2008 Fr\u00f6scher 1991 Kaaja 2003 20.5.1 CBZ vs PRM (cohort studies)</td><td>2</td><td>0 0 1</td><td>49 31 363</td><td>0 0 0 158</td><td>14 3 124</td><td>5.6%</td><td colspan=\"2\">Not estimable 1.03 [0.04 , 25.13] CI) Not estimable Risk Ratio (M-H, Fixed, 95%</td><td>2.84 [0.16, 51.53]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td/><td>4</td><td>490</td><td>1</td><td>119</td><td>12.2%</td><td/><td>0.97 [0.11 , 8.61]</td></tr><tr><td>Koch 1992</td><td/><td/><td>0</td><td>9</td><td>0</td><td>24</td><td/><td/><td>Not estimable</td></tr><tr><td>Meador 2006</td><td/><td/><td>0</td><td>110</td><td>0</td><td>56</td><td/><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td/><td>4</td><td>113</td><td>1</td><td>31</td><td>11.9%</td><td/><td>1.10 [0.13 , 9.47]</td></tr><tr><td>Miskov 2016</td><td/><td/><td>0</td><td>13</td><td>0</td><td>1</td><td/><td/><td>Not estimable</td></tr><tr><td>Motherisk Registry</td><td/><td/><td>1</td><td>15</td><td>0</td><td>16</td><td>3.7%</td><td colspan=\"2\">3.19 [0.14 , 72.69]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td/><td>5</td><td>1033</td><td>4</td><td>416</td><td>43.1%</td><td/><td>0.50 [0.14 , 1.87]</td></tr><tr><td>Omtzigt 1992</td><td/><td/><td>1</td><td>114</td><td>0</td><td>28</td><td>6.0%</td><td colspan=\"2\">0.76 [0.03 , 18.09]</td></tr><tr><td>Pardi 1982</td><td/><td/><td>0</td><td>6</td><td>0</td><td>5</td><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td/><td>4</td><td>1657</td><td>0</td><td>82</td><td>7.2%</td><td/><td>0.45 [0.02 , 8.30]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>4341</td><td/><td>1005</td><td>100.0%</td><td/><td>0.88 [0.43 , 1.82]</td></tr><tr><td>Total events:</td><td/><td/><td>22</td><td/><td>8</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 3.66, df = 8 (P = 0.89); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.35 (P = 0.73)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF226": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>0</td><td>2</td><td>6.1%</td><td>0.36 [0.03 , 4.63]</td></tr><tr><td>Delmi\u0161 1991</td><td>4</td><td>18</td><td>0</td><td>9</td><td>4.0%</td><td>4.74 [0.28 , 79.44]</td></tr><tr><td>Kaaja 2003</td><td>10</td><td>363</td><td>1</td><td>6</td><td>12.0%</td><td>0.17 [0.02 , 1.09]</td></tr><tr><td>Kaneko 1999</td><td>9</td><td>158</td><td>5</td><td>35</td><td>50.0%</td><td>0.40 [0.14 , 1.12]</td></tr><tr><td>Koch 1992</td><td>0</td><td>9</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>12</td><td>113</td><td>3</td><td>35</td><td>28.0%</td><td>1.24 [0.37 , 4.14]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1076</td><td/><td>112</td><td>100.0%</td><td>0.78 [0.41 , 1.48]</td></tr><tr><td>Total events:</td><td>59</td><td/><td>9</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.69, df = 4 (P = 0.15); I\u00b2 = 40%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.77 (P = 0.44)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>20.1.2 CBZ vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>0</td><td>3</td><td>100.0%</td><td>0.32 [0.02 , 4.44]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>703</td><td/><td>3</td><td>100.0%</td><td>0.32 [0.02 , 4.44]</td></tr><tr><td>Total events:</td><td>28</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.84 (P = 0.40)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PRM</td></tr><tr><td>Analysis 20.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF227": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 20.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>CBZ</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>113</td><td>0</td><td>35</td><td>100.0%</td><td>0.95 [0.04 , 22.75]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>119</td><td/><td>39</td><td>100.0%</td><td>0.95 [0.04 , 22.75]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for overall effect: Z = 0.03 (P = 0.97)</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF228": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>113</td><td>1</td><td>35</td><td>100.0%</td><td>0.11 [0.00 , 2.53]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>119</td><td/><td>39</td><td>100.0%</td><td>0.11 [0.00 , 2.53]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.39 (P = 0.17)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PRM</td></tr><tr><td>Analysis 20.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF229": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>113</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PRM</td></tr><tr><td>Analysis 20.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF230": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>4</td><td>113</td><td>0</td><td>35</td><td>100.0%</td><td>2.84 [0.16 , 51.53]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>119</td><td/><td>39</td><td>100.0%</td><td>2.</td></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.71 (P = 0.48)</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF231": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 21. CBZ vs TPM</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">21.1 CBZ vs TPM: All Major Malforma-</td><td>10</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.1.1 CBZ vs TPM (cohort studies)</td><td>8</td><td>4156</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.83 [0.51, 1.33]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.1.2 CBZ vs TPM (database studies)</td><td>2</td><td>1437</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.59 [0.17, 2.06]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.2 CBZ vs TPM: Neural Tube Malfor-</td><td>7</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.2.1 CBZ vs TPM (cohort studies)</td><td>7</td><td>4064</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.91 [0.18, 4.51]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.3 CBZ vs TPM: Cardiac Malforma-</td><td>8</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.3.1 CBZ vs TPM (cohort studies)</td><td>8</td><td>4070</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.73 [0.25, 2.12]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.4 CBZ vs TPM: Oro-Facial Cle /</td><td>7</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.4.1 CBZ vs TPM (cohort studies)</td><td>7</td><td>3571</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.33 [0.13, 0.82]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.5 CBZ vs TPM: Skeletal/Limb Mal-</td><td>7</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">21.5.1 CBZ vs TPM (cohort studies)</td><td>7</td><td>4064</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.34 [0.12, 0.94]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF232": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>2</td><td>5</td><td>0</td><td>1</td><td>2.2%</td><td>1.67 [0.13 , 22.00]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>1</td><td>53</td><td>5.2%</td><td>3.11 [0.43 , 22.52]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>0</td><td>9</td><td>2.9%</td><td>0.96 [0.06 , 14.68]</td></tr><tr><td>Melikova 2020</td><td>1</td><td>36</td><td>0</td><td>2</td><td>2.7%</td><td>0.24 [0.01 , 4.77]</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>14</td><td>1</td><td>6</td><td>4.1%</td><td>0.43 [0.03 , 5.78]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>15</td><td>359</td><td>65.8%</td><td>0.72 [0.39 , 1.31]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>3</td><td>70</td><td>17.0%</td><td>0.61 [0.19 , 1.90]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3651</td><td/><td>505</td><td>100.0%</td><td>0.83 [0.51 , 1.33]</td></tr><tr><td>Total events:</td><td>125</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.40, df = 6 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.78 (P = 0.44)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>21.1.2 CBZ vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>2</td><td>48</td><td>78.9%</td><td>0.70 [0.17 , 2.91]</td></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>0</td><td>1</td><td>21.1%</td><td>0.16 [0.01 , 1.83]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1388</td><td/><td>49</td><td>100.0%</td><td>0.59 [0.17 , 2.06]</td></tr><tr><td>Total events:</td><td>48</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.14, df = 1 (P = 0.29); I\u00b2 = 12%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.83 (P = 0.41)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours TPM</td></tr><tr><td>Analysis 21.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF233": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>331</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>490</td><td>0</td><td>9</td><td>36.6%</td><td>0.26 [0.02 , 4.39]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>0</td><td>359</td><td>27.7%</td><td>2.44 [0.13 , 47.07]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>70</td><td>35.8%</td><td>0.39 [0.02 , 7.09]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3568</td><td/><td>496</td><td>100.0%</td><td>0.</td></tr><tr><td>Total events:</td><td>13</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.50, df = 2 (P = 0.47); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.12 (P = 0.91)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF234": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 21.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF235": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>1</td><td>5</td><td>0</td><td>1</td><td>10.6%</td><td>1.00 [0.06 , 15.99]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>0</td><td>45</td><td>12.4%</td><td>1.25 [0.07 , 22.79]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>490</td><td>0</td><td>9</td><td>13.8%</td><td>0.31 [0.02 , 4.99]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>1</td><td>6</td><td>28.8%</td><td>0.16 [0.01 , 3.36]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1033</td><td>1</td><td>359</td><td>20.9%</td><td>1.04 [0.11 , 9.99]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1657</td><td>0</td><td>70</td><td>13.5%</td><td>1.24 [0.07 , 20.61]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3573</td><td/><td>497</td><td>100.0%</td><td>0.73 [0.25 , 2.12]</td></tr><tr><td>Total events:</td><td>29</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.76, df = 5 (P = 0.88); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.57 (P = 0.57)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours TPM</td></tr><tr><td>Analysis 21.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF236": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>0</td><td>45</td><td>7.2%</td><td>1.25 [0.07 , 22.79]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>5</td><td>359</td><td>61.1%</td><td>0.35 [0.10 , 1.19]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>2</td><td>70</td><td>31.6%</td><td>0.08 [0.02 , 0.45]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3083</td><td/><td>488</td><td>100.0%</td><td>0.33 [0.13 , 0.82]</td></tr><tr><td>Total events:</td><td>13</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.33, df = 2 (P = 0.19); I\u00b2 = 40%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.37 (P = 0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF237": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 22. CBZ vs VPA</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">22.1 CBZ vs VPA: All Major Malforma-</td><td>34</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.1.1 CBZ vs VPA (cohort studies)</td><td>29</td><td/><td>8090</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.44 [0.37, 0.53]</td></tr><tr><td colspan=\"3\">22.1.2 CBZ vs VPA (database studies) 5</td><td/><td>4157</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.42 [0.33, 0.54]</td></tr><tr><td colspan=\"2\">22.2 CBZ vs VPA: Neural Tube Mal-</td><td>22</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.2.1 CBZ vs VPA (cohort studies)</td><td>21</td><td/><td>7459</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.24 [0.14, 0.41]</td></tr><tr><td colspan=\"3\">22.2.2 CBZ vs VPA (database studies) 1</td><td/><td>971</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.19 [0.02, 2.09]</td></tr><tr><td colspan=\"2\">22.3 CBZ vs VPA: Cardiac Malforma-</td><td>23</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.3.1 CBZ vs VPA (cohort studies)</td><td>22</td><td/><td>7465</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.40 [0.28, 0.58]</td></tr><tr><td colspan=\"3\">22.3.2 CBZ vs VPA (database studies) 1</td><td/><td>971</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.38 [0.13, 1.08]</td></tr><tr><td colspan=\"2\">22.4 CBZ vs VPA: Oro-Facial Cle /</td><td>23</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.4.1 CBZ vs VPA (cohort studies)</td><td>22</td><td/><td>6647</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.31 [0.18, 0.54]</td></tr><tr><td colspan=\"3\">22.4.2 CBZ vs VPA (database studies) 1</td><td/><td>971</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.15 [0.03, 0.78]</td></tr><tr><td colspan=\"2\">22.5 CBZ vs VPA: Skeletal/Limb Mal-</td><td>22</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.5.1 CBZ vs VPA (cohort studies)</td><td>21</td><td/><td>7459</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.31 [0.19, 0.51]</td></tr><tr><td colspan=\"3\">22.5.2 CBZ vs VPA (database studies) 1</td><td/><td>971</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.38 [0.02, 6.07]</td></tr><tr><td/><td/><td>CBZ</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>331</td><td>0</td><td>45</td><td>8.6%</td><td>0.42 [0.02 , 10.05]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>0</td><td>9</td><td>9.6%</td><td>0.18 [0.01 , 3.18]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>14</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>5</td><td>359</td><td>72.5%</td><td>0.35 [0.10 , 1.19]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>70</td><td>9.4%</td><td>0.39 [0.02 , 7.09]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>3568</td><td/><td>496</td><td>100.0%</td><td>0.34 [0.12 , 0.94]</td></tr><tr><td>Total events:</td><td/><td>14</td><td/><td>5</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.20, df = 3 (P = 0.98); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.08 (P = 0.04)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF238": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>VPA</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>2</td><td>5</td><td>0</td><td>1</td><td>0.2%</td><td>1.67 [0.13 , 22.00]</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>24</td><td>409</td><td>43</td><td>290</td><td>15.5%</td><td>0.40 [0.25 , 0.64]</td></tr><tr><td>Cassina 2013</td><td>5</td><td>88</td><td>3</td><td>45</td><td>1.2%</td><td>0.85 [0.21 , 3.41]</td></tr><tr><td>D'Souza 1991</td><td>1</td><td>3</td><td>0</td><td>1</td><td>0.2%</td><td>1.50 [0.10 , 22.62]</td></tr><tr><td>Eroglu 2008</td><td>3</td><td>46</td><td>2</td><td>15</td><td>0.9%</td><td>0.49 [0.09 , 2.66]</td></tr><tr><td>Fairgrieve 2000</td><td>4</td><td>109</td><td>4</td><td>74</td><td>1.5%</td><td>0.68 [0.18 , 2.63]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>2</td><td>31</td><td>1</td><td>12</td><td>0.4%</td><td>0.77 [0.08 , 7.77]</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>24</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>1</td><td>8</td><td>0</td><td>8</td><td>0.2%</td><td>3.00 [0.14 , 64.26]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>4</td><td>17</td><td>0.9%</td><td>0.25 [0.02 , 4.11]</td></tr><tr><td>Kaaja 2003</td><td>10</td><td>363</td><td>4</td><td>61</td><td>2.1%</td><td>0.42 [0.14 , 1.30]</td></tr><tr><td>Kaneko 1999</td><td>9</td><td>158</td><td>9</td><td>81</td><td>3.7%</td><td>0.51 [0.21 , 1.24]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>23</td><td>490</td><td>27</td><td>341</td><td>9.8%</td><td>0.59 [0.35 , 1.02]</td></tr><tr><td>Koch 1992</td><td>0</td><td>9</td><td>3</td><td>14</td><td>0.9%</td><td>0.21 [0.01 , 3.72]</td></tr><tr><td>Lindhout 1992</td><td>5</td><td>50</td><td>5</td><td>66</td><td>1.3%</td><td>1.32 [0.40 , 4.31]</td></tr><tr><td>Martinez Ferri 2018</td><td>5</td><td>148</td><td>10</td><td>112</td><td>3.5%</td><td>0.38 [0.13 , 1.08]</td></tr><tr><td>Meador 2006 (1)</td><td>5</td><td>110</td><td>12</td><td>69</td><td>4.5%</td><td>0.26 [0.10 , 0.71]</td></tr><tr><td>Meischenguiser 2004</td><td>2</td><td>16</td><td>3</td><td>21</td><td>0.8%</td><td>0.88 [0.17 , 4.63]</td></tr><tr><td>Melikova 2020</td><td>1</td><td>36</td><td>0</td><td>27</td><td>0.2%</td><td>2.27 [0.10 , 53.66]</td></tr><tr><td>Milan Study 1999</td><td>12</td><td>113</td><td>8</td><td>44</td><td>3.5%</td><td>0.58 [0.26 , 1.33]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>Montreal Series</td><td>5</td><td>32</td><td>4</td><td>15</td><td>1.7%</td><td>0.59 [0.18 , 1.87]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>30</td><td>323</td><td>14.0%</td><td>0.32 [0.20 , 0.53]</td></tr><tr><td>Omtzigt 1992</td><td>4</td><td>114</td><td>7</td><td>60</td><td>2.8%</td><td>0.30 [0.09 , 0.99]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Steegers-Theunissen 1994</td><td>1</td><td>39</td><td>3</td><td>19</td><td>1.2%</td><td>0.16 [0.02 , 1.46]</td></tr><tr><td>Tanganelli 1992</td><td>0</td><td>9</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>82</td><td>1220</td><td>29.0%</td><td>0.39 [0.27 , 0.55]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5133</td><td/><td>2957</td><td>100.0%</td><td>0.44 [0.37 , 0.53]</td></tr><tr><td>Total events:</td><td>198</td><td/><td>264</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 16.76, df = 23 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 8.91 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>22.1.2 CBZ vs VPA (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>21</td><td>315</td><td>39</td><td>330</td><td>22.0%</td><td>0.56 [0.34 , 0.94]</td></tr><tr><td>Finland Health Record Registers</td><td>32</td><td>805</td><td>37</td><td>263</td><td>32.3%</td><td>0.28 [0.18 , 0.44]</td></tr><tr><td>Norwegian Health Record Registers</td><td>20</td><td>685</td><td>21</td><td>333</td><td>16.3%</td><td>0.46 [0.25 , 0.84]</td></tr><tr><td>Sweden Health Record Registers</td><td>28</td><td>703</td><td>26</td><td>268</td><td>21.8%</td><td>0.41 [0.25 , 0.69]</td></tr><tr><td>UK Health Record THIN Register</td><td>10</td><td>298</td><td>10</td><td>157</td><td>7.6%</td><td>0.53 [0.22 , 1.24]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2806</td><td/><td>1351</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>111</td><td/><td>133</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.63, df = 4 (P = 0.33); I\u00b2 = 14%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 6.98 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF239": {
                "text": "Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Footnotes (1) Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Risk Ratio M-H, Fixed, 95% CI 0.1 1 10 Favours CBZ 0.01 Favours VPA 100 Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF240": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Australian Epilepsy and Pregnancy Register</td></tr><tr><td>Cassina 2013</td></tr><tr><td>Eroglu 2008</td></tr><tr><td>Fairgrieve 2000</td></tr><tr><td>Fr\u00f6scher 1991</td></tr><tr><td>Hosny 2021</td></tr><tr><td>Jimenez 2020</td></tr><tr><td>Kaaja 2003</td></tr><tr><td>Kaur 2020</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td></tr><tr><td>Koch 1992</td></tr><tr><td>Martinez Ferri 2018</td></tr><tr><td>Meador 2006</td></tr><tr><td>Meischenguiser 2004</td></tr><tr><td>Melikova 2020</td></tr><tr><td>Milan Study 1999</td></tr><tr><td>Miskov 2016</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>Omtzigt 1992</td></tr><tr><td>Pardi 1982</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td></tr><tr><td>Subtotal (95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF241": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 22.3. AlSheikh 2020 Analysis 22.4.</td><td>CBZ Events 1</td><td>Total 331 Total 5</td><td>VPA Events 7 VPA Events 0</td><td>Total 247 Total 1</td><td>Weight 14.4% Weight 0.9%</td><td>Risk Ratio M-H, Fixed, 95% CI 0.05 [0.00 , 0.87] Risk Ratio M-H, Fixed, 95% CI 1.00 [0.06 , 15.99]</td><td>Risk Ratio M-H, Fixed, 95% CI Risk Ratio M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>4</td><td>88 331</td><td>1 11</td><td>45 247</td><td>3.3% 14.9%</td><td>0.17 [0.01 , 4.15] 0.27 [0.09 , 0.84]</td></tr><tr><td>Cassina 2013</td><td/><td>3</td><td>49 88</td><td>0 2</td><td>16 45</td><td>3.1%</td><td>Not estimable 0.77 [0.13 , 4.43]</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>109 49</td><td>0 0</td><td>74 16</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td/><td>3</td><td>31 109</td><td>0 1</td><td>12 74</td><td>1.4%</td><td>Not estimable 2.04 [0.22 , 19.20]</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>1</td><td>8 31</td><td>0 0</td><td>8 12</td><td>0.8%</td><td>Not estimable 1.22 [0.05 , 28.02]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>7 8</td><td>1 0</td><td>17 8</td><td>1.5%</td><td>0.75 [0.03 , 16.49] Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>363 7</td><td>2 1</td><td>61 17</td><td>5.7% 1.1%</td><td>0.25 [0.04 , 1.48] 0.75 [0.03 , 16.49]</td></tr><tr><td>Kaaja 2003</td><td/><td>2</td><td>7 363</td><td>0 2</td><td>3 61</td><td>4.1%</td><td>Not estimable 0.17 [0.02 , 1.17]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>490 7</td><td>3 0</td><td>341 3</td><td>5.9%</td><td>1.39 [0.35 , 5.53] Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>9 490</td><td>1 20</td><td>14 341</td><td>2.0% 27.9%</td><td>0.50 [0.02 , 11.09] 0.24 [0.10 , 0.57]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>148 9</td><td>3 1</td><td>112 14</td><td>5.7% 1.4%</td><td>0.25 [0.03 , 2.39] 0.50 [0.02 , 11.09]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>3</td><td>110 148</td><td>0 2</td><td>69 112</td><td>2.7%</td><td>Not estimable 1.14 [0.19 , 6.68]</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>16 110</td><td>0 4</td><td>21 69</td><td>6.5%</td><td>Not estimable 0.07 [0.00 , 1.28]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>36 16</td><td>0 1</td><td>27 21</td><td>1.5%</td><td>Not estimable 0.43 [0.02 , 9.94]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>113 36</td><td>5 0</td><td>44 27</td><td>12.0%</td><td>0.08 [0.01 , 0.65] Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>13 113</td><td>0 0</td><td>6 44</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1033 13</td><td>4 0</td><td>323 6</td><td>10.2%</td><td>0.23 [0.05 , 1.04] Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>3</td><td>114 1033</td><td>6 8</td><td>60 323</td><td>14.2% 14.4%</td><td>0.04 [0.00 , 0.71] 0.12 [0.03 , 0.44]</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>6 114</td><td>0 0</td><td>1 60</td><td/><td>Not estimable Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>1657 6</td><td>13 0</td><td>1220 1</td><td>25.0%</td><td>0.23 [0.07 , 0.69] Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>4738 1657</td><td>14</td><td>2721 1220</td><td>100.0% 19.1%</td><td>0.24 [0.14 , 0.41] 0.74 [0.35 , 1.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>18</td><td>4743</td><td>46</td><td>2722</td><td>100.0%</td><td>0.40 [0.28 , 0.58]</td></tr><tr><td>Total events:</td><td/><td>41</td><td/><td>67</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 14.82, df = 13 (P = 0.32); I\u00b2 = 12%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 4.82 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.3.2 CBZ vs VPA (database studies)</td><td>1</td><td>703</td><td>2</td><td>268</td><td>100.0%</td><td>0.19 [0.02 , 2.09]</td></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>7</td><td>703 703</td><td>7</td><td>268 268</td><td>100.0% 100.0%</td><td>0.19 [0.02 , 2.09] 0.38 [0.13 , 1.08]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td>703</td><td>2</td><td>268</td><td>100.0%</td><td>0.38 [0.13 , 1.08]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.82 (P = 0.07)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td colspan=\"2\">Favours CBZ 0.01 0.1</td><td>1</td><td>Favours VPA 10 100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF242": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 22.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">CBZ</td><td/><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>5</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>4</td><td>331</td><td>8</td><td>247</td><td>20.1%</td><td>0.37 [0.11 , 1.23]</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>88</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>49</td><td>1</td><td>16</td><td>4.9%</td><td>0.11 [0.00 , 2.65]</td></tr><tr><td>Fairgrieve 2000</td><td/><td>0</td><td>109</td><td>1</td><td>74</td><td>3.9%</td><td>0.23 [0.01 , 5.50]</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>0</td><td>31</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>8</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>7</td><td>1</td><td>17</td><td>2.0%</td><td>0.75 [0.03 , 16.49]</td></tr><tr><td>Kaaja 2003</td><td/><td>2</td><td>363</td><td>1</td><td>61</td><td>3.8%</td><td>0.34 [0.03 , 3.65]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>7</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>7</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>9</td><td>1</td><td>14</td><td>2.6%</td><td>0.50 [0.02 , 11.09]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>0</td><td>148</td><td>2</td><td>112</td><td>6.2%</td><td>0.15 [0.01 , 3.13]</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>110</td><td>1</td><td>69</td><td>4.0%</td><td>0.21 [0.01 , 5.09]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>16</td><td>2</td><td>21</td><td>4.8%</td><td>0.26 [0.01 , 5.04]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>36</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>113</td><td>0</td><td>44</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>13</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>4</td><td>323</td><td>13.4%</td><td>0.39 [0.11 , 1.45]</td></tr><tr><td>Omtzigt 1992</td><td/><td>1</td><td>114</td><td>0</td><td>60</td><td>1.4%</td><td>1.59 [0.07 , 38.48]</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>13</td><td>1220</td><td>32.8%</td><td>0.23 [0.07 , 0.69]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4260</td><td/><td>2387</td><td>100.0%</td><td>0.31 [0.18 , 0.54]</td></tr><tr><td>Total events:</td><td colspan=\"2\">16</td><td/><td>35</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.65, df = 11 (P = 0.99); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 4.12 (P &lt; 0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">22.4.2 CBZ vs VPA (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>2</td><td>703</td><td>5</td><td>268</td><td>100.0%</td><td>0.15 [0.03 , 0.78]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>703</td><td/><td>268</td><td>100.0%</td><td>0.15 [0.03 , 0.78]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>5</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.26 (P = 0.02)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF243": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>331</td><td>14</td><td>247</td><td>28.6%</td><td>0.05 [0.01 , 0.40]</td></tr><tr><td>Cassina 2013</td><td>0</td><td>88</td><td>2</td><td>45</td><td>5.9%</td><td>0.10 [0.01 , 2.11]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>49</td><td>0</td><td>16</td><td/><td>Not estimable</td></tr><tr><td>Fairgrieve 2000</td><td>0</td><td>109</td><td>1</td><td>74</td><td>3.2%</td><td>0.23 [0.01 , 5.50]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>31</td><td>1</td><td>12</td><td>3.8%</td><td>0.14 [0.01 , 3.11]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>8</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>17</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>1</td><td>363</td><td>1</td><td>61</td><td>3.1%</td><td>0.17 [0.01 , 2.65]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>7</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>490</td><td>4</td><td>341</td><td>8.4%</td><td>0.70 [0.18 , 2.76]</td></tr><tr><td>Koch 1992</td><td>0</td><td>9</td><td>2</td><td>14</td><td>3.6%</td><td>0.30 [0.02 , 5.61]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>148</td><td>0</td><td>112</td><td>1.0%</td><td>3.79 [0.18 , 78.21]</td></tr><tr><td>Meador 2006</td><td>0</td><td>110</td><td>1</td><td>69</td><td>3.3%</td><td>0.21 [0.01 , 5.09]</td></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>16</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>36</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>4</td><td>113</td><td>1</td><td>44</td><td>2.6%</td><td>1.56 [0.18 , 13.55]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>13</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>1033</td><td>5</td><td>323</td><td>13.6%</td><td>0.31 [0.09 , 1.07]</td></tr><tr><td>Omtzigt 1992</td><td>1</td><td>114</td><td>1</td><td>60</td><td>2.3%</td><td>0.53 [0.03 , 8.27]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>10</td><td>1220</td><td>20.6%</td><td>0.29 [0.09 , 0.94]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4748</td><td/><td>2711</td><td>100.0%</td><td>0.31 [0.19 , 0.51]</td></tr><tr><td>Total events:</td><td>22</td><td/><td>43</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 10.22, df = 12 (P = 0.60); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 4.59 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>22.5.2 CBZ vs VPA (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>1</td><td>703</td><td>1</td><td>268</td><td>100.0%</td><td>0.38 [0.02 , 6.07]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>703</td><td/><td>268</td><td>100.0%</td><td>0.38 [0.02 , 6.07]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.68 (P = 0.49)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF244": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">23.4 CBZ vs ZNS: Oro-Facial Cle /</td><td>3</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/></tr><tr><td colspan=\"2\">23.4.1 CBZ vs ZNS (cohort studies)</td><td>3</td><td>1718</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.15 [0.01, 2.66]</td></tr><tr><td colspan=\"2\">23.5 CBZ vs ZNS: Skeletal/Limb Mal-</td><td>3</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">23.5.1 CBZ vs ZNS (cohort studies)</td><td>3</td><td>1718</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.15 [0.01, 2.66]</td></tr><tr><td colspan=\"2\">Analysis 23.1.</td><td/><td/><td/></tr><tr><td colspan=\"2\">23.1 CBZ vs ZNS: All Major Malfor-</td><td>4</td><td/><td>Risk Ratio (M-H, Random, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">23.1.1 CBZ vs ZNS (cohort studies)</td><td>4</td><td>2841</td><td>Risk Ratio (M-H, Random, 95%</td><td>0.86 [0.07, 10.35]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">23.2 CBZ vs ZNS: Neural Tube Mal-</td><td>3</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">23.2.1 CBZ vs ZNS (cohort studies)</td><td>3</td><td>1718</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.06 [0.01, 0.54]</td></tr><tr><td colspan=\"2\">23.3 CBZ vs ZNS: Cardiac Malforma-</td><td>3</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">23.3.1 CBZ vs ZNS (cohort studies)</td><td>3</td><td>1718</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.47 [0.03, 7.72]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF245": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>14</td><td>1</td><td>13</td><td>29.7%</td><td>0.93 [0.06 , 13.37]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1033</td><td>0</td><td>90</td><td>28.8%</td><td>5.54 [0.34 , 89.86]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>43</td><td>1657</td><td>3</td><td>26</td><td>41.5%</td><td>0.22 [0.07 , 0.68]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2711</td><td/><td>130</td><td>100.0%</td><td>0.86 [0.07 , 10.35]</td></tr><tr><td>Total events:</td><td>75</td><td/><td>4</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau\u00b2 = 3.56; Chi\u00b2 = 8.00, df = 2 (P = 0.02); I\u00b2 = 75%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.12 (P = 0.91)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours ZNS</td></tr><tr><td>Analysis 23.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF246": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>1</td><td>26</td><td>100.0%</td><td>0.06 [0.01 , 0.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1678</td><td/><td>40</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>4</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.52 (P = 0.01)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF247": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 23.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CBZ</td><td colspan=\"2\">Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF248": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CBZ</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1657</td><td>0</td><td>26</td><td>100.0%</td><td>0.47 [0.03 , 7.72]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1678</td><td/><td>40</td><td>100.0%</td><td>0.47 [0.03 , 7.72]</td></tr><tr><td>Total events:</td><td>14</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.53 (P = 0.60)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours ZNS</td></tr><tr><td>Analysis 23.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF249": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>26</td><td>100.0%</td><td>0.15 [0.01 , 2.66]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1678</td><td/><td>40</td><td>100.0%</td><td>0.15 [0.01 , 2.66]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.30 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours ZNS</td></tr><tr><td>Analysis 23.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF250": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>14</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>4</td><td>1657</td><td>0</td><td>26</td><td>100.0%</td><td>0.15 [0.01 , 2.66]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1678</td><td/><td>40</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.30 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF251": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">24.1.2 GBP vs LTG (database studies)</td><td>1</td><td>108</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.53 [0.03, 9.48]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.2 GPB vs LTG: Neural Tube Malfor-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.2.1 GBP vs LTG (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.3 GPB vs LTG: Cardiac Malforma-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.3.1 GBP vs LTG (cohort studies)</td><td>2</td><td>368</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>9.57 [1.69, 54.15]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.4 GPB vs LTG: Oro-Facial Cle /Cran-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.4.1 GBP vs LTG (cohort studies)</td><td>1</td><td>329</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.92 [0.11, 33.05]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.5 GPB vs LTG: Skeletal/Limb Malfor-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.5.1 GBP vs LTG (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 24.1</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Comparison 24. GBP vs LTG</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">24.1 GPB vs LTG: All Major Malforma-</td><td>5</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">24.1.1 GBP vs LTG (cohort studies)</td><td>4</td><td>4295</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.92 [0.34, 2.47]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF252": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 24.2.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">GBP</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>20</td><td>406</td><td>17.7%</td><td>0.66 [0.04 , 10.43]</td></tr><tr><td>Miskov 2016</td><td/><td>1</td><td>2</td><td>0</td><td>37</td><td>0.9%</td><td>38.00 [1.94 , 745.87]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>31</td><td>1562</td><td>64.0%</td><td>0.35 [0.05 , 2.53]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>31</td><td>49</td><td>2098</td><td>17.4%</td><td>1.38 [0.20 , 9.69]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>192</td><td/><td>4103</td><td>100.0%</td><td>0.92 [0.34 , 2.47]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>100</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 7.15, df = 3 (P = 0.07); I\u00b2 = 58%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.17 (P = 0.87)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">24.1.2 GBP vs LTG (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>18</td><td>4</td><td>90</td><td>100.0%</td><td>0.53 [0.03 , 9.48]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>18</td><td/><td>90</td><td>100.0%</td><td>0.53 [0.03 , 9.48]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>4</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.43 (P = 0.67)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours GBP</td><td>Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF253": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>24.2.1 GBP vs LTG (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>315</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours LTG</td></tr><tr><td>Analysis 24.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF254": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>24.3.1 GBP vs LTG (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>3</td><td>315</td><td>81.3%</td><td>3.01 [0.16 , 55.67]</td><td/></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>37</td><td>18.7%</td><td>38.00 [1.94 , 745.87]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>16</td><td/><td>352</td><td>100.0%</td><td>9.57 [1.69 , 54.15]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.43, df = 1 (P = 0.23); I\u00b2 = 30%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.55 (P = 0.01)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours LTG</td></tr><tr><td>Analysis 24.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF255": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">LTG</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td/><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>5</td><td>315</td><td>100.0%</td><td>1.92 [0.11 , 33.05]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>14</td><td/><td>315</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>0</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.45 (P = 0.65)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF256": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">Risk Ratio</td><td/></tr><tr><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td colspan=\"2\">Favours GBP</td><td colspan=\"2\">Favours LTG</td></tr><tr><td>Analysis 24.5.</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF257": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 25. GBP vs OXC</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td colspan=\"2\">25.1 GBP vs OXC: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.1.1 GBP vs OXC (cohort studies)</td><td>3</td><td/><td>363</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.53 [0.13, 2.17]</td></tr><tr><td colspan=\"2\">25.1.2 GBP vs OXC (database study)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">25.2 GBP vs OXC: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.2.1 GBP vs OXC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">25.3 GBP vs OXC: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.3.1 GBP vs OXC (cohort studies)</td><td>2</td><td/><td>28</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>3.00 [0.24, 37.67]</td></tr><tr><td colspan=\"2\">25.4 GBP vs OXC: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.4.1 GBP vs OXC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">25.5 GBP vs OXC: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.5.1 GBP vs OXC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">24.5.1 GBP vs LTG (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>315</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF258": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 25.2.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">GBP</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>1</td><td>19</td><td>23.7%</td><td>0.44 [0.02 , 10.16]</td></tr><tr><td>Miskov 2016</td><td/><td>1</td><td>2</td><td>0</td><td>1</td><td>11.0%</td><td>2.00 [0.14 , 28.42]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>4</td><td>182</td><td>65.3%</td><td>0.31 [0.04 , 2.78]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>161</td><td/><td>202</td><td>100.0%</td><td>0.53 [0.13 , 2.17]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>5</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.20, df = 2 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.88 (P = 0.38)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">25.1.2 GBP vs OXC (database study)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>18</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours GBP</td><td>Favours OCX</td></tr></table>",
                "type_str": "table"
            },
            "TABREF259": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>25.2.1 GBP vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>12</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours OXC</td></tr><tr><td>Analysis 25.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF260": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">OXC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>1</td><td>1</td><td>0</td><td>1</td><td>100.0%</td><td>3.00 [0.24 , 37.67]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>15</td><td/><td>13</td><td>100.0%</td><td>3.00 [0.24 , 37.67]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.85 (P = 0.39)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours OXC</td></tr><tr><td>Analysis 25.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF261": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>12</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours OXC</td></tr><tr><td>Analysis 25.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF262": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 26. GBP vs PB</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">26.1 GBP vs PB: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">26.1.1 GBP vs PB (cohort studies)</td><td>3</td><td/><td>365</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.30 [0.08, 1.14]</td></tr><tr><td colspan=\"2\">26.1.2 GBP vs PB (database studies)</td><td>1</td><td/><td>25</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.14 [0.01, 3.09]</td></tr><tr><td colspan=\"2\">26.2 GBP vs PB: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">26.2.1 GBP vs PB (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">26.3 GBP vs PB: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">26.3.1 GBP vs PB (cohort studies)</td><td>2</td><td/><td>24</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>4.00 [0.24, 67.71]</td></tr><tr><td colspan=\"2\">26.4 GBP vs PB: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">26.4.1 GBP vs PB (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">26.5 GBP vs PB: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">26.5.1 GBP vs PB (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">25.5.1 GBP vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF263": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td/><td>PB</td><td/><td/></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>2</td><td/></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>3</td><td>4.4%</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>11</td><td>199</td><td>95.6%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>161</td><td/><td>204</td><td>100.0%</td></tr><tr><td>Total events:</td><td>2</td><td/><td>11</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.95, df = 1 (P = 0.05); I\u00b2 = 75%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.78 (P = 0.08)</td><td/><td/><td/><td/><td/></tr><tr><td>26.1.2 GBP vs PB (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>18</td><td>1</td><td>7</td><td>100.0%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>18</td><td/><td>7</td><td>100.0%</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.24 (P = 0.21)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF264": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 26.2.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>4.00 [0.24 , 67.71]</td><td/><td/></tr><tr><td/><td/><td>0.12 [0.02 , 0.96]</td><td/><td/></tr><tr><td/><td/><td>0.30 [0.08 , 1.14]</td><td/><td/></tr><tr><td/><td/><td>0.14 [0.01 , 3.09]</td><td/><td/></tr><tr><td/><td/><td>0.14 [0.01 , 3.09]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours GBP</td><td colspan=\"2\">Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF265": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>26.2.1 GBP vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours PB</td></tr><tr><td>Analysis 26.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF266": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>1</td><td>2</td><td>0</td><td>3</td><td>100.0%</td><td>4.00 [0.24 , 67.71]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>16</td><td/><td>8</td><td>100.0%</td><td>4.00 [0.24 , 67.71]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.96 (P = 0.34)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours PB</td></tr><tr><td>Analysis 26.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF267": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td/><td>PB</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>5</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours PB</td></tr><tr><td>Analysis 26.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF268": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 27. GBP vs PRM</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td colspan=\"2\">27.1 GBP vs PRM: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">27.1.1 GBP vs PRM (database studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 27.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">26.5.1 GBP vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF269": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">28.5 GBP vs TPM: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">28.5.1 GBP vs TPM (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 28.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>18</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours GBP</td><td>Favours PRM</td></tr><tr><td colspan=\"2\">Comparison 28. GBP vs TPM</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">28.1 GBP vs TPM: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">28.1.1 GBP vs TPM (cohort studies)</td><td>3</td><td/><td/><td>672</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.32 [0.09, 1.19]</td></tr><tr><td colspan=\"2\">28.1.2 GBP vs TPM (database studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">28.2 GBP vs TPM: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">28.2.1 GBP vs TPM (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">28.3 GBP vs TPM: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">28.3.1 GBP vs TPM (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">28.4 GBP vs TPM: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">28.4.1 GBP vs TPM (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF270": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>28.1.1 GBP vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>1</td><td>53</td><td>5.9%</td><td>1.20 [0.05 , 27.98]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>15</td><td>359</td><td>77.6%</td><td>0.17 [0.02 , 1.24]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>31</td><td>3</td><td>70</td><td>16.6%</td><td>0.75 [0.08 , 6.95]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>190</td><td/><td>482</td><td>100.0%</td><td>0.32 [0.09 , 1.19]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>19</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.65, df = 2 (P = 0.44); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.70 (P = 0.09)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>28.1.2 GBP vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>18</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours TPM</td></tr><tr><td>Analysis 28.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF271": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 28.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">GBP</td><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>44</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF272": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>28.3.1 GBP vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>44</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours TPM</td></tr><tr><td>Analysis 28.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF273": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">GBP</td><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>44</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours TPM</td></tr><tr><td>Analysis 28.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF274": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 29.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>44</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours GBP</td><td>Favours TPM</td></tr><tr><td colspan=\"2\">Comparison 29. GBP vs ZNS</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">29.1 GBP vs ZNS: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">29.1.1 GBP vs ZNS (cohort studies)</td><td>2</td><td/><td>292</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.53 [0.10, 2.76]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF275": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 30.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>145</td><td>0</td><td>90</td><td>15.9%</td><td>1.87 [0.08 , 45.41]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>31</td><td>3</td><td>26</td><td>84.1%</td><td>0.28 [0.03 , 2.53]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>176</td><td/><td>116</td><td>100.0%</td><td>0.53 [0.10 , 2.76]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>3</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.92, df = 1 (P = 0.34); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.75 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours GBP</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Comparison 30. LEV vs GBP</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">30.1 LEV vs GBP: All Major Malforma-</td><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.1.1 LEV vs GBP (cohort studies)</td><td>3</td><td/><td>1083</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.61 [0.46, 5.63]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.2 LEV vs GBP: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.2.1 LEV vs GBP (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.3 LEV vs GBP: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.3.1 LEV vs GBP (cohort studies)</td><td>1</td><td/><td>77</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.70 [0.03, 16.42]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.4 LEV vs GBP: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.4.1 LEV vs GBP (cohort studies)</td><td>1</td><td/><td>77</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.70 [0.03, 16.42]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.5 LEV vs GBP: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formation</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">30.5.1 LEV vs GBP (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF276": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>0</td><td>14</td><td>21.3%</td><td>1.18 [0.07 , 20.29]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>1</td><td>145</td><td>35.8%</td><td>3.54 [0.46 , 27.22]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>1</td><td>31</td><td>42.9%</td><td>0.20 [0.02 , 2.19]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>893</td><td/><td>190</td><td>100.0%</td><td>1.61 [0.46 , 5.63]</td></tr><tr><td>Total events:</td><td>18</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.53, df = 2 (P = 0.17); I\u00b2 = 43%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.74 (P = 0.46)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours GBP</td></tr><tr><td>Analysis 30.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF277": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td colspan=\"2\">GBP</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>63</td><td>0</td><td>14</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours GBP</td></tr><tr><td>Analysis 30.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF278": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td colspan=\"2\">GBP</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>63</td><td>0</td><td>14</td><td>100.0%</td><td>0.70 [0.03 , 16.42]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>63</td><td/><td>14</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.22 (P = 0.83)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF279": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">Risk Ratio</td><td/></tr><tr><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td colspan=\"2\">Favours LEV</td><td colspan=\"2\">Favours GBP</td></tr><tr><td>Analysis 30.4.</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF280": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 30.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LEV</td><td colspan=\"2\">GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">30.4.1 LEV vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>63</td><td>0</td><td>14</td><td>100.0%</td><td>0.70 [0.03 , 16.42]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>63</td><td/><td>14</td><td>100.0%</td><td>0.70 [0.03 , 16.42]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.22 (P = 0.83)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF281": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 31.1</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LEV</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">30.5.1 LEV vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>63</td><td>0</td><td>14</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours GBP</td></tr><tr><td colspan=\"2\">Comparison 31. LEV vs LTG</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">31.1 LEV vs LTG: All Major Malforma-</td><td/><td/><td/><td/><td/><td/></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF282": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>20</td><td>406</td><td>23.0%</td><td>0.73 [0.28 , 1.91]</td></tr><tr><td>Hosny 2021</td><td>2</td><td>67</td><td>0</td><td>3</td><td>2.1%</td><td>0.29 [0.02 , 5.16]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>106</td><td>1</td><td>50</td><td>3.1%</td><td>2.36 [0.28 , 19.66]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>31</td><td>2</td><td>111</td><td>2.0%</td><td>3.58 [0.53 , 24.40]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>5</td><td>99</td><td>5</td><td>113</td><td>10.5%</td><td>1.14 [0.34 , 3.83]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>31</td><td>1562</td><td>31.3%</td><td>1.23 [0.62 , 2.43]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>49</td><td>2098</td><td>28.0%</td><td>0.28 [0.07 , 1.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1223</td><td/><td>4389</td><td>100.0%</td><td>0.90 [0.58 , 1.39]</td></tr><tr><td>Total events:</td><td>32</td><td/><td>108</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 7.12, df = 6 (P = 0.31); I\u00b2 = 16%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.47 (P = 0.64)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>31.1.2 LEV vs LTG (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>5</td><td>130</td><td>47</td><td>1235</td><td>56.3%</td><td>1.01 [0.41 , 2.50]</td></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>118</td><td>28</td><td>833</td><td>43.7%</td><td>0.50 [0.12 , 2.09]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>248</td><td/><td>2068</td><td>100.0%</td><td>0.79 [0.37 , 1.69]</td></tr><tr><td>Total events:</td><td>7</td><td/><td>75</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.67, df = 1 (P = 0.41); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.61 (P = 0.54)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours LTG</td></tr><tr><td>Analysis 31.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF283": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>282</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>67</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>0</td><td>50</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>31</td><td>0</td><td>111</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>113</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>2</td><td>1562</td><td>58.5%</td><td>1.74 [0.16 , 19.10]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>2</td><td>2098</td><td>41.5%</td><td>1.38 [0.07 , 28.60]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1128</td><td/><td>4245</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>1</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.01, df = 1 (P = 0.91); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.48 (P = 0.63)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF284": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 31.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LEV</td><td colspan=\"2\">Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF285": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>4</td><td>282</td><td>13.9%</td><td>1.33 [0.15 , 11.67]</td></tr><tr><td>Hosny 2021</td><td>1</td><td>67</td><td>0</td><td>3</td><td>10.3%</td><td>0.18 [0.01 , 3.68]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>1</td><td>50</td><td>14.9%</td><td>1.42 [0.15 , 13.27]</td></tr><tr><td>Martinez Ferri 2018</td><td>1</td><td>31</td><td>2</td><td>111</td><td>9.6%</td><td>1.79 [0.17 , 19.10]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>3</td><td>99</td><td>1</td><td>113</td><td>10.2%</td><td>3.42 [0.36 , 32.39]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>3</td><td>1562</td><td>14.7%</td><td>1.16 [0.12 , 11.10]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>9</td><td>2098</td><td>26.4%</td><td>0.36 [0.02 , 6.21]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1125</td><td/><td>4246</td><td>100.0%</td><td>1.20 [0.51 , 2.85]</td></tr><tr><td>Total events:</td><td>10</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.19, df = 6 (P = 0.78); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.41 (P = 0.68)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours LTG</td></tr><tr><td>Analysis 31.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF286": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 31.5.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LEV</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>9</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>4</td><td>282</td><td>24.1%</td><td>1.33 [0.15 , 11.67]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>67</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>0</td><td>31</td><td>0</td><td>111</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>6</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>99</td><td>0</td><td>113</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>7</td><td>1562</td><td>63.9%</td><td>0.23 [0.01 , 4.04]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>2</td><td>2098</td><td>12.1%</td><td>1.38 [0.07 , 28.60]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1019</td><td/><td>4196</td><td>100.0%</td><td>0.63 [0.15 , 2.68]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>13</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.18, df = 2 (P = 0.56); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.62 (P = 0.54)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LEV</td><td>Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF287": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 32.1</td><td>LEV</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">31.5.1 LEV vs LTG (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>2</td><td>282</td><td>15.7%</td><td>1.05 [0.05 , 21.53]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>67</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>12</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>0</td><td>50</td><td>13.3%</td><td>2.38 [0.12 , 48.74]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>1</td><td>31</td><td>0</td><td>111</td><td>4.3%</td><td>10.50 [0.44 , 251.58]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>6</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>99</td><td>1</td><td>113</td><td>27.4%</td><td>0.38 [0.02 , 9.22]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>2</td><td>1562</td><td>21.9%</td><td>0.69 [0.03 , 14.41]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>3</td><td>2098</td><td>17.4%</td><td>0.98 [0.05 , 18.99]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1128</td><td/><td>4245</td><td>100.0%</td><td>1.36 [0.45 , 4.13]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>8</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.60, df = 5 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.55 (P = 0.58)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours LTG</td></tr><tr><td colspan=\"2\">Comparison 32. LEV vs OXC</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">32.1 LEV vs OXC: All Major Malforma-</td><td>10</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.1.1 LEV vs OXC (cohort studies)</td><td>8</td><td/><td>1166</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.04 [0.51, 2.09]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.1.2 LEV vs OXC (database studies)</td><td>2</td><td/><td>621</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.17 [0.45, 3.06]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.2 LEV vs OXC: Neural Tube Malfor-</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.2.1 LEV vs OXC (cohort studies)</td><td>7</td><td/><td>1058</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.22 [0.05, 29.74]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.3 LEV vs OXC: Cardiac Malforma-</td><td>8</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.3.1 LEV vs OXC (cohort studies)</td><td>8</td><td/><td>1070</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.93 [0.31, 2.76]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.4 LEV vs OXC: Oro-Facial Cle /</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.4.1 LEV vs OXC (cohort studies)</td><td>7</td><td/><td>893</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.25 [0.03, 2.12]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.5 LEV vs OXC: Skeletal/Limb Mal-</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">32.5.1 LEV vs OXC (cohort studies)</td><td>7</td><td/><td>1058</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.80 [0.20, 3.29]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF288": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>32.1.1 LEV vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>1</td><td>19</td><td>12.0%</td><td>0.68 [0.08 , 5.54]</td><td/></tr><tr><td>Hosny 2021</td><td>2</td><td>67</td><td>0</td><td>31</td><td>4.6%</td><td>2.35 [0.12 , 47.60]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>106</td><td>5</td><td>71</td><td>40.7%</td><td>0.67 [0.20 , 2.23]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>31</td><td>0</td><td>22</td><td>4.0%</td><td>3.59 [0.18 , 71.37]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>4</td><td>182</td><td>38.7%</td><td>1.11 [0.36 , 3.45]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>833</td><td/><td>333</td><td>100.0%</td><td>1.04 [0.51 , 2.09]</td><td/></tr><tr><td>Total events:</td><td>25</td><td/><td>10</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.62, df = 4 (P = 0.80); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.10 (P = 0.92)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>32.1.2 LEV vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>5</td><td>130</td><td>10</td><td>316</td><td>81.2%</td><td>1.22 [0.42 , 3.49]</td><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>118</td><td>1</td><td>57</td><td>18.8%</td><td>0.97 [0.09 , 10.43]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>248</td><td/><td>373</td><td>100.0%</td><td>1.17 [0.45 , 3.06]</td><td/></tr><tr><td>Total events:</td><td>7</td><td/><td>11</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.03, df = 1 (P = 0.86); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.32 (P = 0.75)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours OXC</td></tr><tr><td>Analysis 32.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF289": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>32.2.1 LEV vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>67</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>0</td><td>71</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>31</td><td>0</td><td>22</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>0</td><td>182</td><td>100.0%</td><td>1.22 [0.05 , 29.74]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>738</td><td/><td>320</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.12 (P = 0.90)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF290": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 32.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LEV</td><td colspan=\"2\">Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF291": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>32.3.1 LEV vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>0</td><td>9</td><td>13.2%</td><td>0.56 [0.02 , 12.69]</td><td/></tr><tr><td>Hosny 2021</td><td>1</td><td>67</td><td>0</td><td>31</td><td>10.6%</td><td>1.41 [0.06 , 33.71]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>3</td><td>71</td><td>56.1%</td><td>0.67 [0.14 , 3.23]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>1</td><td>31</td><td>0</td><td>22</td><td>9.1%</td><td>2.16 [0.09 , 50.59]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>0</td><td>182</td><td>11.1%</td><td>1.22 [0.05 , 29.74]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>747</td><td/><td>323</td><td>100.0%</td><td>0.93 [0.31 , 2.76]</td><td/></tr><tr><td>Total events:</td><td>7</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.64, df = 4 (P = 0.96); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.13 (P = 0.89)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours OXC</td></tr><tr><td>Analysis 32.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF292": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>32.4.1 LEV vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>0</td><td>9</td><td>28.3%</td><td>0.56 [0.02 , 12.69]</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>67</td><td>0</td><td>31</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>31</td><td>0</td><td>22</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>1</td><td>182</td><td>71.7%</td><td>0.14 [0.01 , 3.30]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>641</td><td/><td>252</td><td>100.0%</td><td>0.25 [0.03 , 2.12]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.39, df = 1 (P = 0.53); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.26 (P = 0.21)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours OXC</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF293": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 33. LEV vs PB Analysis 33.1</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">33.1 LEV vs PB: All Major Malforma-</td><td>6</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.1.1 LEV vs PB (cohort studies)</td><td>5</td><td/><td>1067</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.54 [0.29, 1.02]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.1.2 LEV vs PB (database studies)</td><td>1</td><td/><td>145</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.23 [0.03, 1.55]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.2 LEV vs PB: Neural Tube Malfor-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.2.1 LEV vs PB (cohort studies)</td><td>5</td><td/><td>994</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.74 [0.08, 6.51]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.3 LEV vs PB: Cardiac Malforma-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.3.1 LEV vs PB (cohort studies)</td><td>5</td><td/><td>994</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.33 [0.12, 0.88]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.4 LEV vs PB: Oro-Facial Cle /Cran-</td><td>4</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.4.1 LEV vs PB (cohort studies)</td><td>4</td><td/><td>751</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.08 [0.01, 0.67]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.5 LEV vs PB: Skeletal/Limb Malfor-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mation</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">33.5.1 LEV vs PB (cohort studies)</td><td>5</td><td/><td>994</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.67 [0.15, 2.94]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td>LEV</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">32.5.1 LEV vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>67</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>1</td><td>71</td><td>30.6%</td><td>1.34 [0.12 , 14.50]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>1</td><td>31</td><td>0</td><td>22</td><td>14.9%</td><td>2.16 [0.09 , 50.59]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>1</td><td>182</td><td>54.5%</td><td>0.14 [0.01 , 3.30]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>738</td><td/><td>320</td><td>100.0%</td><td>0.80 [0.20 , 3.29]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>2</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 1.75, df = 2 (P = 0.42); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.30 (P = 0.76)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF294": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>0</td><td>2</td><td>4.2%</td><td>0.24 [0.02 , 3.37]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>106</td><td>8</td><td>137</td><td>30.1%</td><td>0.81 [0.27 , 2.40]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>11</td><td>199</td><td>65.7%</td><td>0.44 [0.19 , 1.00]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>726</td><td/><td>341</td><td>100.0%</td><td>0.54 [0.29 , 1.02]</td></tr><tr><td>Total events:</td><td>21</td><td/><td>19</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.13, df = 2 (P = 0.57); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.89 (P = 0.06)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>33.1.2 LEV vs PB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>118</td><td>2</td><td>27</td><td>100.0%</td><td>0.23 [0.03 , 1.55]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>118</td><td/><td>27</td><td>100.0%</td><td>0.23 [0.03 , 1.55]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.51 (P = 0.13)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PB</td></tr><tr><td>Analysis 33.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF295": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>33.2.1 LEV vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>63</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>1</td><td>137</td><td>65.4%</td><td>0.43 [0.02 , 10.45]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>0</td><td>199</td><td>34.6%</td><td>1.33 [0.05 , 32.52]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>650</td><td/><td>344</td><td>100.0%</td><td>0.74 [0.08 , 6.51]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.24, df = 1 (P = 0.62); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.27 (P = 0.79)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF296": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 33.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LEV</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">33.3.1 LEV vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>63</td><td>0</td><td>5</td><td>7.0%</td><td>0.28 [0.01 , 6.18]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>6</td><td>137</td><td>40.0%</td><td>0.65 [0.17 , 2.52]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>5</td><td>199</td><td>53.0%</td><td>0.09 [0.01 , 0.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>650</td><td/><td>344</td><td>100.0%</td><td>0.33 [0.12 , 0.88]</td></tr><tr><td>Total events:</td><td/><td>5</td><td/><td>11</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.41, df = 2 (P = 0.30); I\u00b2 = 17%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.22 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF297": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>33.4.1 LEV vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>63</td><td>0</td><td>5</td><td>12.8%</td><td>0.28 [0.01 , 6.18]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>4</td><td>199</td><td>87.2%</td><td>0.05 [0.00 , 0.91]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>544</td><td/><td>207</td><td>100.0%</td><td>0.08 [0.01 , 0.67]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>4</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.75, df = 1 (P = 0.39); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.32 (P = 0.02)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PB</td></tr><tr><td>Analysis 33.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF298": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>63</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>2</td><td>137</td><td>45.6%</td><td>1.29 [0.19 , 9.03]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>1</td><td>199</td><td>54.4%</td><td>0.15 [0.01 , 3.61]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>650</td><td/><td>344</td><td>100.0%</td><td>0.67 [0.15 , 2.94]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.30, df = 1 (P = 0.25); I\u00b2 = 23%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.53 (P = 0.60)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PB</td></tr><tr><td>Comparison 34.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF299": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">34.4.1 LEV vs PHT (cohort studies)</td><td>3</td><td>1349</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.37 [0.09, 1.61]</td></tr><tr><td colspan=\"2\">34.5 LEV vs PHT: Skeletal/Limb Mal-</td><td>4</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">34.5.1 LEV vs PHT (cohort studies)</td><td>4</td><td>1574</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.46 [0.11, 1.96]</td></tr><tr><td colspan=\"2\">Analysis 34.1.</td><td/><td/><td/></tr><tr><td colspan=\"2\">34.1 LEV vs PHT: All Major Malforma-</td><td>5</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">34.1.1 LEV vs PHT (cohort studies)</td><td>5</td><td>1705</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.58 [0.34, 0.97]</td></tr><tr><td colspan=\"2\">34.2 LEV vs PHT: Neural Tube Mal-</td><td>4</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">34.2.1 LEV vs PHT (cohort studies)</td><td>4</td><td>1574</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.68 [0.13, 3.44]</td></tr><tr><td colspan=\"2\">34.3 LEV vs PHT: Cardiac Malforma-</td><td>4</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">34.3.1 LEV vs PHT (cohort studies)</td><td>4</td><td>1572</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.43 [0.16, 1.13]</td></tr><tr><td colspan=\"2\">34.4 LEV vs PHT: Oro-Facial Cle /</td><td>3</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF300": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>1</td><td>44</td><td>4.5%</td><td>1.58 [0.19 , 13.19]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>19</td><td>1</td><td>2</td><td>7.8%</td><td>0.05 [0.00 , 0.97]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>106</td><td>7</td><td>119</td><td>19.6%</td><td>0.80 [0.26 , 2.45]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>12</td><td>416</td><td>37.1%</td><td>0.85 [0.38 , 1.90]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>7</td><td>106</td><td>30.9%</td><td>0.10 [0.02 , 0.47]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1018</td><td/><td>687</td><td>100.0%</td><td>0.58 [0.34 , 0.97]</td></tr><tr><td>Total events:</td><td>23</td><td/><td>28</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 9.59, df = 4 (P = 0.05); I\u00b2 = 58%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.07 (P = 0.04)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PHT</td></tr><tr><td>Analysis 34.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF301": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>1</td><td>44</td><td>45.8%</td><td>0.28 [0.01 , 6.65]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>1</td><td>119</td><td>39.6%</td><td>0.37 [0.02 , 9.08]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>0</td><td>416</td><td>14.6%</td><td>2.77 [0.11 , 67.90]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>82</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>913</td><td/><td>661</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>1</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.18, df = 2 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.47 (P = 0.64)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF302": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 34.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LEV</td><td colspan=\"2\">Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF303": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>34.3.1 LEV vs PHT (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>51</td><td>1</td><td>44</td><td>8.7%</td><td>0.86 [0.06 , 13.39]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>5</td><td>119</td><td>38.3%</td><td>0.67 [0.16 , 2.75]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>4</td><td>416</td><td>33.8%</td><td>0.23 [0.03 , 2.06]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>1</td><td>82</td><td>19.2%</td><td>0.09 [0.00 , 2.21]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>911</td><td/><td>661</td><td>100.0%</td><td>0.43 [0.16 , 1.13]</td><td/></tr><tr><td>Total events:</td><td>5</td><td/><td>11</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.86, df = 3 (P = 0.60); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.71 (P = 0.09)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PHT</td></tr><tr><td>Analysis 34.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF304": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>0</td><td>44</td><td>9.9%</td><td>2.50 [0.10 , 59.88]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>2</td><td>416</td><td>47.2%</td><td>0.18 [0.01 , 3.84]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>1</td><td>82</td><td>42.9%</td><td>0.09 [0.00 , 2.21]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>807</td><td/><td>542</td><td>100.0%</td><td>0.37 [0.09 , 1.61]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.34, df = 2 (P = 0.31); I\u00b2 = 14%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.32 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PHT</td></tr><tr><td>Analysis 34.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF305": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>44</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>1</td><td>119</td><td>16.8%</td><td>2.25 [0.21 , 24.41]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>4</td><td>416</td><td>83.2%</td><td>0.10 [0.01 , 1.90]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>82</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>913</td><td/><td>661</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>2</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.71, df = 1 (P = 0.10); I\u00b2 = 63%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.05 (P = 0.30)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF306": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">35.1.1 LEV vs PRM (cohort studies)</td><td>1</td><td>141</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.24 [0.02, 3.37]</td></tr><tr><td colspan=\"2\">Analysis 35.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PHT</td></tr><tr><td colspan=\"2\">Comparison 35. LEV vs PRM</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">35.1 LEV vs PRM: All Major Malforma-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF307": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td colspan=\"2\">36.5.1 LEV vs TPM (cohort studies)</td><td>7</td><td/><td>1526</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.12 [0.02, 0.98]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 36.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LEV</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">35.1.1 LEV vs PRM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>0</td><td>2</td><td>100.0%</td><td>0.24 [0.02 , 3.37]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>139</td><td/><td>2</td><td>100.0%</td><td>0.24 [0.02 , 3.37]</td></tr><tr><td>Total events:</td><td/><td>5</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.06 (P = 0.29)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours PRM</td></tr><tr><td colspan=\"2\">Comparison 36. LEV vs TPM</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td colspan=\"2\">36.1 LEV vs TPM: All Major Malforma-</td><td>9</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.1.1 LEV vs TPM (cohort studies)</td><td>8</td><td/><td>1629</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.57 [0.32, 1.04]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.1.2 LEV vs TPM (database studies)</td><td>1</td><td/><td>166</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.41 [0.06, 2.81]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.2 LEV vs TPM: Neural Tube Malfor-</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.2.1 LEV vs TPM (cohort studies)</td><td>7</td><td/><td>1526</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.39 [0.10, 58.61]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.3 LEV vs TPM: Cardiac Malforma-</td><td>8</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.3.1 LEV vs TPM (cohort studies)</td><td>8</td><td/><td>1536</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.72 [0.21, 2.53]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.4 LEV vs TPM: Oro-Facial Cle /</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.4.1 LEV vs TPM (cohort studies)</td><td>7</td><td/><td>1421</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.19 [0.05, 0.70]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">36.5 LEV vs TPM: Skeletal/Limb Mal-</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF308": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>36.1.1 LEV vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>139</td><td>1</td><td>53</td><td>5.6%</td><td>1.91 [0.23 , 15.94]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>105</td><td>0</td><td>9</td><td>3.5%</td><td>1.04 [0.06 , 17.44]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>5</td><td>99</td><td>1</td><td>6</td><td>7.3%</td><td>0.30 [0.04 , 2.20]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>15</td><td>359</td><td>64.7%</td><td>0.59 [0.27 , 1.26]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>3</td><td>70</td><td>18.9%</td><td>0.15 [0.03 , 0.90]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1124</td><td/><td>505</td><td>100.0%</td><td>0.57 [0.32 , 1.04]</td><td/></tr><tr><td>Total events:</td><td>28</td><td/><td>20</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.93, df = 4 (P = 0.42); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.83 (P = 0.07)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>36.1.2 LEV vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>118</td><td>2</td><td>48</td><td>100.0%</td><td>0.41 [0.06 , 2.81]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>118</td><td/><td>48</td><td>100.0%</td><td>0.41 [0.06 , 2.81]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.91 (P = 0.36)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours TPM</td></tr><tr><td>Analysis 36.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF309": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td colspan=\"2\">TPM</td><td/></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>45</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>5</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>106</td><td>0</td><td>9</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>2</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>6</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>0</td><td>359</td><td>100.0%</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>70</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1030</td><td/><td>496</td><td>100.0%</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.54 (P = 0.59)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF310": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>2.39 [0.10 , 58.61]</td></tr><tr><td>Not estimable</td></tr><tr><td>2.39 [0</td></tr></table>",
                "type_str": "table"
            },
            "TABREF311": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 36.3.</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LEV</td><td/><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF312": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>36.3.1 LEV vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>0</td><td>45</td><td>12.1%</td><td>2.56 [0.11 , 61.23]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>106</td><td>0</td><td>9</td><td>20.5%</td><td>0.65 [0.04 , 11.79]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>3</td><td>99</td><td>1</td><td>6</td><td>42.3%</td><td>0.18 [0.02 , 1.50]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>450</td><td>1</td><td>359</td><td>25.0%</td><td>0.80 [0.05 , 12.71]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>70</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1039</td><td/><td>497</td><td>100.0%</td><td>0.72 [0.21 , 2.53]</td><td/></tr><tr><td>Total events:</td><td>8</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.26, df = 3 (P = 0.52); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.51 (P = 0.61)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours TPM</td></tr><tr><td>Analysis 36.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF313": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>36.4.1 LEV vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>9</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>53</td><td>0</td><td>45</td><td>5.0%</td><td>2.56 [0.11 , 61.23]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>6</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>5</td><td>359</td><td>57.1%</td><td>0.07 [0.00 , 1.31]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>2</td><td>70</td><td>37.9%</td><td>0.05 [0.00 , 0.96]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>933</td><td/><td>488</td><td>100.0%</td><td>0.19 [0.05 , 0.70]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>7</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.83, df = 2 (P = 0.15); I\u00b2 = 48%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.49 (P = 0.01)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours TPM</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF314": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 37. LEV vs ZNS</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">37.1 LEV vs ZNS: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.1.1 LEV vs ZNS (cohort studies)</td><td>4</td><td/><td>995</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.66 [0.25, 1.71]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.2 LEV vs ZNS: Neural Tube Malfor-</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.2.1 LEV vs ZNS (cohort studies)</td><td>3</td><td/><td>455</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.03 [0.00, 0.71]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.3 LEV vs ZNS: Cardiac Malforma-</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.3.1 LEV vs ZNS (cohort studies)</td><td>3</td><td/><td>455</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.98 [0.05, 17.99]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.4 LEV vs ZNS: Oro-Facial Cle /</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.4.1 LEV vs ZNS (cohort studies)</td><td>3</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.5 LEV vs ZNS: Skeletal/Limb Mal-</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">37.5.1 LEV vs ZNS (cohort studies)</td><td>3</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LEV</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">36.5.1 LEV vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>53</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>106</td><td>0</td><td>9</td><td>13.0%</td><td>0.47 [0.02 , 9.08]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>99</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>450</td><td>5</td><td>359</td><td>87.0%</td><td>0.07 [0.00 , 1.31]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>70</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1030</td><td/><td>496</td><td>100.0%</td><td>0.12 [0.02 , 0.98]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.90, df = 1 (P = 0.34); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.98 (P = 0.05)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF315": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>ZNS</td><td/><td/></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>1</td><td/></tr><tr><td>MONEAD 2020</td><td>5</td><td>99</td><td>1</td><td>13</td><td>21.8%</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>450</td><td>0</td><td>90</td><td>10.2%</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>304</td><td>3</td><td>26</td><td>68.0%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>865</td><td/><td>130</td><td>100.0%</td></tr><tr><td>Total events:</td><td>18</td><td/><td>4</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 9.39, df = 2 (P = 0.009); I\u00b2 = 79%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.86 (P = 0.39)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF316": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 37.2.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>0.66 [0.08 , 5.19]</td><td/><td/></tr><tr><td/><td/><td>4.64 [0.28 , 78.05]</td><td/><td/></tr><tr><td/><td/><td>0.06 [0.01 , 0.33]</td><td/><td/></tr><tr><td/><td/><td>0.66 [0.25 , 1.71]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LEV</td><td colspan=\"2\">Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF317": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>1</td><td>26</td><td>100.0%</td><td>0.03 [0.00 , 0.71]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>415</td><td/><td>40</td><td>100.0%</td><td>0.03 [0.00 , 0.71]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.17 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours ZNS</td></tr><tr><td>Analysis 37.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF318": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>3</td><td>99</td><td>0</td><td>13</td><td>100.0%</td><td>0.98 [0.05 , 17.99]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>415</td><td/><td>40</td><td>100.0%</td><td>0.98 [0.05 , 17.99]</td></tr><tr><td>Total events:</td><td>3</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.01 (P = 0.99)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours ZNS</td></tr><tr><td>Analysis 37.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF319": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 37.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LEV</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>12</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>99</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LEV</td><td>Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF320": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LEV</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>99</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>304</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours ZNS</td></tr><tr><td>Comparison 38. LTG vs CZP</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td/><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td>38.1 LTG vs CZP: All Major Malforma-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td>38.1.1 LTG vs CZP (cohort studies)</td><td>3</td><td/><td>2112</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.92 [0.29, 2.91]</td></tr><tr><td colspan=\"2\">38.1.2 LTG vs CZP (database studies) 2</td><td/><td>1084</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.54 [0.53, 4.54]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF321": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Australian Epilepsy and Pregnancy Register</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>Subtotal (95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF322": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"3\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 39. LTG vs LAC Analysis 39.2.</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td/><td colspan=\"2\">No. of partici-</td><td/><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.1 LTG vs LAC: All Major Malforma-</td><td colspan=\"2\">1</td><td/><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.1.1 LTG vs LAC (cohort studies)</td><td colspan=\"2\">1</td><td/><td/><td>0</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">39.2 LTG vs LAC: Neural Tube Malfor-</td><td colspan=\"2\">1</td><td/><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.2.1 LTG vs LAC (cohort studies)</td><td colspan=\"2\">1</td><td/><td/><td>0</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">39.3 LTG vs LAC: Cardiac Malforma-</td><td colspan=\"2\">1</td><td/><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.3.1 LTG vs LAC (cohort studies)</td><td colspan=\"2\">1</td><td/><td/><td>0</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">39.4 LTG vs LAC: Oro-Facial Cle /</td><td colspan=\"2\">1</td><td/><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.4.1 LTG vs LAC (cohort studies)</td><td colspan=\"2\">1</td><td/><td/><td>0</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">39.5 LTG vs LAC: Skeletal/Limb Mal-</td><td colspan=\"2\">1</td><td/><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">39.5.1 LTG vs LAC (cohort studies)</td><td colspan=\"2\">1</td><td/><td/><td>0</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Subtotal (95% CI) Analysis 39.1Jimenez 2020 Events LTG 0</td><td>Total</td><td>0 19</td><td colspan=\"2\">LTG Events 20 1 31 52 LAC Total 406 50 1562 2018 0 Events Total</td><td colspan=\"4\">CZP Events 0 0 2 0 2 1 Weight Total M-H, Fixed, 95% CI Not estimable 26 4 64 94 Weight 16.5% 16.0% 67.5% 100.0% Risk Ratio M-H, Fixed, 95% CI 2.72 [0.17 , 43.76] 0.29 [0.01 , 6.31] 0.64 [0.16 , 2.60] 0.92 [0.29 , 2.91] Risk Ratio Not estimable</td><td colspan=\"2\">Risk Ratio M-H, Fixed, 95% CI Risk Ratio M-H, Fixed, 95% CI</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>28</td><td>833</td><td>2</td><td>113</td><td>57.4%</td><td>1.90 [0.46 , 7.87]</td><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td>4</td><td>90 923</td><td>2</td><td>48 161</td><td>42.6% 100.0%</td><td>1.07 [0.20 , 5.61] 1.54 [0.53 , 4.54] 0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td>32</td><td/><td>4</td><td/><td/><td colspan=\"3\">Favours LTG</td><td>Favours LAC</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours CZP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF323": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">39.2.1 LTG vs LAC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours LAC</td></tr><tr><td colspan=\"2\">Analysis 39.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF324": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">39.3.1 LTG vs LAC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours LAC</td></tr><tr><td>Analysis 39.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF325": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF326": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 39.5.</td><td/><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td colspan=\"2\">Favours LTG</td><td/><td colspan=\"2\">Favours LAC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF327": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 40.1</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>LTG</td><td/><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">39.5.1 LTG vs LAC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours LAC</td></tr><tr><td colspan=\"2\">Comparison 40. LTG vs OXC</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">40.1 LTG vs OXC: All Major Malforma-</td><td>11</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.1.1 LTG vs OXC (cohort studies)</td><td>8</td><td/><td/><td>2541</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.73 [0.33, 1.62]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.1.2 LTG vs OXC (database studies)</td><td>3</td><td/><td/><td>2535</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.24 [0.67, 2.30]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.2 LTG vs OXC: Neural Tube Malfor-</td><td>6</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.2.1 LTG vs OXC (cohort studies)</td><td>6</td><td/><td/><td>2346</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.59 [0.03, 12.15]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.3 LTG vs OXC: Cardiac Malforma-</td><td>8</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tion</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.3.1 LTG vs OXC (cohort studies)</td><td>8</td><td/><td/><td>2407</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.59 [0.15, 2.30]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.4 LTG vs OXC: Oro-Facial Cle /</td><td>6</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.4.1 LTG vs OXC (cohort studies)</td><td>6</td><td/><td/><td>2248</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.64 [0.12, 3.46]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.5 LTG vs OXC: Skeletal/Limb Mal-</td><td>6</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formation</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">40.5.1 LTG vs OXC (cohort studies)</td><td>6</td><td/><td/><td>2346</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.29 [0.06, 1.56]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF328": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>20</td><td>406</td><td>1</td><td>19</td><td>13.6%</td><td>0.94 [0.13 , 6.61]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>5</td><td>71</td><td>29.4%</td><td>0.28 [0.03 , 2.36]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>111</td><td>0</td><td>22</td><td>5.9%</td><td>1.03 [0.05 , 20.69]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1562</td><td>4</td><td>182</td><td>51.0%</td><td>0.90 [0.32 , 2.53]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2208</td><td/><td>333</td><td>100.0%</td><td>0.73 [0.33 , 1.62]</td></tr><tr><td>Total events:</td><td>54</td><td/><td>10</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.04, df = 3 (P = 0.79); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.77 (P = 0.44)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>40.1.2 LTG vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>47</td><td>1235</td><td>10</td><td>316</td><td>85.0%</td><td>1.20 [0.61 , 2.35]</td></tr><tr><td>Norwegian Health Record Registers</td><td>28</td><td>833</td><td>1</td><td>57</td><td>10.0%</td><td>1.92 [0.27 , 13.83]</td></tr><tr><td>Sweden Health Record Registers</td><td>4</td><td>90</td><td>0</td><td>4</td><td>5.1%</td><td>0.49 [0.03 , 7.97]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2158</td><td/><td>377</td><td>100.0%</td><td>1.24 [0.67 , 2.30]</td></tr><tr><td>Total events:</td><td>79</td><td/><td>11</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.61, df = 2 (P = 0.74); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.68 (P = 0.50)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours OXC</td></tr><tr><td>Analysis 40.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF329": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>40.2.1 LTG vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>282</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>0</td><td>71</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>111</td><td>0</td><td>22</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>0</td><td>182</td><td>100.0%</td><td>0.59 [0.03 , 12.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2027</td><td/><td>319</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.35 (P = 0.73)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF330": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 40.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td colspan=\"2\">Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF331": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>40.3.1 LTG vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>0</td><td>9</td><td>18.7%</td><td>0.32 [0.02 , 5.51]</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>31</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>3</td><td>71</td><td>48.0%</td><td>0.47 [0.05 , 4.42]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>111</td><td>0</td><td>22</td><td>16.0%</td><td>1.03 [0.05 , 20.69]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1562</td><td>0</td><td>182</td><td>17.3%</td><td>0.82 [0.04 , 15.80]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2084</td><td/><td>323</td><td>100.0%</td><td>0.59 [0.15 , 2.30]</td><td/></tr><tr><td>Total events:</td><td>10</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.40, df = 3 (P = 0.94); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.76 (P = 0.45)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours OXC</td></tr><tr><td>Analysis 40.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF332": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>40.4.1 LTG vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>0</td><td>9</td><td>35.0%</td><td>0.32 [0.02 , 5.51]</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>31</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>111</td><td>0</td><td>22</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>7</td><td>1562</td><td>1</td><td>182</td><td>65.0%</td><td>0.82 [0.10 , 6.59]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1997</td><td/><td>251</td><td>100.0%</td><td>0.64 [0.12 , 3.46]</td><td/></tr><tr><td>Total events:</td><td>11</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.28, df = 1 (P = 0.59); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.52 (P = 0.61)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours OXC</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF333": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>2</td><td>282</td><td>0</td><td>9</td><td>24.1%</td><td>0.18 [0.01 , 3.44]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>3</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>1</td><td>71</td><td>31.1%</td><td>0.47 [0.02 , 11.32]</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>111</td><td>0</td><td>22</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>1</td><td>182</td><td>44.8%</td><td>0.23 [0.02 , 2.56]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2027</td><td/><td>319</td><td>100.0%</td><td>0.29 [0</td></tr><tr><td>Total events:</td><td>4</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.23, df = 2 (P = 0.89); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.44 (P = 0.15)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF334": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 41.1</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td/><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF335": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>20</td><td>406</td><td>0</td><td>2</td><td>3.3%</td><td>0.30 [0.02 , 3.93]</td></tr><tr><td>Cassina 2013</td><td>0</td><td>26</td><td>5</td><td>67</td><td>10.3%</td><td>0.23 [0.01 , 4.00]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>8</td><td>137</td><td>14.1%</td><td>0.34 [0.04 , 2.67]</td></tr><tr><td>Martinez Ferri 2018</td><td>0</td><td>56</td><td>1</td><td>11</td><td>8.2%</td><td>0.07 [0.00 , 1.62]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1562</td><td>11</td><td>199</td><td>64.2%</td><td>0.36 [0.18 , 0.70]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2156</td><td/><td>421</td><td>100.0%</td><td>0.32 [0.17 , 0.59]</td></tr><tr><td>Total events:</td><td>52</td><td/><td>25</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.07, df = 4 (P = 0.90); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.63 (P = 0.0003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>41.1.2 LTG vs PB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>28</td><td>833</td><td>2</td><td>27</td><td>67.6%</td><td>0.45 [0.11 , 1.81]</td></tr><tr><td>Sweden Health Record Registers</td><td>4</td><td>90</td><td>1</td><td>7</td><td>32.4%</td><td>0.31 [0.04 , 2.42]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>923</td><td/><td>34</td><td>100.0%</td><td>0.41 [0.13 , 1.28]</td></tr><tr><td>Total events:</td><td>32</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.09, df = 1 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.54 (P = 0.12)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PB</td></tr><tr><td>Analysis 41.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF336": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 41.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LTG</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>315</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>26</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>19</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>1</td><td>137</td><td>47.7%</td><td>0.90 [0.04 , 21.79]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>37</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>0</td><td>199</td><td>52.3%</td><td>0.64 [0.03 , 13.28]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2009</td><td/><td>413</td><td>100.0%</td><td>0.76 [0.09 , 6.88]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.02, df = 1 (P = 0.88); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.24 (P = 0.81)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LTG</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF337": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>41.3.1 LTG vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>3</td><td>315</td><td>0</td><td>5</td><td>6.8%</td><td>0.13 [0.01 , 2.30]</td><td/></tr><tr><td>Cassina 2013</td><td>0</td><td>26</td><td>2</td><td>67</td><td>9.8%</td><td>0.50 [0.02 , 10.15]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>6</td><td>137</td><td>22.2%</td><td>0.46 [0.06 , 3.70]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1562</td><td>5</td><td>199</td><td>61.3%</td><td>0.08 [0.02 , 0.32]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1990</td><td/><td>411</td><td>100.0%</td><td>0.21 [0.08 , 0.56]</td><td/></tr><tr><td>Total events:</td><td>7</td><td/><td>13</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.85, df = 3 (P = 0.41); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.10 (P = 0.002)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PB</td></tr><tr><td>Analysis 41.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF338": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>5</td><td>315</td><td>0</td><td>5</td><td>12.1%</td><td>0.21 [0.01 , 3.37]</td></tr><tr><td>Cassina 2013</td><td>0</td><td>26</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>7</td><td>1562</td><td>4</td><td>199</td><td>87.9%</td><td>0.22 [0.07 , 0.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1940</td><td/><td>274</td><td>100.0%</td><td>0.22 [0.07 , 0.68]</td></tr><tr><td>Total events:</td><td>12</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 0.97); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.63 (P = 0.009)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PB</td></tr><tr><td>Analysis 41.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF339": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td>PB</td><td/><td/></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>315</td><td>0</td><td>5</td><td/></tr><tr><td>Cassina 2013</td><td>0</td><td>26</td><td>0</td><td>67</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>2</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>2</td><td>137</td><td>43.2%</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>3</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>1</td><td>199</td><td>56.8%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2009</td><td/><td>413</td><td>100.0%</td></tr><tr><td>Total events:</td><td>2</td><td/><td>3</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.16, df = 1 (P = 0.69); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.99 (P = 0.32)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF340": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>0.54 [0.03 , 11.08]</td></tr><tr><td>Not estimable</td></tr><tr><td>0.25 [0.02 , 2.80]</td></tr><tr><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF341": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 42.1</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td/><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF342": {
                "text": "Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>20</td><td>406</td><td>1</td><td>44</td><td>4.2%</td><td>2.17 [0.30 , 15.76]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>7</td><td>119</td><td>9.6%</td><td>0.34 [0.04 , 2.69]</td></tr><tr><td>Meador 2006 (1)</td><td>1</td><td>98</td><td>4</td><td>56</td><td>11.8%</td><td>0.14 [0.02 , 1.25]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1562</td><td>12</td><td>416</td><td>43.8%</td><td>0.69 [0.36 , 1.33]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>49</td><td>2098</td><td>7</td><td>106</td><td>30.8%</td><td>0.35 [0.16 , 0.76]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4251</td><td/><td>742</td><td>100.0%</td><td>0.55 [0.35 , 0.87]</td></tr><tr><td>Total events:</td><td>102</td><td/><td>31</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 5.24, df = 4 (P = 0.26); I\u00b2 = 24%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.58 (P = 0.010)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>42.1.2 LTG vs PHT (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>4</td><td>90</td><td>7</td><td>103</td><td>100.0%</td><td>0.65 [0.20 , 2.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>90</td><td/><td>103</td><td>100.0%</td><td>0.65 [0.20 , 2.16]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.70 (P = 0.49)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PHT</td></tr><tr><td>Footnotes</td><td/><td/><td/><td/><td/><td/></tr><tr><td>(1)</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF343": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 42.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LTG</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>282</td><td>1</td><td>44</td><td>49.4%</td><td>0.05 [0.00 , 1.28]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>1</td><td>119</td><td>17.1%</td><td>0.78 [0.03 , 18.93]</td></tr><tr><td>Meador 2006</td><td/><td>0</td><td>98</td><td>0</td><td>56</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>0</td><td>416</td><td>15.1%</td><td>1.33 [0.06 , 27.73]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>0</td><td>82</td><td>18.4%</td><td>0.20 [0.01 , 4.09]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4127</td><td/><td>718</td><td>100.0%</td><td>0.40 [0.11 , 1.51]</td></tr><tr><td>Total events:</td><td/><td>4</td><td/><td>2</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.53, df = 3 (P = 0.47); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.36 (P = 0.17)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LTG</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF344": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>42.3.1 LTG vs PHT (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>1</td><td>44</td><td>12.8%</td><td>0.62 [0.07 , 5.46]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>5</td><td>119</td><td>21.8%</td><td>0.48 [0.06 , 3.97]</td><td/></tr><tr><td>Meador 2006</td><td>1</td><td>98</td><td>0</td><td>56</td><td>4.7%</td><td>1.73 [0.07 , 41.70]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1562</td><td>4</td><td>416</td><td>46.6%</td><td>0.20 [0.04 , 0.89]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>9</td><td>2098</td><td>1</td><td>82</td><td>14.2%</td><td>0.35 [0.05 , 2.74]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>4127</td><td/><td>718</td><td>100.0%</td><td>0.41 [0.17 , 0.98]</td><td/></tr><tr><td>Total events:</td><td>18</td><td/><td>11</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.85, df = 4 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.00 (P = 0.05)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PHT</td></tr><tr><td>Analysis 42.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF345": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>42.4.1 LTG vs PHT (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>0</td><td>44</td><td>14.5%</td><td>1.43 [0.08 , 26.13]</td><td/></tr><tr><td>Meador 2006</td><td>0</td><td>98</td><td>0</td><td>56</td><td/><td>Not estimable</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>7</td><td>1562</td><td>2</td><td>416</td><td>53.1%</td><td>0.93 [0.19 , 4.47]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>1</td><td>82</td><td>32.4%</td><td>0.08 [0.01 , 0.85]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>4077</td><td/><td>599</td><td>100.0%</td><td>0.73 [0.23 , 2.28]</td><td/></tr><tr><td>Total events:</td><td>13</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.65, df = 2 (P = 0.16); I\u00b2 = 45%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.55 (P = 0.59)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF346": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>2</td><td>282</td><td>0</td><td>44</td><td>9.5%</td><td>0.80 [0.04 , 16.29]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>1</td><td>119</td><td>9.9%</td><td>0.78 [0.03 , 18.93]</td></tr><tr><td>Meador 2006</td><td>0</td><td>98</td><td>0</td><td>56</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>37</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>4</td><td>416</td><td>69.9%</td><td>0.13 [0.02 , 0.72]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>2098</td><td>0</td><td>82</td><td>10.6%</td><td>0.28 [0.01 , 5.32]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4127</td><td/><td>718</td><td>100.0%</td><td>0.</td></tr><tr><td>Total events:</td><td>7</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.60, df = 3 (P = 0.66); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.21 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF347": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 43. LTG vs PRM</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">43.1 LTG vs PRM: All Major Malforma-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">43.1.1 LTG vs PRM (cohort studies)</td><td>1</td><td>408</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.30 [0.02, 3.93]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">43.1.2 LTG vs PRM (database studies)</td><td>1</td><td>93</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.40 [0.03, 6.16]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 43.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF348": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>20</td><td>406</td><td>0</td><td>2</td><td>100.0%</td><td>0.30 [0.02 , 3.93]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>406</td><td/><td>2</td><td>100.0%</td><td>0.30 [0.02 , 3.93]</td></tr><tr><td>Total events:</td><td>20</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.91 (P = 0.36)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>43.1.2 LTG vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>4</td><td>90</td><td>0</td><td>3</td><td>100.0%</td><td>0.40 [0.03 , 6.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>90</td><td/><td>3</td><td>100.0%</td><td>0.40 [0.03 , 6.16]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.66 (P = 0.51)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours PRM</td></tr><tr><td>Comparison</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF349": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">44.3 LTG vs TPM: Cardiac Malforma-</td><td>8</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.3.1 LTG vs TPM (cohort studies)</td><td>8</td><td>4648</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.58 [0.19, 1.81]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.4 LTG vs TPM: Oro-Facial Cle /</td><td>7</td><td/><td>Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">44.4.1 LTG vs TPM (cohort studies)</td><td>7</td><td>4589</td><td>Risk Ratio (M-H, Random,</td><td>0.22 [0.03, 1.48]</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">44.5 LTG vs TPM: Skeletal/Limb Mal-</td><td>7</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.5.1 LTG vs TPM (cohort studies)</td><td>7</td><td>4627</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.17 [0.06, 0.52]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 44.1.</td><td/><td/><td/></tr><tr><td colspan=\"2\">44.1 LTG vs TPM: All Major Malforma-</td><td>10</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.1.1 LTG vs TPM (cohort studies)</td><td>8</td><td>4780</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.59 [0.36, 0.96]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.1.2 LTG vs TPM (database studies)</td><td>2</td><td>972</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.68 [0.20, 2.37]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.2 LTG vs TPM: Neural Tube Malfor-</td><td>7</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">44.2.1 LTG vs TPM (cohort studies)</td><td>7</td><td>4627</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.62 [0.08, 4.94]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF350": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or Subgroup</td></tr><tr><td>44.1.1 LTG vs TPM (cohort studies)</td></tr><tr><td>AlSheikh 2020</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td></tr><tr><td>Jimenez 2020</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td></tr><tr><td>Melikova 2020</td></tr><tr><td>MONEAD 2020</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.26, df = 4 (P = 0.51); I\u00b2 = 0%</td></tr><tr><td>Test for overall effect: Z = 2.14 (P = 0.03)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF351": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 44.2.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>LTG</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0</td><td>20</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>20</td><td>406</td><td>1</td><td>53</td><td>5.1%</td><td>2.61 [0.36 , 19.06]</td></tr><tr><td/><td/><td>0</td><td>19</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>1</td><td>50</td><td>0</td><td>9</td><td>2.4%</td><td>0.59 [0.03 , 13.43]</td></tr><tr><td/><td/><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td/><td/><td>5</td><td>113</td><td>1</td><td>6</td><td>5.5%</td><td>0.27 [0.04 , 1.93]</td></tr><tr><td/><td/><td>31</td><td>1562</td><td>15</td><td>359</td><td>70.3%</td><td>0.47 [0.26 , 0.87]</td></tr><tr><td/><td/><td>49</td><td>2098</td><td>3</td><td>70</td><td>16.7%</td><td>0.54 [0.17 , 1.71]</td></tr><tr><td/><td/><td/><td>4275</td><td/><td>505</td><td>100.0%</td><td>0.59 [0.36 , 0.96]</td></tr><tr><td/><td/><td>106</td><td/><td>20</td><td/><td/></tr><tr><td colspan=\"2\">Norwegian Health Record Registers</td><td>28</td><td>833</td><td>2</td><td>48</td><td>79.4%</td><td>0.81 [0.20 , 3.29]</td></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>4</td><td>90</td><td>0</td><td>1</td><td>20.6%</td><td>0.20 [0.02 , 2.57]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>923</td><td/><td>49</td><td>100.0%</td><td>0.68 [0.20 , 2.37]</td></tr><tr><td>Total events:</td><td/><td>32</td><td/><td>2</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.95, df = 1 (P = 0.33); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.60 (P = 0.55)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LTG</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF352": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>44.2.1 LTG vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>282</td><td>0</td><td>45</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>0</td><td>9</td><td/><td>Not estimable</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>6</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>0</td><td>359</td><td>45.7%</td><td>1.15 [0.06 , 23.94]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>0</td><td>70</td><td>54.3%</td><td>0.17 [0.01 , 3.49]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>4131</td><td/><td>496</td><td>100.0%</td><td>0.62 [0.08 , 4.94]</td><td/></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.87, df = 1 (P = 0.35); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.45 (P = 0.65)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours TPM</td></tr><tr><td>Analysis 44.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF353": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>44.3.1 LTG vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>0</td><td>45</td><td>13.9%</td><td>1.46 [0.08 , 26.72]</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>50</td><td>0</td><td>9</td><td>13.5%</td><td>0.59 [0.03 , 13.43]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>1</td><td>113</td><td>1</td><td>6</td><td>30.7%</td><td>0.05 [0.00 , 0.75]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>3</td><td>1562</td><td>1</td><td>359</td><td>26.3%</td><td>0.69 [0.07 , 6.61]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>9</td><td>2098</td><td>0</td><td>70</td><td>15.6%</td><td>0.64 [0.04 , 10.93]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>4151</td><td/><td>497</td><td>100.0%</td><td>0.58 [0.19 , 1.81]</td><td/></tr><tr><td>Total events:</td><td>18</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.55, df = 4 (P = 0.47); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.94 (P = 0.35)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours TPM</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF354": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td colspan=\"2\">TPM</td><td/></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>20</td><td>0</td><td>1</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>4</td><td>282</td><td>0</td><td>45</td><td>23.6%</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>5</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td>2</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>6</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>7</td><td>1562</td><td>5</td><td>359</td><td>43.0%</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>2</td><td>70</td><td>33.4%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4101</td><td/><td>488</td><td>100.0%</td></tr><tr><td>Total events:</td><td>13</td><td/><td>7</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau\u00b2 = 1.91; Chi\u00b2 = 6.16, df = 2 (P = 0.05); I\u00b2 = 68%</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.56 (P = 0.12)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF355": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Not estimable</td></tr><tr><td>1.46 [0.08 , 26.72]</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>0.32 [0.10 , 1.01]</td></tr><tr><td>0.03 [0.00 , 0.23]</td></tr><tr><td>0.22 [0</td></tr></table>",
                "type_str": "table"
            },
            "TABREF356": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 44.5.</td><td/><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td/><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF357": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 45.1</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">LTG</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">44.5.1 LTG vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>2</td><td>282</td><td>0</td><td>45</td><td>7.9%</td><td>0.81 [0.04 , 16.66]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>19</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>50</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>1</td><td>113</td><td>0</td><td>6</td><td>8.6%</td><td>0.18 [0.01 , 4.12]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>2</td><td>1562</td><td>5</td><td>359</td><td>74.6%</td><td>0.09 [0.02 , 0.47]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>2098</td><td>0</td><td>70</td><td>8.9%</td><td>0.24 [0.01 , 4.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>4131</td><td/><td>496</td><td>100.0%</td><td>0.17 [0.06 , 0.52]</td></tr><tr><td>Total events:</td><td/><td>8</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.62, df = 3 (P = 0.65); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 3.11 (P = 0.002)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF358": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>5</td><td>113</td><td>1</td><td>13</td><td>20.7%</td><td>0.58 [0.07 , 4.55]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>31</td><td>1562</td><td>0</td><td>90</td><td>10.9%</td><td>3.67 [0.23 , 59.46]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>49</td><td>2098</td><td>3</td><td>26</td><td>68.4%</td><td>0.20 [0.07 , 0.61]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3792</td><td/><td>130</td><td>100.0%</td><td>0.66 [0.26 , 1.65]</td></tr><tr><td>Total events:</td><td>85</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 5.89, df = 2 (P = 0.05); I\u00b2 = 66%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.89 (P = 0.37)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours ZNS</td></tr><tr><td>Analysis 45.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF359": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LTG</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>1</td><td>26</td><td>100.0%</td><td>0.02 [0.00 , 0.26]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2230</td><td/><td>40</td><td>100.0%</td><td>0.02 [0.00 , 0.26]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.06 (P = 0.002)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours ZNS</td></tr><tr><td>Analysis 45.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF360": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>113</td><td>0</td><td>13</td><td>47.4%</td><td>0.37 [0.02 , 8.62]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>9</td><td>2098</td><td>0</td><td>26</td><td>52.6%</td><td>0.24 [0.01 , 4.09]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2211</td><td/><td>39</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>10</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.04, df = 1 (P = 0.85); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.10 (P = 0.27)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF361": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 45.4.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours LTG</td><td colspan=\"2\">Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF362": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>LTG</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>45.4.1 LTG vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>113</td><td>0</td><td>13</td><td/><td>Not estimable</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>2098</td><td>0</td><td>26</td><td>100.0%</td><td>0.06 [0.00 , 1.31]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2211</td><td/><td>39</td><td>100.0%</td><td>0.06 [0.00 , 1.31]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.79 (P = 0.07)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours ZNS</td></tr><tr><td>Analysis 45.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF363": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">46.4 PHT vs GBP: Oro-Facial Cle /</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.4.1 PHT vs GBP (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.5 PHT vs GBP: Skeletal/Limb Mal-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.5.1 PHT vs GBP (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td>LTG</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Analysis 46.1</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>19</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>1</td><td>113</td><td>0</td><td>13</td><td>47.4%</td><td>0.37 [0.02 , 8.62]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>2098</td><td>0</td><td>26</td><td>52.6%</td><td>0.09 [0.00 , 1.70]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2230</td><td/><td>40</td><td>100.0%</td><td>0.22 [0.03 , 1.93]</td></tr><tr><td>Total events:</td><td/><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.46, df = 1 (P = 0.50); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.36 (P = 0.17)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LTG</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Comparison 46. PHT vs GBP</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">46.1 PHT vs GBP: All Major Malforma-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.1.1 PHT vs GBP (cohort studies)</td><td>4</td><td/><td>759</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.15 [0.69, 6.73]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.1.2 PHT vs GBP (database studies)</td><td>1</td><td/><td>121</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.74 [0.16, 46.00]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.2 PHT vs GBP: Neural Tube Malfor-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.2.1 PHT vs GBP (cohort studies)</td><td>2</td><td/><td>61</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.00 [0.04, 23.26]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.3 PHT vs GBP: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">46.3.1 PHT vs GBP (cohort studies)</td><td>2</td><td/><td>61</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.69 [0.09, 5.17]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF364": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>14</td><td>15.1%</td><td>1.00 [0.04 , 23.26]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>1</td><td>2</td><td>24.1%</td><td>0.50 [0.04 , 7.10]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>12</td><td>416</td><td>1</td><td>145</td><td>29.8%</td><td>4.18 [0.55 , 31.89]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>7</td><td>106</td><td>1</td><td>31</td><td>31.1%</td><td>2.05 [0.26 , 16.01]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>567</td><td/><td>192</td><td>100.0%</td><td>2.15 [0.69 , 6.73]</td></tr><tr><td>Total events:</td><td>20</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.80, df = 3 (P = 0.61); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.32 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>46.1.2 PHT vs GBP (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>7</td><td>103</td><td>0</td><td>18</td><td>100.0%</td><td>2.74 [0.16 , 46.00]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>103</td><td/><td>18</td><td>100.0%</td><td>2.74 [0.16 , 46.00]</td></tr><tr><td>Total events:</td><td>7</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.70 (P = 0.48)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF365": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 46.3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PHT</td><td colspan=\"2\">GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">46.2.1 PHT vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>14</td><td>100.0%</td><td>1.00 [0.04 , 23.26]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>45</td><td/><td>16</td><td>100.0%</td><td>1.00 [0.04 , 23.26]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.00 (P = 1.00)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF366": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>46.3.1 PHT vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>14</td><td>38.5%</td><td>1.00 [0.04 , 23.26]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>1</td><td>2</td><td>61.5%</td><td>0.50 [0.04 , 7.10]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>45</td><td/><td>16</td><td>100.0%</td><td>0.69 [0.09 , 5.17]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.11, df = 1 (P = 0.74); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.36 (P = 0.72)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours GBP</td></tr><tr><td>Analysis 46.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF367": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>46.4.1 PHT vs GBP (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>14</td><td/><td>Not estimable</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>2</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours GBP</td></tr><tr><td>Analysis 46.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF368": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">47.1.2 PHT vs OXC (database studies)</td><td>1</td><td/><td>107</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.72 [0.05, 10.93]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.2 PHT vs OXC: Neural Tube Malfor-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.2.1 PHT vs OXC (cohort studies)</td><td>4</td><td/><td>974</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.16 [0.13, 10.29]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.3 PHT vs OXC: Cardiac Malforma-</td><td>5</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.3.1 PHT vs OXC (cohort studies)</td><td>5</td><td/><td>976</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.33 [0.43, 4.17]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.4 PHT vs OXC: Oro-Facial Cle /</td><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.4.1 PHT vs OXC (cohort studies)</td><td>3</td><td/><td>784</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.62 [0.10, 4.05]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.5 PHT vs OXC: Skeletal/Limb Mal-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.5.1 PHT vs OXC (cohort studies)</td><td>4</td><td/><td>974</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.20 [0.23, 6.35]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td>PHT</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>14</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PHT</td><td>Favours GBP</td></tr><tr><td colspan=\"2\">Comparison 47. PHT vs OXC</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">47.1 PHT vs OXC: All Major Malforma-</td><td>7</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">47.1.1 PHT vs OXC (cohort studies)</td><td>6</td><td/><td>989</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.94 [0.48, 1.85]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF369": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 47.2.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>PHT</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>1</td><td>19</td><td>8.9%</td><td>0.43 [0.03 , 6.55]</td></tr><tr><td>Kaaja 2003</td><td/><td>3</td><td>124</td><td>1</td><td>9</td><td>11.9%</td><td>0.22 [0.03 , 1.89]</td></tr><tr><td>Kaur 2020</td><td/><td>1</td><td>2</td><td>0</td><td>1</td><td>3.8%</td><td>2.00 [0.14 , 28.42]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>119</td><td>5</td><td>71</td><td>39.9%</td><td>0.84 [0.28 , 2.53]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>12</td><td>416</td><td>4</td><td>182</td><td>35.5%</td><td>1.31 [0.43 , 4.01]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>706</td><td/><td>283</td><td>100.0%</td><td>0.94 [0.48 , 1.85]</td></tr><tr><td>Total events:</td><td/><td>24</td><td/><td>11</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.77, df = 4 (P = 0.60); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.18 (P = 0.86)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">47.1.2 PHT vs OXC (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>7</td><td>103</td><td>0</td><td>4</td><td>100.0%</td><td>0.72 [0.05 , 10.93]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>103</td><td/><td>4</td><td>100.0%</td><td>0.72 [0.05 , 10.93]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.24 (P = 0.81)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PHT</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF370": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>47.2.1 PHT vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>9</td><td>56.7%</td><td>0.67 [0.03 , 15.19]</td><td/></tr><tr><td>Kaaja 2003</td><td>0</td><td>124</td><td>0</td><td>9</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>0</td><td>71</td><td>43.3%</td><td>1.80 [0.07 , 43.60]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>416</td><td>0</td><td>182</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>703</td><td/><td>271</td><td>100.0%</td><td>1.16 [0.13 , 10.29]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.19, df = 1 (P = 0.66); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.13 (P = 0.90)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours OXC</td></tr><tr><td>Analysis 47.3.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF371": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>47.3.1 PHT vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>9</td><td>15.5%</td><td>0.67 [0.03 , 15.19]</td><td/></tr><tr><td>Kaaja 2003</td><td>0</td><td>124</td><td>0</td><td>9</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>119</td><td>3</td><td>71</td><td>71.3%</td><td>0.99 [0.25 , 4.04]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>0</td><td>182</td><td>13.2%</td><td>3.95 [0.21 , 72.98]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>704</td><td/><td>272</td><td>100.0%</td><td>1.33 [0.43 , 4.17]</td><td/></tr><tr><td>Total events:</td><td>10</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.89, df = 2 (P = 0.64); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.49 (P = 0.62)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours OXC</td></tr><tr><td>Analysis 47.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF372": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td/><td colspan=\"2\">OXC</td><td/></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>9</td><td/></tr><tr><td>Kaaja 2003</td><td>1</td><td>124</td><td>0</td><td>9</td><td>40.0%</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>416</td><td>1</td><td>182</td><td>60.0%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>584</td><td/><td>200</td><td>100.0%</td></tr><tr><td>Total events:</td><td>3</td><td/><td>1</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.43, df = 1 (P = 0.51); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.50 (P = 0.62)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF373": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Not estimable</td></tr><tr><td>0.24 [0.01 , 5.52]</td></tr><tr><td>0.88 [0.08 , 9.59]</td></tr><tr><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF374": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"3\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 47.5.</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF375": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">OXC</td><td/><td/><td>Risk Ratio Risk Ratio</td><td>Risk Ratio Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI M-H, Fixed, 95% CI</td></tr><tr><td>47.5.1 PHT vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>9</td><td/><td/><td>Not estimable Not estimable</td></tr><tr><td>Kaaja 2003</td><td>0</td><td>124</td><td>0</td><td>9</td><td>1.9%</td><td/><td>Not estimable 0.20 [0.01 , 3.94]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>1</td><td>71</td><td>47.4% 3.4%</td><td/><td>0.60 [0.04 , 9.39] 1.09 [0.18 , 6.80]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>1</td><td>182</td><td>52.6% 3.0%</td><td/><td>1.75 [0.20 , 15.55] 0.71 [0.08 , 6.27]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>703</td><td/><td>271</td><td>100.0% 2.4%</td><td/><td>1.20 [0.23 , 6.35] 0.50 [0.03 , 9.46]</td></tr><tr><td>Total events:</td><td>5</td><td/><td>2</td><td/><td>1.9%</td><td/><td>0.34 [0.02 , 5.80]</td></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.36, df = 1 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td>10.1%</td><td/><td>1.80 [0.60 , 5.38]</td></tr><tr><td>Test for overall effect: Z = 0.22 (P = 0.83)</td><td/><td/><td/><td/><td>1.2%</td><td/><td>2.00 [0.14 , 28.42]</td></tr><tr><td/><td/><td/><td/><td/><td>1.6%</td><td/><td>0.84 [0.04 , 18.44]</td></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>15.0%</td><td/><td>1.01 [0.38 , 2.70]</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td>1.7%</td><td/><td>1.00 [0.06 , 17.82]</td><td>Favours PHT</td><td>Favours OXC</td></tr><tr><td/><td/><td/><td/><td/><td>1.6%</td><td/><td>1.53 [0.10 , 22.84]</td></tr><tr><td/><td/><td/><td/><td/><td>4.4%</td><td/><td>2.01 [0.48 , 8.47]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Comparison 48. PHT vs PB</td><td/><td/><td/><td/><td>6.6% 30.0%</td><td/><td>0.68 [0.16 , 2.89] 0.52 [0.23 , 1.16]</td></tr><tr><td/><td/><td/><td/><td/><td>8.5%</td><td/><td>0.09 [0.01 , 1.71]</td></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td colspan=\"3\">Statistical method Not estimable</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td>6.9%</td><td/><td>0.75 [0.17 , 3.35]</td></tr><tr><td>48.1 PHT vs PB: All Major Malforma-</td><td>21</td><td/><td/><td/><td>100.0%</td><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% 0.84 [0.57 , 1.23]</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.1.1 PHT vs PB (cohort studies)</td><td>20</td><td/><td>1729</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>0.84 [0.57, 1.23]</td></tr><tr><td/><td/><td/><td/><td/><td>100.0%</td><td>CI)</td><td>0.48 [0.07 , 3.35]</td></tr><tr><td/><td/><td/><td/><td/><td>100.0%</td><td/><td>0.48 [0.07 , 3.35]</td></tr><tr><td>48.1.2 PHT vs PB (database studies)</td><td>1</td><td/><td>110</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>0.48 [0.07, 3.35]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.2 PHT vs PB: Neural Tube Malfor-mations</td><td>11</td><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% 0.01 0.1 CI) Favours PHT</td><td>1</td><td>Subtotals only 10 100 Favours PB</td></tr><tr><td>48.2.1 PHT vs PB (cohort studies)</td><td>11</td><td/><td>1182</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>0.79 [0.10, 5.94]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>Analysis 48.2.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>48.3 PHT vs PB: Cardiac Malforma-</td><td>11</td><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.3.1 PHT vs PB (cohort studies)</td><td>11</td><td/><td>1182</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>0.56 [0.29, 1.07]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.4 PHT vs PB: Oro-Facial Cle /Cran-</td><td>11</td><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.4.1 PHT vs PB (cohort studies)</td><td>11</td><td/><td>940</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>0.25 [0.07, 0.82]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.5 PHT vs PB: Skeletal/Limb Malfor-</td><td>11</td><td/><td/><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>48.5.1 PHT vs PB (cohort studies)</td><td>11</td><td/><td>1182</td><td/><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95%</td><td>1.31 [0.39, 4.39]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF376": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 48.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PHT</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>5</td><td>48.7%</td><td>0.40 [0.02 , 8.75]</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>22</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Eroglu 2008</td><td/><td>0</td><td>14</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td/><td>0</td><td>3</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>1</td><td>137</td><td>51.3%</td><td>1.15 [0.07 , 18.21]</td></tr><tr><td>Koch 1992</td><td/><td>0</td><td>24</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td/><td>0</td><td>31</td><td>0</td><td>83</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>416</td><td>0</td><td>199</td><td/><td>Not estimable</td></tr><tr><td>Omtzigt 1992</td><td/><td>0</td><td>28</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>707</td><td/><td>475</td><td>100.0%</td><td>0.79 [0.10 , 5.94]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.26, df = 1 (P = 0.61); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.23 (P = 0.81)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PHT</td><td>Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF377": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>48.3.1 PHT vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>5</td><td>4.1%</td><td>0.40 [0.02 , 8.75]</td><td/></tr><tr><td>D'Souza 1991</td><td>2</td><td>22</td><td>1</td><td>4</td><td>7.9%</td><td>0.36 [0.04 , 3.13]</td><td/></tr><tr><td>Eroglu 2008</td><td>1</td><td>14</td><td>0</td><td>5</td><td>3.3%</td><td>1.20 [0.06 , 25.53]</td><td/></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>3</td><td>1</td><td>5</td><td>5.6%</td><td>0.50 [0.03 , 9.46]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>119</td><td>6</td><td>137</td><td>25.9%</td><td>0.96 [0.30 , 3.06]</td><td/></tr><tr><td>Koch 1992</td><td>1</td><td>24</td><td>0</td><td>4</td><td>3.9%</td><td>0.60 [0.03 , 12.71]</td><td/></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>1</td><td>83</td><td>3.8%</td><td>0.88 [0.04 , 20.93]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>5</td><td>199</td><td>31.4%</td><td>0.38 [0.10 , 1.41]</td><td/></tr><tr><td>Omtzigt 1992</td><td>0</td><td>28</td><td>2</td><td>18</td><td>14.0%</td><td>0.13 [0.01 , 2.58]</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>707</td><td/><td>475</td><td>100.0%</td><td>0.56 [0.29 , 1.07]</td><td/></tr><tr><td>Total events:</td><td>14</td><td/><td>16</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.59, df = 8 (P = 0.96); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.75 (P = 0.08)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours PB</td></tr><tr><td>Analysis 48.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF378": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>48.4.1 PHT vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td>1</td><td>22</td><td>0</td><td>4</td><td>8.1%</td><td>0.65 [0.03 , 13.78]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>14</td><td>1</td><td>5</td><td>21.0%</td><td>0.13 [0.01 , 2.84]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>3</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>5</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td>0</td><td>24</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>0</td><td>83</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>416</td><td>4</td><td>199</td><td>53.1%</td><td>0.24 [0.04 , 1.29]</td></tr><tr><td>Omtzigt 1992</td><td>0</td><td>28</td><td>1</td><td>18</td><td>17.8%</td><td>0.22 [0.01 , 5.09]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>593</td><td/><td>347</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>3</td><td/><td>6</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.55, df = 3 (P = 0.91); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.29 (P = 0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF379": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 48.5.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours PHT</td><td colspan=\"2\">Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF380": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>PHT</td><td/><td>PB pants</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"3\">49.5.1 PHT vs PRM (cohort studies)</td><td>2</td><td/><td>75</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.38 [0.14, 79.95]</td></tr><tr><td colspan=\"3\">48.5.1 PHT vs PB (cohort studies)</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">D'Souza 1991</td><td/><td>2</td><td>22</td><td>0</td><td>4</td><td>17.9%</td><td>1.09 [0.06 , 19.33]</td></tr><tr><td colspan=\"2\">Eroglu 2008</td><td/><td>0</td><td>14</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Fr\u00f6scher 1991</td><td/><td>0</td><td>3</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"3\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>2</td><td>137</td><td>40.6%</td><td>0.58 [0.05 , 6.27]</td></tr><tr><td>Koch 1992</td><td colspan=\"2\">Analysis 49.1.</td><td>0</td><td>24</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Milan Study 1999</td><td/><td>1</td><td>31</td><td>1</td><td>83</td><td>11.9%</td><td>2.68 [0.17 , 41.50]</td></tr><tr><td colspan=\"2\">Miskov 2016</td><td/><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"3\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>1</td><td>199</td><td>29.6%</td><td>1.91 [0.22 , 17.01]</td></tr><tr><td colspan=\"2\">Omtzigt 1992</td><td/><td>0</td><td>28</td><td>0</td><td>18</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td/><td/><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Subtotal (95% CI)</td><td/><td/><td>707</td><td/><td>475</td><td>100.0%</td><td>1.31 [0.39 , 4.39]</td></tr><tr><td colspan=\"2\">Total events:</td><td/><td>8</td><td/><td>4</td><td/><td/></tr><tr><td colspan=\"4\">Heterogeneity: Chi\u00b2 = 0.85, df = 3 (P = 0.84); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for overall effect: Z = 0.44 (P = 0.66)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PHT</td><td>Favours PB</td></tr><tr><td colspan=\"3\">Comparison 49. PHT vs PRM</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"3\">49.1 PHT vs PRM: All Major Malforma-</td><td>7</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.1.1 PHT vs PRM (cohort studies)</td><td>6</td><td/><td>463</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.78 [0.39, 1.56]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.1.2 PHT vs PRM (database studies)</td><td>1</td><td/><td>106</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.58 [0.04, 8.44]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.2 PHT vs PRM: Neural Tube Malfor-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.2.1 PHT vs PRM (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.3 PHT vs PRM: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.3.1 PHT vs PRM (cohort studies)</td><td>2</td><td/><td>75</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.38 [0.02, 8.88]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.4 PHT vs PRM: Oro-Facial Cle /</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"3\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.4.1 PHT vs PRM (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">49.5 PHT vs PRM: Skeletal/Limb Mal-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF381": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>49.1.1 PHT vs PRM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>2</td><td>6.6%</td><td>0.20 [0.01 , 3.94]</td><td/></tr><tr><td>Kaaja 2003</td><td>3</td><td>124</td><td>1</td><td>6</td><td>13.5%</td><td>0.15 [0.02 , 1.20]</td><td/></tr><tr><td>Kaneko 1999</td><td>12</td><td>132</td><td>5</td><td>35</td><td>56.1%</td><td>0.64 [0.24 , 1.69]</td><td/></tr><tr><td>Koch 1992</td><td>2</td><td>24</td><td>0</td><td>21</td><td>3.8%</td><td>4.40 [0.22 , 86.78]</td><td/></tr><tr><td>Milan Study 1999</td><td>3</td><td>31</td><td>3</td><td>35</td><td>20.0%</td><td>1.13 [0.25 , 5.19]</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>360</td><td/><td>103</td><td>100.0%</td><td>0.78 [0.39 , 1.56]</td><td/></tr><tr><td>Total events:</td><td>21</td><td/><td>9</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 4.93, df = 4 (P = 0.29); I\u00b2 = 19%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.70 (P = 0.48)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>49.1.2 PHT vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>7</td><td>103</td><td>0</td><td>3</td><td>100.0%</td><td>0.58 [0.04 , 8.44]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>103</td><td/><td>3</td><td>100.0%</td><td>0.58 [0.04 , 8.44]</td><td/></tr><tr><td>Total events:</td><td>7</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.40 (P = 0.69)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours PRM</td></tr><tr><td>Analysis 49.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF382": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td colspan=\"2\">PRM</td><td/></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>0</td><td>35</td></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>4</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF383": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 49.3.</td><td/><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td colspan=\"2\">Favours PHT</td><td/><td colspan=\"2\">Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF384": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>1</td><td>35</td><td>100.0%</td><td>0.38 [0.02 , 8.88]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>36</td><td/><td>39</td><td>100.0%</td><td>0.38 [0.02 , 8.88]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.61 (P = 0.54)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours PRM</td></tr><tr><td>Analysis 49.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF385": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>31</td><td>0</td><td>35</td><td>Not estimable</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>4</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours PRM</td></tr><tr><td>Analysis 49.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF386": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PHT</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>31</td><td>0</td><td>35</td><td>100.0%</td><td>3.38 [0.14 , 79.95]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>5</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>36</td><td/><td>39</td><td>100.0%</td><td>3.</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.75 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF387": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"3\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 50.1</td><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td colspan=\"2\">Favours PHT</td><td/><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF388": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>1</td><td>53</td><td>4.2%</td><td>1.20 [0.08 , 18.71]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>7</td><td>119</td><td>0</td><td>9</td><td>4.3%</td><td>1.25 [0.08 , 20.33]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>12</td><td>416</td><td>15</td><td>359</td><td>74.7%</td><td>0.69 [0.33 , 1.46]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>7</td><td>106</td><td>3</td><td>70</td><td>16.8%</td><td>1.54 [0.41 , 5.76]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>685</td><td/><td>491</td><td>100.0%</td><td>0.88 [0.48 , 1.61]</td></tr><tr><td>Total events:</td><td>27</td><td/><td>19</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.21, df = 3 (P = 0.75); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.42 (P = 0.68)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>50.1.2 PHT vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>7</td><td>103</td><td>0</td><td>1</td><td>100.0%</td><td>0.29 [0.02 , 3.51]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>103</td><td/><td>1</td><td>100.0%</td><td>0.29 [0.02 , 3.51]</td></tr><tr><td>Total events:</td><td>7</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.98 (P = 0.33)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours TPM</td></tr><tr><td>Analysis 50.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF389": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>50.2.1 PHT vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>45</td><td>34.9%</td><td>3.07 [0.13 , 73.31]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>0</td><td>9</td><td>65.1%</td><td>0.25 [0.01 , 5.75]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>416</td><td>0</td><td>359</td><td/><td>Not estimable</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>82</td><td>0</td><td>70</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>661</td><td/><td>483</td><td>100.0%</td><td>1.23 [0.17 , 8.87]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.31, df = 1 (P = 0.25); I\u00b2 = 24%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.21 (P = 0.84)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF390": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 50.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PHT</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">50.3.1 PHT vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>44</td><td>0</td><td>45</td><td>16.3%</td><td>3.07 [0.13 , 73.31]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>119</td><td>0</td><td>9</td><td>30.5%</td><td>0.92 [0.05 , 15.41]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>1</td><td>359</td><td>35.4%</td><td>3.45 [0.39 , 30.74]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>82</td><td>0</td><td>70</td><td>17.8%</td><td>2.57 [0.11 , 62.01]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>661</td><td/><td>483</td><td>100.0%</td><td>2.46 [0.65 , 9.36]</td></tr><tr><td>Total events:</td><td colspan=\"2\">11</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.58, df = 3 (P = 0.90); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.32 (P = 0.19)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF391": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>50.4.1 PHT vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>45</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>416</td><td>5</td><td>359</td><td>71.3%</td><td>0.35 [0.07 , 1.77]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>82</td><td>2</td><td>70</td><td>28.7%</td><td>0.43 [0.04 , 4.61]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>542</td><td/><td>474</td><td>100.0%</td><td>0.37 [0.10 , 1.42]</td><td/></tr><tr><td>Total events:</td><td>3</td><td/><td>7</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.02, df = 1 (P = 0.89); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.45 (P = 0.15)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours TPM</td></tr><tr><td>Analysis 50.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF392": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">51.4.1 PHT vs ZNS (cohort studies)</td><td>1</td><td/><td>108</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.98 [0.04, 23.26]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.5 PHT vs ZNS: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.5.1 PHT vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 51.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>PHT</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">50.5.1 PHT vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>44</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>119</td><td>0</td><td>9</td><td>14.7%</td><td>0.25 [0.01 , 5.75]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>416</td><td>5</td><td>359</td><td>85.3%</td><td>0.69 [0.19 , 2.55]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>82</td><td>0</td><td>70</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>661</td><td/><td>483</td><td>100.0%</td><td>0.63 [0.19 , 2.09]</td></tr><tr><td>Total events:</td><td/><td>5</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.35, df = 1 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.76 (P = 0.45)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours TPM</td></tr><tr><td colspan=\"2\">Comparison 51. PHT vs ZNS</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">51.1 PHT vs ZNS: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.1.1 PHT vs ZNS (cohort studies)</td><td>2</td><td/><td>638</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.28 [0.42, 3.93]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.2 PHT vs ZNS: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.2.1 PHT vs ZNS (cohort studies)</td><td>1</td><td/><td>108</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.11 [0.00, 2.58]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.3 PHT vs ZNS: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.3.1 PHT vs ZNS (cohort studies)</td><td>1</td><td/><td>108</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.98 [0.04, 23.26]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">51.4 PHT vs ZNS: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF393": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>12</td><td>416</td><td>0</td><td>90</td><td>14.6%</td><td>5.46 [0.33 , 91.31]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>7</td><td>106</td><td>3</td><td>26</td><td>85.4%</td><td>0.57 [0.16 , 2.06]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>522</td><td/><td>116</td><td>100.0%</td><td>1.28 [0.42 , 3.93]</td></tr><tr><td>Total events:</td><td>19</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.54, df = 1 (P = 0.11); I\u00b2 = 61%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.44 (P = 0.66)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours ZNS</td></tr><tr><td>Analysis 51.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF394": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>51.2.1 PHT vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>82</td><td>1</td><td>26</td><td>100.0%</td><td>0.11 [0.00 , 2.58]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>82</td><td/><td>26</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.37 (P = 0.17)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF395": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">Risk Ratio</td><td/><td/></tr><tr><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td><td/></tr><tr><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">Favours PHT</td><td colspan=\"3\">Favours ZNS</td></tr><tr><td>Analysis 51.3.</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF396": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 51.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PHT</td><td colspan=\"2\">ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">51.3.1 PHT vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>82</td><td>0</td><td>26</td><td>100.0%</td><td>0.98 [0.04 , 23.26]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>82</td><td/><td>26</td><td>100.0%</td><td>0.98 [0.04 , 23.26]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.02 (P = 0.99)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF397": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>51.4.1 PHT vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>1</td><td>82</td><td>0</td><td>26</td><td>100.0%</td><td>0.98 [0.04 , 23.26]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>82</td><td/><td>26</td><td>100.0%</td><td>0.98 [0.04 , 23.26]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.02 (P = 0.99)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours ZNS</td></tr><tr><td>Analysis 51.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF398": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PHT</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>51.5.1 PHT vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>82</td><td>0</td><td>26</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PHT</td><td>Favours ZNS</td></tr><tr><td>Comparison 52. PB vs OXC</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td/><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/><td/></tr><tr><td>52.1 PB vs OXC: All Major Malforma-</td><td>10</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.1.1 PB vs OXC (cohort studies)</td><td>8</td><td/><td>676</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.61 [0.83, 3.14]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.1.2 PB vs OXC (database studies)</td><td>2</td><td/><td>95</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>3.07 [0.50, 18.92]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.2 PB vs OXC: Neural Tube Malfor-</td><td>6</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.2.1 PB vs OXC (cohort studies)</td><td>6</td><td/><td>654</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.57 [0.06, 37.94]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.3 PB vs OXC: Cardiac Malforma-</td><td>7</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.3.1 PB vs OXC (cohort studies)</td><td>7</td><td/><td>658</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.58 [0.94, 7.09]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>52.4 PB vs OXC: Oro-Facial Cle /Cran-</td><td>5</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td><td/></tr><tr><td>Monotherapy</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF399": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">52.4.1 PB vs OXC (cohort studies)</td><td>5</td><td>446</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.66 [0.41, 32.43]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">52.5 PB vs OXC: Skeletal/Limb Malfor-</td><td>6</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">52.5.1 PB vs OXC (cohort studies)</td><td>6</td><td>654</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.98 [0.16, 5.97]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 52.1.</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF400": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>2</td><td>1</td><td>19</td><td>3.1%</td><td>2.22 [0.11 , 42.95]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>0</td><td>5</td><td>1</td><td>9</td><td>9.1%</td><td>0.56 [0.03 , 11.57]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>8</td><td>137</td><td>5</td><td>71</td><td>53.0%</td><td>0.83 [0.28 , 2.44]</td></tr><tr><td>Meischenguiser 2004</td><td>1</td><td>5</td><td>0</td><td>35</td><td>1.1%</td><td>18.00 [0.83 , 392.32]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>199</td><td>4</td><td>182</td><td>33.6%</td><td>2.52 [0.82 , 7.76]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>354</td><td/><td>322</td><td>100.0%</td><td>1.61 [0.83 , 3.14]</td></tr><tr><td>Total events:</td><td>20</td><td/><td>11</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.93, df = 4 (P = 0.29); I\u00b2 = 19%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.41 (P = 0.16)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>52.1.2 PB vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>27</td><td>1</td><td>57</td><td>51.1%</td><td>4.22 [0.40 , 44.56]</td></tr><tr><td>Sweden Health Record Registers</td><td>1</td><td>7</td><td>0</td><td>4</td><td>48.9%</td><td>1.88 [0.09 , 37.63]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>34</td><td/><td>61</td><td>100.0%</td><td>3.07 [0.50 , 18.92]</td></tr><tr><td>Total events:</td><td>3</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.17, df = 1 (P = 0.68); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.21 (P = 0.23)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF401": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 52.3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>PB</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">52.2.1 PB vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>2</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>137</td><td>0</td><td>71</td><td>100.0%</td><td>1.57 [0.06 , 37.94]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>5</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>199</td><td>0</td><td>182</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>349</td><td/><td>305</td><td>100.0%</td><td>1.57 [0.06 , 37.94]</td></tr><tr><td>Total events:</td><td/><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.28 (P = 0.78)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF402": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>52.3.1 PB vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>137</td><td>3</td><td>71</td><td>85.6%</td><td>1.04 [0.27 , 4.02]</td><td/></tr><tr><td>Meischenguiser 2004</td><td>1</td><td>5</td><td>0</td><td>35</td><td>3.1%</td><td>18.00 [0.83 , 392.32]</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>199</td><td>0</td><td>182</td><td>11.3%</td><td>10.06 [0.56 , 180.76]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>352</td><td/><td>306</td><td>100.0%</td><td>2.58 [0.94 , 7.09]</td><td/></tr><tr><td>Total events:</td><td>12</td><td/><td>3</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.12, df = 2 (P = 0.13); I\u00b2 = 51%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.84 (P = 0.07)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours OXC</td></tr><tr><td>Analysis 52.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF403": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>52.4.1 PB vs OXC (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>12</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>4</td><td/><td>Not estimable</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>5</td><td>0</td><td>35</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>199</td><td>1</td><td>182</td><td>100.0%</td><td>3.66 [0.41 , 32.43]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>212</td><td/><td>234</td><td>100.0%</td><td>3.66 [0.41 , 32.43]</td><td/></tr><tr><td>Total events:</td><td>4</td><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.16 (P = 0.24)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF404": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">OXC</td><td/></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>12</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>4</td><td/></tr><tr><td>Kaur 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>137</td><td>1</td><td>71</td><td>55.8%</td></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>5</td><td>0</td><td>35</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>199</td><td>1</td><td>182</td><td>44.2%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>349</td><td/><td>305</td><td>100.0%</td></tr><tr><td>Total events:</td><td>3</td><td/><td>2</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 0.95); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.02 (P = 0.98)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF405": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 53.1</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>1.04 [0.10 , 11.24]</td><td/><td/></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>0.91 [0.06 , 14.52]</td><td/><td/></tr><tr><td/><td/><td>0.98 [0.16 , 5.97]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td>Favours PB</td><td colspan=\"2\">Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF406": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Delmi\u0161 1991</td><td>4</td><td>58</td><td>0</td><td>9</td><td>6.4%</td><td>1.53 [0.09 , 26.21]</td></tr><tr><td>Kaaja 2003</td><td>0</td><td>5</td><td>1</td><td>6</td><td>10.3%</td><td>0.39 [0.02 , 7.88]</td></tr><tr><td>Kaneko 1999</td><td>4</td><td>79</td><td>5</td><td>35</td><td>51.8%</td><td>0.35 [0.10 , 1.24]</td></tr><tr><td>Koch 1992</td><td>0</td><td>4</td><td>0</td><td>21</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>4</td><td>83</td><td>3</td><td>35</td><td>31.5%</td><td>0.56 [0.13 , 2.38]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>241</td><td/><td>110</td><td>100.0%</td><td>0.50 [0.21 , 1.16]</td></tr><tr><td>Total events:</td><td>12</td><td/><td>9</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.93, df = 3 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.62 (P = 0.11)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>53.1.2 PB vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>1</td><td>7</td><td>0</td><td>3</td><td>100.0%</td><td>1.50 [0.08 , 29.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>7</td><td/><td>3</td><td>100.0%</td><td>1.50 [0.08 , 29.15]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.27 (P = 0.79)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours PRM</td></tr><tr><td>Analysis 53.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF407": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 53.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>PB</td><td/><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>83</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF408": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>83</td><td>1</td><td>35</td><td>100.0%</td><td>0.42 [0.03 , 6.55]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>95</td><td/><td>39</td><td>100.0%</td><td>0.42 [0.03 , 6.55]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.62 (P = 0.54)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours PRM</td></tr><tr><td>Analysis 53.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF409": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>83</td><td>0</td><td>35</td><td>Not estimable</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>12</td><td>0</td><td>4</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours PRM</td></tr><tr><td>Analysis 53.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF410": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>83</td><td>0</td><td>35</td><td>100.0%</td><td>1.29 [0.05 , 30.82]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>12</td><td>0</td><td>4</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>95</td><td/><td>39</td><td>100.0%</td><td>1.</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.16 (P = 0.88)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF411": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"3\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 54.1</td><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td>Favours PB</td><td/><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF412": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>2</td><td>1</td><td>53</td><td>1.3%</td><td>6.00 [0.30 , 118.36]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>8</td><td>137</td><td>0</td><td>9</td><td>7.9%</td><td>1.23 [0.08 , 19.84]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>199</td><td>15</td><td>359</td><td>90.8%</td><td>1.32 [0.62 , 2.82]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>340</td><td/><td>426</td><td>100.0%</td><td>1.38 [0.68 , 2.81]</td></tr><tr><td>Total events:</td><td>19</td><td/><td>16</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.95, df = 2 (P = 0.62); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.89 (P = 0.38)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>54.1.2 PB vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>27</td><td>2</td><td>48</td><td>64.3%</td><td>1.78 [0.27 , 11.91]</td></tr><tr><td>Sweden Health Record Registers</td><td>1</td><td>7</td><td>0</td><td>1</td><td>35.7%</td><td>0.75 [0.05 , 12.34]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>34</td><td/><td>49</td><td>100.0%</td><td>1.41 [0.30 , 6.68]</td></tr><tr><td>Total events:</td><td>3</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.25, df = 1 (P = 0.62); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.43 (P = 0.66)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours TPM</td></tr><tr><td>Analysis 54.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF413": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>54.2.1 PB vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>44</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>137</td><td>0</td><td>9</td><td>100.0%</td><td>0.22 [0.01 , 5.00]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>199</td><td>0</td><td>359</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>343</td><td/><td>417</td><td>100.0%</td><td>0.22 [0.01 , 5.00]</td><td/></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.95 (P = 0.34)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF414": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 54.4.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>PB</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">54.3.1 PB vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>44</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>2</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>6</td><td>137</td><td>0</td><td>9</td><td>56.7%</td><td>0.94 [0.06 , 15.55]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>199</td><td>1</td><td>359</td><td>43.3%</td><td>9.02 [1.06 , 76.67]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>343</td><td/><td>417</td><td>100.0%</td><td>4.44 [0.98 , 20.12]</td></tr><tr><td>Total events:</td><td colspan=\"2\">11</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.60, df = 1 (P = 0.21); I\u00b2 = 37%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.94 (P = 0.05)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF415": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>54.4.1 PB vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>44</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>199</td><td>5</td><td>359</td><td>100.0%</td><td>1.44 [0.39 , 5.31]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>206</td><td/><td>408</td><td>100.0%</td><td>1.44 [0.39 , 5.31]</td><td/></tr><tr><td>Total events:</td><td>4</td><td/><td>5</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.55 (P = 0.58)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours TPM</td></tr><tr><td>Analysis 54.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF416": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">55.5 PB vs ZNS: Skeletal/Limb Malfor-</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">55.5.1 PB vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 55.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>PB</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">54.5.1 PB vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>44</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>2</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>2</td><td>137</td><td>0</td><td>9</td><td>20.7%</td><td>0.36 [0.02 , 7.05]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>199</td><td>5</td><td>359</td><td>79.3%</td><td>0.36 [0.04 , 3.07]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>343</td><td/><td>417</td><td>100.0%</td><td>0.36 [0.06 , 2.19]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 1.00); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.11 (P = 0.27)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours TPM</td></tr><tr><td colspan=\"2\">Comparison 55. PB vs ZNS</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">55.1 PB vs ZNS: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">55.1.1 PB vs ZNS (cohort studies)</td><td>2</td><td/><td>292</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>10.46 [0.62,</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>175.67]</td></tr><tr><td colspan=\"2\">55.2 PB vs ZNS: Neural Tube Malfor-</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">55.2.1 PB vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">55.3 PB vs ZNS: Cardiac Malforma-</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">55.3.1 PB vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">55.4 PB vs ZNS: Oro-Facial Cle /Cran-</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">55.4.1 PB vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF417": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>55.1.1 PB vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>11</td><td>199</td><td>0</td><td>90</td><td>100.0%</td><td>10.46 [0.62 , 175.67]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>201</td><td/><td>91</td><td>100.0%</td><td>10.46 [0.62 , 175.67]</td><td/></tr><tr><td>Total events:</td><td>11</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.63 (P = 0.10)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours ZNS</td></tr><tr><td>Analysis 55.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF418": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 55.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>PB</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours ZNS</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF419": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">55.3.1 PB vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours ZNS</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Analysis 55.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF420": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>PB</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">55.4.1 PB vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours ZNS</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF421": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 56. TPM vs ZNS</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"3\">56.1 TPM vs ZNS: All Major Malforma-</td><td>4</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.1.1 TPM vs ZNS (cohort studies)</td><td/><td>4</td><td/><td/><td>570</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.59 [0.54, 4.66]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">56.2 TPM vs ZNS: Neural Tube Malfor-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.2.1 TPM vs ZNS (cohort studies)</td><td/><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.3 TPM vs ZNS: Cardiac Malforma-</td><td/><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.3.1 TPM vs ZNS (cohort studies)</td><td/><td>3</td><td/><td/><td>121</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>6.00 [0.28, 129.16]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.4 TPM vs ZNS: Oro-Facial Cle /</td><td/><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.4.1 TPM vs ZNS (cohort studies)</td><td/><td>3</td><td/><td/><td>121</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.90 [0.09, 38.34]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.5 TPM vs ZNS: Skeletal/Limb Mal-</td><td/><td>3</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">56.5.1 TPM vs ZNS (cohort studies)</td><td/><td>3</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>PB</td><td/><td/><td>ZNS</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">55.5.1 PB vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td/><td>2</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours ZNS</td></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF422": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">TPM</td><td>ZNS</td><td/><td/></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>1</td><td>13</td><td>10.9%</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>15</td><td>359</td><td>0</td><td>90</td><td>13.8%</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>3</td><td>70</td><td>3</td><td>26</td><td>75.4%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>440</td><td/><td>130</td><td>100.0%</td></tr><tr><td>Total events:</td><td>19</td><td/><td>4</td><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.75, df = 2 (P = 0.09); I\u00b2 = 58%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.85 (P = 0.40)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF423": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 56.2.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>Not estimable</td><td/><td/></tr><tr><td/><td/><td>2.17 [0.16 , 29.10]</td><td/><td/></tr><tr><td/><td/><td>7.84 [0.47 , 129.74]</td><td/><td/></tr><tr><td/><td/><td>0.37 [0.08 , 1.73]</td><td/><td/></tr><tr><td/><td/><td>1.59 [0.54 , 4.66]</td><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours TPM</td><td colspan=\"2\">Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF424": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">TPM</td><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">56.2.1 TPM vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>6</td><td>0</td><td>13</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Analysis 56.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF425": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td>1</td><td>6</td><td>0</td><td>13</td><td>100.0%</td><td>6.00 [0.28 , 129.16]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>70</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>81</td><td/><td>40</td><td>100.0%</td><td>6.00 [0.28 , 129.16]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.14 (P = 0.25)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours ZNS</td></tr><tr><td>Analysis 56.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF426": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/></tr><tr><td>MONEAD 2020</td><td>0</td><td>6</td><td>0</td><td>13</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>2</td><td>70</td><td>0</td><td>26</td><td>100.0%</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>81</td><td/><td>40</td><td>100.0%</td></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.42 (P = 0.68)</td><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF427": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Not estimable</td></tr><tr><td>Not estimable</td></tr><tr><td>1.90 [0.09 , 38.34]</td></tr><tr><td>1</td></tr></table>",
                "type_str": "table"
            },
            "TABREF428": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 56.5.</td><td/><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours TPM</td><td/><td>Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF429": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 57.1</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">TPM</td><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">56.5.1 TPM vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>5</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>MONEAD 2020</td><td/><td>0</td><td>6</td><td>0</td><td>13</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>0</td><td>70</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Comparison 57. TPM vs LAC</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">57.1 TPM vs LAC: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">57.1.1 TPM vs LAC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">57.2 TPM vs LAC: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">57.2.1 TPM vs LAC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">57.3 TPM vs LAC: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">57.3.1 TPM vs LAC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">57.4 TPM vs LAC: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">57.4.1 TPM vs LAC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">57.5 TPM vs LAC: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">57.5.1 TPM vs LAC (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF430": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours LAC</td></tr><tr><td>Analysis 57.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF431": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours LAC</td></tr><tr><td>Analysis 57.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF432": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF433": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 57.4.</td><td/><td/><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td colspan=\"2\">Favours TPM</td><td/><td colspan=\"2\">Favours LAC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF434": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours LAC</td></tr><tr><td>Analysis 57.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF435": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td></tr><tr><td colspan=\"2\">58.4 VPA vs GBP: Oro-Facial Cle /</td><td/><td>2</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.4.1 VPA vs GBP (cohort studies)</td><td/><td>2</td><td/><td/><td>293</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.38 [0.09, 22.19]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.5 VPA vs GBP: Skeletal/Limb Mal-</td><td/><td>2</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.5.1 VPA vs GBP (cohort studies)</td><td/><td>2</td><td/><td/><td>293</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.72 [0.04, 12.14]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td colspan=\"2\">TPM</td><td/><td colspan=\"2\">LAC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td/><td>5</td><td>0</td><td/><td>1</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours TPM</td><td>Favours LAC</td></tr><tr><td colspan=\"2\">Comparison 58. VPA vs GBP</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td></tr><tr><td colspan=\"3\">58.1 VPA vs GBP: All Major Malforma-</td><td>5</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.1.1 VPA vs GBP (cohort studies)</td><td/><td>4</td><td/><td/><td>2031</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>4.27 [1.60, 11.35]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">58.1.2 VPA vs GBP (database studies)</td><td>1</td><td/><td/><td>286</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.74 [0.24, 59.08]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">58.2 VPA vs GBP: Neural Tube Malfor-</td><td>2</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.2.1 VPA vs GBP (cohort studies)</td><td/><td>2</td><td/><td/><td>293</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.83 [0.05, 13.81]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.3 VPA vs GBP: Cardiac Malforma-</td><td/><td>2</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">58.3.1 VPA vs GBP (cohort studies)</td><td/><td>2</td><td/><td/><td>293</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.46 [0.08, 2.70]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF436": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>0</td><td>14</td><td>14.9%</td><td>4.48 [0.29 , 69.38]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>1</td><td>2</td><td>32.9%</td><td>0.14 [0.01 , 2.60]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>1</td><td>145</td><td>21.6%</td><td>13.47 [1.85 , 97.81]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>82</td><td>1220</td><td>1</td><td>31</td><td>30.6%</td><td>2.08 [0.30 , 14.49]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1839</td><td/><td>192</td><td>100.0%</td><td>4.27 [1.60 , 11.35]</td></tr><tr><td>Total events:</td><td>155</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 7.08, df = 3 (P = 0.07); I\u00b2 = 58%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.90 (P = 0.004)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>58.1.2 VPA vs GBP (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>26</td><td>268</td><td>0</td><td>18</td><td>100.0%</td><td>3.74 [0.24 , 59.08]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>268</td><td/><td>18</td><td>100.0%</td><td>3.74 [0.24 , 59.08]</td></tr><tr><td>Total events:</td><td>26</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.94 (P = 0.35)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF437": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 58.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">VPA</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>7</td><td>271</td><td>0</td><td>14</td><td>100.0%</td><td>0.83 [0.05 , 13.81]</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>277</td><td/><td>16</td><td>100.0%</td><td>0.83 [0.05 , 13.81]</td></tr><tr><td>Total events:</td><td/><td>7</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.13 (P = 0.89)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours GBP</td></tr></table>",
                "type_str": "table"
            },
            "TABREF438": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>10</td><td>271</td><td>0</td><td>14</td><td>31.1%</td><td>1.16 [0.07 , 18.84]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>1</td><td>2</td><td>68.9%</td><td>0.14 [0.01 , 2.60]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>277</td><td/><td>16</td><td>100.0%</td><td>0.46 [0.08 , 2.70]</td></tr><tr><td>Total events:</td><td>10</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.04, df = 1 (P = 0.31); I\u00b2 = 4%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.86 (P = 0.39)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours GBP</td></tr><tr><td>Analysis 58.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF439": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>12</td><td>271</td><td>0</td><td>14</td><td>100.0%</td><td>1.38 [0.09 , 22.19]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>277</td><td/><td>16</td><td>100.0%</td><td>1.38 [0.09 , 22.19]</td></tr><tr><td>Total events:</td><td>12</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.23 (P = 0.82)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours GBP</td></tr><tr><td>Analysis 58.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF440": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VPA</td><td/><td>GBP</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>6</td><td>271</td><td>0</td><td>14</td><td>100.0%</td><td>0.72 [0.04 , 12.14]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>277</td><td/><td>16</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>6</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.23 (P = 0.82)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF441": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 59.2.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours GBP</td></tr><tr><td colspan=\"2\">Comparison 59. VPA vs LAC</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">59.1 VPA vs LAC: All Major Malforma-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">59.1.1 VPA vs LAC (cohort studies)</td><td>1</td><td>18</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.00 [0.08, 12.56]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF442": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VPA</td><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>1</td><td>100.0%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>17</td><td/><td>1</td><td>100.0%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.76 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LAC</td></tr><tr><td>Analysis 59.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF443": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VPA</td><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>1</td><td>100.0%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>17</td><td/><td>1</td><td>100.0%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.76 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LAC</td></tr><tr><td>Analysis 59.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF444": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VPA</td><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>1</td><td>100.0%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>17</td><td/><td>1</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.76 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF445": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 59.5.</td><td/><td/><td/><td/></tr><tr><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td colspan=\"2\">Favours VPA</td><td/><td colspan=\"2\">Favours LAC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF446": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">Trusted evidence.</td><td/><td/><td/><td/></tr><tr><td>Library</td><td colspan=\"2\">Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 60.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Experimental</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>17</td><td>0</td><td>1</td><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours LAC</td></tr><tr><td colspan=\"2\">Comparison 60. VPA vs LEV</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">60.1 VPA vs LEV: All Major Malforma-</td><td/><td/><td/><td/><td/></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF447": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>5</td><td>139</td><td>21.7%</td><td>4.12 [1.67 , 10.18]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>2</td><td>67</td><td>1.9%</td><td>1.51 [0.08 , 29.04]</td></tr><tr><td>Jimenez 2020</td><td>4</td><td>17</td><td>0</td><td>12</td><td>1.9%</td><td>6.50 [0.38 , 110.51]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>27</td><td>341</td><td>5</td><td>106</td><td>24.5%</td><td>1.68 [0.66 , 4.25]</td></tr><tr><td>Martinez Ferri 2018</td><td>10</td><td>112</td><td>2</td><td>31</td><td>10.1%</td><td>1.38 [0.32 , 5.99]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>11</td><td>450</td><td>29.6%</td><td>3.80 [1.93 , 7.47]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>82</td><td>1220</td><td>2</td><td>304</td><td>10.3%</td><td>10.22 [2.53 , 41.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2342</td><td/><td>1143</td><td>100.0%</td><td>3.77 [2.48 , 5.74]</td></tr><tr><td>Total events:</td><td>196</td><td/><td>27</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 7.22, df = 6 (P = 0.30); I\u00b2 = 17%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 6.21 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>60.1.2 VPA vs LEV (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>39</td><td>330</td><td>5</td><td>130</td><td>70.8%</td><td>3.07 [1.24 , 7.62]</td></tr><tr><td>Norwegian Health Record Registers</td><td>21</td><td>333</td><td>2</td><td>118</td><td>29.2%</td><td>3.72 [0.89 , 15.63]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>663</td><td/><td>248</td><td>100.0%</td><td>3.26 [1.51 , 7.03]</td></tr><tr><td>Total events:</td><td>60</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.05, df = 1 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.02 (P = 0.003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LEV</td></tr><tr><td>Analysis 60.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF448": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>7</td><td>247</td><td>0</td><td>53</td><td>17.9%</td><td>3.27 [0.19 , 56.33]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>12</td><td>12.7%</td><td>2.17 [0.10 , 49.07]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>0</td><td>106</td><td>16.6%</td><td>2.19 [0.11 , 42.06]</td></tr><tr><td>Martinez Ferri 2018</td><td>3</td><td>112</td><td>0</td><td>31</td><td>17.0%</td><td>1.98 [0.11 , 37.39]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>1</td><td>450</td><td>18.3%</td><td>5.57 [0.63 , 49.63]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>0</td><td>304</td><td>17.5%</td><td>6.74 [0.40 , 113.14]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2298</td><td/><td>1048</td><td>100.0%</td><td>3.</td></tr><tr><td>Total events:</td><td>31</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.73, df = 5 (P = 0.98); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.31 (P = 0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF449": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 60.3.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VPA</td><td colspan=\"2\">Favours LEV</td></tr></table>",
                "type_str": "table"
            },
            "TABREF450": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>11</td><td>247</td><td>1</td><td>53</td><td>15.9%</td><td>2.36 [0.31 , 17.89]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>1</td><td>67</td><td>3.4%</td><td>2.52 [0.11 , 57.27]</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>12</td><td>5.6%</td><td>2.17 [0.10 , 49.07]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>3</td><td>106</td><td>44.2%</td><td>2.07 [0.63 , 6.84]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>112</td><td>1</td><td>31</td><td>15.1%</td><td>0.55 [0.05 , 5.91]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>1</td><td>450</td><td>8.1%</td><td>11.15 [1.40 , 88.67]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1220</td><td>0</td><td>304</td><td>7.7%</td><td>7.24 [0.43 , 121.10]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2299</td><td/><td>1057</td><td>100.0%</td><td>3.04 [1.46 , 6.34]</td></tr><tr><td>Total events:</td><td>56</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.38, df = 6 (P = 0.63); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.97 (P = 0.003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LEV</td></tr><tr><td>Analysis 60.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF451": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 60.5.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>1</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>8</td><td>247</td><td>1</td><td>53</td><td>39.0%</td><td>1.72 [0.22 , 13.44]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>12</td><td>13.7%</td><td>2.17 [0.10 , 49.07]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>112</td><td>0</td><td>31</td><td>18.4%</td><td>1.42 [0.07 , 28.75]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>0</td><td>450</td><td>9.9%</td><td>12.53 [0.68 , 231.88]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>0</td><td>304</td><td>18.9%</td><td>6.74 [0.40 , 113.14]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1958</td><td/><td>951</td><td>100.0%</td><td>3.75 [1.19 , 11.77]</td></tr><tr><td>Total events:</td><td/><td>28</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.90, df = 4 (P = 0.75); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 2.26 (P = 0.02)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours LEV</td></tr></table>",
                "type_str": "table"
            },
            "TABREF452": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 61.1</td><td>VPA</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>14</td><td>247</td><td>0</td><td>53</td><td>11.1%</td><td>6.31 [0.38 , 104.23]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>17</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>2</td><td>106</td><td>41.1%</td><td>0.62 [0.12 , 3.35]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>0</td><td>112</td><td>1</td><td>31</td><td>31.5%</td><td>0.09 [0.00 , 2.26]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>6</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>0</td><td>450</td><td>5.6%</td><td>15.31 [0.85 , 275.93]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>10</td><td>1220</td><td>0</td><td>304</td><td>10.8%</td><td>5.25 [0.31 , 89.27]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2298</td><td/><td>1048</td><td>100.0%</td><td>2.41 [0.99 , 5.85]</td></tr><tr><td>Total events:</td><td/><td>33</td><td/><td>3</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 8.80, df = 4 (P = 0.07); I\u00b2 = 55%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.95 (P = 0.05)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours LEV</td></tr><tr><td colspan=\"2\">Comparison 61. VPA vs LTG</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">61.1 VPA vs LTG: All Major Malforma-</td><td>16</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.1.1 VPA vs LTG (cohort studies)</td><td>12</td><td/><td>6896</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.50 [2.76, 4.46]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.1.2 VPA vs LTG (database studies)</td><td>4</td><td/><td>3590</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.49 [1.86, 3.35]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.2 VPA vs LTG: Neural Tube Malfor-</td><td>11</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.2.1 VPA vs LTG (cohort studies)</td><td>11</td><td/><td>6708</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>7.48 [3.27, 17.13]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.3 VPA vs LTG: Cardiac Malforma-</td><td>12</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.3.1 VPA vs LTG (cohort studies)</td><td>12</td><td/><td>6729</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.39 [2.06, 5.60]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.4 VPA vs LTG: Oro-Facial Cle /</td><td>11</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.4.1 VPA vs LTG (cohort studies)</td><td>11</td><td/><td>6338</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>4.16 [2.14, 8.08]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.5 VPA vs LTG: Skeletal/Limb Mal-</td><td>11</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">61.5.1 VPA vs LTG (cohort studies)</td><td>11</td><td/><td>6708</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>6.09 [2.91, 12.76]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF453": {
                "text": "Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>61.1.1 VPA vs LTG (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>20</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>20</td><td>406</td><td>24.2%</td><td>3.01 [1.81 , 5.01]</td><td/></tr><tr><td>Cassina 2013</td><td>3</td><td>45</td><td>0</td><td>26</td><td>0.9%</td><td>4.11 [0.22 , 76.55]</td><td/></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td><td/></tr><tr><td>Jimenez 2020</td><td>4</td><td>17</td><td>0</td><td>19</td><td>0.7%</td><td>10.00 [0.58 , 173.14]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>27</td><td>341</td><td>1</td><td>50</td><td>2.5%</td><td>3.96 [0.55 , 28.49]</td><td/></tr><tr><td>Martinez Ferri 2018</td><td>10</td><td>112</td><td>2</td><td>111</td><td>2.9%</td><td>4.96 [1.11 , 22.10]</td><td/></tr><tr><td>Meador 2006 (1)</td><td>12</td><td>69</td><td>1</td><td>98</td><td>1.2%</td><td>17.04 [2.27 , 128.04]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td><td/></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>37</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>31</td><td>1562</td><td>15.4%</td><td>4.68 [2.87 , 7.62]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>82</td><td>1220</td><td>49</td><td>2098</td><td>52.2%</td><td>2.88 [2.03 , 4.07]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2459</td><td/><td>4437</td><td>100.0%</td><td>3.50 [2.76 , 4.46]</td><td/></tr><tr><td>Total events:</td><td>211</td><td/><td>104</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.05, df = 7 (P = 0.53); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 10.24 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>61.1.2 VPA vs LTG (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>39</td><td>330</td><td>47</td><td>1235</td><td>41.8%</td><td>3.11 [2.07 , 4.66]</td><td/></tr><tr><td>Norwegian Health Record Registers</td><td>21</td><td>333</td><td>28</td><td>833</td><td>33.7%</td><td>1.88 [1.08 , 3.26]</td><td/></tr><tr><td>Sweden Health Record Registers</td><td>26</td><td>268</td><td>4</td><td>90</td><td>12.6%</td><td>2.18 [0.78 , 6.09]</td><td/></tr><tr><td>UK Health Record THIN Register</td><td>10</td><td>157</td><td>9</td><td>344</td><td>11.9%</td><td>2.43 [1.01 , 5.87]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1088</td><td/><td>2502</td><td>100.0%</td><td>2.49 [1.86 , 3.35]</td><td/></tr><tr><td>Total events:</td><td>96</td><td/><td>88</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.21, df = 3 (P = 0.53); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 6.07 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LTG</td></tr><tr><td>Footnotes</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>(1)</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF454": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>7</td><td>247</td><td>0</td><td>282</td><td>9.2%</td><td>17.12 [0.98 , 298.18]</td></tr><tr><td>Cassina 2013</td><td>1</td><td>45</td><td>0</td><td>26</td><td>12.4%</td><td>1.76 [0.07 , 41.72]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>19</td><td>9.3%</td><td>3.33 [0.14 , 76.75]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>0</td><td>50</td><td>17.1%</td><td>1.04 [0.05 , 19.91]</td></tr><tr><td>Martinez Ferri 2018</td><td>3</td><td>112</td><td>0</td><td>111</td><td>9.8%</td><td>6.94 [0.36 , 132.78]</td></tr><tr><td>Meador 2006</td><td>0</td><td>69</td><td>0</td><td>98</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>2</td><td>1562</td><td>13.4%</td><td>9.67 [1.78 , 52.58]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>2</td><td>2098</td><td>28.8%</td><td>11.18 [2.53 , 49.45]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2415</td><td/><td>4293</td><td>100.0%</td><td>7.48 [3.</td></tr><tr><td>Total events:</td><td>32</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.46, df = 6 (P = 0.75); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 4.76 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF455": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 61.3.</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VPA</td><td/><td>Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF456": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>11</td><td>247</td><td>4</td><td>282</td><td>21.9%</td><td>3.14 [1.01 , 9.73]</td></tr><tr><td>Cassina 2013</td><td>2</td><td>45</td><td>0</td><td>26</td><td>3.7%</td><td>2.93 [0.15 , 58.88]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>19</td><td>2.8%</td><td>3.33 [0.14 , 76.75]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>1</td><td>50</td><td>10.2%</td><td>2.93 [0.40 , 21.37]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>112</td><td>2</td><td>111</td><td>11.8%</td><td>0.99 [0.14 , 6.91]</td></tr><tr><td>Meador 2006</td><td>4</td><td>69</td><td>1</td><td>98</td><td>4.8%</td><td>5.68 [0.65 , 49.73]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>3</td><td>1562</td><td>6.0%</td><td>12.90 [3.44 , 48.35]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1220</td><td>9</td><td>2098</td><td>38.8%</td><td>2.68 [1.16 , 6.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2416</td><td/><td>4313</td><td>100.0%</td><td>3.39 [2.06 , 5.60]</td></tr><tr><td>Total events:</td><td>62</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.04, df = 7 (P = 0.54); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 4.78 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours LTG</td></tr><tr><td>Analysis 61.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF457": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 61.5.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>1</td><td>0</td><td>20</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>8</td><td>247</td><td>4</td><td>282</td><td>41.5%</td><td>2.28 [0.70 , 7.49]</td></tr><tr><td>Cassina 2013</td><td/><td>0</td><td>45</td><td>0</td><td>26</td><td/><td>Not estimable</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>19</td><td>5.3%</td><td>3.33 [0.14 , 76.75]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>112</td><td>0</td><td>111</td><td>5.6%</td><td>4.96 [0.24 , 102.07]</td></tr><tr><td>Meador 2006</td><td/><td>1</td><td>69</td><td>0</td><td>98</td><td>4.6%</td><td>4.24 [0.18 , 102.63]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>7</td><td>1562</td><td>26.7%</td><td>2.76 [0.81 , 9.38]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>2</td><td>2098</td><td>16.4%</td><td>11.18 [2.53 , 49.45]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2075</td><td/><td>4263</td><td>100.0%</td><td>4.16 [2.14 , 8.08]</td></tr><tr><td>Total events:</td><td/><td>29</td><td/><td>13</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 3.14, df = 5 (P = 0.68); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 4.21 (P &lt; 0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours LTG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF458": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td>VPA</td><td/><td>LTG pants</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">62.5.1 VPA vs TPM (cohort studies)</td><td>6</td><td/><td>2689</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.45 [0.55, 3.82]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>14</td><td>247</td><td>2</td><td>282</td><td>28.0%</td><td>7.99 [1.83 , 34.82]</td></tr><tr><td>Cassina 2013</td><td/><td>2</td><td>45</td><td>0</td><td>26</td><td>9.4%</td><td>2.93 [0.15 , 58.88]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>17</td><td>0</td><td>19</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>0</td><td>50</td><td>13.0%</td><td>1.34 [0.07 , 24.56]</td></tr><tr><td colspan=\"2\">Martinez Ferri 2018 Analysis 62.1.</td><td>0</td><td>112</td><td>0</td><td>111</td><td/><td>Not estimable</td></tr><tr><td>Meador 2006</td><td/><td>1</td><td>69</td><td>0</td><td>98</td><td>6.2%</td><td>4.24 [0.18 , 102.63]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td/><td>0</td><td>6</td><td>0</td><td>37</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>2</td><td>1562</td><td>10.3%</td><td>12.09 [2.36 , 62.04]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>10</td><td>1220</td><td>3</td><td>2098</td><td>33.1%</td><td>5.73 [1.58 , 20.79]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2415</td><td/><td>4293</td><td>100.0%</td><td>6.09 [2.91 , 12.76]</td></tr><tr><td>Total events:</td><td/><td>36</td><td/><td>7</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 2.13, df = 5 (P = 0.83); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 4.79 (P &lt; 0.00001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours LTG</td></tr><tr><td colspan=\"2\">Comparison 62. VPA vs TPM</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">62.1 VPA vs TPM: All Major Malforma-</td><td>9</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.1.1 VPA vs TPM (cohort studies)</td><td>7</td><td/><td>2723</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.47 [1.50, 4.08]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.1.2 VPA vs TPM (database studies)</td><td>2</td><td/><td>650</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.27 [0.36, 4.39]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.2 VPA vs TPM: Neural Tube Malfor-</td><td>6</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.2.1 VPA vs TPM (cohort studies)</td><td>6</td><td/><td>2665</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.39 [0.73, 7.80]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.3 VPA vs TPM: Cardiac Malforma-</td><td>6</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.3.1 VPA vs TPM (cohort studies)</td><td>6</td><td/><td>2670</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.48 [1.16, 10.48]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.4 VPA vs TPM: Oro-Facial Cle /</td><td>6</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.4.1 VPA vs TPM (cohort studies)</td><td>6</td><td/><td>2317</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.89 [0.37, 2.13]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">62.5 VPA vs TPM: Skeletal/Limb Mal-</td><td>6</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formation</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF459": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>62.1.1 VPA vs TPM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>1</td><td>53</td><td>7.3%</td><td>7.86 [1.11 , 55.84]</td><td/></tr><tr><td>Jimenez 2020</td><td>4</td><td>17</td><td>0</td><td>5</td><td>3.2%</td><td>3.00 [0.19 , 47.96]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>27</td><td>341</td><td>0</td><td>9</td><td>4.2%</td><td>1.61 [0.11 , 24.54]</td><td/></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>15</td><td>359</td><td>61.0%</td><td>2.22 [1.22 , 4.06]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>82</td><td>1220</td><td>3</td><td>70</td><td>24.4%</td><td>1.57 [0.51 , 4.84]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>2219</td><td/><td>504</td><td>100.0%</td><td>2.47 [1.50 , 4.08]</td><td/></tr><tr><td>Total events:</td><td>186</td><td/><td>19</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.20, df = 4 (P = 0.70); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.54 (P = 0.0004)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>62.1.2 VPA vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>21</td><td>333</td><td>2</td><td>48</td><td>77.9%</td><td>1.51 [0.37 , 6.25]</td><td/></tr><tr><td>Sweden Health Record Registers</td><td>26</td><td>268</td><td>0</td><td>1</td><td>22.1%</td><td>0.39 [0.03 , 4.46]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>601</td><td/><td>49</td><td>100.0%</td><td>1.27 [0.36 , 4.39]</td><td/></tr><tr><td>Total events:</td><td>47</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.95, df = 1 (P = 0.33); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.37 (P = 0.71)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours TPM</td></tr><tr><td>Analysis 62.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF460": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 62.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>7</td><td>247</td><td>0</td><td>45</td><td>21.2%</td><td>2.78 [0.16 , 47.88]</td></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>5</td><td>18.8%</td><td>1.00 [0.05 , 21.42]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>0</td><td>9</td><td>24.4%</td><td>0.20 [0.01 , 3.70]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>0</td><td>359</td><td>11.9%</td><td>10.00 [0.54 , 185.02]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>0</td><td>70</td><td>23.7%</td><td>1.57 [0.09 , 26.14]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2175</td><td/><td>490</td><td>100.0%</td><td>2.39 [0.73 , 7.80]</td></tr><tr><td>Total events:</td><td/><td>28</td><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 4.10, df = 4 (P = 0.39); I\u00b2 = 2%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.44 (P = 0.15)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF461": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>11</td><td>247</td><td>0</td><td>45</td><td>18.9%</td><td>4.27 [0.26 , 71.14]</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>5</td><td>16.8%</td><td>1.00 [0.05 , 21.42]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>0</td><td>9</td><td>21.8%</td><td>1.20 [0.08 , 18.46]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>7</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>1</td><td>359</td><td>21.3%</td><td>8.89 [1.12 , 70.71]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1220</td><td>0</td><td>70</td><td>21.2%</td><td>1.69 [0.10 , 27.98]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2175</td><td/><td>495</td><td>100.0%</td><td>3.48 [1.16 , 10.48]</td></tr><tr><td>Total events:</td><td>54</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.28, df = 4 (P = 0.68); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.22 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours TPM</td></tr><tr><td>Analysis 62.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF462": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>8</td><td>247</td><td>0</td><td>45</td><td>8.3%</td><td>3.15 [0.19 , 53.69]</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>5</td><td>7.4%</td><td>1.00 [0.05 , 21.42]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>5</td><td>359</td><td>46.8%</td><td>0.89 [0.24 , 3.28]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>2</td><td>70</td><td>37.4%</td><td>0.37 [0.09 , 1.62]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1835</td><td/><td>482</td><td>100.0%</td><td>0.89 [0.37 , 2.13]</td></tr><tr><td>Total events:</td><td>26</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 2.12, df = 3 (P = 0.55); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.26 (P = 0.80)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF463": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 63.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>14</td><td>271</td><td>0</td><td>45</td><td>11.4%</td><td>4.90 [0.30 , 80.80]</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>17</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>0</td><td>9</td><td>12.9%</td><td>0.26 [0.02 , 4.56]</td></tr><tr><td>Melikova 2020</td><td/><td>0</td><td>27</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>5</td><td>359</td><td>63.1%</td><td>1.11 [0.32 , 3.80]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>10</td><td>1220</td><td>0</td><td>70</td><td>12.6%</td><td>1.22 [0.07 , 20.63]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2199</td><td/><td>490</td><td>100.0%</td><td>1.45 [0.55 , 3.82]</td></tr><tr><td>Total events:</td><td/><td>33</td><td/><td>5</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.29, df = 3 (P = 0.51); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.75 (P = 0.45)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF464": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>43</td><td>290</td><td>1</td><td>19</td><td>9.9%</td><td>2.82 [0.41 , 19.36]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>4</td><td>17</td><td>0</td><td>4</td><td>4.1%</td><td>2.50 [0.16 , 39.05]</td></tr><tr><td>Kaaja 2003</td><td>4</td><td>61</td><td>1</td><td>9</td><td>9.2%</td><td>0.59 [0.07 , 4.71]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>27</td><td>341</td><td>5</td><td>71</td><td>43.5%</td><td>1.12 [0.45 , 2.82]</td></tr><tr><td>Martinez Ferri 2018</td><td>10</td><td>112</td><td>0</td><td>22</td><td>4.4%</td><td>4.27 [0.26 , 70.39]</td></tr><tr><td>Meischenguiser 2004</td><td>3</td><td>21</td><td>0</td><td>35</td><td>2.0%</td><td>11.45 [0.62 , 211.39]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>30</td><td>323</td><td>4</td><td>182</td><td>26.9%</td><td>4.23 [1.51 , 11.81]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1183</td><td/><td>378</td><td>100.0%</td><td>2.48 [1.42 , 4.31]</td></tr><tr><td>Total events:</td><td>121</td><td/><td>11</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.93, df = 6 (P = 0.33); I\u00b2 = 13%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 3.21 (P = 0.001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>63.1.2 VPA vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Denmark Health Record Registers</td><td>39</td><td>330</td><td>10</td><td>316</td><td>23.4%</td><td>3.73 [1.90 , 7.35]</td></tr><tr><td>Finland Health Record Registers</td><td>37</td><td>263</td><td>23</td><td>130</td><td>70.5%</td><td>0.80 [0.49 , 1.28]</td></tr><tr><td>Norwegian Health Record Registers</td><td>21</td><td>333</td><td>1</td><td>57</td><td>3.9%</td><td>3.59 [0.49 , 26.20]</td></tr><tr><td>Sweden Health Record Registers</td><td>26</td><td>268</td><td>0</td><td>4</td><td>2.2%</td><td>0.99 [0.07 , 14.00]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1194</td><td/><td>507</td><td>100.0%</td><td>1.60 [1.11 , 2.29]</td></tr><tr><td>Total events:</td><td>123</td><td/><td>34</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 15.05, df = 3 (P = 0.002); I\u00b2 = 80%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.54 (P = 0.01)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours OXC</td></tr><tr><td>Analysis 63.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF465": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 63.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">VPA</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>7</td><td>247</td><td>0</td><td>9</td><td>19.6%</td><td>0.60 [0.04 , 9.87]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>4</td><td>16.0%</td><td>0.83 [0.04 , 17.48]</td></tr><tr><td>Kaaja 2003</td><td/><td>2</td><td>61</td><td>0</td><td>9</td><td>17.6%</td><td>0.81 [0.04 , 15.59]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>0</td><td>71</td><td>16.9%</td><td>1.47 [0.08 , 28.22]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>3</td><td>112</td><td>0</td><td>22</td><td>17.0%</td><td>1.42 [0.08 , 26.66]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>21</td><td>0</td><td>35</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>0</td><td>182</td><td>13.0%</td><td>5.08 [0.28 , 93.89]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1133</td><td/><td>364</td><td>100.0%</td><td>1.55 [0.49 , 4.89]</td></tr><tr><td>Total events:</td><td colspan=\"2\">20</td><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 1.42, df = 5 (P = 0.92); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.74 (P = 0.46)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF466": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>11</td><td>247</td><td>0</td><td>9</td><td>9.1%</td><td>0.93 [0.06 , 14.65]</td></tr><tr><td>Hosny 2021</td><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>4</td><td>7.4%</td><td>0.83 [0.04 , 17.48]</td></tr><tr><td>Kaaja 2003</td><td>2</td><td>61</td><td>0</td><td>9</td><td>8.1%</td><td>0.81 [0.04 , 15.59]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>3</td><td>71</td><td>46.9%</td><td>1.39 [0.42 , 4.55]</td></tr><tr><td>Martinez Ferri 2018</td><td>2</td><td>112</td><td>2</td><td>111</td><td>19.0%</td><td>0.99 [0.14 , 6.91]</td></tr><tr><td>Meischenguiser 2004</td><td>1</td><td>21</td><td>0</td><td>35</td><td>3.6%</td><td>4.91 [0.21 , 115.29]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>0</td><td>182</td><td>6.0%</td><td>9.60 [0.56 , 165.40]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1140</td><td/><td>457</td><td>100.0%</td><td>1.80 [0.84 , 3.88]</td></tr><tr><td>Total events:</td><td>45</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.02, df = 6 (P = 0.81); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.51 (P = 0.13)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours OXC</td></tr><tr><td>Analysis 63.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF467": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 63.5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">VPA</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>1</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>8</td><td>247</td><td>0</td><td>9</td><td>20.2%</td><td>0.69 [0.04 , 11.06]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>4</td><td>16.4%</td><td>0.83 [0.04 , 17.48]</td></tr><tr><td>Kaaja 2003</td><td/><td>1</td><td>61</td><td>0</td><td>9</td><td>18.1%</td><td>0.48 [0.02 , 11.07]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>2</td><td>112</td><td>0</td><td>111</td><td>10.5%</td><td>4.96 [0.24 , 102.07]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>2</td><td>21</td><td>0</td><td>35</td><td>8.0%</td><td>8.18 [0.41 , 162.65]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>1</td><td>182</td><td>26.8%</td><td>2.25 [0.25 , 20.01]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>793</td><td/><td>385</td><td>100.0%</td><td>2.14 [0.76 , 6.06]</td></tr><tr><td>Total events:</td><td colspan=\"2\">18</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 2.95, df = 5 (P = 0.71); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.43 (P = 0.15)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF468": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 64.2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td colspan=\"2\">OXC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td colspan=\"2\">Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>14</td><td>247</td><td>0</td><td>9</td><td/><td>20.2%</td><td>1.17 [0.07 , 18.24]</td></tr><tr><td>Hosny 2021</td><td/><td>0</td><td>8</td><td>0</td><td>31</td><td/><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>17</td><td>0</td><td>4</td><td/><td>1.8%</td><td>Not estimable 0.90 [0.07 , 11.43]</td></tr><tr><td>Kaaja 2003</td><td/><td>1</td><td>61</td><td>0</td><td>9</td><td/><td>18.1% 7.1%</td><td>0.48 [0.02 , 11.07] 0.89 [0.22 , 3.55]</td></tr><tr><td>Kaur 2020</td><td/><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>1.5%</td><td>Not estimable 0.83 [0.05 , 13.02]</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>1</td><td>71</td><td/><td>34.8% 2.7%</td><td>0.83 [0.09 , 7.34] 0.67 [0.08 , 5.88]</td></tr><tr><td>Martinez Ferri 2018</td><td/><td>0</td><td>112</td><td>0</td><td>22</td><td/><td>2.5%</td><td>Not estimable 0.42 [0.03 , 5.43]</td></tr><tr><td>Meischenguiser 2004</td><td/><td>0</td><td>21</td><td>0</td><td>35</td><td/><td>1.5%</td><td>Not estimable 1.50 [0.11 , 21.31]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>1</td><td>182</td><td/><td>26.9% 1.6%</td><td>2.82 [0.33 , 23.93] 0.87 [0.05 , 14.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1133</td><td/><td>364</td><td/><td>100.0% 7.2%</td><td>1.37 [0.42 , 4.49] 2.19 [0.70 , 6.84]</td></tr><tr><td>Total events:</td><td/><td>24</td><td/><td>2</td><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 1.08, df = 3 (P = 0.78); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.52 (P = 0.60)</td><td/><td/><td/><td/><td/><td>20.3%</td><td>1.36 [0.63 , 2.91]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>1.3%</td><td>2.33 [0.14 , 37.80]</td></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>2.5%</td><td>1.97 [0.24 , 16.06]</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>3.2%</td><td>0.98 [0.14 , 6.97]</td><td>Favours VPA</td><td>Favours OXC</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>2.9%</td><td>0.71 [0.09 , 5.51]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>4.9%</td><td>3.77 [1.20 , 11.83]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Comparison 64. VPA vs PB</td><td/><td/><td/><td/><td/><td>4.3%</td><td>1.33 [0.30 , 5.96]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>24.2%</td><td>1.68 [0.86 , 3.28]</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-pants</td><td>8.2% 1.1%</td><td>Statistical method 0.70 [0.20 , 2.43] Not estimable 4.55 [0.26 , 81.03]</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>1.2%</td><td>1.31 [0.07 , 22.78]</td></tr><tr><td colspan=\"2\">64.1 VPA vs PB: All Major Malforma-</td><td>25</td><td/><td/><td/><td/><td>100.0%</td><td>Risk Ratio (M-H, Fixed, 95% 1.49 [1.08 , 2.07]</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.1.1 VPA vs PB (cohort studies)</td><td>23</td><td/><td>2316</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.49 [1.08, 2.07]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>65.5%</td><td>0.85 [0.21 , 3.44]</td></tr><tr><td colspan=\"2\">64.1.2 VPA vs PB (database studies)</td><td>2</td><td/><td>635</td><td/><td/><td>34.5% 100.0%</td><td>Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.11 , 4.32] 0.79 [0.26 , 2.42]</td><td>0.79 [0.26, 2.42]</td></tr><tr><td colspan=\"2\">64.2 VPA vs PB: Neural Tube Malfor-</td><td>14</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">64.2.1 VPA vs PB (cohort studies)</td><td>14</td><td/><td>1720</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% Favours VPA</td><td>3.04 [1.27, 7.30] Favours PB</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.3 VPA vs PB: Cardiac Malforma-</td><td>14</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.3.1 VPA vs PB (cohort studies)</td><td>14</td><td/><td>1720</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.84 [0.50, 1.43]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.4 VPA vs PB: Oro-Facial Cle /Cran-</td><td>14</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.4.1 VPA vs PB (cohort studies)</td><td>14</td><td/><td>1257</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.54 [0.23, 1.27]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.5 VPA vs PB: Skeletal/Limb Malfor-</td><td>14</td><td/><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">64.5.1 VPA vs PB (cohort studies)</td><td>14</td><td/><td>1720</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.62 [0.70, 3.74]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF469": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>7</td><td>271</td><td>0</td><td>5</td><td>15.9%</td><td>0.33 [0.02 , 5.16]</td></tr><tr><td>Cassina 2013</td><td>1</td><td>45</td><td>0</td><td>67</td><td>6.6%</td><td>4.43 [0.18 , 106.50]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>2</td><td>13.9%</td><td>0.50 [0.03 , 9.63]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>1</td><td>137</td><td>23.2%</td><td>1.21 [0.13 , 11.49]</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>4</td><td>12.2%</td><td>1.00 [0.05 , 20.83]</td></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>21</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>5</td><td>44</td><td>0</td><td>83</td><td>5.7%</td><td>20.53 [1.16 , 362.99]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>0</td><td>199</td><td>10.1%</td><td>5.56 [0.30 , 102.64]</td></tr><tr><td>Omtzigt 1992</td><td>6</td><td>60</td><td>0</td><td>18</td><td>12.4%</td><td>4.05 [0.24 , 68.61]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1174</td><td/><td>546</td><td>100.0%</td><td>3.04 [1.27 , 7.30]</td></tr><tr><td>Total events:</td><td>28</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 7.06, df = 7 (P = 0.42); I\u00b2 = 1%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.49 (P = 0.01)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours PB</td></tr><tr><td>Analysis 64.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF470": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>10</td><td>271</td><td>0</td><td>5</td><td>3.6%</td><td>0.46 [0.03 , 7.03]</td></tr><tr><td>Cassina 2013</td><td>2</td><td>45</td><td>2</td><td>67</td><td>5.9%</td><td>1.49 [0.22 , 10.19]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>1</td><td>5</td><td>7.5%</td><td>0.15 [0.01 , 3.25]</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>2</td><td>3.1%</td><td>0.50 [0.03 , 9.63]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>6</td><td>137</td><td>31.2%</td><td>1.34 [0.55 , 3.26]</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>4</td><td>2.7%</td><td>1.00 [0.05 , 20.83]</td></tr><tr><td>Meischenguiser 2004</td><td>1</td><td>21</td><td>1</td><td>5</td><td>5.9%</td><td>0.24 [0.02 , 3.19]</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>1</td><td>83</td><td>3.8%</td><td>0.62 [0.03 , 14.96]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>5</td><td>199</td><td>22.5%</td><td>0.99 [0.33 , 2.97]</td></tr><tr><td>Omtzigt 1992</td><td>0</td><td>60</td><td>2</td><td>18</td><td>13.9%</td><td>0.06 [0.00 , 1.24]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1174</td><td/><td>546</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>43</td><td/><td>18</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 6.82, df = 9 (P = 0.66); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.64 (P = 0.53)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF471": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 64.4.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VPA</td><td colspan=\"2\">Favours PB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF472": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>12</td><td>271</td><td>0</td><td>5</td><td>8.1%</td><td>0.55 [0.04 , 8.28]</td></tr><tr><td>Cassina 2013</td><td>0</td><td>45</td><td>0</td><td>67</td><td/><td>Not estimable</td></tr><tr><td>Eroglu 2008</td><td>1</td><td>16</td><td>1</td><td>5</td><td>12.6%</td><td>0.31 [0.02 , 4.14]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>2</td><td>7.1%</td><td>0.50 [0.03 , 9.63]</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>6</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>4</td><td>6.2%</td><td>1.00 [0.05 , 20.83]</td></tr><tr><td>Meischenguiser 2004</td><td>2</td><td>21</td><td>0</td><td>5</td><td>6.5%</td><td>1.36 [0.08 , 24.76]</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>0</td><td>83</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>4</td><td>199</td><td>40.8%</td><td>0.62 [0.16 , 2.44]</td></tr><tr><td>Omtzigt 1992</td><td>0</td><td>60</td><td>1</td><td>18</td><td>18.9%</td><td>0.10 [0.00 , 2.44]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>839</td><td/><td>418</td><td>100.0%</td><td>0.54 [0.23 , 1.27]</td></tr><tr><td>Total events:</td><td>21</td><td/><td>6</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.81, df = 6 (P = 0.94); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.41 (P = 0.16)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours PB</td></tr><tr><td>Analysis 64.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF473": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>6</td><td>271</td><td>0</td><td>5</td><td>11.7%</td><td>0.29 [0.02 , 4.53]</td></tr><tr><td>Cassina 2013</td><td>2</td><td>45</td><td>0</td><td>67</td><td>4.8%</td><td>7.39 [0.36 , 150.43]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td>1</td><td>12</td><td>0</td><td>5</td><td>8.2%</td><td>1.38 [0.07 , 29.26]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>17</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Kaur 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>2</td><td>137</td><td>34.1%</td><td>0.80 [0.15 , 4.34]</td></tr><tr><td>Koch 1992</td><td>2</td><td>14</td><td>0</td><td>4</td><td>9.0%</td><td>1.67 [0.10 , 29.18]</td></tr><tr><td>Meischenguiser 2004</td><td>0</td><td>21</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>44</td><td>1</td><td>83</td><td>8.3%</td><td>1.89 [0.12 , 29.44]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>1</td><td>199</td><td>14.8%</td><td>3.08 [0.36 , 26.18]</td></tr><tr><td>Omtzigt 1992</td><td>1</td><td>60</td><td>0</td><td>18</td><td>9.1%</td><td>0.93 [0.04 , 22.00]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>12</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1174</td><td/><td>546</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>22</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.64, df = 7 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.14 (P = 0.25)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF474": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td colspan=\"3\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">65.1.1 VPA vs PHT (cohort studies)</td><td>21</td><td>3897</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.92 [1.44, 2.56]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td>44</td><td>2.6%</td><td/><td>6.52 [0.92 , 46.18]</td></tr><tr><td colspan=\"2\">65.1.2 VPA vs PHT (database studies)</td><td>1</td><td>371</td><td>22 14 3</td><td>3.1% 1.1%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% Not estimable 0.93 [0.15 , 5.76] CI) 0.92 [0.05 , 18.50]</td><td>1.43 [0.64, 3.19]</td></tr><tr><td/><td/><td/><td/><td>27</td><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">65.2 VPA vs PHT: Neural Tube Malfor-mations</td><td>14</td><td/><td>124 132 2</td><td>3.0% 13.6% 2.6%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% 2.71 [0.63 , 11.73] 1.22 [0.54 , 2.77] CI) 0.25 [0.01 , 4.23]</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>24</td><td>0.7%</td><td/><td>1.67 [0.08 , 35.30]</td></tr><tr><td colspan=\"2\">65.2.1 VPA vs PHT (cohort studies)</td><td>14</td><td>3393</td><td>119</td><td>15.5%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% 1.35 [0.60 , 3.01]</td><td>3.75 [1.57, 8.94]</td></tr><tr><td/><td/><td/><td/><td>24</td><td>2.2%</td><td>CI)</td><td>2.57 [0.49 , 13.57]</td></tr><tr><td/><td/><td/><td/><td>17</td><td>2.4%</td><td/><td>1.29 [0.16 , 10.31]</td></tr><tr><td colspan=\"2\">65.3 VPA vs PHT: Cardiac Malforma-tions</td><td>14</td><td/><td>56 31 1</td><td>6.6% 5.2%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% 2.43 [0.83 , 7.14] 1.88 [0.54 , 6.52] CI) Not estimable</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>44</td><td>4.5%</td><td/><td>1.96 [0.64 , 6.00]</td></tr><tr><td colspan=\"2\">65.3.1 VPA vs PHT (cohort studies)</td><td>14</td><td>3393</td><td>416 28 5</td><td>15.6% 1.0%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% 3.22 [1.68 , 6.19] 7.13 [0.42 , 120.64] CI) Not estimable</td><td>1.90 [1.07, 3.36]</td></tr><tr><td/><td/><td/><td/><td>8</td><td>1.0%</td><td/><td>3.15 [0.18 , 54.83]</td></tr><tr><td colspan=\"2\">65.4 VPA vs PHT: Oro-Facial Cle /</td><td>14</td><td/><td>106</td><td>19.2%</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% 1.02 [0.48 , 2.15]</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td>1247</td><td>100.0%</td><td>CI)</td><td>1.92 [1.44 , 2.56]</td></tr><tr><td colspan=\"2\">65.4.1 VPA vs PHT (cohort studies)</td><td>14</td><td>2944</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.24 [0.89, 5.58]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">65.5 VPA vs PHT: Skeletal/Limb Mal-formations</td><td>14</td><td/><td>103 103</td><td>100.0% 100.0%</td><td colspan=\"2\">Risk Ratio Subtotals only M-H, Fixed, 95% CI Risk Ratio (M-H, Fixed, 95% 1.43 [0.64 , 3.19] CI) 1.43 [0.64 , 3.19]</td></tr><tr><td colspan=\"2\">65.5.1 VPA vs PHT (cohort studies)</td><td>14</td><td>3394</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>2.12 [1.01, 4.45]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours PHT</td></tr><tr><td>Footnotes</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">(1) Data from Mawer et al 2010 is not included here due to it's overlap with Meador 2006</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours PB</td></tr><tr><td colspan=\"2\">Comparison 65. VPA vs PHT</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td colspan=\"3\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">65.1 VPA vs PHT: All Major Malforma-</td><td>22</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF475": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>7</td><td>247</td><td>1</td><td>44</td><td>26.0%</td><td>1.25 [0.16 , 9.89]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>0</td><td>14</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>2</td><td>61</td><td>0</td><td>124</td><td>5.1%</td><td>10.08 [0.49 , 206.78]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>341</td><td>1</td><td>119</td><td>22.7%</td><td>1.05 [0.11 , 9.97]</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>24</td><td>5.7%</td><td>5.00 [0.22 , 115.05]</td></tr><tr><td>Meador 2006</td><td>0</td><td>69</td><td>0</td><td>56</td><td/><td>Not estimable</td></tr><tr><td>Milan Study 1999</td><td>5</td><td>44</td><td>0</td><td>31</td><td>9.0%</td><td>7.82 [0.45 , 136.50]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>0</td><td>416</td><td>6.7%</td><td>11.58 [0.63 , 214.37]</td></tr><tr><td>Omtzigt 1992</td><td>6</td><td>60</td><td>0</td><td>28</td><td>10.4%</td><td>6.18 [0.36 , 106.02]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>0</td><td>82</td><td>14.4%</td><td>1.84 [0.11 , 30.60]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2419</td><td/><td>974</td><td>100.0%</td><td>3.75 [1.57 , 8.94]</td></tr><tr><td>Total events:</td><td>41</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.95, df = 7 (P = 0.79); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.98 (P = 0.003)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours PHT</td></tr><tr><td>Analysis 65.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF476": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>11</td><td>247</td><td>1</td><td>44</td><td>9.6%</td><td>1.96 [0.26 , 14.80]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>1</td><td>14</td><td>9.0%</td><td>0.29 [0.01 , 6.69]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>2</td><td>61</td><td>0</td><td>124</td><td>1.9%</td><td>10.08 [0.49 , 206.78]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>20</td><td>341</td><td>5</td><td>119</td><td>41.9%</td><td>1.40 [0.54 , 3.64]</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>1</td><td>24</td><td>4.2%</td><td>1.71 [0.12 , 25.31]</td></tr><tr><td>Meador 2006</td><td>4</td><td>69</td><td>0</td><td>56</td><td>3.1%</td><td>7.33 [0.40 , 133.29]</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>8</td><td>323</td><td>4</td><td>416</td><td>19.8%</td><td>2.58 [0.78 , 8.48]</td></tr><tr><td>Omtzigt 1992</td><td>0</td><td>60</td><td>0</td><td>28</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1220</td><td>1</td><td>82</td><td>10.6%</td><td>0.94 [0.13 , 7.07]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2419</td><td/><td>974</td><td>100.0%</td><td>1</td></tr><tr><td>Total events:</td><td>60</td><td/><td>13</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 4.49, df = 7 (P = 0.72); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.19 (P = 0.03)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF477": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 65.4.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VPA</td><td colspan=\"2\">Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF478": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>8</td><td>247</td><td>0</td><td>44</td><td>12.9%</td><td>3.08 [0.18 , 52.50]</td></tr><tr><td>Eroglu 2008</td><td>1</td><td>16</td><td>0</td><td>14</td><td>8.1%</td><td>2.65 [0.12 , 60.21]</td></tr><tr><td>Fr\u00f6scher 1991</td><td>0</td><td>12</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>1</td><td>61</td><td>1</td><td>124</td><td>10.0%</td><td>2.03 [0.13 , 31.95]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>6</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Koch 1992</td><td>1</td><td>14</td><td>0</td><td>24</td><td>5.7%</td><td>5.00 [0.22 , 115.05]</td></tr><tr><td>Meador 2006</td><td>1</td><td>69</td><td>0</td><td>56</td><td>8.4%</td><td>2.44 [0.10 , 58.83]</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>44</td><td>0</td><td>31</td><td/><td>Not estimable</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>323</td><td>2</td><td>416</td><td>26.5%</td><td>2.58 [0.47 , 13.98]</td></tr><tr><td>Omtzigt 1992</td><td>0</td><td>60</td><td>0</td><td>28</td><td/><td>Not estimable</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>1</td><td>82</td><td>28.5%</td><td>0.87 [0.12 , 6.60]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2084</td><td/><td>860</td><td>100.0%</td><td>2.24 [0.89 , 5.58]</td></tr><tr><td>Total events:</td><td>29</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.18, df = 6 (P = 0.98); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.72 (P = 0.09)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours PHT</td></tr><tr><td>Analysis 65.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF479": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>14</td><td>247</td><td>0</td><td>45</td><td>7.9%</td><td>5.38 [0.33 , 88.60]</td></tr><tr><td>Eroglu 2008</td><td>0</td><td>16</td><td>0</td><td>14</td><td/><td>Not estimable</td></tr><tr><td>Fr\u00f6scher 1991</td><td>1</td><td>12</td><td>0</td><td>3</td><td>7.2%</td><td>0.92 [0.05 , 18.50]</td></tr><tr><td>Garza-Morales 1996</td><td>0</td><td>5</td><td>0</td><td>27</td><td/><td>Not estimable</td></tr><tr><td>Kaaja 2003</td><td>1</td><td>61</td><td>0</td><td>124</td><td>3.1%</td><td>6.05 [0.25 , 146.33]</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>4</td><td>341</td><td>1</td><td>119</td><td>13.9%</td><td>1.40 [0.16 , 12.37]</td></tr><tr><td>Koch 1992</td><td>2</td><td>14</td><td>0</td><td>24</td><td>3.5%</td><td>8.33 [0.43 , 162.13]</td></tr><tr><td>Meador 2006</td><td>1</td><td>69</td><td>0</td><td>56</td><td>5.2%</td><td>2.44 [0.10 , 58.83]</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>44</td><td>1</td><td>31</td><td>11.0%</td><td>0.70 [0.05 , 10.84]</td></tr><tr><td>Miskov 2016</td><td>0</td><td>6</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>5</td><td>323</td><td>4</td><td>416</td><td>32.9%</td><td>1.61 [0.44 , 5.95]</td></tr><tr><td>Omtzigt 1992</td><td>1</td><td>60</td><td>0</td><td>28</td><td>6.4%</td><td>1.43 [0.06 , 33.95]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>1</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>10</td><td>1220</td><td>0</td><td>82</td><td>8.8%</td><td>1.43 [0.08 , 24.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2419</td><td/><td>975</td><td>100.0%</td><td>2.</td></tr><tr><td>Total events:</td><td>40</td><td/><td>6</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 3.03, df = 9 (P = 0.96); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.99 (P = 0.05)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF480": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Weight</td><td/><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td colspan=\"2\">11.9%</td><td>1.00 [0.08 , 12.56]</td></tr><tr><td/><td/><td colspan=\"2\">10.3%</td><td>17.13 [1.06 , 277.48]</td></tr><tr><td/><td/><td colspan=\"2\">77.8%</td><td>0.58 [0.20 , 1.72]</td></tr><tr><td/><td/><td colspan=\"2\">100.0%</td><td>2.34 [0.95 , 5.80]</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours ZNS</td></tr><tr><td>Analysis 66.2.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours PHT</td></tr><tr><td>Comparison 66. VPA vs ZNS</td><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td>pants</td><td/><td/></tr><tr><td>66.1 VPA vs ZNS: All Major Malforma-</td><td>3</td><td/><td colspan=\"3\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF481": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 66.3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>VPA</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">66.2.1 VPA vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td/><td>1</td><td>17</td><td>0</td><td>1</td><td>31.5%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td colspan=\"2\">UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>1</td><td>26</td><td>68.5%</td><td>0.28 [0.04 , 2.04]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>1237</td><td/><td>27</td><td>100.0%</td><td>0.29 [0.06 , 1.51]</td></tr><tr><td>Total events:</td><td/><td>14</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.01, df = 1 (P = 0.92); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.47 (P = 0.14)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours ZNS</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>306</td></tr></table>",
                "type_str": "table"
            },
            "TABREF482": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>66.3.1 VPA vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>1</td><td>47.9%</td><td>0.33 [0.02 , 5.75]</td><td/></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>14</td><td>1220</td><td>0</td><td>26</td><td>52.1%</td><td>0.64 [0.04 , 10.47]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>1237</td><td/><td>27</td><td>100.0%</td><td>0.49 [0.07 , 3.65]</td><td/></tr><tr><td>Total events:</td><td>15</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.11, df = 1 (P = 0.74); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.69 (P = 0.49)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours ZNS</td></tr><tr><td>Analysis 66.4.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF483": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>1</td><td>17</td><td>0</td><td>1</td><td>47.9%</td><td>0.33 [0.02 , 5.75]</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>13</td><td>1220</td><td>0</td><td>26</td><td>52.1%</td><td>0.60 [0.04 , 9.79]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1237</td><td/><td>27</td><td>100.0%</td><td>0.47 [0.06 , 3.49]</td></tr><tr><td>Total events:</td><td>14</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.08, df = 1 (P = 0.77); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.74 (P = 0.46)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours ZNS</td></tr><tr><td>Analysis 66.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF484": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>VPA</td><td/><td>ZNS</td><td/><td/><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>17</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>UK and Ireland Epilepsy and Pregnancy Register</td><td>10</td><td>1220</td><td>0</td><td>26</td><td>100.0%</td><td>0.46 [0.03 , 7.72]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1237</td><td/><td>27</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>10</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.53 (P = 0.59)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF485": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">67.1.2 CZP vs VPA (database studies)</td><td>2</td><td>762</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.34 [0.13, 0.94]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.2 CZP vs VPA: Neural Tube Malfor-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.2.1 CZP vs VPA (cohort studies)</td><td>1</td><td>345</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>9.77 [0.58, 165.35]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.3 CZP vs VPA: Cardiac Malforma-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.3.1 CZP vs VPA (cohort studies)</td><td>1</td><td>345</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.67 [0.12, 23.92]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.4 CZP vs VPA: Skeletal/Limb Mal-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.4.1 CZP vs VPA (cohort studies)</td><td>1</td><td>345</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>7.60 [0.47, 123.14]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours VPA</td><td>Favours ZNS</td></tr><tr><td colspan=\"2\">Comparison 67. CZP vs VPA</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">67.1 CZP vs VPA: All Major Malforma-</td><td>6</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">67.1.1 CZP vs VPA (cohort studies)</td><td>4</td><td>1050</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.29 [0.09, 0.90]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF486": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Australian Epilepsy and Pregnancy Register</td></tr><tr><td>D'Souza 1991</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td></tr><tr><td>Subtotal (95% CI)</td></tr><tr><td>Total events:</td></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.57, df = 2 (P = 0.46); I\u00b2 = 0%</td></tr><tr><td>Test for overall effect: Z = 2.14 (P = 0.03)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF487": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td/><td>VPA</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td>0</td><td>26</td><td>43</td><td>290</td><td>40.8%</td><td>0.12 [0.01 , 1.96]</td></tr><tr><td/><td>0</td><td>1</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td/><td>0</td><td>4</td><td>27</td><td>341</td><td>4.4%</td><td>1.24 [0.09 , 17.67]</td></tr><tr><td/><td>2</td><td>64</td><td>30</td><td>323</td><td>54.8%</td><td>0.34 [0.08 , 1.37]</td></tr><tr><td/><td/><td>95</td><td/><td>955</td><td>100.0%</td><td>0.29 [0.09 , 0.90]</td></tr><tr><td/><td>2</td><td/><td>100</td><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>113</td><td>21</td><td>333</td><td>57.4%</td><td>0.28 [0.07 , 1.18]</td></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>26</td><td>268</td><td>42.6%</td><td>0.43 [0.11 , 1.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>161</td><td/><td>601</td><td>100.0%</td><td>0.</td></tr><tr><td>Total events:</td><td>4</td><td/><td>47</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 0.17, df = 1 (P = 0.68); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 2.09 (P = 0.04)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF488": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 67.2.</td><td/><td/><td/></tr><tr><td/><td/><td/><td colspan=\"2\">Risk Ratio</td></tr><tr><td/><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours CZP</td><td colspan=\"2\">Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF489": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td colspan=\"2\">VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td/><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>4</td><td>3</td><td>341</td><td>100.0%</td><td>9.77 [0.58 , 165.35]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4</td><td/><td>341</td><td>100.0%</td><td>9.77 [0.58 , 165.35]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>3</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.58 (P = 0.11)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours VPA</td></tr><tr><td>Analysis 67.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF490": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td/><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td/><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>4</td><td>20</td><td>341</td><td>100.0%</td><td>1.67 [0.12 , 23.92]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4</td><td/><td>341</td><td>100.0%</td><td>1.67 [0.12 , 23.92]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.38 (P = 0.71)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours VPA</td></tr><tr><td>Analysis 67.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF491": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td colspan=\"2\">VPA</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td/><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>4</td><td>4</td><td>341</td><td>100.0%</td><td>7.60 [0.47 , 123.14]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>4</td><td/><td>341</td><td>100.0%</td><td>7</td></tr><tr><td>Total events:</td><td>0</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.43 (P = 0.15)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF492": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 68.1</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours VPA</td></tr><tr><td colspan=\"2\">Comparison 68. CZP vs LEV</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">68.1 CZP vs LEV: All Major Malforma-</td><td>4</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">68.1.1 CZP vs LEV (cohort studies)</td><td>3</td><td>789</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.06 [0.32, 3.44]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">68.1.2 CZP vs LEV (database studies)</td><td>1</td><td>231</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.04 [0.15, 7.29]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF493": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CZP</td><td/><td>LEV</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>68.1.1 CZP vs LEV (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>5</td><td>139</td><td>35.5%</td><td>0.47 [0.03 , 8.28]</td><td/></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>4</td><td>5</td><td>106</td><td>9.8%</td><td>1.95 [0.12 , 30.51]</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>2</td><td>64</td><td>11</td><td>450</td><td>54.7%</td><td>1.28 [0.29 , 5.64]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>94</td><td/><td>695</td><td>100.0%</td><td>1.06 [0.32 , 3.44]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>21</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.56, df = 2 (P = 0.76); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.09 (P = 0.93)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>68.1.2 CZP vs LEV (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>113</td><td>2</td><td>118</td><td>100.0%</td><td>1.04 [0.15 , 7.29]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>113</td><td/><td>118</td><td>100.0%</td><td>1.04 [0.15 , 7.29]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>2</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.04 (P = 0.97)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours LEV</td></tr><tr><td>Comparison 69. OXC vs PRM</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td/><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/><td/></tr><tr><td>69.1 OXC vs PRM: All Major Malforma-</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>69.1.1 OXC vs PRM (cohort studies)</td><td>2</td><td/><td>36</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.58 [0.08, 4.03]</td></tr><tr><td>69.1.2 OXC vs PRM (database studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF494": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 70.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">OXC</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>1</td><td>19</td><td>0</td><td>2</td><td>42.0%</td><td>0.45 [0.02 , 8.70]</td></tr><tr><td>Kaaja 2003</td><td/><td>1</td><td>9</td><td>1</td><td>6</td><td>58.0%</td><td>0.67 [0.05 , 8.73]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>28</td><td/><td>8</td><td>100.0%</td><td>0.58 [0.08 , 4.03]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.04, df = 1 (P = 0.84); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.56 (P = 0.58)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">69.1.2 OXC vs PRM (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>4</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours OXC</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF495": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>1</td><td>19</td><td>1</td><td>53</td><td>4.6%</td><td>2.79 [0.18 , 42.42]</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>5</td><td>71</td><td>0</td><td>9</td><td>7.6%</td><td>1.53 [0.09 , 25.59]</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>182</td><td>15</td><td>359</td><td>87.8%</td><td>0.53 [0.18 , 1.56]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>279</td><td/><td>427</td><td>100.0%</td><td>0.71 [0.28 , 1.77]</td></tr><tr><td>Total events:</td><td>10</td><td/><td>16</td><td/><td/><td/></tr><tr><td>Heterogeneity: Chi\u00b2 = 1.55, df = 2 (P = 0.46); I\u00b2 = 0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.74 (P = 0.46)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>70.1.2 OXC vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>1</td><td>57</td><td>2</td><td>48</td><td>100.0%</td><td>0.42 [0.04 , 4.50]</td></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>61</td><td/><td>49</td><td>100.0%</td><td>0.42 [0.04 , 4.50]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.72 (P = 0.47)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours TPM</td></tr><tr><td>Analysis 70.2.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF496": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>9</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>Kerala Epilepsy and Pregnancy Registry</td><td>0</td><td>71</td><td>0</td><td>9</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>0</td><td>182</td><td>0</td><td>359</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF497": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 70.4.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">OXC</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td/><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>9</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>4</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>3</td><td>71</td><td>0</td><td>9</td><td>46.5%</td><td>0.97 [0.05 , 17.47]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>0</td><td>182</td><td>1</td><td>359</td><td>53.5%</td><td>0.66 [0.03 , 16.02]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>269</td><td/><td>419</td><td>100.0%</td><td>0.80 [0.09 , 6.81]</td></tr><tr><td>Total events:</td><td/><td>3</td><td/><td>1</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.03, df = 1 (P = 0.86); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.20 (P = 0.84)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours OXC</td><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF498": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td/><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>AlSheikh 2020</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>9</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>1</td><td>182</td><td>5</td><td>359</td><td>100.0%</td><td>0.39 [0.05 , 3.35]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>198</td><td/><td>410</td><td>100.0%</td><td>0.39 [0.05 , 3.35]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.85 (P = 0.39)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours TPM</td></tr><tr><td>Analysis 70.5.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF499": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">71.5 OXC vs ZNS: Skeletal/Limb Mal-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>formations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">71.5.1 OXC vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 71.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">OXC</td><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>9</td><td>0</td><td>45</td><td/><td>Not estimable</td></tr><tr><td>Jimenez 2020</td><td/><td>0</td><td>4</td><td>0</td><td>5</td><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Kerala Epilepsy and Pregnancy Registry</td><td>1</td><td>71</td><td>0</td><td>9</td><td>20.7%</td><td>0.42 [0.02 , 9.55]</td></tr><tr><td colspan=\"2\">North American Epilepsy and Pregnancy Register</td><td>1</td><td>182</td><td>5</td><td>359</td><td>79.3%</td><td>0.39 [0.05 , 3.35]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>266</td><td/><td>418</td><td>100.0%</td><td>0.40 [0.07 , 2.44]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>5</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.00, df = 1 (P = 0.98); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.99 (P = 0.32)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours OXC</td><td>Favours TPM</td></tr><tr><td colspan=\"2\">Comparison 71. OXC vs ZNS</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">71.1 OXC vs ZNS: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">71.1.1 OXC vs ZNS (cohort studies)</td><td>2</td><td/><td>277</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>4.48 [0.24, 82.23]</td></tr><tr><td colspan=\"2\">71.2 OXC vs ZNS: Neural Tube Malfor-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">71.2.1 OXC vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">71.3 OXC vs ZNS: Cardiac Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">71.3.1 OXC vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">71.4 OXC vs ZNS: Oro-Facial Cle /</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td colspan=\"2\">Craniofacial Malformations</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">71.4.1 OXC vs ZNS (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF500": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>71.1.1 OXC vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>North American Epilepsy and Pregnancy Register</td><td>4</td><td>182</td><td>0</td><td>90</td><td>100.0%</td><td>4.48 [0.24 , 82.23]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>186</td><td/><td>91</td><td>100.0%</td><td>4.48 [0.24 , 82.23]</td><td/></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.01 (P = 0.31)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours ZNS</td></tr><tr><td>Analysis 71.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF501": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td colspan=\"2\">ZNS</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours ZNS</td></tr><tr><td>Analysis 71.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF502": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 71.4.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">OXC</td><td>ZNS</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours ZNS</td></tr></table>",
                "type_str": "table"
            },
            "TABREF503": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td>ZNS</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">71.4.1 OXC vs ZNS (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours ZNS</td></tr><tr><td>Analysis 71.5.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF504": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td colspan=\"2\">ZNS</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OXC</td><td>Favours ZNS</td></tr><tr><td>Comparison 72.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF505": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 72.1</td><td/><td/><td/></tr><tr><td colspan=\"2\">72.1 PRM vs TPM: All Major Malfor-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">72.1.1 PRM vs TPM (cohort studies)</td><td>1</td><td>55</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>6.00 [0.30, 118.36]</td></tr><tr><td colspan=\"2\">72.1.2 PRM vs TPM (database stud-</td><td>1</td><td>0</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>ies)</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF506": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 73.1</td><td colspan=\"2\">PRM</td><td colspan=\"2\">TPM</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>2</td><td>1</td><td>53</td><td>100.0%</td><td>6.00 [0.30 , 118.36]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>2</td><td/><td>53</td><td>100.0%</td><td>6.00 [0.30 , 118.36]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>1</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 1.18 (P = 0.24)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">72.1.2 PRM vs TPM (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PRM</td><td>Favours TPM</td></tr><tr><td colspan=\"2\">Comparison 73. PRM vs VPA</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">73.1 PRM vs VPA: All Major Malforma-</td><td>7</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.1.1 PRM vs VPA (cohort studies)</td><td>6</td><td/><td colspan=\"2\">594</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.74 [0.39, 1.40]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.1.2 PRM vs VPA (database studies)</td><td>1</td><td/><td colspan=\"2\">271</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.27 [0.09, 17.39]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.2 PRM vs VPA: Neural Tube Malfor-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.2.1 PRM vs VPA (cohort studies)</td><td>2</td><td/><td>84</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.11 [0.01, 1.99]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.3 PRM vs VPA: Cardiac Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.3.1 PRM vs VPA (cohort studies)</td><td>2</td><td/><td>84</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.75 [0.16, 89.32]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.4 PRM vs VPA: Oro-Facial Cle /Cran-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>iofacial Malformations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.4.1 PRM vs VPA (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.5 PRM vs VPA: Skeletal/Limb Malfor-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">73.5.1 PRM vs VPA (cohort studies)</td><td>2</td><td/><td>84</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.42 [0.02, 9.92]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF507": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">PRM</td><td>VPA</td><td/><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>73.1.1 PRM vs VPA (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>2</td><td>43</td><td>290</td><td>4.9%</td><td>1.11 [0.09 , 14.21]</td><td/></tr><tr><td>Kaaja 2003</td><td>1</td><td>6</td><td>4</td><td>61</td><td>3.9%</td><td>2.54 [0.34 , 19.25]</td><td/></tr><tr><td>Kaneko 1999</td><td>5</td><td>35</td><td>9</td><td>81</td><td>29.7%</td><td>1.29 [0.46 , 3.56]</td><td/></tr><tr><td>Koch 1992</td><td>0</td><td>21</td><td>3</td><td>14</td><td>22.8%</td><td>0.10 [0.01 , 1.75]</td><td/></tr><tr><td>Milan Study 1999</td><td>3</td><td>35</td><td>8</td><td>44</td><td>38.8%</td><td>0.47 [0.14 , 1.65]</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>103</td><td/><td>491</td><td>100.0%</td><td>0.74 [0.39 , 1.40]</td><td/></tr><tr><td>Total events:</td><td>9</td><td/><td>67</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 5.05, df = 4 (P = 0.28); I\u00b2 = 21%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.92 (P = 0.36)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>73.1.2 PRM vs VPA (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>26</td><td>268</td><td>100.0%</td><td>1.27 [0.09 , 17.39]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>3</td><td/><td>268</td><td>100.0%</td><td>1.27 [0.09 , 17.39]</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>26</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.18 (P = 0.86)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PRM</td><td>Favours VPA</td></tr><tr><td>Analysis 73.2.</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF508": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 73.3.</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">PRM</td><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>35</td><td>5</td><td>44</td><td>100.0%</td><td>0.11 [0.01 , 1.99]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>39</td><td/><td>45</td><td>100.0%</td><td>0.11 [0.01 , 1.99]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>5</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for overall effect: Z = 1.49 (P = 0.14)</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PRM</td><td>Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF509": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PRM</td><td colspan=\"2\">VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>1</td><td>35</td><td>0</td><td>44</td><td>100.0%</td><td>3.75 [0.16 , 89.32]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>39</td><td/><td>45</td><td>100.0%</td><td>3.75 [0.16 , 89.32]</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.82 (P = 0.41)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PRM</td><td>Favours VPA</td></tr><tr><td>Analysis 73.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF510": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PRM</td><td colspan=\"2\">VPA</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>35</td><td>0</td><td>44</td><td>Not estimable</td><td/></tr><tr><td>Pardi 1982</td><td>0</td><td>4</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours PRM</td><td>Favours VPA</td></tr><tr><td>Analysis 73.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF511": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">PRM</td><td colspan=\"2\">VPA</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Milan Study 1999</td><td>0</td><td>35</td><td>1</td><td>44</td><td>100.0%</td><td>0.42 [0.02 , 9.92]</td></tr><tr><td>Pardi 1982</td><td>0</td><td>4</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>39</td><td/><td>45</td><td>100.0%</td><td>0.</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.54 (P = 0.59)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF512": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 74. LEV vs LAC</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">74.1 LEV vs LAC: All Major Malforma-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">74.1.1 LEV vs LAC (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 74.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours PRM</td><td>Favours VPA</td></tr></table>",
                "type_str": "table"
            },
            "TABREF513": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td/><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td/><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LEV</td><td>Favours LAC</td></tr><tr><td>Comparison 75. CBZ vs LAC</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">75.1 CBZ vs LAC: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">75.1.1 CBZ vs LAC (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 75.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF514": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 76. OXC vs LAC</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">76.1 OXC vs LAC: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">76.1.1 OXC vs LAC (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 76.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>CBZ</td><td/><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CBZ</td><td>Favours LAC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF515": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">OXC</td><td/><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours OXC</td><td>Favours LAC</td></tr><tr><td>Comparison 77. PB vs LAC</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">77.1 PB vs LAC: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td>77.1.1 PB vs LAC (cohort studies)</td><td/><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 77.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF516": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 78. LAC vs ZNS</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">78.1 LAC vs ZNS: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">78.1.1 LAC vs ZNS (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 78.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>PB</td><td/><td colspan=\"2\">LAC</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>2</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours LAC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF517": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LAC</td><td/><td>ZNS</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>1</td><td>0</td><td/><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LAC</td><td>Favours ZNS</td></tr><tr><td>Comparison 79. GBP vs PGB</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">79.1 GBP vs PGB: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">79.1.1 GBP vs PGB (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 79.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF518": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 80. GBP vs CZP</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td colspan=\"2\">80.1 GBP vs CZP: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">80.1.1 GBP vs CZP (database studies)</td><td>1</td><td/><td>66</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.52 [0.03, 10.25]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 80.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GBP</td><td/><td>PGB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">79.1.1 GBP vs PGB (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>14</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours PGB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF519": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>GBP</td><td/><td>CZP</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>18</td><td>2</td><td>48</td><td>100.0%</td><td>0.52 [0.03 , 10.25]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>18</td><td/><td>48</td><td>100.0%</td><td>0.52 [0.03 , 10.25]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>2</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.43 (P = 0.66)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours GBP</td><td>Favours CZP</td></tr><tr><td>Comparison 81. VPA vs BNZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td>81.1 VPA vs BNZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>81.1.1 VPA vs BNZ (cohort studies)</td><td>2</td><td/><td/><td>49</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.50 [0.11, 21.31]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF520": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 82. LTG vs BNZ</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">pants</td></tr><tr><td colspan=\"2\">82.1 LTG vs BNZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">82.1.1 LTG vs BNZ (cohort studies)</td><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 82.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>VPA</td><td/><td>BNZ</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>4</td><td>17</td><td>0</td><td/><td>2</td><td>100.0%</td><td>1.50 [0.11 , 21.31]</td></tr><tr><td>Melikova 2020</td><td>0</td><td>27</td><td>0</td><td/><td>3</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>44</td><td/><td/><td>5</td><td>100.0%</td><td>1.50 [0.11 , 21.31]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for overall effect: Z = 0.30 (P = 0.76)</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours VPA</td><td>Favours BNZ</td></tr></table>",
                "type_str": "table"
            },
            "TABREF521": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>LTG</td><td/><td>BNZ</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>19</td><td>0</td><td/><td>2</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>7</td><td>0</td><td/><td>3</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours LTG</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 83. LEV vs BNZ</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">83.1 LEV vs BNZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">83.1.1 LEV vs BNZ (cohort studies)</td><td>2</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF522": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">LEV</td><td colspan=\"2\">BNZ</td><td/><td colspan=\"2\">Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>12</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>0</td><td>6</td><td>0</td><td>3</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours LEV</td><td>Favours BNZ</td></tr><tr><td>Comparison 84. CBZ vs BNZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td/><td colspan=\"2\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">84.1 CBZ vs BNZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">84.1.1 CBZ vs BNZ (cohort studies)</td><td>2</td><td/><td>48</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.32 [0.02, 6.71]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF523": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CBZ</td><td colspan=\"2\">BNZ</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td>7</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Melikova 2020</td><td>1</td><td>36</td><td>0</td><td>3</td><td>100.0%</td><td>0.32 [0.02 , 6.71]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>43</td><td/><td>5</td><td>100.0%</td><td>0</td></tr><tr><td>Total events:</td><td>1</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.73 (P = 0.47)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF524": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 85.1</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td>Risk Ratio</td></tr><tr><td/><td/><td/><td/><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CBZ</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 85. OXC vs BNZ</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">85.1 OXC vs BNZ: All Major Malforma-</td><td>1</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">85.1.1 OXC vs BNZ (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF525": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">OXC</td><td>BNZ</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"3\">85.1.1 OXC vs BNZ (cohort studies)</td><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>4</td><td>0</td><td/><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours OCX</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 86. PB vs BNZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">86.1 PB vs BNZ: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">86.1.1 PB vs BNZ (cohort studies)</td><td>1</td><td/><td/><td>0</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 86.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF526": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>PB</td><td/><td/><td>BNZ</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td/><td>2</td><td>0</td><td/><td>2</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours PB</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 87. LAC vs BNZ</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td></tr><tr><td colspan=\"3\">87.1 LAC vs BNZ: All Major Malforma-</td><td>1</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">87.1.1 LAC vs BNZ (cohort studies)</td><td/><td>1</td><td/><td/><td>0</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF527": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">LAC</td><td/><td>BNZ</td><td/><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td colspan=\"2\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">87.1.1 LAC vs BNZ (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td/><td>1</td><td>0</td><td/><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Favours LAC</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 88. ZNS vs BNZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"3\">88.1 ZNS vs BNZ: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">88.1.1 ZNS vs BNZ (cohort studies)</td><td/><td>1</td><td/><td/><td>0</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Analysis 88.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF528": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 90.1</td><td/><td/><td/><td/><td/></tr><tr><td/><td>ZNZ</td><td/><td/><td>BNZ</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td colspan=\"2\">Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Jimenez 2020</td><td>0</td><td/><td>1</td><td>0</td><td/><td>2</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td/><td>0</td><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td/><td>0</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours ZNS</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 89. CZP vs TPM</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td/><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td>pants</td></tr><tr><td colspan=\"3\">89.1 CZP vs TPM: All Major Malforma-</td><td>3</td><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">89.1.1 CZP vs TPM (cohort studies)</td><td/><td>1</td><td/><td/><td>79</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.67 [0.03, 15.83]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF529": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CZP</td><td/><td colspan=\"2\">OXC</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>1</td><td>19</td><td>100.0%</td><td>0.25 [0.01 , 5.75]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>26</td><td/><td>19</td><td>100.0%</td><td>0.25 [0.01 , 5.75]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.87 (P = 0.38)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>90.1.2 CZP vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>113</td><td>1</td><td>57</td><td>59.4%</td><td>1.01 [0.09 , 10.89]</td></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>0</td><td>4</td><td>40.6%</td><td>0.51 [0.03 , 9.21]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>161</td><td/><td>61</td><td>100.0%</td><td>0.81 [0.13 , 5.06]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>1</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.13, df = 1 (P = 0.72); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.23 (P = 0.82)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours OXC</td></tr><tr><td>Comparison 91. CZP vs COZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>91.1 CZP vs COZ: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td>91.1.1 CZP vs COZ (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 91.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF530": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td colspan=\"2\">COZ</td><td/></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>2</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF531": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">92.1.2 CZP vs ESM (database studies)</td><td>1</td><td>56</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.92 [0.05, 17.58]</td></tr><tr><td colspan=\"2\">Analysis 92.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours COZ</td></tr><tr><td colspan=\"2\">Comparison 92. CZP vs ESM</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">92.1 CZP vs ESM: All Major Malforma-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">92.1.1 CZP vs ESM (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF532": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CZP</td><td/><td colspan=\"2\">ESM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>92.1.1 CZP vs ESM (cohort studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>5</td><td/><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>92.1.2 CZP vs ESM (database studies)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>0</td><td>8</td><td>100.0%</td><td>0.92 [0.05 , 17.58]</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>8</td><td>100.0%</td><td>0.92 [0.05 , 17.58]</td><td/></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.06 (P = 0.95)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours ESM</td></tr><tr><td>Comparison 93. CZP vs PRG</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td/><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/><td/></tr><tr><td>93.1 CZP vs PRG: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>93.1.1 CZP vs PRG (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr></table>",
                "type_str": "table"
            },
            "TABREF533": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 94. CZP vs PRM</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">94.1 CZP vs PRM: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">94.1.1 CZP vs PRM (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">94.1.2 CZP vs PRM (database studies)</td><td>1</td><td/><td>51</td><td/><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.41 [0.02, 7.13]</td></tr><tr><td colspan=\"2\">Analysis 94.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CZP</td><td/><td colspan=\"2\">PRG</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CZP</td><td>Favours PRG</td></tr></table>",
                "type_str": "table"
            },
            "TABREF534": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">CZP</td><td colspan=\"2\">PRM</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>94.1.2 CZP vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>0</td><td>3</td><td>100.0%</td><td>0.41 [0.02 , 7.13]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>3</td><td>100.0%</td><td>0.41 [0.02 , 7.13]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.61 (P = 0.54)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours PRM</td></tr><tr><td>Comparison 95.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF535": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">95.1 CZP vs VGB: All Major Malforma-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">95.1.1 CZP vs VGB (cohort studies)</td><td>1</td><td>0</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">95.1.2 CZP vs VGB (database studies)</td><td>1</td><td>51</td><td>Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.41 [0.02, 7.13]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF536": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CZP</td><td/><td colspan=\"2\">VGB</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>1</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>95.1.2 CZP vs VGB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>0</td><td>3</td><td>100.0%</td><td>0.41 [0.02 , 7.13]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>48</td><td/><td>3</td><td>100.0%</td><td>0.41 [0.02 , 7.13]</td></tr><tr><td>Total events:</td><td>2</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.61 (P = 0.54)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours VGB</td></tr><tr><td>Comparison 96. TPM vs BNZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>96.1 TPM vs BNZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td>96.1.1 TPM vs BNZ (cohort studies)</td><td>2</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 96.1</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF537": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">TPM</td><td colspan=\"2\">BNZ</td><td/></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/></tr><tr><td>Jimenez 2020</td><td>0</td><td>5</td><td>0</td><td>2</td></tr><tr><td>Melikova 2020</td><td>0</td><td>2</td><td>0</td><td>3</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Not applicable</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF538": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">97.1.1 ESM vs VPA (cohort studies)</td><td>1</td><td>295</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.56 [0.04, 8.03]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">97.1.2 ESM vs VPA (database studies)</td><td>1</td><td>276</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>0.56 [0.04, 8.54]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 97.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours TPM</td><td>Favours BNZ</td></tr><tr><td colspan=\"2\">Comparison 97. ESM vs VPA</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">97.1 ESM vs VPA: All Major Malforma-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF539": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td colspan=\"2\">ESM</td><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Study or Subgroup</td><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">97.1.1 ESM vs VPA (cohort studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>43</td><td>290</td><td>100.0%</td><td>0.56 [0.04 , 8.03]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>5</td><td/><td>290</td><td>100.0%</td><td>0.56 [0.04 , 8.03]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>43</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.43 (P = 0.67)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">97.1.2 ESM vs VPA (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>0</td><td>8</td><td>26</td><td>268</td><td>100.0%</td><td>0.56 [0.04 , 8.54]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>8</td><td/><td>268</td><td>100.0%</td><td>0.56 [0.04 , 8.54]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>26</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.41 (P = 0.68)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours VPA</td></tr><tr><td colspan=\"2\">Comparison 98. ESM vs CBZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td colspan=\"2\">98.1 ESM vs CBZ: All Major Malfor-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">98.1.1 ESM vs CBZ (cohort studies)</td><td>1</td><td/><td>414</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.39 [0.10, 20.37]</td></tr><tr><td colspan=\"2\">98.1.2 ESM vs CBZ (database stud-</td><td>1</td><td/><td>711</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>1.37 [0.09, 20.78]</td></tr><tr><td>ies)</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF540": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">ESM</td><td>CBZ</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>24</td><td>409</td><td>100.0%</td><td>1.39 [0.10 , 20.37]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>409</td><td>100.0%</td><td>1.39 [0.10 , 20.37]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>24</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.24 (P = 0.81)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>98.1.2 ESM vs CBZ (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>28</td><td>703</td><td>100.0%</td><td>1.37 [0.09 , 20.78]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>8</td><td/><td>703</td><td>100.0%</td><td>1.37 [0.09 , 20.78]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>28</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.23 (P = 0.82)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours CBZ</td></tr><tr><td>Comparison 99. ESM vs PRM</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>99.1 ESM vs PRM: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/></tr><tr><td>99.1.1 ESM vs PRM (cohort studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">99.1.2 ESM vs PRM (database studies) 1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>Analysis 99.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF541": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">ESM</td><td colspan=\"2\">PRM</td><td/></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>2</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/></tr><tr><td>99.1.2 ESM vs PRM (database studies)</td><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>0</td><td>3</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF542": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 100. ESM vs PB</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">100.1 ESM vs PB: All Major Malforma-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">100.1.1 ESM vs PB (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">100.1.2 ESM vs PB (database studies)</td><td>1</td><td>15</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.30 [0.01, 6.29]</td></tr><tr><td colspan=\"2\">Analysis 100.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF543": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">ESM</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td>Not estimable</td></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>100.1.2 ESM vs PB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>1</td><td>7</td><td>100.0%</td><td>0.30 [0.01 , 6.29]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>8</td><td/><td>7</td><td>100.0%</td><td>0.30 [0.01 , 6.29]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.78 (P = 0.44)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours PB</td></tr><tr><td>Comparison 101.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF544": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 101.1</td><td/><td/><td/></tr><tr><td colspan=\"2\">101.1 ESM vs PHT: All Major Malfor-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">101.1.1 ESM vs PHT (cohort studies)</td><td>1</td><td>49</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.50 [0.11, 54.68]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">101.1.2 ESM vs PHT (database stud-</td><td>1</td><td>111</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.77 [0.05, 12.42]</td></tr><tr><td>ies)</td><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF545": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">ESM</td><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>1</td><td>44</td><td>100.0%</td><td>2.50 [0.11 , 54.68]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>44</td><td>100.0%</td><td>2.50 [0.11 , 54.68]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.58 (P = 0.56)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>101.1.2 ESM vs PHT (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>7</td><td>103</td><td>100.0%</td><td>0.77 [0.05 , 12.42]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>8</td><td/><td>103</td><td>100.0%</td><td>0.77 [0.05 , 12.42]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>7</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.18 (P = 0.85)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours PHT</td></tr><tr><td>Comparison 102. ESM vs OXC</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>102.1 ESM vs OXC: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>102.1.1 ESM vs OXC (cohort studies)</td><td>1</td><td/><td>24</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>1.11 [0.05, 23.88]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>102.1.2 ESM vs OXC (database studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF546": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">ESM</td><td colspan=\"2\">OXC</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>1</td><td>19</td><td>100.0%</td><td>1.11 [0.05 , 23.88]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>19</td><td>100.0%</td><td>1.</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.07 (P = 0.95)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>102.1.2 ESM vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>0</td><td>4</td><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF547": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 103. ESM vs VGB</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">103.1 ESM vs VGB: All Major Malfor-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">103.1.1 ESM vs VGB (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">103.1.2 ESM vs VGB (database stud-</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>ies)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Analysis 103.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF548": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">ESM</td><td colspan=\"2\">VGB</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>0</td><td>1</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>103.1.2 ESM vs VGB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>0</td><td>3</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours VGB</td></tr></table>",
                "type_str": "table"
            },
            "TABREF549": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 104.1</td><td/><td/><td/></tr><tr><td colspan=\"2\">104.1 ESM vs LTG: All Major Malforma-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">104.1.1 ESM vs LTG (cohort studies)</td><td>1</td><td>411</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.65 [0.11, 24.30]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">104.1.2 ESM vs LTG (database studies) 1</td><td>98</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>1.12 [0.07, 19.24]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF550": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">ESM</td><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>20</td><td>406</td><td>100.0%</td><td>1.65 [0.11 , 24.30]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>406</td><td>100.0%</td><td>1.65 [0.11 , 24.30]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.37 (P = 0.71)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>104.1.2 ESM vs LTG (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>4</td><td>90</td><td>100.0%</td><td>1.12 [0.07 , 19.24]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>8</td><td/><td>90</td><td>100.0%</td><td>1.12 [0.07 , 19.24]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.08 (P = 0.94)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours LTG</td></tr><tr><td>Comparison 105. ESM vs TPM</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>105.1 ESM vs TPM: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>105.1.1 ESM vs TPM (cohort studies)</td><td>1</td><td/><td>58</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>3.00 [0.14, 65.77]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>105.1.2 ESM vs TPM (database studies)</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF551": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">ESM</td><td colspan=\"2\">TPM</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>1</td><td>53</td><td>100.0%</td><td>3.00 [0.14 , 65.77]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>53</td><td>100.0%</td><td>3.00 [0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.70 (P = 0.49)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>105.1.2 ESM vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>8</td><td>0</td><td>1</td><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF552": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 107.1</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours ESM</td><td/><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF553": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">VGB</td><td>VPA</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>43</td><td>290</td><td>100.0%</td><td>1.67 [0.15 , 18.73]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td/><td>290</td><td>100.0%</td><td>1.67 [0.15 , 18.73]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>43</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.42 (P = 0.68)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>107.1.2 VGB vs VPA (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>26</td><td>268</td><td>100.0%</td><td>1.27 [0.09 , 17.39]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3</td><td/><td>268</td><td>100.0%</td><td>1.27 [0.09 , 17.39]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>26</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.18 (P = 0.86)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VGB</td><td>Favours VPA</td></tr><tr><td>Comparison 108. VGB vs CBZ</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>108.1 VGB vs CBZ: All Major Malforma-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>108.1.1 VGB vs CBZ (cohort studies)</td><td>1</td><td/><td>410</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>4.18 [0.37, 47.57]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>108.1.2 VGB vs CBZ (database stud-</td><td>1</td><td/><td>706</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>3.09 [0.23, 42.31]</td></tr><tr><td>ies)</td><td/><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF554": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VGB</td><td/><td>CBZ</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td/><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>24</td><td>409</td><td>100.0%</td><td>4.18 [0.37 , 47.57]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td/><td>409</td><td>100.0%</td><td>4.18 [0.37 , 47.57]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>24</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.15 (P = 0.25)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>108.1.2 VGB vs CBZ (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>28</td><td>703</td><td>100.0%</td><td>3.09 [0.23 , 42.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3</td><td/><td>703</td><td>100.0%</td><td>3.09 [0</td></tr><tr><td>Total events:</td><td>0</td><td/><td>28</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.84 (P = 0.40)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF555": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 109. VGB vs PRM</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">109.1 VGB vs PRM: All Major Malfor-</td><td>2</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">109.1.1 VGB vs PRM (cohort studies)</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td colspan=\"2\">109.1.2 VGB vs PRM (database stud-</td><td>1</td><td>0</td><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Not estimable</td></tr><tr><td>ies)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Analysis 109.1.</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">Favours VGB</td><td>Favours CBZ</td></tr></table>",
                "type_str": "table"
            },
            "TABREF556": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VGB</td><td colspan=\"2\">PRM</td><td/><td>Risk Ratio</td><td colspan=\"2\">Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td colspan=\"2\">M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>0</td><td>2</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>109.1.2 VGB vs PRM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>0</td><td>3</td><td>Not estimable</td><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td>Not estimable</td><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VGB</td><td>Favours PRM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF557": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 112. VGB vs OXC</td><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">112.1 VGB vs OXC: All Major Malforma-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">112.1.1 VGB vs OXC (cohort studies)</td><td>1</td><td>20</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.33 [0.19, 57.71]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">112.1.2 VGB vs OXC (database studies)</td><td>1</td><td>0</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 112.1.</td><td/><td/><td/></tr><tr><td colspan=\"2\">110.1 VGB vs PB: All Major Malforma-</td><td>1</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">110.1.1 VGB vs PB (database studies)</td><td>1</td><td>10</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>0.67 [0.03, 12.96]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF558": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VGB</td><td colspan=\"2\">OXC</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>1</td><td>19</td><td>100.0%</td><td>3.33 [0.19 , 57.71]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td/><td>19</td><td>100.0%</td><td>3.</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.83 (P = 0.41)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>112.1.2 VGB vs OXC (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>0</td><td>4</td><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF559": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">Risk Ratio</td><td/><td/></tr><tr><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td><td/></tr><tr><td>Not estimable</td><td/><td/><td/><td/></tr><tr><td>Not estimable</td><td/><td/><td/><td/></tr><tr><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td colspan=\"2\">Favours VGB</td><td colspan=\"3\">Favours OXC</td></tr></table>",
                "type_str": "table"
            },
            "TABREF560": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 113.1</td><td/><td/><td/></tr><tr><td colspan=\"2\">113.1 VGB vs LTG: All Major Malforma-</td><td>2</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">113.1.1 VGB vs LTG (cohort studies)</td><td>1</td><td>408</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>3.31 [0.25, 43.03]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">113.1.2 VGB vs LTG (database studies) 1</td><td>93</td><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.53 [0.16, 39.34]</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF561": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">VGB</td><td>LTG</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>2</td><td>20</td><td>406</td><td>100.0%</td><td>3.31 [0.25 , 43.03]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>2</td><td/><td>406</td><td>100.0%</td><td>3.31 [0.25 , 43.03]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>20</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.91 (P = 0.36)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>113.1.2 VGB vs LTG (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>4</td><td>90</td><td>100.0%</td><td>2.53 [0.16 , 39.34]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>3</td><td/><td>90</td><td>100.0%</td><td>2.53 [0.16 , 39.34]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>4</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.66 (P = 0.51)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VGB</td><td>Favours LTG</td></tr><tr><td>Comparison 114. VGB vs TPM</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td colspan=\"2\">pants</td><td/><td/></tr><tr><td>114.1 VGB vs TPM: All Major Malfor-</td><td>2</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>114.1.1 VGB vs TPM (cohort studies)</td><td>1</td><td/><td>54</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>9.00 [0.51, 159.15]</td></tr><tr><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>114.1.2 VGB vs TPM (database stud-</td><td>1</td><td/><td>0</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95%</td><td>Not estimable</td></tr><tr><td>ies)</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF562": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">VGB</td><td colspan=\"2\">TPM</td><td/><td/><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td/><td>Weight</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>1</td><td>53</td><td>100.0%</td><td>9.00 [0.51 , 159.15]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td/><td>53</td><td>100.0%</td><td>9.00 [</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.50 (P = 0.13)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>114.1.2 VGB vs TPM (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Sweden Health Record Registers</td><td>0</td><td>3</td><td>0</td><td>1</td><td/><td/></tr><tr><td>Subtotal (95% CI)</td><td/><td>0</td><td/><td>0</td><td/><td/></tr><tr><td>Total events:</td><td>0</td><td/><td>0</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF563": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td colspan=\"4\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 116.1</td><td/><td/><td/></tr><tr><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td colspan=\"2\">Favours VGB</td><td/><td>Favours TPM</td></tr></table>",
                "type_str": "table"
            },
            "TABREF564": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>CZP</td><td/><td>PB</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>0</td><td>2</td><td/><td>Not estimable</td></tr><tr><td>D'Souza 1991</td><td>0</td><td>1</td><td>1</td><td>4</td><td>100.0%</td><td>0.83 [0.05 , 13.02]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>27</td><td/><td>6</td><td>100.0%</td><td>0.83 [0.05 , 13.02]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>1</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.13 (P = 0.90)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>116.1.2 CZP vs PB (database studies)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Norwegian Health Record Registers</td><td>2</td><td>113</td><td>2</td><td>27</td><td>64.9%</td><td>0.24 [0.04 , 1.62]</td></tr><tr><td>Sweden Health Record Registers</td><td>2</td><td>48</td><td>1</td><td>7</td><td>35.1%</td><td>0.29 [0.03 , 2.81]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>161</td><td/><td>34</td><td>100.0%</td><td>0.26 [0.06 , 1.12]</td></tr><tr><td>Total events:</td><td>4</td><td/><td>3</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Chi\u00b2 = 0.02, df = 1 (P = 0.89); I\u00b2 = 0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.81 (P = 0.07)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours CZP</td><td>Favours PB</td></tr><tr><td>Comparison 117. CZP vs PHT</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/><td/><td/></tr><tr><td>117.1 CZP vs PHT: All Major Malfor-</td><td>3</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/></tr><tr><td>117.1.1 CZP vs PHT (cohort studies)</td><td>2</td><td/><td>93</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.71 [0.10, 5.11]</td></tr><tr><td>117.1.2 CZP vs PHT (database stud-</td><td>1</td><td/><td>151</td><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed, 95% CI)</td><td>0.61 [0.13, 2.84]</td></tr><tr><td>ies)</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF565": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 118. ESM vs LEV</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"3\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td colspan=\"2\">pants</td><td/></tr><tr><td colspan=\"2\">118.1 ESM vs LEV: All Major Malforma-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>tions</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">118.1.1 ESM vs LEV (cohort studies)</td><td>1</td><td/><td colspan=\"2\">144</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>2.12 [0.13, 34.10]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">Analysis 118.1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CZP</td><td/><td>PHT</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>26</td><td>1</td><td>44</td><td>52.0%</td><td>0.56 [0.02 , 13.16]</td></tr><tr><td>D'Souza 1991</td><td/><td>0</td><td>1</td><td>6</td><td>22</td><td>48.0%</td><td>0.88 [0.07 , 10.64]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>27</td><td/><td>66</td><td>100.0%</td><td>0.71 [0.10 , 5.11]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>7</td><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Chi\u00b2 = 0.05, df = 1 (P = 0.82); I\u00b2 = 0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.34 (P = 0.74)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">117.1.2 CZP vs PHT (database studies)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Sweden Health Record Registers</td><td>2</td><td>48</td><td>7</td><td>103</td><td>100.0%</td><td>0.61 [0.13 , 2.84]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>48</td><td/><td>103</td><td>100.0%</td><td>0.61 [0.13 , 2.84]</td></tr><tr><td>Total events:</td><td/><td>2</td><td/><td>7</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.63 (P = 0.53)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"4\">Test for subgroup differences: Chi\u00b2 = 0.00, df = 1 (P &lt; 0.00001), I\u00b2 = 0%</td><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours CZP</td><td>Favours PHT</td></tr></table>",
                "type_str": "table"
            },
            "TABREF566": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td colspan=\"2\">ESM</td><td colspan=\"2\">LEV</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td>Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>5</td><td>139</td><td>100.0%</td><td>2.12 [0.13 , 34.10]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>5</td><td/><td>139</td><td>100.0%</td><td>2.12 [0.13 , 34.10]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 0.53 (P = 0.60)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours ESM</td><td>Favours LEV</td></tr><tr><td>Comparison 119. ESM vs Controls</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td>119.1 ESM vs Controls: All Major Malfor-</td><td>1</td><td/><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td>119.1.1 ESM vs WWE -No Medication (co-</td><td>1</td><td/><td/><td>181</td><td/><td colspan=\"2\">Risk Ratio (M-H, Fixed,</td><td>2.68 [0.17, 43.16]</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF567": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Comparison 120. VGB vs Controls</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"3\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">120.1 VGB vs Controls: All Major Malfor-</td><td>1</td><td/><td/><td/><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td>mations</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">120.1.1 VGB vs WWE -No Medication (co-</td><td>1</td><td/><td/><td>177</td><td/><td>Risk Ratio (M-H, Fixed, 95%</td><td>8.05 [0.64,</td></tr><tr><td>hort studies)</td><td/><td/><td/><td/><td/><td/><td>CI)</td><td>101.76]</td></tr><tr><td>Analysis 120.1.</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">ESM</td><td colspan=\"2\">Control</td><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">Events</td><td>Total</td><td>Events</td><td>Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"2\">Australian Epilepsy and Pregnancy Register</td><td>0</td><td>5</td><td>5</td><td>176</td><td>100.0%</td><td>2.68 [0.17 , 43.16]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td>5</td><td/><td>176</td><td>100.0%</td><td>2.68 [0.17 , 43.16]</td></tr><tr><td>Total events:</td><td/><td>0</td><td/><td>5</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z = 0.70 (P = 0.49)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Favours ESM</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF568": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Monotherapy</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">VGB</td><td colspan=\"2\">Control</td><td/><td/><td>Risk Ratio</td><td>Risk Ratio</td></tr><tr><td>Events</td><td>Total</td><td>Events</td><td colspan=\"2\">Total</td><td>Weight</td><td>M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Australian Epilepsy and Pregnancy Register</td><td>0</td><td>1</td><td>5</td><td>176</td><td>100.0%</td><td>8.05 [0.64 , 101.76]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td>1</td><td/><td>176</td><td>100.0%</td><td>8.05 [0.64 , 101.76]</td></tr><tr><td>Total events:</td><td>0</td><td/><td>5</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z = 1.61 (P = 0.11)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Favours VGB</td><td>Favours Controls</td></tr></table>",
                "type_str": "table"
            },
            "TABREF569": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"3\">A D D I T I O N A L T A B L E S</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>Cohort</td><td/><td/><td/><td>Database</td><td/><td/><td/><td>All</td><td/><td/><td/></tr><tr><td>ASM</td><td>Total</td><td>Percent-</td><td>Lower</td><td>Upper</td><td>Total</td><td>Percent-</td><td>Lower</td><td>Upper 95% CI</td><td>Total</td><td>Percent-</td><td>Lower</td><td>Upper</td></tr><tr><td/><td/><td>age</td><td>95% CI</td><td>95% CI</td><td/><td>age</td><td>95% CI</td><td/><td/><td>age</td><td>95% CI</td><td>95% CI</td></tr><tr><td>CBZ</td><td>5415</td><td>4.7</td><td>3.7</td><td>5.9</td><td>2806</td><td>4.0</td><td>2.9</td><td>5.4</td><td>8221</td><td>4.4</td><td>3.7</td><td>5.3</td></tr><tr><td>CZP</td><td>95</td><td>2.1</td><td>0.2</td><td>17.3</td><td>161</td><td>2.5</td><td>0.0</td><td>131.8</td><td>256</td><td>2.3</td><td>0.8</td><td>6.6</td></tr><tr><td>GBP</td><td>192</td><td>2.0</td><td>0.1</td><td>32.2</td><td>18</td><td>ND</td><td>ND</td><td>ND</td><td>210</td><td>1.4</td><td>0.3</td><td>6.8</td></tr><tr><td>LAC</td><td>1</td><td>ND</td><td>ND</td><td>ND</td><td>0</td><td>ND</td><td>ND</td><td>ND</td><td>1</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>LEV</td><td>1242</td><td>2.6</td><td>1.6</td><td>4.4</td><td>248</td><td>2.8</td><td>0.0</td><td>321.9</td><td>1490</td><td>2.8</td><td>1.8</td><td>4.3</td></tr><tr><td>LTG</td><td>4704</td><td>2.7</td><td>1.9</td><td>3.8</td><td>2502</td><td>3.5</td><td>2.5</td><td>4.9</td><td>7206</td><td>2.9</td><td>2.3</td><td>3.7</td></tr><tr><td>OXC</td><td>378</td><td>2.8</td><td>1.1</td><td>6.6</td><td>507</td><td>4.8</td><td>0.7</td><td>31.5</td><td>885</td><td>3.1</td><td>1.3</td><td>7.4</td></tr><tr><td>PB</td><td>840</td><td>6.3</td><td>4.8</td><td>8.3</td><td>34</td><td>8.8</td><td>0.0</td><td>9722.4</td><td>874</td><td>6.4</td><td>4.9</td><td>8.4</td></tr><tr><td>PHT</td><td>1327</td><td>5.4</td><td>3.6</td><td>8.1</td><td>103</td><td>6.8</td><td>0.1</td><td>701.2</td><td>1430</td><td>5.5</td><td>3.9</td><td>87.9</td></tr><tr><td>PRM</td><td>112</td><td>7.9</td><td>2.6</td><td>21.5</td><td>3</td><td>ND</td><td>ND</td><td>ND</td><td>115</td><td>7.6</td><td>2.5</td><td>21.0</td></tr><tr><td>TPM</td><td>510</td><td>3.9</td><td>2.3</td><td>6.5</td><td>49</td><td>4.1</td><td>0.0</td><td>27,060.0</td><td>559</td><td>3.9</td><td>2.4</td><td>6.3</td></tr><tr><td>VPA</td><td>3018</td><td>9.8</td><td>8.1</td><td>11.9</td><td>1482</td><td>9.7</td><td>7.1</td><td>13.4</td><td>4500</td><td>9.7</td><td>8.4</td><td>11.3</td></tr><tr><td>ZNS</td><td>130</td><td>2.7</td><td>0.1</td><td>47.3</td><td>0</td><td>ND</td><td>ND</td><td>ND</td><td>130</td><td>2.6</td><td>0.1</td><td>68.2</td></tr><tr><td>No med</td><td>1708</td><td>3.0</td><td>2.1</td><td>4.2</td><td>11,286</td><td>3.2</td><td>1.7</td><td>6.1</td><td>12,994</td><td>3.1</td><td>2.4</td><td>3.9</td></tr><tr><td colspan=\"2\">Gen POP 3537</td><td>2.1</td><td>1.5</td><td>3.0</td><td>373,028</td><td>3.3</td><td>1.5</td><td>7.1</td><td>376,565</td><td>2.5</td><td>1.8</td><td>3.3</td></tr><tr><td>348</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF570": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Specific prevalences are weighted for cohort size.</td></tr><tr><td>CBZ: Carbamazepine</td></tr><tr><td>CI: Confidence Interval</td></tr><tr><td>CZP: Clonazepam</td></tr><tr><td>GBP: Gabapentin</td></tr><tr><td>LAC: Lacosamide</td></tr></table>",
                "type_str": "table"
            },
            "TABREF571": {
                "text": "Summary of findings table -Oxcarbazepine(Continued)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>a Random-e ects RR calculated due to heterogeneity</td></tr><tr><td>ASM: Anti-Seizure Medication</td></tr><tr><td>CBZ: Carbamazepine</td></tr><tr><td>CI: Confidence Interval</td></tr><tr><td>LEV: Levetiracetam</td></tr><tr><td>LTG: Lamotrigine</td></tr><tr><td>N/A: Not Available</td></tr><tr><td>OXC: Oxcarbazepine</td></tr><tr><td>TPM: Topiramate</td></tr><tr><td>VPA: Sodium Valproate</td></tr></table>",
                "type_str": "table"
            },
            "TABREF572": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>LEV 2.8% (0.0, 321.9)</td><td colspan=\"2\">3.26 (1.51, 7.03) (2)</td></tr><tr><td/><td>studies</td><td/><td/><td/><td/></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>LEV 2.8% (1.7, 4.5)</td><td>N/A</td></tr><tr><td>Valproate vs</td><td colspan=\"3\">Cohort studies VPA 9.8% (8.1, 11.9)</td><td>LTG 2.7% (1.9, 3.8)</td><td colspan=\"2\">3.50 (2.76, 4.46) (12)</td></tr><tr><td>lamotrigine</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>LTG 0.68% (0.20, 2.37)</td><td colspan=\"2\">2.49 (1.86, 3.35) (4)</td></tr><tr><td/><td>studies</td><td/><td/><td/><td/></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>LTG 2.9% (2.3, 3.7)</td><td>N/A</td></tr><tr><td>Valproate</td><td colspan=\"3\">Cohort studies VPA 9.8% (8.1, 11.9)</td><td>OXC 2.8% (1.1, 6.6)</td><td colspan=\"2\">2.48 (1.42, 4.31) (11)</td></tr><tr><td>vs oxcar-</td><td/><td/><td/><td/><td/></tr><tr><td>bazepine</td><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>OXC 4.8% (0.7, 31.5)</td><td>1.60 (1.11,</td><td>(4)</td></tr><tr><td/><td>studies</td><td/><td/><td/><td>2.29) a</td></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>OXC 3.0% (1.4, 5.4)</td><td>N/A</td></tr><tr><td>Valproate vs</td><td colspan=\"3\">Cohort studies VPA 9.8% (8.1, 11.9)</td><td>TPM 3.9% (2.3, 6.5)</td><td colspan=\"2\">2.47 (1.50, 4.08) (7)</td></tr><tr><td>topiramate</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>TPM 4.1% (0.0, 27060.0)</td><td colspan=\"2\">1.27 (0.36, 4.39) (2)</td></tr><tr><td/><td>studies</td><td/><td/><td/><td/></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>TPM 3.9% (1.5, 8.4)</td><td>N/A</td></tr><tr><td>Carba-</td><td colspan=\"3\">Cohort studies VPA 9.8% (8.1, 11.9)</td><td>CBZ 4.7% (3.7, 5.9)</td><td colspan=\"2\">0.44 (0.37, 0.53) (29)</td></tr><tr><td>mazepine vs</td><td/><td/><td/><td/><td/></tr><tr><td>valproate</td><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>CBZ 4.0% (2.9, 5.4)</td><td colspan=\"2\">0.42 (0.33, 0.54) (5)</td></tr><tr><td/><td>studies</td><td/><td/><td/><td/></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>CBZ 5.5% (4.5, 6.6)</td><td>N/A</td></tr><tr><td>Valproate vs</td><td colspan=\"3\">Cohort studies VPA 9.8% (8.1, 11.9)</td><td>ZNS 2.7% (0.1, 47.3)</td><td>2.34 (0.95,</td><td>(3)</td></tr><tr><td>zonisamide</td><td/><td/><td/><td/><td>5.80) a</td></tr><tr><td/><td colspan=\"2\">Database</td><td>VPA 9.7% (7.1, 13.4)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td/><td>studies</td><td/><td/><td/><td/></tr><tr><td/><td>EURAP</td><td/><td>VPA 10.3% (8.8, 12.0)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></table>",
                "type_str": "table"
            },
            "TABREF573": {
                "text": "Summary of findings table -Valproate(Continued)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>a Random-e ects RR calculated due to heterogeneity</td></tr><tr><td>ASM: Anti-Seizure Medication</td></tr><tr><td>CBZ: Carbamazepine</td></tr><tr><td>CI: Confidence Interval</td></tr><tr><td>Gen pop: General population</td></tr><tr><td>LEV: Levetiracetam</td></tr><tr><td>LTG: Lamotrigine</td></tr><tr><td>N/A: Not Available</td></tr><tr><td>OXC: Oxcarbazepine</td></tr><tr><td>TPM: Topiramate</td></tr><tr><td>VPA: Sodium Valproate</td></tr></table>",
                "type_str": "table"
            },
            "TABREF574": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF575": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td>to</td><td/><td/><td>to</td><td>to</td><td>to</td><td/><td>to</td><td/><td/><td>to</td></tr><tr><td/><td/><td/><td>1.56)</td><td/><td/><td>3.37)</td><td>3.93)</td><td>4.03)</td><td/><td>1.56)</td><td/><td/><td>1.40)</td></tr><tr><td>TPM</td><td>4.07 (1.64</td><td>1.37 (0.57</td><td>0.83</td><td>0.67</td><td>0.32</td><td>0.57</td><td>0.59</td><td>0.71</td><td>1.38 (0.680</td><td>0.88</td><td>6.00</td><td/><td>2.47</td><td>1.59</td></tr><tr><td/><td>to 10.14)</td><td>to 3.27)</td><td>(0.51</td><td>(0.03</td><td>(0.09</td><td>(0.32</td><td>(0.36</td><td>(0.28</td><td>to 2.81)</td><td>(0.48</td><td>(0.30</td><td/><td>(1.50</td><td>(0.54</td></tr><tr><td/><td/><td/><td>to</td><td>to</td><td>to</td><td>to</td><td>to</td><td>to</td><td/><td>to</td><td>to</td><td/><td>to</td><td>to</td></tr><tr><td/><td/><td/><td>1.33)</td><td>15.83)</td><td>1.19)</td><td>1.04)</td><td>0.96)</td><td>1.77)</td><td/><td>1.61)</td><td>118.36)</td><td/><td>4.08)</td><td>4.66)</td></tr><tr><td>VPA</td><td>5.53 (3.29</td><td>2.77 (2.03</td><td>0.44</td><td>0.29</td><td>4.27</td><td>3.77</td><td>3.50</td><td>2.48</td><td>1.49 (1.08</td><td>1.92</td><td>0.74</td><td>2.47 (1.50</td><td/><td>2.34</td></tr><tr><td/><td>to 9.29)</td><td>to 3.79)</td><td>(0.37</td><td>(0.09</td><td>(1.60</td><td>(2.48</td><td>(2.76</td><td>(1.42</td><td>to 2.07)</td><td>(1.44</td><td>(0.39</td><td>to 4.08)</td><td/><td>(0.95</td></tr><tr><td/><td/><td/><td>to</td><td>to</td><td>to</td><td>to</td><td>to</td><td>to</td><td/><td>to</td><td>to</td><td/><td/><td>to</td></tr><tr><td/><td/><td/><td>0.53)</td><td>0.90)</td><td>11.35)</td><td>5.74)</td><td>4.46)</td><td>4.31)</td><td/><td>2.56)</td><td>1.40)</td><td/><td/><td>5.80)</td></tr><tr><td>ZNS</td><td>1.13 (0.21</td><td>3.20 (1.09</td><td>0.94,</td><td>ND</td><td>0.53</td><td>0.66</td><td>0.66</td><td>4.48</td><td>10.46 (0.62</td><td>1.28</td><td>ND</td><td>1.59 (0.54</td><td>2.34</td></tr><tr><td/><td>to 6.11)</td><td>to 9.43)</td><td>(0.36</td><td/><td>(0.10</td><td>(0.25</td><td>(0.26</td><td>(0.24</td><td>to 175.67)</td><td>(0.42to</td><td/><td>to 4.66)</td><td>(0.95</td></tr><tr><td/><td/><td/><td>to</td><td/><td>to</td><td>to</td><td>to</td><td>to</td><td/><td>3.93)</td><td/><td/><td>to</td></tr><tr><td/><td/><td/><td>2.44)</td><td/><td>2.76)</td><td>1.71)</td><td>1.65)</td><td>82.23)</td><td/><td/><td/><td/><td>5.80)</td></tr><tr><td>357</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF576": {
                "text": "Relative risks (RRs) for specific ASM comparisons(Continued)",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"3\">Bold indicates statistically significant</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">ASM: Anti-Seizure Medication</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">CBZ: Carbamazepine</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">CZP: Clonazepam</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">GBP: Gabapentin</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">LEV: Levetiracetam</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">LTG: Lamotrigine</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">ND: No Data</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">NE: Not Estimable</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">OXC: Oxcarbazepine</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">PB: Phenobarbital</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">PHT: Phenytoin</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">POP: Population</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">PRM: Primidone</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">RR: Relative Risk</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">TPM: Topiramate</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">VPA: Sodium Valproate</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">ZNS: Zonisamide</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>Gen</td><td>No Med</td><td>CBZ</td><td>CZP</td><td>GBP</td><td>LEV</td><td>LTG</td><td>OXC</td><td>PB</td><td>PHT</td><td>PRM</td><td>TPM</td><td>VPA</td><td>ZNS</td></tr><tr><td/><td>Pop</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>CBZ</td><td>0.02</td><td>0.01 (0.00 to</td><td/><td>0.04,</td><td>0.02</td><td>0.01</td><td>0.01</td><td>0.01</td><td>-0.01</td><td>-0.01 (-0.02 to</td><td>-0.02</td><td>-0.01</td><td>-0.05</td><td>0.00</td></tr><tr><td/><td>(0.01</td><td>0.02)</td><td/><td/><td/><td>(0.00</td><td>(0.00</td><td/><td>(-0.03</td><td>0.01)</td><td>(-0.09</td><td>(-0.02</td><td>(-0.06</td></tr></table>",
                "type_str": "table"
            },
            "TABREF577": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF578": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>to</td><td/><td/><td>(-0.00</td><td>(-0.00</td><td>to</td><td>to</td><td>( -0.01</td><td>to</td><td/><td>to</td><td>to</td><td>to</td><td>(-0.03</td></tr><tr><td/><td>0.03)</td><td/><td/><td>to</td><td>to</td><td>0.02)</td><td>0.02)</td><td>to</td><td>0.01)</td><td/><td>0.05)</td><td>0.01)</td><td>-0.04)</td><td>to</td></tr><tr><td/><td/><td/><td/><td>0.08)</td><td>0.04)</td><td/><td/><td>0.03)</td><td/><td/><td/><td/><td/><td>0.03)</td></tr><tr><td>CZP</td><td>0.02</td><td>-0.03</td><td>0.04,</td><td/><td>-0.04</td><td>-0.01</td><td>0.01</td><td>-0.05</td><td>-0.08</td><td>-0.04 (-0.13 to</td><td>NE</td><td>-0.02</td><td>-0.09</td><td>ND</td></tr><tr><td/><td>(-0.03 to 0.07)</td><td>(-0.11 to 0.04)</td><td>(-0.00 to 0.08)</td><td/><td>(-0.14 to 0.05)</td><td>(-0.05 to 0.03)</td><td>(-0.03 to 0.04)</td><td>(-0.18 to 0.07)</td><td>(-0.66 to 0.51)</td><td>0.06)</td><td/><td>(-0.09 to 0.05)</td><td>(-0.13 to 0.04)</td></tr><tr><td>GBP</td><td>0.19</td><td>0.01 (-0.05 to</td><td>0.02</td><td>-0.04</td><td/><td>0.01</td><td>-0.01</td><td>-0.01</td><td>-0.04</td><td>0.02</td><td>ND</td><td>-0.03</td><td>0.08</td><td>-0.03</td></tr><tr><td/><td>(-0.37 to 0.74)</td><td>0.07)</td><td>(-0.00 to 0.04)</td><td>(-0.14 to 0.05)</td><td/><td>(-0.01 to 0.03)</td><td>(-0.03 to 0.01)</td><td>(-0.04 to 0.01)</td><td>(-0.08 to 0.00)</td><td>(-0.00 to 0.04)</td><td/><td>(-0.05 to -0.01)</td><td>(0.01 to 0.14)</td><td>(-0.15 to 0.10)</td></tr><tr><td>LEV</td><td>0.01</td><td>-0.01 (-0.03 to</td><td>0.01</td><td>-0.01</td><td>0.01</td><td/><td>-0.00</td><td>0.00</td><td>-0.02</td><td>-0.02 (-0.04 to</td><td>0.04</td><td>-0.02</td><td>0.07</td><td>0.01</td></tr><tr><td/><td>(-0.00 to 0.03)</td><td>0.00)</td><td>(0.00 to 0.02)</td><td>(-0.05 to 0.03)</td><td>(-0.01 to 0.03)</td><td/><td>(-0.01 to 0.01)</td><td>(-0.02 to 0.03)</td><td>(-0.05 to 0.01)</td><td>-0.00)</td><td>(-0.39 to 0.46)</td><td>(-0.04 to 0.00)</td><td>(0.05 to 0.08)</td><td>(-0.04 to 0.03)</td></tr><tr><td>LTG</td><td>0.01</td><td>0.00 (-0.01 to</td><td>0.01</td><td>0.01</td><td>-0.01</td><td>-0.00</td><td/><td>-0.01</td><td>-0.04</td><td>-0.02 (-0.03 to</td><td>0.05</td><td>-0.02</td><td>0.06</td><td>-0.03</td></tr><tr><td/><td>(0.00 to 0.03)</td><td>0.01)</td><td>(0.00 to 0.02)</td><td>(-0.03 to 0.04)</td><td>(-0.03 to 0.01)</td><td>(-0.01 to 0.01)</td><td/><td>(-0.03 to 0.02)</td><td>(-0.07 to -0.01)</td><td>-0.00)</td><td>(-0.37 to 0.47)</td><td>(-0.03 to 0.00)</td><td>(0.05 to 0.08)</td><td>(-0.16 to 0.11)</td></tr><tr><td>OXC</td><td>0.01</td><td>0.02 (-0.03 to</td><td>0.01</td><td>-0.05</td><td>-0.01</td><td>0.00</td><td>-0.01</td><td/><td>0.02</td><td>0.00 (-0.03 to</td><td>-0.02</td><td>-0.01</td><td>0.06</td><td>0.02</td></tr><tr><td/><td>(-0.02 to 0.04)</td><td>0.07)</td><td>( -0.01 to 0.03)</td><td>(-0.18 to 0.07)</td><td>(-0.04 to 0.01)</td><td>(-0.02 to 0.03)</td><td>(-0.03 to 0.02)</td><td/><td>(-0.02 to 0.06)</td><td>0.03)</td><td>(-0.34 to 0.30)</td><td>(-0.04 to 0.02)</td><td>(0.03 to 0.09)</td><td>(-0.01 to 0.05)</td></tr><tr><td>PB</td><td>0.04</td><td>0.02 (-0.01 to</td><td>-0.01</td><td>-0.08</td><td>-0.04</td><td>-0.02</td><td>-0.04</td><td>0.02</td><td/><td>-0.01 (-0.03 to</td><td>-0.05</td><td>0.02</td><td>0.04</td><td>0.05</td></tr><tr><td/><td>(0.01 to 0.07)</td><td>0.06)</td><td>(-0.03 to 0.01)</td><td>(-0.66 to 0.51)</td><td>(-0.08 to 0.00)</td><td>(-0.05 to 0.01)</td><td>(-0.07 to -0.01)</td><td>(-0.02 to 0.06)</td><td/><td>0.02)</td><td>(-0.12 to 0.02)</td><td>(-0.02 to 0.05)</td><td>(0.01 to 0.06)</td><td>(0.02 to 0.09)</td></tr><tr><td>PHT</td><td>0.03</td><td>0.03 (0.01 to</td><td>-0.01</td><td>-0.04</td><td>0.02</td><td>-0.02</td><td>0.02</td><td>0.00</td><td>-0.01</td><td/><td>-0.02</td><td>-0.00</td><td>0.05</td><td>0.00</td></tr><tr><td>358</td><td>(0.01 to 0.06)</td><td>0.05)</td><td>(-0.02 to 0.01)</td><td>(-0.13 to 0.06)</td><td>(-0.00 to 0.04)</td><td>(-0.04 to -0.00)</td><td>(-0.00 to 0.04)</td><td>(-0.03 to 0.03)</td><td>(-0.03 to 0.02)</td><td/><td>(-0.09 to 0.06)</td><td>(-0.03 to 0.02)</td><td>(0.03 to 0.07)</td><td>(-0.11 to 0.11)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF579": {
                "text": "(Continued)",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"3\">Cochrane Library</td></tr><tr><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF580": {
                "text": "Copyright \u00a9 2023 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>PRM</td><td>NE</td><td>0.07 (0.00 to</td><td>-0.02</td><td>NE</td><td>ND</td><td>0.04</td><td>0.05</td><td>-0.02</td><td>-0.05</td><td>-0.02 (-0.09 to</td><td/><td>-0.02</td><td>0.04</td><td>ND</td></tr><tr><td/><td/><td>0.14)</td><td>(-0.09 to 0.05)</td><td/><td/><td>(-0.39 to 0.46)</td><td>(-0.37 to 0.47)</td><td>(-0.34 to 0.30)</td><td>(-0.12 to 0.02)</td><td>0.06)</td><td/><td>(-0.44 to 0.41)</td><td>(-0.13 to 0.04)</td></tr><tr><td>TPM</td><td>0.03</td><td>0.01 (-0.03 to</td><td>-0.01</td><td>-0.02</td><td>-0.03</td><td>-0.02</td><td>-0.02</td><td>-0.01</td><td>0.02</td><td>-0.00 (-0.03 to</td><td>-0.02</td><td/><td>0.07</td><td>0.02</td></tr><tr><td/><td>(0.01 to 0.06)</td><td>0.04)</td><td>(-0.02 to 0.01)</td><td>(-0.09 to 0.05)</td><td>(-0.05 to -0.01)</td><td>(-0.04 to 0.00)</td><td>(-0.03 to 0.00)</td><td>(-0.04 to 0.02)</td><td>(-0.02 to 0.05)</td><td>0.02)</td><td>(-0.44 to 0.41)</td><td/><td>(0.02 to 0.11)</td><td>(0.02 to 0.06)</td></tr><tr><td>VPA</td><td>0.07</td><td>0.06 (0.04 to</td><td>-0.05</td><td>-0.09</td><td>0.08</td><td>0.07</td><td>0.06</td><td>0.06</td><td>0.04</td><td>0.05 (0.03 to</td><td>0.04</td><td>0.07</td><td/><td>0.04</td></tr><tr><td/><td>(0.04 to 0.10)</td><td>0.07)</td><td>(-0.06 to -0.04)</td><td>(-0.13 to 0.04)</td><td>(0.01 to 0.14)</td><td>(0.05 to 0.08)</td><td>(0.05 to 0.08)</td><td>(0.03 to 0.09)</td><td>(0.01 to 0.06)</td><td>0.07)</td><td>(-0.13 to 0.04)</td><td>(0.02 to 0.11)</td><td/><td>(0.11 to 0.19)</td></tr><tr><td>ZNS</td><td>-0.00</td><td>0.07 (-0.03 to</td><td>0.00</td><td>ND</td><td>-0.03</td><td>0.01</td><td>-0.03</td><td>0.02</td><td>0.05</td><td>0.00</td><td>ND</td><td>0.02</td><td>0.04</td></tr><tr><td/><td>(-0.03 to 0.02)</td><td>0.18)</td><td>(-0.03 to 0.03)</td><td/><td>(-0.15 to 0.10)</td><td>(-0.04 to 0.03)</td><td>(-0.16 to 0.11)</td><td>(-0.01 to 0.05)</td><td>(0.02 to 0.09)</td><td>(-0.11 to 0.11)</td><td/><td>(0.02 to 0.06)</td><td>(0.11 to 0.19)</td></tr><tr><td>359</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF581": {
                "text": "(Continued)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Bold indicates statistical significance</td></tr><tr><td>ASM: Anti-Seizure Medication</td></tr><tr><td>CBZ: Carbamazepine</td></tr><tr><td>CZP: Clonazepam</td></tr><tr><td>GBP: Gabapentin</td></tr><tr><td>LEV: Levetiracetam</td></tr><tr><td>LTG: Lamotrigine</td></tr><tr><td>ND: No Data</td></tr><tr><td>NE: Not Estimable</td></tr><tr><td>OXC: Oxcarbazepine</td></tr><tr><td>PB: Phenobarbital</td></tr><tr><td>PHT: Phenytoin</td></tr><tr><td>POP: Population</td></tr><tr><td>PRM: Primidone</td></tr><tr><td>TPM: Topiramate</td></tr><tr><td>VPA: Sodium Valproate</td></tr><tr><td>ZNS: Zonisamide</td></tr></table>",
                "type_str": "table"
            },
            "TABREF582": {
                "text": "or Diphenylhydatanoin or Ditoinate or Ekko or Elepsindon or Enkelfel or Epamin or Epanutin or Epasmir or Epdantoin* or Epelin or Epifenyl or Epihydan or Epilan or Epilantin or Epinat or Epised or Eptal or Eptoin or Fenantoin or Fenidantoin or Fenitoin* or Fentoin or Fenylepsin or Fenytoin* or \"Gerot-epilan-D\" or Hidan or Hidant* or Hindatal or Hydant* or Ictalis or Idantoi* or Iphenylhydantoin or Kessodanten or Labopal or Lehydan or Lepitoin or Lepsin or Mesantoin or Minetoin or \"Neos-Hidantoina\" or Neosidantoina or Novantoina or Novophenytoin or \"Om-hidantoina\" or \"Om-Hydantoine\" or Oxylan or Phanantin* or Phenatine or Phenatoine or Phenhydan* or Phenitoin or Phentoin or Phentytoin or Phenytek or Phenytex or Phenytoin* or PHT or Ritmenal or Saceril or Sanepil or Silantin or Sinergina or Sodanthon or Sodanto* or Solantin or Solantoin or Solantyl or Sylantoic or Tacosal or Thilophenyl or TOIN or Zentronal or Zentropil).mp.92.(Lyrica or Pregabalin*).mp.93.(Mysoline or Primidon* or Sertan).mp.94. (Gabrene or Garene or Halogabide or Halogenide or Progabid*).mp.95. (Ecovia or Remacemid*).mp.96.(\"D-23129\" or \"D23129\" or EZG or Ezogabin* or Retigabin* or RTG or Trobalt or Potiga).mp.97.(Rilutek or Riluzol* or Trifluoromethoxybenzothiazol*).mp.98. (Inovelon or Rufinamid* or Xilep).mp.Cochrane Database of Systematic Reviews Encorate or Epanutin or Epiject or Epilepax or Epilex or Epilim or Episenta or Epitol or Epival or Eptoin or Equetro or Ergenyl or Erimin or Eslicarbazepin* or Estazolam* or Ethadion* or Ethosuximid* or Ethotoin* or Ethylphenacemide or Exalief or Exceglan or Excegram or Excegran or Ezogabin* or Fanatrex or Felbamat* or Felbatol or Fenitoin* or Fenytoin* or Flunarizin* or Fosphenytoin* or Frisium or Fycompa or Gabapentin* or Gabarone or Gabitril or Gabrene or Ganaxolon* or Garene or GBP or Gralise or GVG or Halogabide or Halogenide or Hibicon or Hypnovel or Iktorivil or Inovelon or Insoma or Intensl or Keppra or Klonopin or Kriadex or Lacosamid* or Lamict* or Lamitor or Lamitrin or Lamogine or Lamotrigin* or Lamotrine or Landsen or LEV or Levetiracetam* or Liskantin or Loraz or Lorazepam* or Losigamon* or LTG or Luminal or Lyrica or \"Magnesium sulfat*\" or \"Magnesium sulphat*\"or Mebaral or Medazepam* or Mephenytoin* or Mephobarbit* or Mephyltaletten or Meprobamat* or Mesantoin or Mesuximide or Methazolamid* or Methsuximid* or Methylphenobarbit* or Midazolam* or Mogadon or Mylepsinum or Mylproin or Mysoline or Neogab or Neptazane or Neurontin or Neurotop or Nimetazepam* or Nitrados or Nitrazadon or Nitrazepam* or Normison or Novo-Clopate or Nupentin or Nydrane or Onfi or Orfiril or Orlept or Ormodon or Ospolot or OXC or Oxcarbazepin* or Pacisyn or Paraldehyd* or Paramethadion* or Paxadorm or Paxam or PB or Peganone or Pentothal or Perampanel* or Petinutin or Petril or Phemiton or Phenacemid* or Pheneturid* or Phenobarbit* or Phensuximid* or Phenytek or Phenytoin* or PHT or Posedrine or Potiga or Pregabalin* or Primidon* or Prodilantin or Progabid* or Prominal or Propofol* or Prysoline or Qudexy or Ravotril or Remacemid* or Remnos or Resimatil or Restoril or Retigabin* or Rilutek or Riluzol* or Riv?tril or Rufinamid* or Sabril or Seclar or Selenica or Seletracetam* or Sertan or Somnite or Stavzor or Stedesa or Stiripentol* or Sulthiam* or Sultiam* or Talampanel* or Tegret?l or Temazep* or Temesta or Teril or Thiopent* or Tiagabin* or Tiletamin* or Timonil or Topamax or Topiramat* or Topiramic or TPM or Tranxene or Tridione or Trileptal or Trileptin or Trimethadion* or Trobalt or Urban?l or Valance or Valcote or Valium or Valnoctamid* or Valparin or Valpro* or Versed or Vigabatrin* or Vimpat or VPA or Xcopri or Xilep or YKP3089 or Zalkote or Zarontin or Zebinix or ZNS or Zonegran or Zonisamid*))) AND (((((TITLE-ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR \"parallel group\" OR crossover OR \"cross over\" OR cluster OR \"head to head\") W/4 (analy* OR design OR evaluat* OR investigat* OR method OR procedure OR study OR studies OR trial))) OR (TITLE-ABS((prospective) W/4 (analys* OR cohort* OR data OR evaluat* OR investigat* OR series OR study OR studies OR trial)))) AND NOT (TITLE(animal OR mouse OR mice OR murine OR rat OR rodent OR dog OR canine OR zebrafish) AND NOT TITLE(human* OR patient OR child* OR infant* OR adolescen* OR adult OR elderly OR man OR men OR male OR wom?n OR female))) AND NOT (TITLE(case PRE/0 (report OR study OR studies)))) OR (TITLE-ABS-KEY((registr* OR register) W/4 (analy* OR data OR study OR studies OR trial))))) AND (PUBYEAR > 2013)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            }
        }
    }
}